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Treatment of essential tremor and Parkinson’s disease tremor by
MRI guided Focused Ultrasound: a report of 38 consecutive cases
in a single center
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Objectives
Thalamotomy of the ventral intermediate nucleus (VIM) is effective in
alleviating medication resistant tremor in patients with essential
tremor (ET) and Parkinson’s disease (PD). MRI guided Focused Ultra-
sound (MRgFUS) is an innovative technology that enables non-
invasive thalamotomy via thermal ablation.
Methods
Thirty eight ET and PD patients with severe medication resistant
tremor underwent MRgFUS underwent unilateral VIM thalamot-
omy using MRgFUS. Effect was evaluated using clinical Rating
Scale of Tremor (CRST) in ET patients and Unified PD Rating Scale
motor part (UPDRS) in PD patients. Quality of life was assessed
by Quality of life in ET Questionnaire (QUEST) and PD Questionaire
(PDQ-39).
Results
Tremor stopped in the treated hand in 37 patients immediately
following the treatment. In one patients tremor was modified but
not abolished. At one month post-treatment, the ET patients’
CRST score decreased from 38.6 ± 12.0 to 9.3 ± 7.7 (p < 0.001) and
QUEST scores decreased from 44.8 ± 17.8 to 13.1 ± 15.9 (p <
0.001). In PD patients UPDRS-motor part decreased from 26.2 ±
8.7 to 16.3 ± 11.0 (p = 0.0087) and PDQ39 decreased from 40.8 ±
18.2 to 26.5 ± 15.1 (p = 0.027). During follow up of 1-24 months
(mean 10.9 ± 8.1 months) tremor reappeared in seven of the pa-
tients, but in all but three, to a lesser degree than before the
procedure.
Adverse events that transiently occurred during sonication in-
cluded: Headache (n = 11), short lasting vertigo (n = 17) and dizzi-
ness (n = 4), nausea (n = 4), burning scalp sensation (n = 3),
vomiting (n = 3) and lip paresthesia (n = 2). Adverse events that
lasted after the procedure included gait ataxia (n = 5), unsteady
feeling when walking (n = 4,) unilateral taste disturbances (n = 3)
and hand ataxia (n = 3). All adverse events were transient and
none lasted beyond 3 months.
Conclusions
MRgFUS VIM thalamotomy to relieve medication resistant tremor
was safe and effective in ET, and PD. Current results emphasize its
low adverse events profile and high efficacy in treating tremor. Large
randomized studies are needed to assess prolonged efficacy and
safety.© The Author(s). 2016 Open Access This artic
International License (http://creativecommons
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the Creative Commons license, and indicate if
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Focused Ultrasound likely dominates deep brain stimulation and
stereotactic radiosurgery for medically-refractory essential tremor:
an initial decision and cost-effectiveness analysis
Jonathon Parker1, Vinod Ravikumar1, Pejman Ghanouni1, Sherman Stein2,
Casey Halpern1
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Objectives
Essential Tremor (ET) is one of the most common neurologic condi-
tions, and conservative measures are frequently suboptimal. Recent
data from a multi-institution, randomized controlled clinical trial
demonstrated that Magnetic Resonance-guided Focused Ultrasound
(MRgFUS) thalamotomy improves upper limb tremor in medically re-
fractory ET. This study assesses the cost-effectiveness of this novel
therapy in comparison to existing procedural options.
Methods
PubMed and Cochrane Library searches were performed for studies of
MRgFUS, Deep Brain Stimulation (DBS), and Stereotactic Radiosurgery
(SRS) for ET. Pre- and post-operative tremor-related disability scores
were collected from 32 studies involving 83 MRgFUS, 615 DBS, and 260
SRS cases. Utility (defined as percent change in functional disability)
was calculated, and Medicare reimbursements were collected as a
proxy for societal cost – costs of MRgFUS for ET were derived from a
combination of available costs of approved indications and SRS costs
where appropriate. A decision and cost-effectiveness analysis was then
constructed, implementing meta-analytic techniques.
Results
MRgFUS thalamotomy resulted in significantly higher utility scores
compared with DBS and SRS based on estimates of Medicare reim-
bursement (p < 0.001). MRgFUS was also the most inexpensive pro-
cedure out of the three (p < 0.001).
Conclusions
Preliminary experience with MRgFUS for ET suggests that this novel
therapeutic may be more effective than available alternatives and
potentially less costly for society. It thus will likely “dominate” DBS
and SRS as a more cost-effective option for medically refractory ET.
Our findings support further investigation of MRgFUS for ET and
broad adoption.
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Tractography-based VIM identification for Focused Ultrasound
thalamotomy: initial results
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Fig. 2 (abstract A3). Postoperative sagittal T1 projection
demonstrating the relationship between pyramidal tract and medial
lemniscus in relation to thalamotomy lesion
Fig. 3 (abstract A3). Postoperative axial T1 projection
demonstrating the relationship between pyramidal tract and medial
lemniscus in relation to thalamotomy lesion
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The ventral intermediate nucleus (VIM) is not visible on conven-
tional Magnetic Resonance Imaging (MRI). A novel method for
tractography-based VIM identification has recently been de-
scribed. We report the short-term clinical results of prospective
VIM targeting with tractography in a cohort of patients undergo-
ing Focused Ultrasound thalamotomy.
Methods
All patients underwent structural and diffusion weighted imaging
(60 diffusion directions, 2 mm isovoxel) with 3 Tesla MRI scanner
(Philips Ingenia CX). The images were processed using streamline
tractography (Stealth Viz, Medtronic Inc.). The lateral and poster-
ior borders of VIM were defined by tracking the pyramidal tract
and medial lemniscus respectively. A VIM region of interest (ROI)
was placed 3 mm away from these borders (Figs. 1, 2 and 3).
The structural connectivity of this VIM ROI was confirmed to the
motor cortex (M1) and cerebellum. The coordinates of
tractography-based VIM in relation to posterior commissure were
noted for surgical targeting. The parameters analyzed include a
clinical tremor scale (pre-, intraoperative, and post operative), op-
erative time, and number of sonications.
Results
Tractography-based VIM targeting was successful in 7 out of 8
patients. The coordinates of tractography-based VIM were signifi-
cantly different from the standard coordinates (3-D distance 3.9 ±
2.4 mm). Therapeutic sonication (>55 °C temperature, 10 seconds)
at the tractography target resulted in >50 % tremor improvement
with intraoperative objective tremor assessment without any
motor or sensory side-effects. The mean operative time was 78 ±
3.3 minutes with 12.8 ± 3.9 average sonications. Overall the
tremor scores significantly improved one month after surgery
(preop CRST total 62.1 ± 15.5 versus 30.3 ± 14.1, two tailed t-test
p = 0.006). None of the patients experienced sensory deficits or
motor weakness during follow-up.
Conclusions
We report that prospective tractography-based VIM targeting is safe
and feasible. The short-term clinical results are satisfactory. Long-
term tremor efficacy outcomes are desirable to further assess the
usefulness of this technique.Fig. 1 (abstract A3). Axial T1 projection showing the relation of VIM
target 3 mm medial and anterior to pyramidal tract and medial
lemniscus respectivelyA4
Targeted delivery of brain-penetrating non-viral GDNF gene
vectors to the striatum with MRI-guided Focused Ultrasound
reverses neurodegeneration in a Parkinson’s disease model
Brian Mead1, Namho Kim2, Panagiotis Mastorakos2, Jung Soo Suk2,
Wilson Miller1, Alexander Klibanov1, Justin Hanes2, Richard Price1
1University of Virginia, Charlottesville, Virginia, USA; 2Center for
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Objectives
Parkinson’s disease (PD) is characterized by the degeneration of dopa-
minergic neurons in the motor control pathways of the brain. Gene ther-
apy using glial cell derived neurotrophic factor (GDNF) has shown some
limited promise for treating PD; however, we hypothesize that outcomes
could be further improved by enhancing gene vector distribution. We
previously developed a gene therapy approach that entails delivering
systemically administered non-viral gene-bearing nanoparticles (BPN)
across the Blood-Brain Barrier with MRI-guided Focused Ultrasound
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ethylene glycol, and this approach mediates efficient and localized trans-
gene expression in the brain of healthy rats. Here, we tested whether
the FUS-mediated delivery of GDNF plasmid-bearing BPN (GDNF-BPN)
reverses neurodegeneration in the rat 6-OHDA PD model.
Methods
6-OHDA rats were ultrasonically coupled to a 1.15 MHz MRI-compatible
FUS transducer. T2 and T2* pre-treatment scans were obtained to allow
FUS targeting of striatum. Microbubbles (2x105/g) and 100 μg of
~50 nm non-viral GDNF plasmid-bearing BPN (polyethylene glycol/
polyethylenimine) were co-injected i.v. and FUS was applied at 0.6 MPa,
with a 0.5 % duty cycle, for 2 min. Contrast T1 and T2* images allowed
semi-real time confirmation of BBB disruption and safety, respectively.
Efficacy was assessed using an ELISA for GDNF, tyrosine hydroxylase
(TH) and VMAT2 immunolabeling for neural degeneration, HPLC for
dopamine, and behavioral analysis (i.e. apomorphine-induced rotational
asymmetry and forepaw use bias in 6-OHDA rats).
Results
Striatum-targeted delivery of GDNF plasmid-bearing BPN with FUS
led to an ~80 % reduction in apomorphine-induced rotational asym-
metry, eliminated forepaw use bias (Fig. 4a,b), and fully restored TH+
dopaminergic neuron density in both the substantia nigra pars com-
pacta (SNpc) and striatum compared to untreated 6-OHDA rats
(Fig. 4c,d). T2* MRI confirmed safety of the BBB opening approach.
Conclusions
FUS-mediated delivery of systemically circulating non-viral GDNF-BPN
to the striatum of 6-OHDA rats confers a significant behavioral bene-
fit as well as a restoration of TH+ cell number in the nigrostriatal
pathway, indicating cessation and/or reversal of neurodegeneration.
Our studies indicate that delivery of GDNF-BPN with FUS may pro-
vide a powerful, non-invasive and highly tailorable gene therapy ap-
proach to slow or stop the neurodegenerative process in PD.Fig. 4 (abstract A4). Graphs of rotational bias (a) or forepaw use
bias (b) following 6-OHDA injection. (c) Representative images of
TH-immunlolabeled sections through the SNpc. Graphs represent
TH+ cell number in SNpc (d) and staining intensity in the striatum
(e). * p < 0.05A5
Focused ultrasound facilitated gene delivery for neuro-restoration
in Parkinson’s disease mice
Shutao Wang, Oluyemi Olumolade, Tara Kugelman, Vernice Jackson-
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Elisa Konofagou
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Objectives
Over the past ten years consistent effort has been put forward at the
University of Toronto to develop Focused Ultrasound methods for
the treatment of AD. This talk will review the progress made so far.
Methods
The first studies demonstrated safe antibody delivery in AD mouse
model with significant reduction in the plaque load. A follow up
studies with two-photon microscopy showed that blood vessels with
plague deposits showed a different type of opening than vessels in
normal brain but large molecule delivery into the brain was still pos-
sible in these animals. Another study demonstrated that plaque re-
duction can be achieved by just opening the BBB with microbubbles.
Results
The histology revealed stimulation of neurogenesis. Multiple treat-
ments of old mice resulted in memory rescue without any observ-
able side-effects. A follow up study demonstrated that this
neurogenesis was not induced with exposures that did not cause ob-
servable BBB opening even with the presence of the microbubbles.
An ongoing study in large animals has shown that half-brain BBB
opening can be safely and repeatable performed indicating the feasi-
bility of clinical translation.
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Scanning Focused Ultrasound disruption of the blood-brain barrier
as an Alzheimer’s disease therapy
Gerhard Leinenga1, Rebecca Nisbet2, Robert Hatch1, Anneke Van der
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1Clem Jones Centre for Ageing Dementia Research, Queensland Brain
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Objectives
Alzheimer’s disease is the most common form of dementia. Patho-
logical abnormalities in the Alzheimer’s disease brain includes the
presence of amyloid-beta plaques, hyperphosphorylation and intra-
cellular aggregation of tau and synaptic degeneration. Focused ultra-
sound combined with intravenous injection of microbubbles has
been shown to reversibly open the blood-brain-barrier (BBB). By
moving the focus in scanning mode we are able to open the BBB
throughout the brain of a mouse. Here we tested the effects of re-
peated scanning ultrasound (SUS) in APP23 amyloid plaque-bearing
mice, pR5 tau mice and wild-type mice to determine the effects of
SUS on amyloid, tau and dendritic spines.
Methods
The device used was the Therapy Imaging Probe System (TIPS,
Philips Research), which has an eight-element annular array trans-
ducer with a focal length of 80 mm a radius of curvature of 80 mm,
a 33 mm central opening, and a motorized 3D positioning system.
The focus 6 dB size was 1.5 mm x 1.5 mm x 12 mm at 1 MHz. Set-
tings that were applied were 1 MHz centre frequency, 0.7 MPa peak
rarefactional pressure applied outside the skull, 10 Hz pulse repeti-
tion frequency, 10 ms pulse length and 10 % duty cycle immediately
after retroorbital injection of in-house made microbubbles. APP23
Journal of Therapeutic Ultrasound 2016, 4(Suppl 1):31 Page 4 of 113mice that accumulate amyloid beta, pR5 mice that overexpress FTD-
mutant tau, and wild-type C57Bl/6 mice were treated weekly by
scanning ultrasound (SUS) for periods of 4 to 7 weeks.
Results
In APP23 mice we used repeated scanning ultrasound (SUS) treat-
ments of the mouse brain to remove amyloid-beta. Spinning disk
confocal microscopy revealed extensive internalization of Abeta into
the lysosomes of activated microglia in mouse brains subjected to
SUS. Plaque burden was reduced in SUS-treated AD mice compared
to sham-treated animals. Treated AD mice also displayed improved
performance on three memory tasks.
In PR5 mice we investigated the efficacy of a novel tau isoform-
specific single chain antibody fragment, RNX, delivered by passive
immunization in the P301L human tau transgenic pR5 mouse model.
When administration of RNX was combined with scanning ultrasound
(SUS), RNX delivery into the brain and uptake by neurons were mark-
edly increased, as were reductions in tau phosphorylation and
anxiety-like behavior.
In wild-type mice we investigated the effects of SUS on neuronal ex-
citability and morphology. We performed patch-clamp recordings
from hippocampal CA1 pyramidal neurons in wild-type mice 2 and
24 hours after a single SUS treatment, and one-week and three
months after six weekly SUS treatments. No change in CA1 neuronal
excitability was observed compared to sham-treated neurons at any
time-point. Multiple SUS treatments had the effect of preventing the
loss of CA1 synapses that occurred in sham-treated neurons.
Conclusions
We show that scanning Focused Ultrasound disruption of the BBB
has multiple biological effects in the brain which make it an attract-
ive candidate for an Alzheimer disease therapy. SUS reduced plaque
burden and amyloid-beta levels in APP23 amyloid mice, through acti-
vation of microglia, and improved performance on tests of memory
function. In pR5 tau mice SUS alone reduced hyperphosphorylation
of tau, and enhanced the delivery of anti-tau antibodies resulting in
improved reductions in pathology and behavioral abnormalities. In
wild-type mice SUS was shown to have no effect on the firing of hip-
pocampal neurons or their morphology, but prevented spine loss at
3 months after six weekly SUS treatments. If these effects on Abeta
and tau pathology, and dendritic morphology are recapitulated in
human patients SUS may emerge as a promising AD therapy.
A8
Scanning ultrasound as a treatment tool of proteinopathies
including Alzheimer’s disease
Jürgen Götz1, Rebecca Nisbet1, Ann Van der Jeugd1, Harrison Evans1,
Gerhard Leinenga2
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Objectives
Neurological disorders constitute a substantial social and economic
burden, as they cause considerable ill health but few direct deaths.
Treatment strategies for neurodegenerative diseases are hampered
by the fact that the Blood-Brain Barrier (BBB) establishes an efficient
barrier for therapeutic agents (Leinenga et al., Nature Reviews Neur-
ology 2016). We have recently shown that scanning ultrasound (SUS)
allows microglial-mediated clearance of extracellularly deposited
amyloid-beta in APP mutant APP23 mice and restores memory func-
tions in three cognitive tests to wild-type levels, in the absence of
overt damage to the brain (Leinenga and Götz, Science Translational
Medicine 2015) However, it had not been determined whether SUS
treatment reduces the intracellular tau pathology that together with
amyloid deposition characterizes Alzheimer’s disease.
Methods
We investigated the efficacy of a novel tau-specific single chain anti-
body fragment, delivered by passive immunization in the human tau
transgenic pR5 mouse model, a model of the tau pathology of
Alzheimer’s disease (Götz et al., Science 2001). To further assess theefficacy and drug-delivering ability of SUS, we established four ex-
perimental groups, using the novel anti-tau antibody that was
injected weekly over four weeks, either on its own, or together with
SUS. A third group used SUS only, and a fourth was the anaesthesia
control group. The mice were analysed on the elevated plus maze,
histologically and biochemically. Furthermore, uptake of the antibody
by the brain was determine using fluorescently labelled single-chain
antibody fragments.
Results
A histological and biochemical analysis of the pR5 tau transgenic
mice revealed that SUS as well as the employed antibody amelio-
rated the tau pathology that characterizes the pR5 mice. In addition,
the anxiety-like behaviour that characterizes pR5 mice was signifi-
cantly reduced. We furthermore found enhanced delivery of the anti-
body using SUS yielding a synergistic therapeutic effect as
determined by histology and using the elevated plus maze.
Conclusions
Our study suggests that SUS is a method that benefits diseases with
protein aggregates more generally, whether they are intra- or extra-
cellular. The therapeutic delivery combined with SUS could offer sig-
nificant clinical benefits for the treatment of patients with
Alzheimer’s disease and related tauopathies. Considering that the
yearly costs of passive immunotherapy for AD is expected to exceed
$25,000 per patient, combining SUS with antibody delivery could
drastically reduce these costs.
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Objectives
FUS mediated Blood-Brain Barrier disruption (BBBD) can enable even
large therapeutics such as stem cells to enter brain from the blood-
stream and could be a major advance in cell delivery over current in-
vasive methods of brain injection. The efficiency of cellular entry
after FUS mediated BBBD alone however is low. We hypothesized
that this process could be enhanced by combining it with a comple-
mentary strategy termed magnetic targeting. Stem cells can be safely
loaded with super-paramagnetic iron oxide nanoparticles (SPION) in
culture, allowing cells to be attracted by an external magnet. Our
previous study showed SPION loaded stem cells to have enhanced
brain retention near a magnet on the skull in a rat model of trau-
matic brain injury, where BBBD also occurs. The goal of our current
project was to determine if magnetic attraction of SPION loaded
stem cells would also enhance their delivery to brain after FUS medi-
ated BBBD.
Methods
With a small animal MRI guided FUS device (Image Guided Therapy,
IGT and 7 T Bruker MRI), we sonicated young adult rats (~120 g) with
both radiologic (enhancement of the target region with gadolinium
on post-sonication TI MRI), and histologic (staining with Evans’ blue
dye) evidence of BBBD, without tissue damage or hemorrhage.
Confirmation of the cells within brain as those injected was per-
formed by staining with Perl’s reagent for iron and by immuno-
histochemistry with a human specific antigen. The procedure was
then combined with the application of a powerful magnet to the
head directly after IV injection of hNPCs.
Results
With BBBD alone human neuro-progenitor cells (hNPCs) loaded with
SPION were observed in rat brain after intravenous (IV) injection dir-
ectly after sonication only within the treated regions. To demonstrate
the effect of magnetic attraction, we injected equal numbers of
SPION and non-SPION labeled cells, where each cell type was labeled
with a different fluorophore. In animals that had FUS mediated BBBD
Journal of Therapeutic Ultrasound 2016, 4(Suppl 1):31 Page 5 of 113followed by a magnet applied to the head, significantly greater num-
bers of SPION labeled cells were observed compared to the non-
labeled cells. This result was most pronounced in regions of the brain
close to the skull (cerebral cortex) and magnet surface. More power-
ful magnets including magnetic arrays resulted in more effective re-
tention of SPION labeled cells in even deeper brain regions such as
the striatum. There, 90 % of hNPCs observed contained SPIONs com-
pared to 60-70 % with a less powerful magnet.
Conclusions
These results demonstrate that the use of magnetic attraction can
substantially enhance delivery of stem cells after BBBD. In prior pub-
lished work, stem cells were delivered to brain after FUS mediated
BBBD using cells injected directly into the carotid artery. In an effort
to accomplish this goal in a safer and less invasive manner, our study
utilized IV cell injection (tail vein), supporting the view that the com-
bination of FUS mediated BBBD and magnetic attraction can allow
stem cells to enter brain with a minimally invasive strategy.Fig. 5 (abstract A10). BBB opening and fluorescence delivery: T1-w
MRI showing BBB opening at pressures (a) 450, (b) 600 and (c) 750
kPa. Fluorescence delivery (green) and DAPI (blue) in two horizontal
sections of mouse brains sonicated at (d) 600 and (e) 750 kPaA10
Fluorescent lipid microbubbles for targeted brain drug delivery
through the Focused Ultrasound-induced blood-brain barrier
opening in vivo
Carlos Sierra Sanchez, Camilo Acosta, Cherry Chen, Shih-Ying Wu,
Maria Eleni (Marilena) Karakatsani, Elisa Konofagou
Columbia University, New York, New York, USA
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Objectives
Focused ultrasound (FUS) in the presence of lipid microbubbles can
induce non-invasive, transient and reversible Blood-Brain Barrier
(BBB) opening. This study entailed assessment of the feasibility of
fluorescently loaded microbubbles, labeled with the fluorophore 5-
dodecanoylaminfluorescein (C-12), as a vector for targeted brain drug
delivery. Compared to prior studies by our group, where
fluorescently-labeled dextrans were co-administered with microbub-
bles, this new methodology improves the safety and allows a more
targeted drug delivery with potentially lower toxicity, avoiding sys-
temic exposure. The main objective was thus to determine feasibility
and safety of using the loaded microbubbles as carriers towards tar-
geted brain drug delivery with simultaneous cavitation monitoring.
Methods
A spherical, single-element, FUS transducer (center frequency
1.5 MHz) was used. A pulse-echo transducer (center frequency
10 MHz), confocally mounted at the center of the FUS transducer,
was utilized for passive cavitation detection (PCD). FUS (pulse length
10,000 cycles; pulse repetition frequency 5 Hz; duration 5 minutes;
acoustic pressure 450-750 kPa) targeted mouse brains in vivo, in
combination with fluorescent microbubbles for C-12 delivery, which
was evaluated by in vivo transcranial PCD, through the quantification
of inertial (ICD) and stable harmonic (SCDh) and ultraharmonic
(SCDu) cavitation doses at 30, 60 and 300 s; together with ex vivo
fluorescence imaging. The BBB opening was verified using in vivo T1-
w Magnetic Resonance Imaging (MRI). The safety of this technique
was assessed through ex vivo hematoxylin & eosin staining for
microhemorrhage detection and immunohistochemistry (Iba-1 for
microglial activation) together with in vivo T2-w MRI for edema
assessment.
Results
Successful targeted C-12 delivery was achieved at 600 and 750 kPa
in six out of 14 cases (Fig. 5). Comparison of ICD, SCDh and SCDu be-
tween successful and unsuccessful cases yielded a statistically signifi-
cant linear relationship between the successful targeted drug
delivery and CD and specific thresholds for efficient delivery were
identified.
No edema was detected in mice sacrificed on Day 0 but edema ap-
peared on Day 1 on mice sacrificed on Day 7. In all cases cases (ex-
cept one) it was repaired within a week. Microhemorrhages were
observed after sonication in some cases but were also cleared within
the first week. However, a higher number of cell nuclei was observed
in the sonicated region compared to the unsonicated side in somemice survived up to one week after opening. Iba-1 immunohisto-
chemistry also showed microglial activation.
Conclusions
FUS was applied in conjunction with fluorescent microbubbles and,
for the first time, the existence of CD thresholds for assessing suc-
cessful drug delivery was defined. For CD above these thresholds,
significant fluorescent enhancement was observed, demonstrating C-
12 targeted delivery. One week after sonication, edema was cleared
out but microglial activation was observed in certain cases. There-
fore, this study indicates the feasibility and safety of a new method-
ology of FUS-induced BBB opening for targeted albeit potentially
riskier brain drug delivery and provides a platform for predicting suc-
cessful delivery via PCD.A11
Ultrasound-mediated delivery of gadolinium and fluorescent–
labelled liposomes through the Blood-Brain Barrier
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Objectives
The main objectives of this study were: 1) to examine whether gado-
linium and fluorescent labelled liposomes can extravasate into the
brain parenchyma after ultrasound mediated Blood-Brain Barrier dis-
ruptions; and 2) to test whether extravasated liposomes were size
dependent or not. The liposomes were labelled with gadolinium (Gd)
and fluorophore, thus enabling detection of extravasated liposomes
via MRI in vivo and fluorescence methods in tissue, respectively.
Methods
Liposomes labelled with gadolinium and fluorophore were prepared
using lipid film hydration and extrusion to two different sizes; ~70-
85 nm and ~ 130-150 nm. Animals were divided into two different
groups based on the use of particle sizes; group A (~70-85 nm) and
group B (~130-150 nm). Focused ultrasound mediated Blood-Brain
Barrier disruption (BBBD) was produced in one hemisphere in 15
Fig. 6 (abstract A12). pFUS +MB elicits a transient
microenvironmental response in the brain that reflects a
sterile inflammation
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(0.69 MHz at 0.42 MPa) were performed in two locations combine
with Definity (10 μl/kg). Acoustic emissions were recorded during
FUS. T1-weighted contrast enhanced and T2*-weighted MRI were
used to confirm Gd leakage and damage detection respectively. Mice
were euthanized 5-24 hours after FUS and post-process for fluores-
cence measurement.
Results
In T1-weighted contrast enhanced MRI, gadolinium-leakage was able
to detect on sonicated area at 5-24 after FUS but not on non-
sonicated area (control). Detection of fluorescence signal from brain
tissue homogenates confirm the liposomal particles extravasation on
sonicated locations. On group A, gadolinium and fluorescence signal
intensities on sonicated locations were increased by 26 % and 62 %
respectively as compared with control and signal enhancement were
statistically significant compared with control ( p = 0.017 and p = 0.02
respectively, two-tailed, paired ttest). On group B, gadolinium and
fluorescence signal intensities on sonicated locations were increased
by 24 % and 40 % respectively as compared with control. Compari-
son of fluorescence signal intensities between two groups on soni-
cated location was statically significant whereas it was not significant
on controls (p < 0.05 and p = 0.07 respectively, one-tailed unpaired
ttest).
Conclusions
Overall, this work demonstrates that ultrasound can deliver upto ~
150 nm liposomes that labelled with gadolinium and fluorophore
through the Blood-Brain Barrier. The results indicate that the extrava-
sation of liposomes were size dependent.
A12
Sterile inflammatory response (SIR) in the brain following exposure
to low intensity pulsed Focused Ultrasound and microbubble
infusion
Zsofia Kovacs1, Saejeong Kim1, Neekita Jikaria1, Farhan Qureshi2,
Michele Bresler2, Joseph Frank2
1National Institutes of Health, Bethesda, Maryland, USA; 2National
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Objectives
Magnetic Resonance Imaging (MRI)-guided pulsed Focused Ultra-
sound (pFUS) in combination with systemic injection of microbubbles
(MB) is being advocated to increase drug or gene delivery by causing
localized Blood-Brain Barrier (BBB) disruption (D). The objective of
this study is to investigate the molecular and cellular responses fol-
lowing pFUS +MB associated with BBBD in the rat brain.
Methods
Female Sprague Dawley rats (<200 g) were sonicated at 0.3 MPa
acoustic pressures with 10 ms burst length and 1 % duty cycle (9
focal points, 120 sec/9 focal points) using a single-element spherical
FUS transducer (589.636 kHz; FUS Instruments). 100 μl Optison™ MB
(GE Healthcare) was administered intravenously. Gadofosveset-
enhanced T1w images were obtained with a 3.0 T MRI (Phillips).
Proteomic and mRNA expression in the brain following pFUS +MB
were analyzed with ELISA, Western blot, quantitative real-time PCR or
immunofluorescent staining (Fig. 6a). Proteomics were normalized to
sham and statistical analysis was performed by one-way ANOVA cor-
rected for multiple comparisons. Rats were also injected with 8 mg/
kg Rhodamine encapsulated magnetic polymers (MicroTRACK™; Bio-
Pal) 3 days prior to sonication to label splenic macrophages (CD68)
to monitor tropism to the brain.
Results
Post contrast T1w MRI and histology showed open BBB without evi-
dence of microhemorrhage. Within 5 minutes following sonication,
increased expression of pro-inflammatory and anti-inflammatory cy-
tokines, chemokines and trophic factors (CCTF) was detected in the
parenchyma lasting up to 24 hours (Fig. 6b). Increases in heat shock
protein 70 (HSP70), tumor necrosis alpha (TNFa), and interleukin (IL)
1a, 1b and 18 consistent with damage associated molecular patterns
(DMAP)1 and activation of nuclear factor kappa-light-chain-enhancer
of activated B cells (NFkB) inflammatory pathways were observedwith SIR to injury2 (Fig. 6b). NFkB pathway-related gene activation
along with anti-apoptotic genes, immune cell chemoattractants,
selectins, and cell adhesion molecules showed significant (>2fold) in-
creases in mRNA expression (Fig. 6c). Histological analysis showed
significant increases (p < 0.05) in the following: number of TUNEL
positive cells within 6 hrs, GFAP and Iba1 staining for activated astro-
cytes and microglia (1-24 hrs) and increase of ICAM up to 24 hrs post
sonication. We also detected a >4 fold greater (p < 0.05) CD68 posi-
tive cells on day 6 post sonication containing intracellular fluorescent
beads within the pFUS +MB treated hemisphere compared to
contralateral hemisphere.
Conclusions
The temporal molecular response to pFUS +MB is indicative of SIR2
originating from the parenchyma. The pattern of cytokines immedi-
ately after pFUS +MB is initiated by cellular release of DAMPs and
TNFa observed with mild cerebral trauma or ischemia [1,2]. Increases
in monocyte chemoattractant protein (MCP-1), vascular endothelial
growth factors (VEGF), stromal derived factor 1 (SDF-1), erythropoi-
etin (EPO) and brain derived neurotropic factor (BDNF) are associated
with BBBD stimulating angiogenesis, neurogenesis and stem cell mi-
gration observed with ischemia and trauma. These results indicate
that pFUS +MB rapidly affects the cerebral vasculature as evident by
BBBD in addition to the shockwave from MB collapse that induces
mild stress within various cellular elements in the parenchyma indu-
cing a SIR.
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Objectives
Transcranial MR-guided Focused Ultrasound (tcMRgFUS) applied
within a small central brain volume has achieved excellent outcomes
in treatment of movement disorders (Elias NEJM 2013). Although
Table 1 (abstract A13). MR scan parameters. TR – Repetition time, TE –
Echo time, FA – Flip angle, BW – Bandwidth (readout), FOV – Field of









FOV (mm) Matrix Res. (mm) Tacq
(s)
GRE 9.2 4 12 15.63 240x240x48 192x96x16 1.25x2.50x3.00 14.3
EPI 52 14.4 30 250 220x220x145 192x192x50 1.15x1.15x2.90 62
Fig. 7 (abstract A13). Three orthogonal views of GRE temperature
maps overlaid on magnitude image
Fig. 8 (abstract A13). Temporal evolution of heating comparing
focal spot to far-field next to petrous bone
Journal of Therapeutic Ultrasound 2016, 4(Suppl 1):31 Page 7 of 113transducers used in tcMRgFUS have been designed with large aper-
tures to spread the beam energy over as much skull as possible to
reduce skull and cortex heating, currently used MR temperature im-
aging (MRTI) methods cannot monitor the temperature increase over
the entire insonified brain volume. Instead, temperatures are typically
measured in one 2D slice, leaving the majority of the insonified brain
volume unmonitored. We have previously developed and published
methods to achieve fully 3D MRTI covering the entire insonified brain
with good spatial and temporal resolution (Todd MRM 2009/2010)
but the techniques have not been evaluated on clinical tcMRgFUS
systems. In this work-in-progress study we demonstrate the value of
volumetric MRTI with two different pulse sequences applied during
heating on a clinical tcMRgFUS system.
Methods
PRF MRTI was performed with a product 3D gradient recalled
echo (GRE) pulse sequence and a custom-implemented 3D GRE
segmented echo planar imaging (EPI) pulse sequence on a 3 T
MRI (Discovery 750 T, GEMS). tcFUS heatings were performed in
an ex vivo human skull filled with tissue-mimicking gel (ATS
Laboratories) in a clinical tcMRgFUS system (ExAblate Neuro,
Insightec).
Pulse sequences parameters are listed in Table 1. All data were
zero filled interpolated (ZFI) to 1-mm isotropic spacing (GRE data
additionally ZFI to 0.5-mm spacing). The skull was physically posi-
tioned in the FUS system, and the focus electronically steered, to
target deep brain-structures located outside the normal treatment
envelope. FUS sonications were applied at 940 W for 30/60 s
while imaging with the GRE/EPI sequences, respectively. The EPI
sequence used an echotrain length of 16 with bi-polar readout
gradient, sampling 192 phase encodings in each direction, so that
full “positive only” and “negative only” images could be
reconstructed.
k-space data were retrospectively down sampled by a factor of R = 4
and 8 (split into multiple time-frames without throwing any data
away) for the GRE and EPI experiments, respectively, giving acquisi-
tions times of 3.6 and 7.8 s, and reconstructed with a temporally con-
strained reconstruction algorithm (Todd MRM 2009).
Results
Figure 7 shows three orthogonal views of temperature maps overlaid
on magnitude images in the GRE experiment. Attempting to focus
this far outside the normal treatment envelope results in severe near-
and far-field heating. Heating on both the cortex and in the far-field
along the petrous bone is visible. In Fig. 8 the temperature evolution
at the focal spot is compared to that near the petrous bone. The gel
near the bone shows a delayed and greater maximum temperature
compared to the focus.
Three orthogonal views of the larger FOV in the segmented EPI ex-
periment are shown in Fig. 9. Heating along large parts of the cortex
can be seen. In the underlying magnitude images it can be seen that
the EPI sequence experiences more artifacts than the GRE sequence.
The focal spot position (evaluated as the temperature center-of-
mass) was tracked as a function of time during the heating in the
GRE data ZFI to 0.5 mm (data not shown). The focal spot did not ex-
perience any shift to within the finer ZFI spacing.
Conclusions
This study shows that volumetric thermometry over a FOV cover-
ing the focal spot and the skull base can be achieved with read-
ily available pulse sequences. With custom implemented pulse
sequences the fully insonified FOV (from skull cap to skull base)
can be covered. Even though the reconstruction is done retro-
spectively, the described methods are valuable as research tools
in e.g. treatment envelope evaluations. By utilizing 3D imaging
ZFI can be performed in all directions to minimize partial volume
effects, and very accurate dynamic focal spot localization can be
performed.
Future studies will compare the accuracy and precision of the de-
scribed methods to standard 2D MR thermometry. Experimentscomparing 3D MRTI with fiber optic probe measurements at poten-
tial target positions outside the currently available treatment enve-
lope will also be performed (Monteith JNS 2016).
Fig. 9 (abstract A13). Three orthogonal views of EPI temperature
maps overlaid on magnitude image
Fig. 10 (abstract A14). Comparison of MR thermometry images
when phase encoding is S/I. The single echo thermometry (a,b)
demonstrates numerous ghosting artifacts (yellow arrows) that are
not seen in ME thermometry (c,d). (a,b,d) are from the same patient
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Objectives
The choice of receive bandwidth in MR thermometry acquisitions
needs to balance two competing choices. Low bandwidths improve
SNR, while high bandwidths reduce spatial shift of the hotspot due
to the temperature off-resonance. The low bandwidth MR thermom-
etry sequence in use in essential tremor MRgFUS treatments required
repeated swapping of phase and frequency directions since the loca-
tion of the hotspot could only be trusted in the phase encode
direction.
A solution is to use multiple high bandwidth acquisitions, which
when averaged, regain much of the SNR of the lower bandwidth
image. Such a multiecho sequence has recently become available
for clinical use. The purpose of this work was to compare the
performance of the multi-echo (ME) MR thermometry to the sin-
gle echo (SE) MR thermometry in clinical treatments of essential
tremor.
Methods
Fifteen patients were treated for essential tremor, 12 with only single
echo thermometry (TE and BW/pix = 12.8 and 44), 2 with only multi-
echo thermometry (TE and BW/pix = 3, 8, 13, 18, 22 and 278), and 1
with both sequences. All other image parameters remained the
same, including TR = 100. All thermometry images were processed
offline in Matlab with a single baseline subtraction (α = -0.00909),
followed by referenceless processing for constant and linear terms.
The multi-echo thermometry was further processed with a phase un-
wrapping algorithm in the TE dimension. The multiple echoes were
then combined with a weighting by the square of the temperature
SNR of each image.
Results
The decrease in sampling time for the ME thermometry dictates a
theoretical decrease in temperature SNR of only 11 % due to the de-
crease in sampling time alone. In the one patient that had both se-
quences in the same scan planes for two sonications, there was a
9 % decrease in SNR in the ME thermometry as measured in the
frame used for the referenceless processing, comparing well with
theory.A review of all sonications with ME thermometry when phase encod-
ing was S/I revealed much reduced artifacts over SE thermometry
with phase encoding in the S/I direction. Example images are pro-
vided in Fig. 10. The region of interest measurement indicated a
30 % improvement in temperature SNR for the ME over the single
echo, due to this artifact reduction.
The spatial shifts should theoretically be reduced by a factor of 6.3 in
the ME thermometry, as compared to the SE thermometry, due to
the increase in receive BW. For example, a 23 °C temperature rise
would result in a 0.6 mm shift with the single echo, and only a
0.1 mm shift with the multi-echo.
Conclusions
When phase encoding is S/I, multi-echo thermometry is superior
to single echo thermometry due to a reduction in ghosting arti-
facts and spatial shifts. Alignment of the focal spot should not re-
quire swapping phase and frequency directions. Future work will
include a prospective study to verify this. In the other directions,
ME thermometry is comparable to SE thermometry with the re-
duction of spatial shifts coming with a loss of temperature SNR
of about 10 %.A15
High-resolution whole-brain MR thermometry with a 3D EPI stack-
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Objectives
Real-time whole-brain MR thermometry is needed for transcranial
MR-guided Focused Ultrasound to accurately track rapid heating at
the focus and to monitor for unsafe heating in the near- and far-
field. Previous efforts to meet this need have been based on 3D seg-
mented echo planar imaging (EPI) and spiral MR readouts (Fielden
et al., 2014). Here, we propose a 3D EPI stack-of-stars temperature
mapping pulse sequence that enables greater volume coverage than
has been reported with previous approaches. The sequence allows
flexible adjustment of the scan acceleration factor and does not re-
quire a high density of receive coils for high frame rate thermometry.
Methods
Readout Trajectory: Fig. 11 shows the proposed readout trajectory.
Each TR comprises a 2D EPI plane that is frequency-encoded in the
axial (x-y) and phase-encoded in the slice (z) dimensions. The plane
is rotated between TRs by 111.25 degrees to sample a golden angle
Fig. 12 (abstract A15). Brain images acquired with the proposed
sequence. The sagittal and lower axial slice images contain
distortions and dropout in regions with large frequency offsets
(white arrows), which are diminished when multiple shots are used
to shorten each readout
Fig. 13 (abstract A15). Phantom temperature map reconstructions
(a) and hot spot temperature curves (b) at three acceleration factors.
Significant aliasing does not appear until the scan is accelerated by
14.1x. There is good reference standard agreement at
all accelerations
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Achieva 3 Tesla scanner with parameters: field-of-view = 28.0 x 28.0 x
11.9 cm, 43 slices, in-plane resolution = 1.50 x 1.50 x 2.75 mm, 17 ms
TE/45 ms TR, 14.5° flip angle, spectrally-selective fat suppression.
In vivo Experiment: To confirm the achievable brain volume
coverage and image quality, with local IRB approval, brain images
in a healthy volunteer were acquired without heating using the
pulse sequence with one, two, and three interleaved shots and
with an 8-channel receive coil array. Fully-sampled images were
reconstructed using the density-compensated conjugate gradient
method.
Phantom Heating Experiment: A tissue-mimicking gel phantom
was sonicated using a clinical MR-HIFU system (Philips Sonalleve)
operated at 1.2 MHz and 80 W for 12 s, while scanning with the
proposed sequence with one shot and with 5 abdominal receive
coils. Temperature maps were reconstructed in one second incre-
ments using the k-space hybrid method at three scan acceler-
ation factors.
Results
In vivo Results: Distortions and signal dropouts caused by off reson-
ance are visible in the sagittal and lower axial single-shot brain im-
ages in Fig. 12 (white arrows). The distortions can be reduced by
increasing the number of EPI shots per angle, which increases the
pixel bandwidth in z. An axial slice positioned for monitoring Fo-
cused Ultrasound thalamotomy (red arrow) is also shown, which con-
tains no visible distortions at any multishot factor.
Phantom Heating Results: Fig. 13a shows reconstructed sagittal
and axial temperature maps through the middle of the phantom
at peak heat. Significant temperature aliasing does not appear
until the scan is accelerated by a factor of 14.1 or a 1 second
window width. The hotspot temperature curve plots in Fig. 13b
show that the reconstructed temperatures all coincide, though
the 14.1x curve appears noisier. Importantly, at all acceleration
factors, there is agreement with a hotspot measurement obtained
by a 2D multislice Cartesian EPI temperature mapping pulse se-
quence (7 slices, same in-plane resolution) which was used as a
reference standard.
A video of the entire sonication monitored using this pulse sequence
can be viewed at https://www.youtube.com/watch?v=z3cVXjkgyLg.
Conclusions
A 3D EPI stack-of-stars temperature mapping pulse sequence was
proposed and validated against a 2D multislice Cartesian EPI
temperature mapping pulse sequence. The sequence enables fine
spatiotemporal resolution with large volume coverage, without re-
quiring temporally-regularized reconstruction or a large number of
receive coils.Fig. 11 (abstract A15). Illustration of the 3D k-space trajectory. A
2D EPI plane is scanned each TR and rotated by 111.25 degrees
between TRs to sample a 3D volume. Scan acceleration is achieved
by using a small number of consecutive rotated planes/TRs
for reconstructionA16
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Objectives
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Results
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Conclusions
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Tissue stiffness imaging with interleaved multiple-point MR-ARFI
Dennis Parker, Joshua de Bever, Henrik Odéen, Allison Payne, Douglas
Christensen
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Objectives
Although Focused Ultrasound (FUS) has the potential to treat a num-
ber of pathologies the methods used to guide treatment are still
Fig. 14 (abstract A17). a Individual images, b Composite
displacement, c simultaneous heating
Fig. 15 (abstract A17). Ghosting (a) is corrected by navigator
echoes (b) allowing clean mpMR-ARFI displacement
measurement (c,d)
Fig. 16 (abstract A17). mpMR-ARFI displacement measurements in
an excised pig brain before (a) and after (c) MRgFUS ablation with
estimated cumulative dose in CEM (b)
Journal of Therapeutic Ultrasound 2016, 4(Suppl 1):31 Page 10 of 113limited in the ability to identify effective treatment endpoints.
Changes in MRI parameters such as proton density and T1 and T2 re-
laxation times may result from reversible edema instead of tissue
death. While dynamic contrast enhanced and late Gd-enhanced MRI
are more specific, Gd contrast cannot be administered multiple times
during a procedure to monitor treatment progression. MRI acoustic
radiation force impulse imaging (MR-ARFI) can monitor tissue stiff-
ness, but the acquisition is relatively slow, and must be repeated to
measure tissue displacement at more than a single point [1]. The
purpose of this work was to develop an efficient method to use MR-
ARFI to measure tissue displacement volumetrically with an array of
points as a first step towards monitoring tissue stiffness changes dur-
ing MRgFUS procedures.
Methods
A 3D segmented gradient echo (GRE) echo-planar pulse sequence,
designed to simultaneously measure tissue displacement with MR-
ARFI and the corresponding tissue heating [2–5], was further modi-
fied to allow interleaved acquisition of multiple point MR-ARFI
(mpMR-ARFI) volumes. Phase change due to displacement was sepa-
rated from that due to temperature by complex subtraction of an in-
terleaved volume acquired with no FUS applied. Temperature was
obtained using the proton resonance frequency method with a refer-
enceless background phase subtraction [6].
Experiments were performed in a gelatin phantom and excised pig
brain on 3 T MRI scanners (Siemens Tim Trio and PrismaFit). Pulse se-
quence parameters were: TR/TE = 73/43 ms, FA = 30°, readout band-
width = 752 Hz/pixel, echotrain length = 7, FOV = 160x114x55mm,
matrix = 128x91x22 giving voxel dimensions of 1.25x1.25x2.5 mm be-
fore zero filled-interpolation. Bipolar motion-encoding gradients
(MEG) of 15 ms duration (each bipolar lobe) were applied prior to
signal readout. Ultrasound pulses of 50 acoustic watts were applied
during the second 15 ms bipolar MEG lobe. Navigator echoes were
used to measure and compensate for B0 field drift due to gradient
heating caused by high MEG strength and duty cycle. The same navi-
gators echoes can be used for respiratory correction in vivo [7].
Results
Results from a13-point mpMR-ARFI acquisition in a gelatin phantom
using the Siemens Tim Trio and MEG = 20mT/m are given in Fig. 14.
An example cropped single slice from 10 of the 13 acquired displace-
ment volumes is shown in Fig. 14a with a cropped slice of the
mpMR-ARFI composite of all 13 displacement volumes shown in
Fig. 14b. The corresponding temperature increase measured during
the mpMR-ARFI acquisition is shown in Fig. 14c and was relatively
low (<3 °C). (For all mpMR-ARFI images, point separation is 5 mm).
Figure 15 shows the improved image quality achieved by the phase-
navigator correction in mpMR-ARFI measurements obtained using a
PrismaFit 3 T MRI scanner with MEG = 40 mT/m. The ghosting artifact
in Fig. 15a due to B0 field drift caused by high amplitude (40mT/m)
and duty cycle (40 %) MEG gradients during mpMR-ARFI acquisition.
After correction (Fig. 15b) mpMR-ARFI displacement images have
negligible artifact.
Results of the displacement measured in excised pig brain using the
Siemens PrismaFit 3 T MRI scanner and MEG = 40 are shown in Fig. 16
before (Fig. 16a) and after (Fig. 16c) FUS ablation. An estimate of the
cumulative thermal dose is shown in Fig. 16b. Note the decreased
displacement at central point.
Conclusions
Measuring tissue stiffness (displacement as a function of ultra-
sound intensity) and changes in displacement before, during, and
after the procedure provides the unique potential to remotely
palpate the ablated volume to monitor the formation of lesions
created with MRgFUS. It will also provide a crucially needed as-
sessment of tissue change in regions of fat where conventional
MR thermometry fails.
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Fig. 17 (abstract A18). In vitro experimental setup for mimicking
BBB opening
Fig. 18 (abstract A18). Ultraharmonics ratio (3/2 to 15/2 over 1/2)
recorded during in vitro thermal ablation
Table 2 (abstract A18). ultraharmonic (5/2 over 1/2) and harmonic







in vitro Reference: no
skull
-5 1
Monkey skull -8 -21
Human skull -35 -26
in vivo Macaque -13 no signal
Thermal necrosis
(US only in calf brain)
in vitro Reference: no
skull
-10 -14
Monkey skull -29 -38
Human skull -28 -30
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Cavitation activity may occur during BBB disruption (due to UCA
injections) and also during HIFU treatment due to nucleation
under high negative pressure. The corresponding microbubble ac-
tivity has to be monitored to assess the safety and efficiency of
brain treatments by ultrasound. The purpose of this study is to
binary discriminate the position of microbubbles, inside or out-
side the skull, in order to know whether cavitation occurs in the
brain of the patient or not.
Binary localization is achieved here by taking advantage of the
attenuation properties of the skull. The skull acts indeed as a low
pass filter for acoustic signals. Thus we hypothesize that the har-
monic content of signals from cavitation events could be used as
a binary indicator of their localization: inside or outside the brain
case.
Methods
A wideband Passive Cavitation Detector (PCD) recorded the acoustic
signals from microbubbles activity.
An in vitro setup (Fig. 17) mimics a BBB opening configuration (con-
trast agent flow with 0.6 MPa sonication during 10 ms at focus) or a
thermal ablation (calf brain sample at focus with 3-4 MPa sonication
during 0.3 s at focus). Experiments were performed either with no
skull in place, or with human (6 samples) or monkey (1 sample) skull
in front of the PCD.
In vivo BBB opening were conducted on macaque (900 kHz, 0.6 MPa
at focus) with the same PCD mounted on the monkey head.
The spectra are computed from data recorded by the PCD and reveal
harmonics, subharmonic and ultraharmonics of the excitation fre-
quency (900 kHz in all cases).
The ratio of a high frequency harmonics over a lower frequency har-
monic was then calculated. This ratio is expected to decrease when
the acoustic signal from cavitation activity crosses through the skull.
In order to achieve binary localization, two types of ratio have been
computed: ultraharmonic ratios (e.g. 5/2 over 1/2) and harmonic ra-
tios (e.g. 4 over 2).
Results
The ultraharmonics ratio obtained during in vitro thermal-like
ablation is plotted in Fig. 18. This ratio significantly decreases
when acoustic signal crosses through the skull. Thus a threshold
can be introduced to binary localize cavitation inside/outside
the skull.
Table 2 summarises the results for harmonic ratio 4 over 2 and ultra-
harmonic ratio 5/2 over 1/2 obtained in vitro and in vivo during BBB
opening and thermal necrosis. For BBB opening, neither the sub- nor
the ultraharmonics appears in vivo, probably due to the confinment
of the largest microbubbles by the vasculature. Thankfully in vitro ex-
periments point out that the harmonic ratio remains relevant to bin-
ary localize microbubbles in the human case. Indeed the harmonic
ratio 4 over 2 exhibits a -30 ± 3 dB decrease when crossing through
human skull.
In order to ensure the repeatability of this method, each configur-
ation was statistically investigated by plotting receiver operating
characteristics (ROC) curves. These plots (Fig. 19) illustrate the per-
formance of this approach. Except for in vivo BBB opening on mon-
key, ROC curves demonstrate that a sensitivity and a specificity
which are simultaneously nearly 100 % can be obtained for the bin-
ary localization of cavitation activity.
Conclusions
This preliminary study, mainly done in vitro, shows that a low-cost
and easy-to-use PCD can binary localize cavitation activity inside/out-
side the skull using the filtrating effect of the skull on the harmonic
content of the spectra. The statistical study shows that the method is
able to localize microbubble activity inside or outside the skull with
high sensibility and high sensitivity. We look forward to testing ex-
tensively this technique in vivo for both BBB opening and thermal
necrosis.
Fig. 19 (abstract A18). Receiver operating characteristics for
ultraharmonic (5/2 over 1/2) ratio and harmonic ratio (4 over 2)
during thermal ablation and BBB opening
Fig. 20 (abstract A19). a Temperature in the third temperature
image (*) b does not always rise monotonically with power. c The
distance from ACPC plane to the top and bottom edges of zone 2
were measured on images thresholded at the zone 1 signal intensity
Fig. 21 (abstract A19). a The lesion top edge is moving superior to
the ACPC plane with increasing sonication number. b As the lesion
is moving out of the measured scan plane, the temperature is
increasingly underestimated, giving rise to a temperature inflection
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Objectives
During tcMRgFUS, power levels are progressively increased to align,
verify treatment location, and create a durable ablation. It is pre-
dicted that the measured temperature at the focus for a consistent
timepoint will increase monotonically with power. However, the
temperature rise is often observed to actually decrease with increas-
ing power, creating an inflection in the peak temperature vs. power
graph (Fig. 20). The purpose of this work was to show this behavior
in the temperature rise is correlated with a lack of alignment be-
tween the thermal lesion and the monitored scan plane.
Methods
Fifteen ET datasets were included in this study. Post-treatment 3D
T2-weighted FSE images (FOV 24 cm, matrix 320x320, slice thickness
1 mm) were thresholded at the signal intensity of zone 1 (Fig. 20).
Measurements from the targeted ACPC plane to the top and bottom
edges of zone 2 were made in the sagittal plane.
MR thermometry (TE/TR = 12.8/100 (n = 13); TE/TR = 3,8,13,18,22/100,
(n = 2)) was processed with a single baseline subtraction (α = -0.00909),
followed by referenceless processing for constant and linear
terms. The maximum temperature of the third time point (k-
space center 8.8 s after sonication initiation) in the axial scan
plane was plotted vs. power. This time point was chosen because
all sonications were at least 10s in duration. The number of soni-
cations after any inflection was noted.
In 12 cases, temperature-power curves from early sonications in the
axial scan plane were extrapolated to higher power levels. The
amount that the measured temperature was below the estimated
temperature was measured.
Results
The results are shown in Fig. 21. While the distance from the treat-
ment plane to the inferior aspect of the lesion remains essentially
constant, the distance from the treatment plane to the superior as-
pect of the lesion increases with number of sonications after inflec-
tion. While it is expected that multiple sonications at the same
location may increase lesion size, this data demonstrates that lesion
size increases preferentially in the direction of the transducer as we
increase sonications after inflection.
The movement of the lesion superiorly from the AC-PC plane is cor-
related with the difference between the actual and estimated
temperature (✰). Although this was quantitated only in the axial
scan plane, the inflection was seen in all three scan planes. Prior
work demonstrated that the lesion is double oblique (the superioraspect of the lesion is posterior and medial); therefore, movement of
the focal spot towards the effective transducer aperture moves it also
out of the monitored sagittal and coronal scan planes.
Conclusions
One interpretation of this data is that an increase in the acoustic ab-
sorption effectively shields the focal spot, with subsequent hotspots
located closer to the transducer. A second explanation is that the
acoustic properties of the skull may be changing during treatment.
An additional implication of this work is for comparison of simulation
with thermometry. To simplify this comparison without the complica-
tion of the alignment of the thermometry plane, a sonication early in
the treatment should be used for comparison.A20
MR-guided Focused Ultrasound pig brain tissue and its histology
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Objectives
This study is to investigate the effects of Magnetic Resonance-guided
Focused Ultrasound (MRgFUS) on in vivo pig brain tissue by compari-
son of the tissue damage in histology with the changes in MR im-
ages as a function of thermal dose (TD) up to 200 cumulative
equivalent minutes (CEM) at 43 °C.
Methods
We have implemented a PI (proportional-Integral) control system in a
laptop with an Arduino-based controller to modulate pulse duration
of a FUS system (ExAblate 4000 Neuro 650 kHz system, InSightec)
based on the temperature difference between target temperature
and focal temperature as measured by an MRI system (Discovery
MR75-3.0 T, GE Medical systems) with proton resonant frequency
(PRF) thermometry. Accumulated thermal dose in CEM was calcu-
lated every 3.7 seconds and used to stop the sonication when a pre-
scribed thermal dose of interest was reached and delivered to the
Journal of Therapeutic Ultrasound 2016, 4(Suppl 1):31 Page 13 of 113target brain tissue. After tuning of a closed loop control system in a
phantom, one acute and seven chronic pig experiments with three-
day survival were conducted to investigate the correlation of lesions
between the MR images of pig brain tissue with the corresponding
histology. Craniectomy was performed to create an acoustic window,
and sonication was applied on 4 spots in the thalamus of each pig.
Absolute temperature in pig brain tissue was computed based on
the MR thermometry using the rectal temperature as a baseline. TD
varied from 7 to 195 CEM with target temperature between 46 and
52 °C at appropriate acoustic powers. This pig study was approved
by the University of
Results
From the acute pig experiment, we observed one large and 2 small
lesions on MR images 1 hour after a sonication and subsequent hist-
ology showed 4 lesions of target. For the chronic pig experiments,
22 sonication spots in 6 pigs were analyzed through MR images and
histology. One pig was excluded due to air bubbles introduced be-
tween the dura and scalp during the surgery procedure, and 2 sonic-
ation spots were failed to generate due to technical problems.
Results show that large brain tissue damage was observed in MR im-
ages in all 7 spots with doses larger than 100 CEM and the corre-
sponding histology results confirmed infarction with necrotic center
for all except one with a dose of 101 CEM. The diameter of those le-
sions on T2-weighted axial MR images was measured to 2.9 ± 0.
4 mm (mean ± SD,) with a mean volume of 30.7 ± 12.9 mm3. All with
TD lower than 17 CEM produced no visible lesions in either MR im-
ages or histology. There was a discrepancy in generating lesions with
TD between 18 and 100 CEM, so that six smaller lesions (3 in volume)
were shown except one large change in MR images at
Conclusions
In conclusion, large tissue damages were observed on MR images
and histology for all TD above104 CEM, but no change was shown
for all TD below 17 CEM. There is a variability in tissue changes be-
tween these TD levels. These results may contribute toward prescrip-
tion of thermal dose rather than peak temperature or acoustic power
for brain treatments, and expand the treatment envelope beyond
the current limitations in selecting targets and patients.
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Objectives
The interactions between particular transcranial transducer and skull
geometries are challenging to understand without interactive visual
computing tools. Such a tool has been created to allow the visual ex-
ploration of the estimated treatment envelope of a transcranial trans-
ducer given a patient specific imaging dataset. The impetus for
developing such a system is to aid in understanding treatment enve-
lope constraints and to serve as a tool for specifying the input to
various acoustic simulation systems.
Methods
A visualization application was created which makes heavy use of a
modern GPU to interactively display a transcranial Focused Ultra-
sound transducer, patient specific brain and skull anatomy, and the
interaction of each transducer element beam path with the skull. The
incident angle of each transducer element beam axis with the outer
table of the skull is calculated and displayed in an interactive fashion
as the natural focus of the transducer is moved within the intracra-
nial volume. Skull geometry is derived from a treatment compatible
CT dataset. An MR dataset is registered with the CT for targeting.
Due to the interactive nature of the tool, presumptive targets can be
rapidly and intuitively explored and understood in terms of geomet-
ric constraints and estimated treatment efficiency.
Results
The visualization system functions will be demonstrated including
targeting, transducer positioning and assessment of transducer effi-
ciency in terms of effective transducer element count.Conclusions
An interactive visualization system has proven valuable for facilitating
understanding of the complex interaction of transducer and skull
geometries. Future applications of this system may include patient
screening, post-treatment analysis, indication feasibility screening
and acoustic simulation initialization.
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Objectives
Pediatric patients have distinctive neuroanatomic features and spe-
cific disorders that make them unique candidates for transcranial
MR-guided Focused Ultrasound treatment. Children have thinner
skulls, and neonates in particular, possess a natural acoustic window
through their fontanelle. This results in lower phase aberration and
decreases the need for the larger hemispherical dome transducers
used for current adult transcranial procedures. These systems also re-
quire fixation of the head in a stereotactic frame, which is dangerous
for their fragile skull. In addition, neonates often require MR-
compatible incubators and dedicated neuro-interventional coils for
imaging. Focal brain ablation/disconnection for medical refractory
epilepsy and lysis of intra-ventricular hemorrhage are some of the
proposed noninvasive treatment options for this population. To pro-
vide such treatment, we have developed HOPE – HIFU for Pediatric
Operations – an integrated neonatal HIFU treatment system.
Methods
HOPE is composed of multiple elements: a 5 degree of freedom MR-
compatible robot positioning device, a 256 element phased-array trans-
ducer, an 8 channel neuro-interventional coil, and a real-time Python-
based treatment planning and delivery software system. The specifica-
tions for HOPE were determined by a team of clinicians and researchers
as follows: compatible with clinical neonatal incubators and MRI tech-
niques, imaging coil integrated into the incubator, positioning system
to couple and deliver the HIFU treatment and real-time control/moni-
toring of the treatment (Fig. 22). The hardware elements are designed
and tested with a Philips Achieva 3.0TX MRI with an Imasonic 256 elem-
ent transducer. For coupling, a custom designed water bag system was
created to interface with the patients’ head. The software platform in-
cludes robot kinematics, robot visualization, registration, transducer
control and MRI communication. A calibration procedure was devel-
oped using a series of Vitamin E markers visible in a 3D gradient echo
sequence without fat suppression; the markers were attached to an ex-
tension of the robot that recreates the acoustic cone of the HIFU beam.
A user-interface module was developed to calculate the center of mass
of each marker and to co-register the coordinate systems of the MRI
and the robot.
Results
The hardware system of HOPE has been designed and tested to show
it can perform T1, T2 and DTI imaging that is comparable to clinical
coils while delivering HIFU treatment in a phantom model. The neuro-
interventional coils provide high resolution images for treatment plan-
ning (Fig. 23). The MR-conditional robotic system positions the trans-
ducer to an accuracy of 0.59 +/- 0.25 mm and delivers thermal ablation
treatment to targets in a Philips HIFU quality assurance phantom. The
custom water coupler bag provided a transmission path for the HIFU
with minimal energy loss. The HOPE software platform controls each of
the robotic positioning axes with hardware safety switches in a real-
time Python interface (Fig. 24). The software registration of the patient,
MRI and robot frame allows the user to select specific brain targets.
During treatment, real-time thermometry is displayed.
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HOPE is an MR-guided Focused Ultrasound system aimed at delivering
HIFU therapy (both thermal ablation and cavitation-based treatment)
for neonatal and pediatric patients. The system has been designed to
operate within an incubator and clinical MRI system which minimizes
the impact to the patient. Future work involves characterizing the treat-
ment accuracy and performing in vivo animal studies to test the overall
system feasibility and usability for treatment of epilepsy and IVH clots.
Other treatments that will be investigated are thermal ablation of brain
tumors, hyperthermia and targeted drug delivery.Fig. 23 (abstract A22). Coil comparison in a T1-TFE image of a por-
cine brain in vivo (Left: Prototype 8 channel neuro-interventional coil,
Right: Philips clinical 32 channel head coil)
Fig. 24 (abstract A22). HOPE software interface with robot,
treatment planning and real-time monitoring of HIFU exposure in
phantom material
Fig. 22 (abstract A22). HOPE Concept (1 – incubator, 2 – coil, 3 –
neonatal patient, 4 – transducer, 5 – robot and 6 – MR bore)A23
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Objectives
Low-intensity transcranial Focused Ultrasound (FUS) is making
progress as a new mode of non-invasive brain stimulation, having
potential for superior spatial selectivity and depth penetration
compared to transcranial direct current stimulation (tDCS) or
transcranial magnetic stimulation (TMS). With accumulating evi-
dences of the FUS-mediated neuromodulatory effects in small
and large animal models, the sonication given to the primary
somatosensory cortex (SI) has recently shown to be capable of
eliciting tactile sensations in humans. Here, we further investi-
gated the creation of tactile sensations induced by simultaneous
FUS stimulation of the secondary somatosensory cortex (SII) and
SI of the hand.
Methods
Ten healthy volunteers (two females, ages = 23–34, average of
27.8 ± 4.1 yrs) participated, and all procedures were conducted
under the approval of the local Institutional Review Board of the
Catholic University of Korea. For targeting of FUS focus to the in-
dividual functional neuroanatomy, each participant’s brain image
was acquired using a 3-T MR scanner with anatomical (T1-
weighted) and functional MRI (fMRI, T2*-weighted) protocols. The
SI and SII areas were mapped while using four types of external
tactile stimuli to the palm of the right hand—vibrotactile, pres-
sure, warmth, and coolness. CT scan of the head was also ac-
quired for the planning of transcranial sonication path. As guided
by these individual-specific neuroimage data, FUS sonication
(210 kHz, single-element FUS transducer with focal length of
38 mm) was administered to the SI and SII simultaneously (or
separately), with an incident acoustic intensity of 35 W/cm2
Isppa, tone-burst-duration of 1 ms, pulse-repetition frequency of
500 Hz (yielding a 50 % duty cycle), and a sonication duration of
500 ms. The SII was targeted as divided into four sub-regions
that are specifically activated by the external tactile stimuli.
Results
Across the differential selective stimulations (i.e., SI only, SII only,
or SI and SII simultaneously), participants felt various types of
elicited tactile sensations (while ‘tingling’ was dominant) from the
hand areas contralateral to the sonication, such as the palmar/
dorsal side of the hand or as single/multiple adjacent fingers.
These results were similar to our previous study on FUS stimula-
tion of the SI, while the elicitations of ‘vibrotactile’ and ‘warmth’
sensations were newly reported in the present study. The types
of tactile sensations did not match to the sensations that are as-
sociated with the specific sub-regions in the SII. However, two in-
dividuals reported matching types of sensations (‘vibrotactile’,
‘pressure’, and ‘warmth’) during stimulation of the SI/SII simultan-
eously or the SII only. The stimulatory effects of the FUS were
transient and reversible, and the sonication procedures did not
induce any discomforts or adverse changes in the subjects’
physical/mental status.
Conclusions
Simultaneous stimulation of the SI/SII in the same hemisphere was
achieved by using multiple FUS transducers, which elicited various
types of tactile sensations. Stimulation of the SII only also induced
the creation of tactile sensations. The ability to stimulate multiple
region-specific brain areas may shed light on examining the causal
relationships between regional brain activities and subsequent be-
havioral/cognitive outcomes.
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Objectives
Transcranial Focused Ultrasound (FUS) has been suggested as a new
non-invasive modality of regional brain stimulation, with potential to
be more spatially-selective and to reach deep cortical/subcortical
areas compared to the conventional methods of transcranial mag-
netic stimulations (TMS) or transcranial direct current stimulation
(tDCS). In humans, low-intensity FUS sonication has been demon-
strated to temporarily change the neural activities in the primary
somatosensory cortex (SI), based on the observations of subjective
sensory manifestations and electrophysiological responses. However,
functional neuroimaging evidence of increased neural activity in the
stimulated region, as well as the associated network-wide brain re-
sponses, has not yet been shown in humans. Here, we administered
stimulatory FUS to the primary visual cortex (V1) as guided by the
individual-specific neuroanatomy. Concurrent functional MRI was ac-
quired to assess the brain regions that were activated due to the
stimulation.
Methods
19 healthy volunteers (five females, ages 20–45, average 26.1 ±
5.4 yrs) participated, and all procedures were conducted under the
approval of the Institutional Review Boards of both the Catholic Uni-
versity of Korea and Korea University. Functional MRI (fMRI; for map-
ping of the visual areas) and cranial CT were obtained from each
participant to provide the individual-specific V1 location for sonic-
ation planning/targeting. Then, in a separate session, an MR-
compatible sonication setup (270 kHz, single-element FUS transducer
with radius-of-curvature of 30 mm) was used to deliver FUS to the
V1 under a clinical 3-T MR scanner for the image-guidance and the
simultaneous acquisition of fMRI data. Separate from the FUS-fMRI
session, electroencephalographic (EEG) potentials elicited by the FUS
stimulation were also measured. We used a pulsing scheme having a
sonication duration of 300 ms with a tone-burst-duration of 1 ms re-
peated at a pulse repetition frequency of 500 Hz (yielding a 50 %
duty cycle). The incident acoustic intensity at the FUS focus was
16.6 W/cm2 Isppa. Retrospective numerical simulation of the trans-
cranial acoustic wave propagation was performed proximal to the
sonicated area to estimate the in situ acoustic intensity and spatial
accuracy of sonication.
Results
Simultaneous acquisition of fMRI during FUS sonication to the V1 re-
vealed the elicited activation not only from the sonicated brain area,
but also from the network of regions involved in visual and higher-
order cognitive processes. Accompanying phosphene perception was
also reported. The EEG responses showed distinct peaks associated
with the sonication, having similarities with the classical visual
evoked potentials (VEP) generated by photic stimulation. The proce-
dures did not induce any discomforts or adverse effects from the
participants, based on the subjective reporting and neuroradiologi-
cal/neurological examinations. Retrospective numerical simulation of
the transcranial FUS suggested the variability in individual respon-
siveness to the stimulation.
Conclusions
Simultaneous fMRI acquisition during FUS application to the V1 re-
vealed the functional neuroimaging-based evidence in humans that
the FUS stimulation activates the sonicated brain area and concur-
rently elicits the associated phosphene perception. Successful stimu-
lation of the V1 was also supported by the presence of the evoked
EEG potentials associated with FUS. The individual variability in re-
sponsiveness to the stimulation suggested needs for an elaborate
image-guidance.A25
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Objectives
Focused ultrasound (FUS) is a promising tool for neuromodulation
because of its noninvasivness and better spatial precision com-
pared to other noninvasive methods, such as transcranial mag-
netic stimulation (TMS) or transcranial direct current stimulation
(tDCS). FUS neuromodulation has been demonstrated in multiple
animal models, including a prior study where ultrasound was ap-
plied transcranially over macaque frontal eye field (FEF) to influ-
ence saccade response time in an anti-saccade task. In this work,
we applied FUS through a craniotomy over the macaque FEF
while measuring saccade response times and EEG signals associ-
ated with selective attention.
Methods
A single element focused transducer was positioned through a
craniotomy over FEF, a cortical area that plays a key role in the
eye movement and attention systems. FUS stimulation was applied
during a complex visual search task where the monkey was re-
quired to shift its gaze to a target among distractors. We alter-
nated blocks of trials with or without FUS stimulation (300 ms of
pulsed FUS with a 50 % duty cycle starting 150 ms before search
display onset, center frequency 500 kHz, repetition frequency
2 kHz, pulse duration 0.25 ms, peak negative pressures of 250 kPa
or 425 kPa, warming of brain tissue < 1.5 °C). Saccade response
time and intracranial EEG recordings were acquired in two mon-
keys performing 9 sessions each.
Results
In both monkeys, event-related potentials (ERPs) associated with se-
lective attention (N2pc) were significantly reduced during stimulation
with both intensities. FUS stimulation attenuated the N2pc over the
entire session block, rather than on a trial-by-trial basis. In one mon-
key with a craniotomy positioned directly over FEF, the mean sac-
cade response times were reduced by 5 ms by FUS stimulation at
425 kPa (p < 0.001) when the target appeared in the upper hemifield
contralateral to the FUS stimulation, while another animal with a cra-
niotomy more ventrally did not show such a systematic behavioral
modulation.
Conclusions
We are continuing to explore potential spatial relationships between
stimulation location and behavioral modulations in ongoing work.
Overall, our findings demonstrate prolonged FUS modulation of at-
tention ERPs and suggest potential spatial selectivity based on the lo-
cation of stimulation.
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Objectives
Focused ultrasound has been identified as a non-invasive technique
for modulating brain activity. Most studies involving sedate rodents
utilize frequencies in the kilohertz-range, which allow for optimal
transmission of acoustic power through the skull. The tradeoff with
using lower frequencies involves producing larger acoustic foci and
resultant poor target-specificity. Megahertz-range frequencies can
therefore be used to improve target-specificity. This study demon-
strates that Focused Ultrasound in the megahertz range can be used
to evoke motor and ocular responses in mice under deep anesthesia
by targeting cortical and subcortical structures, respectively.
Fig. 26 (abstract A26). Histological evaluation of brain at 1.93 MPa
(left) and 3 MPa (right) revealed now red blood cell extravasation
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stimulating cortical regions, demonstrating the ability of megahertz-
range FUS to stimulate activity in highly-targeted regions. Addition-
ally, pupil dilation was observed when deep-seated anxiety-related
structures were targeted, demonstrating the ability of FUS to modu-
late activity in a small subcortical structures.
Methods
For this study, wild-type adult male mice were anesthetized with
intraperitoneal injections of sodium pentobarbital (65 mg/kg) and
fixed in a stereotaxic frame. A single-element FUS transducer with
fundamental frequency of 1.94 MHz was fixed to a 3D positioning
system for accurate navigation through the brain. A 6x6 mm grid
centered +2 mm anterior of the lambda skull suture was soni-
cated in a random order using a center frequency of 1.9 MHz,
pulse repetition frequency of 1 kHz, 50 % duty cycle, 1 second
pulse duration, 1 second inter-pulse interval for a total of 10
pulse repetitions. The acoustic pressure applied was varied in
order to evaluate thresholds for eliciting physiological responses
like motor movement, eye movement, or pupil dilation. Motor
movements were validated using video recordings and intramus-
cular electromyography recordings from the biceps femoris in
both hind limbs. Pupil movement and dilation from subcortical
modulation were evaluated using a high-resolution camera aimed
at the right eye and frame-by-frame processing technique.
Results
The minimum peak rarefactional pressure required to elicit hind limb
movements was 1.45 MPa when targeting cortical regions, calibrated
using an excised mouse skull. Higher pressures increased the success
rate from 20 % (at the 1.45 MPa threshold) to 70 % (1.79 MPa)
(Fig. 25). Targeting eye-motor and anxiety-related regions of the
brain elicited eye movements and pupil dilations up to 20 %. Sonic-
ating the superior colliculus resulted in both eye movement and
pupil dilation at a lower threshold pressure (1.20 MPa) than the
hippocampus and locus coeruleus, which required pressures greater
than 1.80 MPa. A histological evaluation performed in five mice at
1.93 MPa and 3 MPa peak rarefactional pressure resulted in no red
blood cell extravasation (Fig. 26).
Conclusions
This study successfully demonstrated that megahertz-range Focused
Ultrasound can be used to elicit motor and ocular responses with
high specificity in mice in vivo. It was also shown that the success
rate of stimulation increased with acoustic pressure for motor move-
ments associated with cortical modulation but depends greatly on
the region of the brain targeted. These findings emphasize the com-
plex and yet to be determined mechanism of action involved in
ultrasonic neuromodulation.Fig. 25 (abstract A26). Evaluation of the pressure threshold when
applying FUS to location within the somatosensory cortex. This
location resulted in contralateral hind-limb movement relative to the
sonication siteA27
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Objectives
Focused ultrasound (FUS)-microbubble treatment has been used to
open the Blood-Brain Barrier (BBB) for targeted delivery of a wide
variety of therapeutics. Here we propose to deliver neurotransmitter
chemicals such as GABA or glutamate for the purpose of non-
invasive neuromodulation. These chemicals function to transmit or
suppress signals across the chemical synapses that connect neurons
in the brain. This novel approach affects signaling between neurons,
as opposed to existing neuromodulation techniques that affect the
transmission of electrical signals along neurons. Such an approach
could be an important new complimentary tool for basic neurosci-
ence or lead to new therapies for neurological disorders.
Previously, we used electrophysiology measurements to demonstrate
functional blockade via BBB disruption and GABA administration.
Here we present initial results demonstrating the proof of concept in
a rodent model using delivered GABA to modulate neuronal activity
and functional MRI to measure the effects.
Methods
Sprague-Dawley rats underwent bilateral hindpaw electrical stimula-
tion (1-5 mA, 0.3 ms duration, 2 Hz) to elicit a functional response of
the somatosensory network. Varying levels of GABA were systemic-
ally injected under conditions No BBB opening and BBB opening.
Functional activity in the thalamus and S1 was measured using fMRI
to quantify any effects of neuromodulation.
BBB opening: Microbubbles injected (Optison, 200 μl/kg), 274 kHz
dual aperture transcranial FUS with 32 ms bursts applied at 4 Hz for
60 seconds.
GABA delivery: Systemic tail vein bolus injection in doses from
10 mg/kg to 50 mg/kg.
fMRI: Images acquired on a Bruker 7 T scanner with a single shot EPI
sequence (TR = 1.5 s, TE = 18 ms, 18 slices, 300 images). Stimulation
performed in a 40 s OFF, 20 s ON block design over 7.5 total mi-
nutes. T-scores obtained using general linear model analysis in SPM
12.
Results
BBB Closed: Fig. 27 shows activation results in S1 for the case of
No BBB opening. Compared to the baseline case of No GABA
injected, a GABA injection of 10 mg/kg showed significant de-
crease in activity (p < 0.05) but GABA injections of 25 mg/kg and
50 mg/kg did not.
BBB Open: Fig. 28 shows activation results in the thalamus for the
case of BBB opening. BBB opening was targeted, and confirmed
through gadolinium imaging, in the right hemisphere. Bilateral acti-
vation was seen in the thalamus for the baseline case of No GABA
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activation was seen in the right (opened) ROI (p < 0.001), but not the
left (unopened) ROI. For GABA injection of 50 mg/kg, a significant de-
crease in activation was seen in both ROIs (p < 0.001).
Conclusions
More experiments on a number of rats are necessary to confirm and
expand these findings. However, these very preliminary results are a
promising indicator that a neurotransmitter such as GABA can be de-
livered through the opened BBB for targeted manipulation of neur-
onal activity.Fig. 28 (abstract A27). fMRI results with BBB opening in right
thalamus. Top: T-score values overlaid on a T1w image. Left: Extent
of BBB opening. Bar plots show t-score metrics from right ROI
(yellow/opened) and left ROI (green/closed). ** = p < 0.001
Fig. 27 (abstract A27). fMRI results without BBB opening. Top: T-
score values overlaid on a T1w image. Bottom: Paxinos/Watson rat
brain atlas with hindleg S1 area colored red and bar plots for t-score
metrics comparing the activity for the various GABA doses. * = p < 0.05A28
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Magnetic Resonance-guided Focused Ultrasound (MRgFUS) has been
shown to reversibly open the Blood-Brain Barrier (BBB) for targeted
drug delivery [1]. Research on animal models, including non-human pri-
mates [2], has been conducted to investigate the effectiveness and
characteristics of BBB openings. Here we describe our initial experience
in a pilot clinical study to establish the feasibility, safety and preliminary
efficacy of Focused Ultrasound to temporarily open the BBB to deliver
chemotherapy to brain tumors.
Methods
This phase-one clinical trial of BBB opening by Focused Ultrasound was
approved by Health Canada. A modified clinical MRgFUS brain system
(ExAblate 4000, 230 kHz, Insightec, Tirat Carmel, Israel) was used with a
3 T MR scanner (Signa MR750, GE Healthcare, Milwaukee, WI, USA). Two
hours before the procedure, liposomal doxorubicin Caelyx (Janssen, To-
ronto, Ontario, Canada) was intravenously infused over 1 hour at a dose
of 30 mg/m2. The patient’s head was then shaved and positioned in
the FUS array with a stereotactic frame. Two targets close to the poster-
ior margin of the glial tumor were chosen based on T2 images (Fig. 29).
Each target consisted of a 3x3 grid of 9 spots at 3 mm spacing. For
each spot, 2.6 ms on, 30.4 ms off FUS pulses were repeated for 300 ms
before steering to the next spot. The pattern was repeated periodically
resulting in an overall pulse repetition frequency (PRF) for each spot of
0.9 %. A bolus injection of 4 ul/kg of Definity microbubbles (Lantheus
Medical Imaging, N. Billerica, MA, USA) was applied simultaneously with
each sonication (1/5th of the clinical dose for ultrasound imaging). With
the first injection of microbubbles, 10s short sonications at 5 W, 7 W
and 9 W acoustic power were applied to find the appropriate power
level based on feedback of cavitation signals. Cavitation signals were
detected by two receivers and sampled at a rate of 2 MHz. Spectrum
integration from 75 kHz to 155 kHz was calculated and two threshold
levels of the spectrum integration were defined as a safety mechanism
based on pre-clinical studies on a trans-human skull pig model [3]. 9 W
was found to be adequate for these targets. 50 s sonications at 9 W
were then applied at each target, with a separate bolus injection of
microbubbles for each. Post sonication, Gd (Gadovist, Bayer)-enhanced
3D FSPGR images were acquired to verify the BBB openings, and T2*-
weighted GRE images (TE = 15 ms) were collected to detect potential
hemorrhage. After the treatment, the patient was released from the
head frame and MR scans were repeated with an 8-channel head coil
for better quality images. The patient underwent routine tumor resec-
tion the next day and tissue samples at the two BBB opening targets
were collected for quantification of chemotherapy drug concentration.
Results
The opening of the BBB was successful at both locaitons with
clear Gd enhancement in the 3x3 grid pattern. (Figs. 30 and 31).
Despite using the same power level, the actual acoustic pressure
at the 2nd target was lower than the first due to steering of the
FUS beam. Low-level extravasation of red blood cells were seen
as small dark signals within individual sonicated sponts in the
T2* image (Fig. 32). The quantification of drug concentration is
pending further analysis.
Conclusions
The 3 mm spacing of the 9 spots was intentionally designed to form a
grid pattern of Gd enhancement for easier confirmation in heteroge-
neous tumors for the initial cases. We do not expect an impact on other
parameters if the spacing needs to be reduced for a more uniform drug
distribution within the BBB opening volume. There was a small level of
RBC extravasation but this was not a concern in the tumor enviromment.
Our animal experiments have shown that the cavitation signal can be
used during the sonications to control the power level for eliminating
the RBC exravasations [4]. The current system did not use this method
during sonications.
The tumor in this patient was in the right temporal lobe adjacent
to the skull. The two targets were ~4 cm lateral from the midline of
the brain, and the 2nd target was also ~2.5 cm posterior. Thermal
ablations by FUS at these off-centre locations are technically chal-
lenging due to excessive skull heating. However, successful BBB
openings at these locations were demonstrated at low powers at
230 kHz. If these results can be repeated in other patients without
complications, then the method may provide a new way to deliver
Journal of Therapeutic Ultrasound 2016, 4(Suppl 1):31 Page 18 of 113therapeutic agents into brain for the treatment of tumors and other
brain diseases.
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4. O’Reilly MA et al. Radiology 2012;263:96-106.Fig. 29 (abstract A28). Intraoperative T2w MR image showing the
tumor and the first BBB target
Fig. 30 (abstract A28). a Axial Gd-enhanced T1w MR images show-
ing the first (top arrow) and second (bottom) BBB openings
Fig. 31 (abstract A28). b Coronal view across the second target
Fig. 32 (abstract A28). T2*w image shows low level of RBC
extravasation (small dark spots) within the two target volumesA29
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Objectives
Malignant glioma is the most severe form of primary brain tumors
with an extremely high recurrence rate and the poorest prognosis.
Current anti-angiogenic monoclonal antibody (mAb) treatment failed to
show therapeutic efficacy due to transient “vascular normalization” stage
Journal of Therapeutic Ultrasound 2016, 4(Suppl 1):31 Page 19 of 113that restores BBB integrity in tumor regions and restricts anti-angiogenic
mAb penetration, preventing angiogenic suppression of tumor cells in
the CNS and diminishing the improvement in overall survival in clinical
treatment observation. The purpose of this study is to demonstrate that
transcranial Focused Ultrasound (FUS) enhances Blood-Brain Barrier (BBB)
permeability of the antiangiogenic monoclonal antibody, bevacizumab,
for glioblastoma multiforme (GBM) treatment.
Methods
Transcranial FUS in the presence of microbubbles was used to transi-
ently open BBB, and enhance CNS penetration of bevacizumab in
normal and glioma-bearing mice. Bevacizumab was quantitated by
high-performance liquid chromatography (HPLC), and Western blotting
confirmed bevacizumab in the CNS. Bevacizumab permeability was es-
timated in vivo via contrast-enhanced Magnetic Resonance Imaging
(CE-MRI), and glioma progression was longitudinally followed via T2-
MRI. Morphological changes and vascular inhibition were confirmed
histologically with H&E and CD-31 immunohistochemistry (Fig. 33).
Results
HPLC confirmed that FUS significantly enhanced CNS delivery of
bevacizumab from 5.7- to 56.7-fold. The high correlations be-
tween CE-MRI imaging indices and bevacizumab concentration
(r2 = 0.56-0.7378) suggested feasible non-invasive in vivo im-
aging of large-molecule BBB penetration. FUS-enhanced bevaci-
zumab delivery significantly inhibited glioma progression, and
improved median survival (ISTmedian = 135 %, compared to
48 % in bevacizumab-administration alone, Fig. 34).
Conclusions
In conclusion, anti-angiogenic glioma therapy is enhanced via our
proof-of-concept study that FUS enhances large molecule bevacizu-
mab BBB permeability, and combining Focused Ultrasound to open
the Blood-Brain Barrier with bevaczumab delivery can overcome bev-
aczumab vascular normalization and potentiate bevacizumab’s anti–
angiogenic tumor therapy effect.Fig. 33 (abstract A29). a Representative imaging indexes obtained
from DCE -MRI analysis (T1-WI, R1-AUC, Ktrans, and Ve). b CD-31 IHC
fluorescent microcopies. Bar = 100 μm
Fig. 34 (abstract A29). Kaplan–Meier plot to demonstrate animal
survival among each experimental groups. BEV = BevacizumabA30
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Objectives
Microbubble-mediated Focused Ultrasound (FUS) can induce
targeted drug delivery through Blood-Brain Barrier disruption
(BBBD). Real-time feedback control of cavitation is critical to
realize desired treatment outcome while avoiding tissue
damage. Here, we propose an acoustic emissions-based control-
ling paradigm that can sustain stable cavitation (harmonic emis-
sion, HE) while suppressing inertial cavitation (broadband
emission, BE). Our objective is to deliver desired drug dose by
controlling HE strength during BBBD, while keeping the brain
damage-free.
Methods
A dual-aperture FUS setup (f = 274.3 kHz) produced a sub-
centimeter focal depth in rats’ brain (n = 50) in vivo, and a
passive detector (fcentral = 650 kHz) monitored cavitation
activity. HE and BE were analyzed during 32-ms bursts in real
time and fed back for control of the next pulse. The impact of
multiple FUS parameters and microbubble (Optison) injection
protocol on the controller performance was studied. To avoid
inertial cavitation, the pressure was reduced if BE was detected
and terminated if it crossed a set threshold. Both wild type and
F98 glioma (ATCC # CRL-2397) models have been used in this
study. Delivery of a model drug (Trypan Blue; 960 Da) and
chemotherapeutic drug (Doxorubicin) was assessed using fluor-
escent imaging of formalin-fixed tissue blocks 1-h post
sonication.
Results
Pilot study demonstrated the HE-pressure linearity (R2 = 0.93)
and found that the BE threshold decreased as bubble dose (up
to 400 μl/kg) was augmented. To optimize controller perform-
ance in sustaining HE while suppressing BE, a Phase-1 study
demonstrated that: 1) 4-Hz PRF (compared to 1-Hz, P < 0.001)
significantly suppressed the HE signal variance; 2) Infusing
microbubbles after an initial bolus prevented the decline of HE
and a corresponding increase in pressure, and further improved
HE stability (P < 0.05 for all comparisons, Fig. 35a) while redu-
cing the likelihood of BE (33.7 % vs. 16.7 %).
Using optimal settings, a Phase-2 study investigated HE control
and Trypan Blue delivery (Fig. 35b). Integrated HE was
exponentially correlated with epi-fluorescence intensity (R2 =
0.82; red symbols in Fig. 35c). Based on this calibration, a
Phase-3 study tested if we could deliver a desired amount of
drug by sonicating until the HE reached a preset goal. The
resulting fluorescent intensity matched well with the reference
curve for three different goals (n > 5 per group, green symbols
in Fig. 35c).
Conclusions
Our proposed controlling system and method has been
demonstrated to effectively sustain the stable cavitation behavior
while suppressing the inertial cavitation at a minimum level.
Moreover, this real-time closed-loop controller can enable the
reliable delivery of a pre-determined amount of drug to the
brain.
Fig. 35 (abstract A30). a Signal stability assessment (*: P < 0.05,
***: P < 0.001, ****: P < 0.0001); b Cavitation control profile (HE in
black and BE in red) and Trypan blue delivery; c Calibrated BBBD
correlation (in red) and controlled delivery results (in green)
Fig. 36 (abstract A31). a T1weighted images before contrast
administration. The red arrow indicates the tumor. b No
difference in enhancement of the tumor is observed after
contrast administration (ΔSI = 0.4 %). c After focused ultrasound-
mediated Blood-Brain Barrier disruption, the tumor enhances
after contrast administration (ΔSI = 30.1 %)
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Objectives
Treatment options for breast cancer patients with metastases in the
brain are limited. The blood-brain barrier (BBB) prevents most drugs
from entering the brain and tumor. Although survival in patients with
extracranial metastases of HER2-positive breast cancer can be pro-
longed by the use of antibody therapies like trastuzumab and pertu-
zumab, the response of brain metastases to these drugs is poor [1].
We aim to improve antibody delivery by temporary disruption of the
BBB using magnetic resonance (MR)-guided focused ultrasound
(MRgFUS) in combination with microbubbles. The treatment benefit
was evaluated using MR imaging.
Methods
The treatment effect of the antibodies trastuzumab and pertu-
zumab in combination with MRgFUS to disrupt the BBB was
evaluated. MDA-MB-361 cells (HER2-positive human cancer cells)
were injected in the brain. Six weekly treatments started
5 weeks later. Three groups of 10 nude rats were included: a
control-group that received no treatment; a group that only re-
ceived both antibodies; and a FUS + antibody-group that
received the antibodies in combination with BBB disruption
using MRgFUS. The ultrasound treatments took place in a 7 T
MR-system using a spherically-focused 690 kHz-transducer. Be-
fore and after the sonications, T2-weighted (T2w) and T1w im-
ages were obtained for targeting and confirmation of BBB
disruption. At the start of each sonication (duration 60s, 10-ms
bursts, burst repetition frequency 1 Hz), the ultrasound contrast
agent Optison (100 μl/kg) was injected. The complete tumor
was treated in 4 to 14 sonications using peak negative pres-
sures between 0.46 and 0.62 MPa.
After the sonications gadolinium (Magnevist) was injected and T1w
was repeated to confirm BBB disruption. The difference in signal in-
tensity change in pre- and post-contrast T1w images was determined
between the tumor and contralateral brain region (=ΔSI%). In two
animals tumor leakiness was studied before the tumors were soni-
cated and quantified similarly.
Every other week, high-resolution T2w imaging was performed to de-
termine tumor volume. The volumes were fitted with: volume(t) =
a*exp(r*t), in which r is the growth rate and t is the time in days. r
was determined for the treatment period (week 5 to 11) and thefollow-up period (week 11 till sacrifice). An animal was classified as
‘responder’ if the growth rate r was lower than the mean r of the
control animals minus two standard deviations.
The animal was euthanized if its condition was poor or the tumor
diameter exceeded 13 mm. Brains were stained for hematoxylin and
eosin (H&E) and HER2.
Results
BBB disruption was successful in all sessions with an average
ΔSI% of 21.2 % (range 4.5–77.6 %). The mean ΔSI% of two tu-
mors before BBB disruption during the six treatment weeks were
0.4 % and 0.6 %, indicating that the tumors were not leaky be-
fore disruption.
In the FUS + antibody-group, 4/10 animals were classified as re-
sponders during the treatment period with an average growth rate
of 0.010 ± 0.007, compared to 0.043 ± 0.013 for the non-responders.
There was no difference in the average ΔSI% of the responding rats
(21.8 % ± 16.7) and the non-responding rats (20.7 % ± 9.7). None of
the control or antibody-only animals were classified as responder.
For the follow-up period, none of the animals was classified as
responder.
High-resolution T2w imaging showed that the tumor was
homogenous in most animals till week 13-15, when cystic and
necrotic areas started to develop. The tumors showed also a
heterogeneous appearance on H&E-stained sections and the
complete tumor was HER2-expressing in the examined brains
(Fig. 37).
Conclusions
In this study, we demonstrate that BBB disruption using MRgFUS
in combination with antibody therapy can slow down the growth
of breast cancer brain metastasis. As the tumors were not leaky
before BBB disruption and there were no responders in the
antibody-only group, the disruption of the BBB is necessary for
drug delivery to these brain metastasis. Part of the rats
responded to the treatment, while the other animals had the
same growth rate as the control-group. This is in line with a pre-
vious study [2], where antibody therapy was combined with FUS
in a different breast cancer brain metastasis model and only in
part of the animals a response was observed. The difference in
response could not be explained by the tumor volume at the
start of the treatment, nor was there a difference in contrast-
enhancement after BBB disruption or in HER2-expression. Better
understanding of why certain animals respond is needed and will
help in translating this technique to the clinic.
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Fig. 37 (abstract A31). a T2w image of an animal that not responded
to the therapy and was euthanized after imaging (at week 21 after
implantation). The tumor shows a heterogeneous appearance with cysts
b The H&E-stained section shows a similar appearance. c HER2-stained
section shows that the complete tumor is HER2-expressing
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Objectives
The Blood-Brain Barrier (BBB) limits the delivery and efficacy of sys-
temically administered drugs to the brain. Pre-clinical studies have
demonstrated that ultrasound-induced disruption of the BBB can sig-
nificantly increase the intracerebral concentration of chemotherapy.
To harness this approach, our group has developed an implantable
ultrasound device, SonoCloud®, that allows for simple and repeated
disruption of the BBB. The goal of this work was to determine the
safety of repeated disruption of the BBB using the SonoCloud® de-
vice in patients with recurrent glioblastoma prior to receiving carbo-
platin chemotherapy.
Methods
A Phase 1/2a clinical trial was initiated at the Hospital Pitie Salpe-
triere in Paris, France in July 2014. Patients with recurrent glioblast-
oma were implanted with an 11.5-mm diameter biocompatible
1 MHz ultrasound transducer. The device was fixed to the skull bone
in a standard burr hole, after which the skin was closed. Once a
month, the device was connected to an external generator system
using a transdermal needle connection and patients received a
150 second ultrasound sonication (25,000 cycles/burst, 1 Hz) in com-
bination with systemic administration of an ultrasound contrast
agent. BBB disruption was monitored immediately after sonication
using gadolinium-enhanced Magnetic Resonance Imaging (MRI). Sys-
temic intravenous injection of carboplatin chemotherapy (AUC 4-6)
was administered immediately following acquisition of each patient’s
post-sonication MRI (<1 hr after BBB disruption). Patients followed a
progression of ultrasound dose in which the acoustic pressure was
increased from 0.5 to 1.1 MPa throughout the course of the study.
Results
Fifteen patients were included in this on-going study from July 2014-
January 2016. A total of 41 BBB disruption sessions were performed.
Contrast-enhanced MRI indicated that the BBB was disrupted at
acoustic pressure levels up to 1.1 MPa without detectable adverse ef-
fects on MRI or clinical examination.
Conclusions
Our preliminary results from this Phase I/IIa study indicate that re-
peated disruption of the BBB using the SonoCloud® device is safeand well tolerated in patients with recurrent GBM and may improve
chemotherapy delivery in the brain.
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Objectives
Focused ultrasound thermal therapies have been explored for brain
applications including treatment of essential tremors, Parkinson’s dis-
ease, and stroke. Histotripsy, a cavitation based ultrasound therapy, is
being investigated for treatment of brain tumor and intracerebral
hemorrhage, but there are concerns that excessive hemorrhage may
be induced in the brain during histotripsy treatment by disrupting
blood vessels. This study investigates the in vivo feasibility and safety
of generating targeted lesions in the porcine brain using histotripsy.
The goal is to demonstrate that lesion generation may be accom-
plished safely and without excess hemorrhage, edema, or other
major complications associated with treatment. We also seek to in-
vestigate the histotripsy dose required to fully ablate target brain
regions.
Methods
Histotripsy treatments were delivered to brains of 11 pigs using a
1.5 MHz focused transducer following a craniotomy. Lesions gener-
ated were targeted in the cortex at depths of 5 to 20 mm from the
exposed surface of the brain. Using ultrasound imaging guidance,
treatment regions were targeted to be contained within individual
gyri to avoid perforations into the sulci. During dosage studies, single
lesions were generated using between 1 and 200 histotripsy pulses
delivered at ≤10Hz PRF with an estimated peak negative pressure of
45 MPa. Large lesions were generated by incrementally repositioning
the histotripsy target site during treatment to ablate entire target
volumes. 7 acute pigs were sacrificed within 6 hours of treatment
and brains were removed for MRI and histology. 4 sub-acute pigs
were survived for 3 days after treatment. To assess lesion damage,
hemorrhage and edema surrounding the lesions, MR images of the
brains were acquired at 1 hour and at 3 days after treatment for sub-
acute pigs. After euthanization brains were dissected for histology.
Results
In 4 acute pigs, with ultrasound guidance, histotripsy was used to
generate precise single lesions of 1.5x2.5 mm within the gyri. Dosage
studies revealed that a single histotripsy pulse was sufficient to gen-
erate identifiable damage in the brain in MRI and complete cell frac-
tionation in lesions was achieved by 50 pulses. In 3 acute pigs, 5
Fig. 38 (abstract A35). Treatment preplanning, on-line targeting
and monitoring, and post assessment
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the brain. MRI and histology revealed that lesions confined to within
the gyri show no hemorrhage or other major complication associated
with treatment. In 4 sub-acute pigs, 6 single lesions were generated
by 10 and 50 pulses, and two larger square lesions of 3.5 mm were
created. MRI following treatment showed no hemorrhage or damage
outside the target regions and at 3 days showed no additional
hemorrhage and only minor edema near the lesion boundary. No
midline shift or brain herniation was observed. Histology showed
damage confined to within target volumes, with well demarcated
boundaries between treated and untreated tissues and no evidence
of hemorrhage, ischemic changes, encephalitis, or acute, sub-acute
or chronic inflammatory infiltrate beyond the areas of the lesion.
Conclusions
The results of this study demonstrate that histotripsy may be used to
generate targeted lesions in the brain without causing excess
hemorrhage, edema, or other major complications associated with
treatment. Lesions were observed to have well defined boundaries
between treated and untreated tissues, with little damage beyond
the confines of the lesion area. Tissues surrounding the lesions ap-
pear very viable with no acute, sub-acute or chronic inflammatory
infiltrate, and tissues in adjacent gyri appear uninvolved and unre-
markable. These results demonstrate that histotripsy may be applied
in the brain without causing major complications and suggest the
potential of histotripsy for use in brain therapy applications.
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Objectives
Focused ultrasound (FUS) has shown great promise for noninvasive
brain treatment, including surgical ablation, Blood-Brain Barrier (BBB)
opening and drug delivery, and neuromodulation. Accurate and pre-
cise targeting with personalized planning is the key for treatment
success. Furthermore, repetitive procedure is often required for BBB
opening and drug delivery as well as neuromodulation, which entails
the demand for a portable system apart from the current MR-guided
FUS system requiring a dedicated and custom-built suite. In this
study, a neuronavigation-guided FUS system was developed (Fig. 38),
combined with in silico preplanning based on CT and MRI as well as
real-time acoustic mapping in visualizing the location and intensity
of the cavitation events associated with BBB opening. The system
was evaluated in non-human primates with BBB opening, with the
treatment preplanning and targeting accuracy validated both in silico
and in vivo.
Methods
Three rhesus macaques were sonicated (N = 15) and the subcortical
structure of the basal ganglia was targeted, which is associated with
neurodegenerative diseases including Parkinson’s and Huntington’s
disease. Both CT and MRI were acquired for personalized pre-
planning and neuronavigation guidance (Brainsight). The 3D
numerical simulation of the acoustic pressure field was performed
for pre-planning and post comparison with the BBB opening. A
single-element, 0.5-MHz FUS transducer (diameter: 64 mm) with in-
house microbubbles were used for sonication, and a programmable
data acquisition system (Verasonics) with an array of acoustic detec-
tors for real-time passive cavitation mapping. Both the FUS and cavi-
tation mapping were guided with the neuronavigation system in real
time during the FUS procedure. After sonication, the contrast en-
hanced T1-weighted MRI was used to confirm the location and size
of BBB opening. The accuracy of both the FUS targeting and cavita-
tion mapping were assessed.
Results
The target shift was on average 2.0 mm laterally and 3.5 mm axially
in the in vivo experiment, and the shift due to the skull waspredicted to be 0-1 mm laterally and 1.0-5.5 mm axially in silico.
Real-time cavitation mapping confirmed the sonicated area with and
without BBB opening, and distance between the centroid of the cavi-
tation map and that of the resulting BBB opening was under 2 mm.
In order to achieve the desired BBB opening volume, the pressure
and focal spot size in situ were estimated in silico and tailored for
targeting in each subject. Simulation results showed a smaller focal
spot size through the skull (2.6 mm laterally and 16.7 mm axially,
compared with the original size of 4.0 mm laterally and 35.3 mm ax-
ially), which corresponded to the BBB opening volume under specific
peak negative pressures (NHP 1 at 200 kPa, NHP 2 at 600 kPa). This
pressure difference between individuals was due to the difference in
skull attenuation, since the in silico pressure reduction was estimated
to be 30.9 % ± 12.4 % and 53.9 % ± 14.3 % in NHP 1 and NHP 2,
respectively.
Conclusions
In conclusion, the new portable neuronavigation-guided FUS with
in silico preplanning and real-time cavitation mapping was shown
feasible and could facilitate the BBB opening and neuromodula-
tion applications while maintaining translational capability to a
clinical setting.A36
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Objectives
The latest advances in cancer immunotherapy have improved our
understanding of how to stimulate the patient’s immune system to
fight their own disease. Notwithstanding the unparalleled success of
treating melanoma tumours and non-small cell lung cancer with im-
mune checkpoint inhibitors, patients are not all getting the same
benefit. In this context, pancreatic cancer presents unique challenges.
Its dense stroma characteristics result in limited immune cell infiltra-
tion in the tumour microenvironment. In addition the low number of
mutations in pancreatic cancer cells result in few tumour antigens,
thereby reducing their immunogenicity. HIFU may address some of
these limitations by ablating segments of the tumour to induce a
stronger inflammatory response and degrade the stroma to facilitate
enhanced diffusion of tumour antigens out of the tumour, and in-
creased penetration of lymphocytes to the tumour. We propose to
co-treat pancreatic tumours with HIFU and immune checkpoint in-
hibitors to elicit an effective anti-tumour immune
Fig. 39 (abstract A37). a Tumor growth in immunocompetant
C57BL/6 hosts. *P < 0.05 vs. control. b Immune cell representation in
tumors in C57BL/6 hosts. c Tumor growth in immunocompromised
Rag1-/- hosts. d Immune cell representation in tumors in
Rag1-/- hosts
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In vitro characterization of the effects of heat on the presentation of
cell surface receptors associated with the immune response has been
undertaken in human colon cancer HCT116 cells and mouse pancre-
atic cancer Panc02 cells using FACS analysis. A KPC-derived pancre-
atic cancer cell line will be transplanted in C57BL/6 subjects to form
syngeneic subcutaneous and orthotopic pancreatic tumours. These
tumours will be treated with HIFU, and within vivo monoclonal anti-
CLTA-4 and anti-PD-1 antibodies. The phenotype of markers of the
adaptive immune response will be assessed to identify whether HIFU
exposures can initiate intrinsic anti-tumoural cellular immunity at the
site of treatment. Analysis by flow cytometry and immunohistochem-
istry of both effector cells (cytotoxic CD8+ T cells, dendritic cells),
and immunosuppressive cells (Tregs, myeloid derived suppressor
cells), as well as cytokines and chemokines at various time points
post HIFU will be performed. Tumour growth will be determined
using high resolution ultrasound imaging, and the results will be cor-
related with overall survival.
Results
Thermal exposure of cancer cells results in a time-dependent regula-
tion of the transmembrane receptor CD47. CD47 decreases immedi-
ately after, and 1 day after treatment, and increases 3 and 4 days
after treatment relative to the sham-exposed cancer cells. Further
data on the effects of thermal exposures on the regulation of
immune-associated pancreatic cancer cell surface receptors will be
presented.
Conclusions
Detailed pre-clinical studies in various mouse models of pancreatic
cancer can provide a mechanistic understanding of the combinatorial
effects of HIFU and immune checkpoint inhibitors. Strong evidence
that HIFU stimulates endogenous immunity against pancreatic tumor
cells, and augments the immunotherapy treatment of poorly im-
munogenic pancreatic tumours could be used as proof-of-concept
for the initiation of Phase 1 clinical trials of HIFU-enhanced immuno-
therapy in patients with pancreatic cancer.
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Objectives
Melanoma incidence continues to rise, while Stage IV 5 year survival
remains below 20 %. Targeted immunotherapy approaches, designed
to enhance natural anti-tumor mechanisms or inhibit the immuno-
suppressive tumor microenvironment, have shown promise in early
clinical use. The programmed death receptor and its ligand (PD-1
and PD-L1) have drawn considerable attention. PD-L1 is known to in-
hibit the activity of anti-tumorigenic cytotoxic T cells, promoting a
pro-tumor immune profile, and ultrasound (US) can promote the
infiltration of immune cells into the tumor. Here, we tested the hy-
pothesis that a combination of pulsed US, microbubbles (MBs) and
anti-PD-1 will improve tumor growth control in a mouse model of
melanoma in a manner dependent on the adaptive immune system.
Melanoma incidence continues to rise, while Stage IV 5 year survival
remains below 20 %. Targeted immunotherapy approaches, designed
to enhance natural anti-tumor mechanisms or inhibit the immuno-
suppressive tumor microenvironment, have shown promise in early
clinical use.
Methods
Eight week old immunocompetent C57BL/6 male mice were inocu-
lated unilaterally with B16-F10 melanoma cells and divided into four
groups: Control (untreated), US + MBs, αPD-1, or US +MBs + αPD-1.
Immunocompromised Rag1-/- mice were similarly inoculated and
divided into two groups: Control (untreated) or US +MBs. On day 11
post-inoculation, animals receiving US were anesthetized andsonicated with a 0.75” unfocused 1 MHz transducer as previously de-
scribed1 for 60 minutes. MBs (105/g b.w.) were injected i.v. through-
out the sonication. The αPD-1 groups were given an IP injection of
250 μg of αPD-1 on Days 10, 13 and 16. Tumors were monitored
until Day 18, when tumors were resected for flow cytometry. Helper
T cells (CD4+), cytotoxic T cells (CD8+), T regulatory cells (Treg), mac-
rophages and natural killer cells (NK) were counted in immunocom-
petent mice, and dendritic cells (DC), natural killer cells, M1 and non-
M1 macrophages were counted in immunocompromised mice.
Results
In immunocompetent mice, treatment with US + MBs provided
improved tumor growth control compared to all other groups
(Fig. 39a) as well as a significant survival benefit (not shown).
Additionally, US + MBs generated a significant increase in macro-
phages (not shown) and Tregs (Fig. 39b) compared to control.
Interestingly, the αPD-l and US + MBs groups performed similarly
in CD4+ and CD8+ cell counts (Fig. 39b), but the combined US +
MBs + αPD-1 treatment generated fewer T cells than either
treatment alone. In immunocompromised animals, treatment with
US + MBs did not provide tumor growth control (Fig. 39c) or a
survival benefit (not shown), but did generate a significant de-
crease in M1 macrophages within the tumor (Fig. 39d), although
total myeloid cell counts remained the same (not shown).
Conclusions
US indiscriminately increases the numbers of immune cells within
subcutaneous melanoma; therefore, we expected that US-
enhanced delivery of αPD-1 would provide an additional benefit;
namely, a shift towards an anti-tumorigenic immune profile. How-
ever, αPD-1 did not synergize with US + MB treatment. While the
mechanism is not yet understood, low power noninvasive US +
MBs provided excellent tumor growth control and may serve as a
stand-alone clinical treatment. Furthermore, this anti-tumor effect
is clearly dependent on the adaptive immune system, since US +
MBs treatment in immunocompromised mice produced no
benefit. A better understanding of this mechanism may identify
adjunct treatments that would synergize with US and further en-
hance the anti-tumor effect demonstrated here.
Reference
1. Burke, C. W. et al. Ultrasound-activated agents comprised of 5FU-bearing
nanoparticles bonded to microbubbles inhibit solid tumor growth and
improve survival. Mol. Ther. 22, 321–8 (2014).
Fig. 40 (abstract A39). Multiple retroperitoneal lymphnodes in
patient with pancreatic cancer
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Stress response of cancer cells after low intensity Focused Ultrasound
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Objectives
Low intensity Focused Ultrasound (LOFU) results in sublethal stress
to tumor cells. We investigated the cell surface expression of immu-
nomodulatory molecules in three murine cell lines (Lewis lung, breast
and prostate adenocarcinoma). The immunomodulation was exam-
ined by flow cytometry of cell surface stress proteins: HSP70 & calre-
ticulin, of immunomodulatory co-activating signals: CD40, CD80,
CD86 and other receptors: MHC I, Fas). Surface expression of these
molecules trigger activation of or phagocytosis by dendritic cells.
Additionally, the activation of the unfolded protein response (indi-
cated by phosphorylation of PERK or IRE1α or cleavage of ATF6α) can
trigger apoptosis – a programmed cellular death pathway which can
also activate the immune system. We hypothesize that by altering
the total acoustic power of LOFU, we can modulate the stress signals
both on the cell surface and within the cells.
Methods
LOFU treatment was performed on the Philips Therapy and Imaging
Probe System (TIPS, Philips Research Briarcliff, USA) using 3 W or 5 W,
100 % duty cycle, 1.5 seconds, 1 mm spacing. LOFU treatment was per-
formed on a cell pellet which were then replated and incubated at 37 °C,
5 % CO2 for the specified time. At the end of the incubation time, cells
were lightly scraped for flow cytometry staining or lysis buffer was added
to the adherent cells and then scraped for Western blot analysis.
Results
The analysis of murine lung and breast cancer indicates that there is a
significant surface localization of both HSP70 and calreticulin as early as
4 hours after LOFU treatment and this localization diminishes by 24 hours
post treatment. For murine prostate cancer cells, however, the surface
localization of HSP70 increases at 4 hours after treatment and increases
further at 24 hours. Additionally, there is a significant increase in surface
localization of both HSP70 and calreticulin with a higher output power of
5 W compared to 3 W. For immunomodulatory co-activating signals,
there is increased surface expression in Lewis lung carcinoma and pros-
tate adenocarcinoma, but not breast carcinoma. Results of the activation
of the unfolded protein response are still pending at the time of submis-
sion, but preliminary results indicate the both phosphorylation of PERK
and IRE1α are increased following LOFU treatment.
Conclusions
Tumor stress response to LOFU treatment can be altered by the total
acoustic power of LOFU treatment. The increased surface localization
of HSP70, calreticulin, CD40, CD80 and CD86 have the capacity to
augment the immune response to the tumor. Therefore, LOFU can
be used in combination with ablative therapies in order to induce
anti-tumor immunity and destroy the primary tumor.
A39
The “abscopal” effect after USgHIFU treatment of advanced
pancreatic cancer
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Objectives
Pancreatic cancer is considered one of the main big “killers” in
Oncology, with still a very poor prognosis, both in patients amen-
able to resection and of course in more advanced stage disease.
More than 50 % of patients are diagnosed with an advanced
stage disease, where chemotherapy is usually the main therapyoption. External radiotherapy is the most common palliative loco-
regional treatment in pancreatic cancer, but in the last few years
HIFU has been proposed as an alternative option for palliation in
advanced stage.
From our specific experience of USgHIFU for pancreatic cancer, we
report few cases of ABSCOPAL effect: where after a local treatment
not only the target tumor but also the distant deposits will shrink
Methods
From 2008 until April 2016, 72 consecutive patients affected by pan-
creatic tumors were selected by a dedicated Tumor Board for receiv-
ing treatment with USgHIFU, for local tumor control and palliation.
64 % of patients were affected by pancreatic adenocarcinoma and
84 % of all the treated tumors were located at the level of pancreatic
head. Majority of the patients had at least two lines of chemotherapy
and 45 % of them received concurrent and/or consequent external
RT. USgHIFU treatment was performed always during general
anesthesia with GI catheter and abdominal compression with a dedi-
cated water balloon in order to reduce the distance between the
HIFU probe and the target and for push the bowel loop away from
the acoustic treatment window. Patients were than evaluated by clin-
ical and instrumental follow up.
Results
All the procedures were technically successful, with only one
main complication due to a complete portal thrombosis devel-
oped 24 hrs after treatment. Objective response (OR) at MDCT,
MRI and PET was 64 % with a disease control (DC) up to 90 %
of all the patients. Pain was palliated in 23/27 of symptomatic
patients. In four patients (4/46 with adenocarcinoma) the imaging
follow up after the treatment revealed the shrinkage of metasta-
ses located in other sites: 2 retroperitoneal lymphnode (Figs. 40
and 41), 1 liver and 1 lung.
Conclusions
In advanced pancreatic carcinoma, HIFU can have a role in locally
advanced unresectable disease. Based on our limited experience,
HIFU could be also suggested in a metastatic setting (Stage IV),
together with systemic therapy, with the potential benefit of be-
ing effective also outside the treated target (abscopal effect).
There are few papers reporting the effect of HIFU as a booster of
immune response in cancer patients, but there are still no data
supporting the use of this non-invasive approach in advanced
cancer patient just for this purpose. Specific dedicated clinical
trial should be conducted for better understand the biological
mechanism behind it.
Fig. 41 (abstract A39). 18 months after HIFU, CT shows the
complete response at the level of metastatic lymphnodes Fig. 42 (abstract A40). Intrarenal cytokine concentrations 48 hours
after BH and SHAM treatment
Fig. 43 (abstract A40). Immunohistochemistry appearance of CD8+
T-cells in BH treated (*) tumor (T) kidney, in the BH treated contralat-
eral kidney, and in SHAM treated
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Characterizing the immune response to boiling histotripsy ablation
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Objectives
Boiling histotripsy (BH) is an experimental non-invasive Focused
Ultrasound (US) technology. BH uses milliseconds-long US pulses at
low duty cycle to mechanically homogenize targeted tissue. We aim
to evaluate the adaptive immune response to BH ablation of spon-
taneous renal tumors in the Eker rat hereditary renal carcinoma
(RCC) model.
Methods
Genotyped Eker rats (Tsc2 heterozygotes) were monitored for de
novo RCCs with serial US until tumors were ≥8 mm. Syngeneic Wild-
type (WT) (planned total n = 36) and Eker rats (planned total n = 48)
were then randomly assigned to BH (n = 10 total to date) or an US
SHAM procedure (n = 22 to date). BH was performed extracorporeally
using US-guided small animal FUS system (VIFU-2000, Alpinion). The
1.5 MHz transducer was operated at duty cycle of 1 %, 10 ms pulses,
525-550 W electric power. Treatments targeted a ~0.5 cc area of the
lower pole in WT rats and the largest RCC with a margin of normal
kidney in the Eker rats. Blood samples were collected immediately
before treatment and serially post-treatment. Rats were euthanized
at 48 hrs, 7 days, 14 days, or 56 days following treatment. At euthan-
asia, ipsilateral and contralateral kidneys, hilar lymph nodes, and the
spleen were collected. Intrarenal and circulating plasma cytokines
were assessed using a 10 cytokine multiplex assay. Renal/tumor infil-
trating leukocyte populations were assessed using immunohisto-
chemistry. Leukocyte populations in tumor draining hilar lymph
nodes and spleens were assessed with flow cytometry.
Results
BH treatment has been successful in all treated (n = 4 Eker, n = 6
WT to date) subjects, producing hypoechoic regions on US con-
sistent with BH treatment effect. BH treatment was associated
with significantly increased mean relative-plasma TNF-α vs. sham
treatment at 0.25 (p = 0.02), 1 (p0.04), and 24 (p = 0.05) hours. At
48 hours, significant differences in intra-renal cytokines were ob-
served in BH (n = 4) vs SHAM (n = 4) treated rats: IFN-gamma, IL-
10, and IL-8 with trend towards differences in TNF-alpha and IL-6
(Fig. 42). On immunohistochemistry, BH treated Eker rats had in-
creased CD8+ T-cells in both the treated and contralateral kidney
compared to SHAM treated rats at 48 hours (Fig. 43). Addition-
ally, increased infiltration of f4/80+ M1 macrophages into the
treated kidney, was observed in 2/4 BH treated rats vs. SHAM at
48 hours. Longer-term data is pending at this time.Conclusions
These data represent preliminary findings indicating differences in
cytokines and tumor infiltrating leukocytes between BH treated and
SHAM treated Eker rats up to 48 hours post-treatment. Assessment
of longer-term immune effects of BH treatment and their significance
is on-going and will be reported.A41
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Objectives
In High Intensity Focused Ultrasound (HIFU) applications, nonlinear
acoustic effects can result in the formation of high-amplitude shock
fronts in focal waveforms, with amplitudes exceeding 100 MPa. The
presence of such shocks leads to increased tissue heating which can
be beneficial for HIFU thermal therapy. The goal of this work was to
evaluate the efficacy of different shock-wave exposures to accelerate
thermal ablation of tissue volumes while enabling safer conditions
for intervening tissues.
Methods
Simulation studies were performed for a multi-element 1.2 MHz HIFU
phased array of a clinical system (Fig. 44a, Sonalleve V1, Philips, Van-
taa, Finland) for three different peak intensity levels at the array ele-
ments of 1.2, 8, and 15 W/cm2. A pulsing scheme was combined
with discrete electronic steering of the array focus over a series of
foci separated about 1 mm and arranged in 4 concentric circles
(Fig. 44b). The circles were positioned in a plane at 25 mm depth in
liver tissue of 50 mm thickness (Fig. 44a). The period between con-
secutive pulses was 20 ms. Pulse duration was varied to keep a con-
stant time-average intensity at the array elements: 20 ms at 1.2 W/
cm2, 3 ms at 8 W/cm2, and 1.6 ms at 15 W/cm2. The Westervelt
equation combined with the bioheat equation was used for
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in tissue was 20 °C, sonication was performed starting from the center
and spiraling outward until a thermal dose of 1.76 s at 56 °C (equivalent
to 240 CEM at 43 °C) was reached at each circle of the trajectory.
Results
The focal waveforms simulated in tissue for different peak intensities
representing quasilinear sonication (1.2 W/cm2), sonication with a fully
developed shock of 95 MPa at the focus (8 W/cm2), and sonication with
higher focal shock amplitude of 118 MPa (15 W/cm2). Tissue ablation
was achieved much faster at higher peak intensities with more clearly de-
fined boundary between treated and untreated tissue. While temperature
distributions and thermal dose contours in the focal plane were similar in
shape for each trajectory and intensity level, corresponding distributions
in the axial plane varied greatly. Slower heating at 1.2 W/cm2 resulted in
strong heat diffusion in the axial direction and much larger ablation vol-
umes. On the contrary, with rapid shock-wave heating, the ablated tissue
volume followed the geometry of the targeted heat deposition. Although
overall ablated volumes were smaller at higher peak intensities, the abla-
tion rate was the highest at 15 W/cm2.
Conclusions
In comparison with conventional HIFU treatments, shock-wave expo-
sures provide higher ablation rates at target sites with less heat diffu-
sion to the surrounding tissues. Shock-wave heating regimes may
therefore be clinically advantageous for accelerating thermal HIFU
treatments, reducing the heating of surrounding tissues, and providing
sharper margins of lesion volumes.Fig. 44 (abstract A41). a Geometry of the numerical experiment: US
beam is focused at the center of a 5 cm thick tissue layer. b Trajectory
of the focus in the focal plane comprising 4 circles of 1, 2, 3, and 4 mm
radii with 1 mm distance between the foci in each circle
Fig. 45 (abstract A42). MRI of ex vivo sample following treatment.
Scan plane orthogonal to transducer acoustic axis and positioned at
geometric focusA42
Effects of dosing and focal spacing in rapid ablation of large tissue
volume using histotripsy with electronic focal steering
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Objectives
Current tumor ablation techniques, typically thermal-based, are either
limited to treating tumors <3 cm in diameter (RFA and microwave) or are
very slow (HIFU). Because histotripsy uses microsecond-length pulses sep-
arated by up to seconds of off-time for a given focus, it is possible to
electronically steer the therapy focus of a phased array transducer to ex-
cite cavitation events throughout a large volume consisting of many foci
during the off-time. We hypothesize that histotripsy combined with elec-
tronic focal steering can achieve rapid ablation of a large volume. This hy-
pothesis was investigated in this paper, and the effects of number of
pulses per focal location and focal spacing on tissue damage generated
using histotripsy with electrical focal steering were studied.
Methods
Histotripsy was applied using a 250 kHz, 256-element hemispherical
phased array transducer with a 15 cm focal distance, generating 1.5-cycle,
6-microsecond pulses. Each element produced ~0.5 MPa P- individually,
but focal pressure produced by all elements could not be measured dueto cavitation. To establish treatment parameters including pulse repeti-
tion frequency (PRF) and number of pulses (dose) to deliver, a single-
focus lesion was generated in tissue-mimicking phantoms containing a
thin layer of red blood cells (RBCs) and monitored by optical imaging.
Based on these results, 35 ex vivo bovine hepatic tissue samples were
treated by electronically scanning the therapy focus at 200 Hz over 1000
sites (or .2 Hz per focal site) (Fig. 45). To evaluate the dose required for
complete tissue fractionation, dose was varied between 20-120 pulses
per focus. Focal spacing was varied from 2.5, 3.15, and 3.5 mm in the
lateral direction and held constant at 4.1 mm in the axial direction to as-
sess the extent of overlap between adjacent foci required to achieve
complete homogenization. Lesion size was assessed by gross morph-
ology and Magnetic Resonance Imaging (MRI). The degree of tissue frac-
tionation was examined by histology (Fig. 46). Surrounding tissue
temperature was measured by thermocouples 1 cm from the lesion.
Results
RBC phantom results suggested that fractionation efficiency was optimal
near 0.2 Hz and that 120 pulses were sufficient to achieve complete
homogenization. Using lateral spacing≥ 3.15 mm or < 100 pulses, unfrac-
tionated tissue structures were observed between foci. Using 2.5 mm lat-
eral focal spacing and 120 pulses per focal location, complete,
homogeneous tissue ablation of 43 +/- 6 mL region was achieved within
10 minutes, resulting in an ablation rate of 4.3 mL/min. A temperature in-
crease of ~4 ° C was measured at the surrounding tissue. This work dem-
onstrates that histotripsy combined with electronic focal steering can
achieve rapid ablation of large volume at a rate more than double the
rate of current available ablation techniques such as RFA.
Conclusions
Treatment of large and multiple tumor nodules remains a challenge for
current tumor interventions, which are mostly thermal-based. This work
demonstrates that histotripsy combined with electronic focal steering
achieved homogenous and complete ablation of a large target volume
at a rate greater than two-fold faster than microwave and RF ablation.
Since histotripsy is non-thermal, the treatment should not be affected
by the heat sink effect and is expected to remain effective and efficient
even in highly vascular organs. With the capability of achieving rapid,
homogenous cell disruption, histotripsy has the potential to substan-
tially improve upon current tumor ablation methods.
Fig. 46 (abstract A42). H&E histology. Left to right: inside lesion;
lesion boundary; > 1 mm outside lesion boundary
Fig. 47 (abstract A43) The screenshot shows the TRANS-FUSIMO
treatment system during the execution of a sonication in
a phantom
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Objectives
The movement of the liver under breathing and its partial occlusion
by the rib cage challenge the application of High Intensity Focused
Ultrasound (HiFU/MRgFUS) for the thermal treatment of tumors. To
explore the full potential of extracorporeal FUS to safely and
precisely destroy tissue in the depth of the moving liver requires
sophisticated technology. The European FUSIMO consortium
(www.fusimo.eu) has shown in a proof of concept experiment that
patient specific image processing, mathematical modeling of the or-
gan’s motion, ultrasound propagation in the moving organ, and tis-
sue heating is such enabling technology that empowers a physician
to perform safe, effective and efficient ablation of tumors and to
facilitate prediction of the outcome. In TRANS-FUSIMO (www.trans-
fusimo.eu) the consortium is currently developing a prototype of a
fully integrated system for the FUS treatment of the liver, which will
be evaluated in an animal study and a patient study.
Methods
The TRANS-FUSIMO system comprises three sub-systems:
1. a planning software that incorporates image processing,
motion modeling and prediction, as well as FUS simulations.
This part of the system allows to plan and to assess the
feasibility of the treatment;
2. a treatment system that performs the actual treatment control
using previously evaluated treatment plans, as well as model
based MR/US motion tracking and prediction and MR
thermometry (Fig. 47);
3. a training system which acts as a treatment simulator that is
based on real cases and the simulation of FUS propagation,
tissue heating, and organ motion.
Thereby, the treatment system fully integrates with the GE MR scan-
ner and the InSightec ExAblate Conformal Bone System (CBS). The
control system and the model components have been validated in
phantom and ex vivo experiments. Currently, the safety, efficacy and
efficiency of the system are being evaluated in an in vivo animal
study. Following, a two-arm study (neoadjuvant TRANS-FUSIMO
MRgFUS + resection, TRANS-FUSIMO MRgFUS only) for human pa-
tients with metastases or HCC will show the feasibility of the TRANS-
FUSIMO prototype for the clinical setting.
Results
The core of the TRANS-FUSIMO system comprises patient specific
models for the motion of the liver under breathing, ultrasound
propagation, and thermal damage. On the one hand the models areused for the planning of the treatment and in the training system.
On the other hand the models are used to augment US/MR data dur-
ing the treatment in order to achieve motion compensation and
thermal monitoring.
Conclusions
The ex vivo validations show the safety and efficacy of the system
under regulated motion of phantoms. Furthermore the validations
show that the system fulfills all specification requirements. The cur-
rently running animal study will be the basis for a following two arm
patient study.A44
Multifunctional robotic platform for USgFUS
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Objectives
Despite its promising results, FUS suffers from limited flexibility in
therapy delivery, which narrows the applicability to non-moving and
non-essential organs, mainly under Magnetic Resonance Imaging
(MRI). We strongly believe that a robotic-assisted approach may offer
the chance to overcome the current limitations of FUS by guarantee-
ing high robustness, flexibility/adaptability and precision of therapy.
In this framework, the FUTURA (Focused Ultrasound Therapy Using
Robotic Approaches) project (www.futuraproject.eu) is developing an
autonomous, multi-functional and multi-robotic assisted platform
able to perform non-invasive FUS on abdominal organs under US
monitoring (USgFUS).
The FUTURA platform (Fig. 48) consist of: i) two six degrees of
freedoms anthropomorphic manipulators, ii) a dedicated broad-
band 16 channels wave generator and a 16 channels annular
array HIFU transducer; iii) two different US probes both con-
nected to an acquisition system (SonixTablet, Analogic Ultra-
sound). The control architecture is implemented by using Robot
Operating System software (ROS) with a purposely developed
HMI.
Methods
The FUTURA architecture allows to maximize the flexibility of the
procedure both for organs targeting and during the sonication pro-
cedure and lesion assessment. In addition, the FUTURA robotic inte-
grated approach allows for safe interaction and cooperation between
robots, patient and medical staff by using environmental reconstruc-
tion sensors.
In order to demonstrate the unique features of the FUTURA plat-
form, several tests have been performed in in vitro and ex vivo
static conditions by using a home-made tissue-mimicking phan-
tom made up by a bulk of agar gel with internal cylinders (repre-
senting the targets of the therapy), based on polyacrylamide gel
Fig. 49 (abstract A44). Workflow of the robotic-assisted FUS
procedure that includes: a Pre-Treatment; b Treatment and c
Post-Treatment phases
Fig. 50 (abstract A44). Optical images of the lesion induced by the
HIFU transducer during the sonication phase into a tissue-mimicking
phantom (a) and into ex-vivo tissues - porcine liver (b) and breast
chicken (c)
Journal of Therapeutic Ultrasound 2016, 4(Suppl 1):31 Page 28 of 113(PAA) mixed with egg white and ex vivo material (i.e. porcine
liver or breast chicken instead of PAA cylinders into an Agar
structure).
The complete workflow of the FUTURA procedure is reported in
Fig. 49; more specifically, the effective use of two US imaging
probes during different phases of the lesion treatment has been
carried out. The sonication is composed by 10 repetitions of
1 second with 90 % duty cycle. The value of frequency and
acoustic power of the sonication are 1200 kHz and 120 Watts,
respectively.
Results
During the target identification phase, both the US imaging
probes are used. Although the US confocal probe is rigidly at-
tached to the HIFU transducer, the FUTURA platform maintains
US imaging flexibility thanks to the 3D US probe mounted on
the second manipulator. The 3D US phantom reconstruction and
the related 2D US confocal images acquired before sonication
show the target without any lesion. In addition, the estimated
HIFU transducer focus, located in the center of the target, as-
sesses the correctness in positioning of the therapeutic manipula-
tor (intersection of blue lines in pictures B.I-II-III). During the
sonication process an on-line monitoring of the lesion is per-
formed by exploiting a PWM signal for the HIFU transducer gen-
erator. Finally, the 3D US phantom reconstruction and the related
2D US confocal images acquired after sonication allow the lesion
assessment (i.e., accuracy better than 1 mm). An optical assess-
ment on the sectioned targets in proximity of the performed le-
sion was also carried out (Fig. 50). Finally, a specific analysis of
the HIFU properties has been performed by observing the typical
dimensions of the lesions induced by the transducer into the
breast chicken tissue at different output power and duration of
exposure (Fig. 51).
Conclusions
The most important features of FUTURA platform have been
demonstrated. This work assesses the possibility to use a robotic
platform for USgFUS treatment, using two US imaging probe for
the different phases of the procedure. Synchronizing the HIFU
transducer shot with the US imaging acquisition enables to moni-
tor the lesion progress during the sonication phase, which is very
important for patient safety. In addition, the use of both US
probes during the sonication phase enables the tracking of mov-
ing 3D organs.
Future work will be carried out to assess the accuracy of USg-
FUS treatment under dynamic condition and a qualitative
temperature estimation technique (e.g., by means of elastogra-
phy) for the assessment of thermal effects will be integrated in
the analysis.Fig. 48 (abstract A44). FUTURA platform
Fig. 51 (abstract A44). Optical images and typical dimensions of
the lesions induced by the HIFU transducer into breast chicken
at different output power and duration of exposure. In the
first image, sonication power of 64 W for 5 sec, the lesion
is imperceptible
Fig. 52 (abstract A45). Liver motion tracking on US image. Arrows
show the displacement of the feature related to a reference image
due to liver motion. The red discs show a relative measure of
positional uncertainty
Fig. 53 (abstract A45). Liver motion tracking on MR-EPI images.
The arrows show the displacement from the reference frame. Blue
discs show the position uncertainty
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Objectives
The ablation with HIFU/FUS would be a fantastic tool for liver tumor
treatment and would lead to an invaluable benefit for patients suffer-
ing from malignant liver metastasis or hepatocellular carcinoma. How-
ever, FUS of liver has still not yet reached a significant clinical spread,
particularly in the western world. There are two major challenges for
FUS ablation of the liver: the rib cage and the permanent motion of the
liver, e.g. due to respiration. Both, MRI as well as diagnostic US imaging
are suitable to provide real-time information about the liver positon.
For several years, we have been developing and improving US and MR
based motion tracking for HIFU/FUS, e.g. currently in the European
TRANS-FUSIMO project (www.trans-fusimo.eu). A further goal of the
presented work is the automated detection of suited tracking features
and the assessment of feature quality on MR and US image data.
Methods
US or MR image streams are analyzed in real-time to track liver mo-
tion. In a first step, pronounced structures, like the diaphragm, or
landmarks/features like liver vessels are automatically detected or
manually defined on 2D US or MR-EPI images. For motion tracking, a
particle filter-based algorithm evaluates state hypotheses of local af-
fine transformations to follow these features through the image
stream. Data fidelity is assured by not only tracking each landmark
separately, but also incorporating information about global motion.
For each landmark, an estimate of the current position and the
current uncertainty of that estimate is provided. Features with high
uncertainty may then be ignored in following processing steps or re-
placed by more stable landmarks by the algorithm. For use in an ap-
plication, the output of the algorithm is sent to the HIFU/FUS
treatment unit, which can incorporate the data into further motion
compensating components. This may either be established through
direct beam steering of the FUS focus or by gating the therapy.
Results
US as well as MR based liver tracking was evaluated in different
phantom experiments and on data from volunteers. Figures 52
and 53 show US and MR liver images with sample data provided
by the algorithm. The arrows show the displacement of the fea-
ture related to a reference image due to liver motion. The discs
indicate a relative measure of positional uncertainty. Automated
feature detection, e.g. of blood vessels in EPI liver images, en-
abled fast and reliable definition of tracking features. Automated
tracking quality assessment allowed a reliable detection of poor
quality features which were replaced to allow a stable and reliable
tracking over longer time periods. The mean tracking error on US
liver images was 1.5 mm in 2D and 2.79 mm in 3D with a process-
ing time of about 2 ms/frame. 1.7 mm was the mean error of MR
based liver tracking with a computing time of 2 ms/frame and
feature.
Conclusions
Quasi real-time liver motion tracking in 2D and 3D based on diagnostic
ultrasound image streams as well as on ultra-fast MR image data is
feasible, reliable and offers a sufficient precision for motion compen-
sated HIFU/FUS therapy. Besides regular and irregular respiratory mo-
tion also liver drifts due to peristalsis and gravity on longer time scales
can be compensated, since this technique is based on live image data.
Integration of the tracking into existing clinical USgFUS and MRgFUS
therapy units should be possible without great efforts. The presented
tracking method is currently being integrated into an MRgFUS therapy
setup for the treatment of liver tumors within the TRANS-FUSIMO pro-
ject. A first clinical trial is planned at the beginning of 2017.A46
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Fig. 55 (abstract A46). HMIFU results in a KPC tumor. The tumor is
delineated on the high-resolution Bmode image (a). The variation of
the mean HMI displacement in the tumor during ablation is moni-
tored (b). Corresponding HMI maps with values relative to the base-
line at t = 0 are shown for t = 4 s, 32 s and 60 s (c) showing the
progressive stiffening of the ablated tissue
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Pancreatic ductal adenocarcinoma (PDA) is one of the deadliest can-
cers with the lowest prognosis due to late diagnosis. PDA is charac-
terized by an unusually dense stroma limiting chemotherapy
perfusion. Harmonic Motion Imaging (HMI) assesses tissue mechan-
ical properties by inducing localized oscillation resulting from a
periodic acoustic radiation force. The amplitude of the induced dis-
placement is directly related to the underlying tissue stiffness. The
sonication is kept short for imaging (HMI) without tissue damage or
the duration is prolonged for simultaneous HMI and HIFU treatment
(Harmonic Motion Imaging for Focused Ultrasound or HMIFU).
This study first aimed at using HMI for characterizing the develop-
ment of pancreatic tumors as a function of size and fibrosis extent in
the KPC genetically-engineered mouse model. Secondly, the tumors
were treated using HMIFU. HMI measurements were then resumed
to monitor the mechanical changes resulting from the treatment.
Methods
A 4.5-MHz Focused Ultrasound transducer (FUS) generated an
amplitude-modulated beam resulting in harmonic tissue oscillations
at its focus. Axial tissue displacement was estimated using 1D cross-
correlation of RF signals acquired with a confocally aligned, 7.8-MHz
diagnostic transducer (P12-5, ATL) using a plane-wave beam se-
quence at a framerate of 1 kHz. Imaging was performed with 0.2 s
sonication for each scan position, when treatment required 60-s long
sonications which were shown to generate lesion in this model ac-
cording to previous work by our group. KPC mice were genetically-
engineered to develop pancreatic tumors with pathophysiological
and molecular features similar to those of human PDA. Pancreatic
tumor growth was monitored for 15 days with HMI scans performed
every two days. For the second part of the study, HMIFU was per-
formed on 5-mm tumors. The success of the treatment was assessed
by measuring both the tumor area and its elasticity up to 14 days.
Results
HMI demonstrated its capability to provide reproducible elasticity mea-
surements in murine pancreatic tumors. Figure 54 shows that stiffening
occurs progressively during pancreatic tumor growth from the very early
stages. When plotting the HMI displacement against the tumor size, an
exponential trend was fitted to the data with R2 > 0.87 in accordance to
general models. When ablated with HMIFU for 60s, the tumor stiffened
displaying a decrease in HMI displacement (Fig. 55). The lesion was con-
firmed by histology. The follow-up of the HMIFU treatment is performed
with HMI to assess long-term tissue mechanical changes after treatment.
Conclusions
These results demonstrate the capability of HMI to provide elasticity
measurements in the KPC murine pancreatic tumor model. The tech-
nique monitored the tumor growth as well as its stiffening when
treated with HMIFU. Post-treatment mechanical changes could also be
assessed with HMI. This study underlines the potential of HMI for moni-
toring tumor growth, treatment and follow-up changes in elasticity.Fig. 54 (abstract A46). Pancreatic tumor development in 3 KPC
mice over time during the early growth. The HMI displacement
which is inversely related to the tissue stiffness is plotted against the
diameter measured on Bmode imagesA47
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Objectives
Endoluminal and endovascular catheter-based high-intensity ultra-
sound offer spatially-controlled thermal ablation in tissue targets ad-
jacent to body lumens, such as the pancreas, liver, prostate, heart,
etc. Due to the size constraints necessary for applicators to traverse
through luminal passages, the integrated therapeutic transducers
have minimal aperture size, limiting the depth of energy and thermal
penetration typically to within a few centimeters beyond lumen bor-
ders. This study introduces concepts for a deployable applicator that
features inflatable balloon reflectors and adjustable fluid-lenses to
permit compact delivery and expansion at target sites (e.g. stomach,
bladder, colon) to augment the effective therapeutic aperture for
deeper and more selective heating generation. A preliminary theoret-
ical analysis of potential designs, incorporating acoustic and thermal
parametric studies, was performed along with benchtop proof-of-
concept experiments as an initial investigation of the feasibility and
capabilities of this design strategy.
Methods
Two applicator designs, representing end-firing and side-firing con-
figurations, were conceptualized and modeled, as shown in Fig. 56.
The end-firing configuration consists of an array of tubular transduc-
ers surrounded by an expandable conical balloon that reflects acous-
tic energy into a fluid lens at the applicator’s distal tip. The side-firing
configuration consists of an array of planar and tubular transducer
segments surrounded by a parabolic reflector balloon that diverts en-
ergy through a fluid lens adjacent to the assembly. Acoustic simula-
tions of the two assemblies were performed using a MATLAB
implementation of the rectangular radiator method and incorpor-
ation of reflection/refraction of wave-fronts at material interfaces
through the method of secondary sources. Thermal modeling,
Fig. 57 (abstract A47). Intensity gain along the central
longitudinal axis for the end-firing assembly as a function of
lens focal length, as simulated in water. The 1.5 MHz tubular
transducer was 8 mm OD x 20 mm height, leading to a 45 mm
reflector/lens aperture diameter
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temperature distributions in homogenous and heterogenous tis-
sue models. Parametric studies were performed to investigate
performance of different potential lens fluids, and to evaluate
acoustic focal gain and heating as functions of applicator/re-
flector/lens dimensions and geometries. Hydrophone beam plot
measurements were made for a proof-of-concept end-firing appli-
cator, consisting of a mounted tubular transducer centered in a
conical brass reflector and covered by a perfluorocarbon fluid
lens with adjustable radius-of-curvature (ROC).
Results
Of the three potential lens fluids investigated (perfluorocarbon, sili-
cone oil, and chloroform), perfluorocarbon offers the best acoustic
transmission at lens focal lengths ranging from 0-100 mm, due to its
greater speed-of-sound mismatch as compared to water or tissue. As
demonstrated in Fig. 57, simulated achievable focal gain for either
device configuration increases as a function of lens focal length to a
maximum between ~20-50 mm, depending on the overall deploy-
able reflector/lens size and tissue attenuation. Thermal simulations in
homogenous muscle tissue with the end-firing configuration indicate
capabilities of creating localized (~1 cm long X 5 mm wide) or
volumetric (~3 cm long X 2 cm wide) ellipsoid thermal lesions at vari-
able depths up to and beyond 5-6 cm in the tissue, as demonstrated
in Fig. 58. Hydrophone beam plots of the preliminary proof-of-
concept assembly illustrated capability of dynamically adjusting the
focal plane depth between ~1-5 cm by adjusting the lens ROC, as
shown in Fig. 59.
Conclusions
Preliminary theoretical and experimental investigations illustrate cap-
abilities of using reflector and fluid lens assemblies coupled with
endoluminal ultrasound to produce deeper and dynamically-variable
acoustic focuses and thermal lesions.Fig. 56 (abstract A47). Endoluminal ultrasound applicators with
deployable balloon reflectors and adjustable fluid lenses, in either a)
end-firing or b) side-firing configurations
Fig. 58 (abstract A47). Simulated temperature distributions and
52 °C contour (black) in muscle tissue using the end-firing as-
sembly, with specifications as in Fig. 57. Sonication duration
was for (a) 10 s and (b) 120 s at 5 W/cm2 constant surface
intensity input
Fig. 59 (abstract A47). Hydrophone pressure-squared contours for
the proof-of-concept end-firing assembly, showing tight focusing
capabilities at two distinct lens focal lengths, a ~20 mm and
b ~35 mm
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Objectives
Systemic therapies for advanced stage IV abdominal tumors as stand-
ard chemotherapy regimens usually lack efficacy, and often this is
substantially reduced by means of toxicity. Hyperthermic therapies
have demonstrated efficacy alone by themselves and as well as con-
current treatments along with chemotherapy and/or radiotherapy.
Focused ultrasound has been increasingly used as a method to en-
hance drug delivery. Several previous experiences have used this ap-
proach to improve tumor control in different types of tumors and
with different chemotherapy drugs.
Methods
This is a feasibility study to increase delivery of the chemother-
apy drug to the tumor. We have employed Ultrasound guided
High Intensity Focused Ultrasound (USgFUS) along with concur-
rent standard chemotherapy treatments in a clinical setting with
abdominal tumors. We have included advanced stage IV liver
metastases from colo-rectal tumors, advanced stage IV pancreatic
tumors and advanced stage IV retroperitoneal sarcomas. All pa-
tients were previously treated with and failed at least to 2
chemotherapy lines. Patients should not be candidates for tumor
ablation. Patients will receive 3 FUS treatments concurrent with
their chemotherapy infusions. FUS therapies are delivered the day
of the chemotherapy infusion, the day before and the day after
the chemotherapy. FUS treatments are on the range of 100 Watts
for 45 minutes average. The objective is to cover maximum volu-
metric treatment.
Results
We measure performance status, complications rate, quality of
life, symptoms control, pain control, and time to progression.
Blood samples for functional studies and tumor markers as well
as immunological studies: lymphocyte profile, immunoglobulines,
complement, CRP were taken at daily basis during FUS treat-
ments. MRI images were obtained previously and immediate after
FUS treatments.
Conclusions
Study is in progress. We will report updated results at the meeting.
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David Melodelima1, Aurelien Dupre2, Jeremy Vincenot1, Chen Yao2,
David Perol2, Michel Rivoire2
1LabTAU - INSERM U1032, Lyon, France; 2Centre Leon Berard, Lyon,
France
Journal of Therapeutic Ultrasound 2016, 4(Suppl 1):A49Objectives
Surgical resection is the only curative option for colorectal liver me-
tastases (CLM), however, only 10 to 20 % of patients are suitable for
surgery. High intensity focused ultrasound (HIFU) has been proven
effective in a wide range of clinical applications. The liver is a particu-
larly challenging organ for HIFU treatment due to the combined ef-
fect of respiratory-induced liver motion and partial blocking by the
rib cage. A HIFU device based on toroidal transducers has been de-
veloped to enable the destruction of large liver volumes. Preliminary
in vitro and in vivo studies demonstrated the feasibility, efficacy and
safety of such HIFU ablations. This preclinical work is now translated
into clinical practice. The aim of this study was to assess the feasibil-
ity, safety and accuracy of HIFU ablation in patients undergoing hep-
atectomy for CLM.
Methods
This study was a prospective, single-centre phase I/II study. The HIFU
transducer has a toroidal shape and was divided into 32 concentric
rings of equal surface (0.13 cm2). The diameter of the transducer and
its radius of curvature were 70 mm. The operating frequency was
3 MHz. A 7.5 MHz ultrasound imaging probe was placed in the cen-
ter of the device. The imaging plane was aligned with the HIFU
acoustic axis. Nineteen patients were included in Phase I-IIa. In each
patient two HIFU ablations were created. In step 1, ablations were
centered in a target previously identified in ultrasound images. In
step 2, ablations were created at distance from a target. Eight pa-
tients were included in Phase IIb and ten metastases (20 mm max-
imal diameter) were treated until now. HIFU ablations were created
to ablate metastases with safety margins in all directions. The expos-
ure time was adjusted from 40 seconds to 370 seconds according to
the diameter of the metastases. For this first evaluation of the device,
ablations were performed within the areas scheduled for resection.
This study is registered with Clinical-Trials.gov (NCT01489787).
Results
The dimensions of ablations measured on ultrasound imaging were cor-
related (r = 0.88, p < 0.001) with dimensions measured on gross path-
ology. The average dimensions of HIFU ablations obtained in 40 seconds
(Phase I) were a diameter of 21.0 ± 3.9 mm and a long axis of 27.5 ±
6.0 mm. The phase IIa study showed both that the area of ablation could
be precisely created in the liver with a precision of 1-2 mm. It was pos-
sible to target about 90 % of the liver and all major anatomical structures.
In Phase IIb, one metastasis of 10 mm in diameter was ablated in 40 sec-
onds with safety margins. Using electronic focusing nine metastases of
2 cm in diameter were ablated with safety margins (>3 mm in all direc-
tions) in 370 seconds. The dimensions of these HIFU ablations were a
diameter of 48.0 ± 4.9 mm and a long axis of 51.0 ± 3.4 mm. No lesions
occurred in surrounding tissues. Two patients had a post-operative com-
plication (pneumonia with pleural effusion and a urinary tract infection)
not related to the HIFU treatment. There were no significant changes in
hemodynamic and respiratory parameters.
Conclusions
This HIFU device safely achieved large and fast volume of liver ablation,
with a precision of one to two millimeters. HIFU ablations of metastases
with a diameter of less than 2 cm were successfully created with safety
margins of at least 3 mm in all directions. This study is the first clinical
use of intra-operative HIFU in patients with CLM. Reducing the risk of
potential important complications associated with an extracorporeal
approach was among the reasons we developed an intra-operative de-
vice. An open procedure seems also more appropriate since 15-20 % of
additional metastases are discovered intraoperatively. From these pre-
liminary results, intra-operative use of a HIFU toroidal transducer ap-
pears feasible, safe and effective in ablating liver metastases.
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Pancreatic ductal adenocarcinoma (PDA) is the most lethal cancer
and there is a desperate need for new therapeutic strategies. Due to
its characteristic hypovascularity, dense stromal architecture, rapid
progression, and local invasiveness, conventional therapies fail to
cure PAC. Magnetic Resonance guided Focused Ultrasound ablation
(MRgFUS) offers a platform to build combination therapies due to its
ability to debulk tumors, enhance delivery of chemotherapeutics,
and stimulate an immune response. Here, the feasibility of MRgFUS
is evaluated in a syngeneic orthotopic mouse model of PAC devel-
oped from the KrasLSL-G12D/+; Trp53LSL-R172H/+; Pdx-Cre (KPC)
model 1. Further, [18 F]-FDG positron emission tomography (PET) is
used to enhance guidance.
Methods
Murine mT4-2D cells (gift from the Tuveson laboratory, Cold
Spring Harbor, NY) were injected orthotopically by a sterile lapar-
otomy (n = 5, C57BL/6 female mice). Mice were treated with
MRgFUS on day 16 post-implantation with an MR-compatible an-
nular array (Imasonic SAS, 3 MHz center frequency, 4.7 Watt
acoustic power, 5.6 MPa peak negative pressure, 0.5 x 0.5 x
1.5 mm3 focal volume) and positioning system (Image Guided
Therapy) in a Bruker BioSpec 7 T. Tumors were ablated with a
diameter of 2 mm and scanning speed of 1 revolution per sec-
ond for ~40s. In a separate group (n = 6), on days 10 (n = 3 + 1
wild-type) and 14 (n = 3 + 2 wild-type), mice were injected with
200 uCi of [18 F]-FDG, rested for 30 minutes, and scanned with a
Siemens Inveon DPET for 30 minutes. Following PET acquisition,
T1w images were acquired post gadolinium contrast (TE/TR/FA =
11.7 ms/750 ms/180°, 4.3 x 4.3 cm2 FOV, 256 x 256 matrix, 17
slices). Mice were euthanized, organs of interest were harvested,
and radioactivity was measured by Wizard 1470 Automatic
Gamma Counter (PerkinElmer). Maximum intensity projections
were registered with MR images and regions of interest (ROIs)
were drawn on the tumors and normal pancreases using Siemens
Inveon Research Workplace.
Results
[18 F]-FDG-PET images enhanced the visualization of the tumor rim
and demonstrated the heterogeneity of uptake within the tumor
(Fig. 60a). In spite of the heterogeneity, ROI analysis indicated that
primary pancreatic lesions (60.6 %ID/cc) exhibit a higher maximum
uptake of [18 F]-FDG than the normal pancreas (17.8 %ID/cc) at day
14 of tumor progression (p < 0.05). Biodistribution confirmed these
measurements, with 15.5 %ID/g and 16.9 %ID/g in the tumor-bearing
pancreas at day 10 and day 14, respectively, as compared with 5.2
%ID/g in the normal pancreas (p < 0.5). Contrast enhanced T1w MRI
facilitated visualization of lesions within both the pancreas and
spleen (Fig. 60b-c). MRgFUS ablation was successfully completed
under MR guidance (Fig. 60b), mice recovered well from treatment
and the effect was confirmed on histopathology at 24 hours
(Fig. 60d).
Conclusions
[18 F]-FDG facilitated visualization of the tumor rim. Feasibility
of MRgFUS ablation of a syngeneic orthotopic murine model of
PAC was established. Future studies will combine [18 F]-FDG-
PET with MRgFUS to guide therapies and monitor disease
progression.Fig. 60 (abstract A50). a [18 F]-FDG-PET overlaid on MR images
b Real-time thermometry overlay acquired during MRgFUS abla-
tion c T1w MRI confirms locally-invasive disease (red) in the
spleen (yellow) d H&E confirms ablation, hemorrhage and
immune infiltrationA51
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Objectives
To investigate the improvement of prostate cancer inhibition by
combining pulsed Focused Ultrasound (pFUS) exposures and chemo-
therapeutic agents encapsulated nanodroplets under MR guidance
for prostate cancer therapy.
Methods
Prostate cancer (LNCaP) cells were implanted orthotopically. First
we developed nanodroplets encapsulated with chemotherapeutic
agents for both paclitaxel (PTX) and docetaxel (DTX). Secondly,
tumor–bearing mice were randomly divided into 5 groups (n = 5).
Group 1 animals were treated with an i.v injection of DTX-
encapsulated nanodroplets (DTX-ND) + pFUS. Group 2 were
treated with pFUS alone. Group 3 were injected (i.v) with DTX-ND
alone, Group 4 received free DTX and Group 5 was used as con-
trol. Ultrasound treatment parameters were 1 MHz, 25 W acoustic
power, 10 % duty cycle and 60 seconds for each sonication. After
treatment, animals were allowed to survive for 4 weeks. Tumor
volumes were measured on MRI. Third, we repeated the experi-
ment with PTX-ND. Finally we performed study on biodistribution
of PTX-ND for prostate cancer and the treatment effects on
tumor growth delay are being evaluated.
Results
With DTX-ND, significant tumor growth delay was observed in
Group 1 with p = 0.039. There was no significant tumor growth
delay observed for Group 2 (p = 0.477), Group 3 (p = 0.209) and
Group 4 (p = 0.476). The results are consistent with earlier PTX-ND
studies in which significant tumor growth delay was observed in
Group 1 with p = 0.004. There was no significant tumor growth
delay observed for Group 2 (p = 0.285), Group 3 (p = 0.452) and
Group 4 (p = 0.158). The peak of drug update in tumor appeared
at 4 h after injection in the biodistribution study.
Conclusions
Our results showed a great potential of targeted nanodroplets for
prostate cancer therapy, which could be activated by pFUS. Our
study also suggested that the optimal timing for applying pFUS is
4 h after i.v injection of PTX-ND and the treatment effect is being
evaluated.A53
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Fig. 62 (abstract A53). Comparison of passive cavitation image
with the histotripsy ablation zone (outlined in blue). The bar in the
lower right corner corresponds to 1 mm
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Histotripsy is a form of therapeutic Focused Ultrasound that
mechanically ablates tissue. Pre-clinical studies have explored the
potential for histotripsy to treat fetal septal defects, deep vein
thrombosis, liver cancer, and benign prostatic hyperplasia (BPH).
Histotripsy technology is also being tested in a clinical trial for
the treatment of BPH. The bubble clouds generated by histotripsy
are hyperechoic, enabling standard B-mode ultrasound imaging
to be used for image guidance of tissue ablation. The mechanical
oscillations of the bubbles within the cloud generate acoustic
emissions. Information about the amplitude and location of these
acoustic emissions would provide an additional means to monitor
the treatment progress from histotripsy. Passive cavitation im-
aging (PCI) is an ultrasound imaging modality currently under de-
velopment that spatially maps the power of acoustic emissions
generated by cavitation. In this study, the ability of PCI and plane
wave B-mode imaging to predict the location and spatial extent
of histotripsy
Methods
Histotripsy pulses were generated in a prostate tissue phantom
with a 1-MHz, 8 annular element array with a 10-cm aperture
and 9-cm focal length. All elements of the transducer were simul-
taneously driven in parallel by a custom class D amplifier and
matching network. Histotripsy pulses over a range of pulse dura-
tions (5-20 microseconds) and peak negative pressures (12-
23 MPa) were explored in this study. During histotripsy insona-
tion of the phantom, a 128 element linear array controlled with
an ultrasound research scanner was used to monitor cavitation
activity with both PCI and plane wave B-mode imaging (Figs. 61
and 62). After application of the histotripsy pulses, the phantom
was sectioned and stained with a periodic acid-Schiff stain to
delineate the ablation zone. The passive cavitation images and
plane wave B-mode images were co-registered with the histo-
logical images. A receiver operating characteristic curve was used
to quantify the comparison between each imaging modality and
the spatial extent of the ablation zone.
Results
The area under the receiver operating characteristic (AUROC) was
significantly greater than 0.5 for both plane wave B-mode and
PCI, indicating both approaches can be used to predict the
spatial extent of the ablation zone. The AUROC and accuracy
were significantly greater for PCI compared to plane wave B-
mode imaging. Furthermore, the sensitivity for predicting lesion
formation was a factor of 3 larger for PCI compared to plane
wave B-mode imaging.
Conclusions
Overall, these results indicate PCI provides an improved prediction of
lesion formation from histotripsy.Fig. 61 (abstract A53). Comparison of B-mode image with the his-
totripsy ablation zone (outlined in blue). The bar in the lower right
corner corresponds to 1 mmA54
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Objectives
Backscattered RF ultrasound signals have been used clinically in dif-
ferentiating normal and infarcted heart condition. Similarly, backscat-
tered signals from pre and post hifu site are significantly different in
magnitudes that provide correlation on degree of tissue changes.
This is a validation study of Tissue Change Monitoring (TCM) algo-
rithm performed with real-time thermometry. TCM performs spectral
analysis of the RF backscattered (pulse-echo) ultrasound signals ac-
quired before and immediately following the HIFU exposure. The RF
signal analysis generates energy spectra of these signals and the dif-
ference of the energy magnitude is used as an estimator for tissue
changes caused by the HIFU tissue ablation. TCM results are color
coded and displayed on the each HIFU ablative site in Orange, Yel-
low and Green indicating tissue temperatures in the range from 75-
100, 60-75 and 37-60 degrees C respectively.
Methods
Five (5) patients with histologically confirmed, organ confined pros-
tate cancer were enrolled with approved protocol for this study. Four
patients with focal cancer at stereotactic saturation biopsy had hemi-
ablation only and one had a whole gland ablation. The Sonablate
500 HIFU device with Tissue Change Monitoring (TCM) software was
used for the ablative treatment. Specifically designed 18 gauge nee-
dles containing three thermocouples per needle separated by a 1 cm
distance were placed transperineally under TRUS guidance in the
prostate. 4 or 5 needles were placed to cover the ablative sites.
Temperatures from all thermocouples were recorded simultaneously
at 0.5 seconds interval by a multi-channel thermometry system.
Temperature data were acquired from a total of 56 sites,(26 focal
zone sites, 22 posterior sites to the focal zone and 8 sites in the lat-
eral gland of the prostate where there was no HIFU applied). Sixteen
RF signals lines, pre and immediately post HIFU, for each ablative site
were acquired at 50 MHz sampling rate. All RF data lines were proc-
essed by the SB-500 computer in the frequency domain to derive
average energy spectra and change in magnitude for pre and post
HIFU. The magnitude change and temperature from the site were
used to derive cross correlation function and color code to overlay
on the ablative site.
Results
The measured temperatures (Average, Max, and Min) in the HIFU
treatment zones were 84, 114 and 70 degree C respectively. TCM
energy readings were 1.05, 2.6 and 0.4 resulting in 83 % orange (75-
100 degree C) and 17 % yellow (60-75 degree C) indicating an esti-
mated average temperature of 91 degree C. Outside the focal zone,
average recorded temperature was 50 degree C. The temperature
Journal of Therapeutic Ultrasound 2016, 4(Suppl 1):31 Page 35 of 113recorded in the lateral lobe where no HIFU was applied was 40.7 de-
grees C.
Conclusions
The backscattered RF data analysis is capable of estimating tissue
changes reliably during the HIFU procedures in real-time and can be
used as an aid in the operating procedure. TCM was found highly
sensitive to tissue motion. When the tissue reached boiling
temperature, TCM output resulted in higher energy and was beyond
the linear range of temperature monitoring from the RF backscat-
tered signals.A55
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Objectives
Prostate cancer (PCa) therapy undeniably exposes patients to a risk
of impotence and incontinence. Therefore, low-risk localized prostate
cancer is increasingly managed with watchful waiting or active
surveillance, although this management bears some psychological
burden and the risk of under staging and under grading. Alterna-
tively, High Intensity Focused Ultrasound (HIFU) therapy allows non-
invasive partial ablation of detected PCa in a single session (focal
therapy). Aim of this study was to evaluate clinical efficacy and side
effects of a single focal HIFU session in low risk PCa patients.
Methods
66 patients with localized prostate cancer who refused both defini-
tive radical therapy and conservative management and had a strong
desire to preserve potency were treated with focal HIFU. Men with
strong obstructive symptoms, severe calcifications in the target area
or severe prostatitis/abscess history were excluded. Treatments were
performed with Ablatherm® intergrated imaging.
Results
53 % of the patients had positive staging biopsies on the right, 47 %
on the left lobe. Initial PSA (PSAi = at diagnosis) was median 5.58
(1.02- 10.43) and increased to a PSA at treatment (PSAtr) of median
6.01 (0.2-11.4) within 4 months (period of first diagnosis until HIFU
treatment), corresponding to a median pretherapeutic PSA velocity
of 1,29 ng spinal anesthesia in median 50 (27-75) min with 16 french
urethral catheter in place. Applied HIFU lesions were median 138
(86-338). There were no significant therapy related intra-/postopera-
tive side effects within the follow-up period of median 4.4 (0.25-9.85)
years, according to CLAVIEN Score . Based on patient interviews
3 months after HIFU treatment potency was: worse (4.5 %), equal
(93.5 %); better (0 %). PDE-5 inhibitors were used by 74 % of pa-
tients. Urinary continence was preserved in all cases, 3 patients used
a safety pad before and after treatment. There were no rectal dis-
order, fistulae or rectal incontinence. Post-HIFU catheter time was
22.7 % 5 days occurred. No late HIFU induced side effects were ob-
served. PSA was reduced from median PSAtr (6.45) to a median Nadir
of 1.45 ng/ml within median 12.5 weeks and showed a trend to re-
lapse with a post-HIFU PSA velocity
Conclusions
Focal HIFU - a non invasive single session therapy performed
under spinal anesthesia - demonstrated high potency- and con-
tinence preservation while treating diagnosed prostate cancer
lesions. There were no significant therapy related intra-/postop-
erative side effects within the follow-up period. Focal HIFU re-
sults in a significant deceleration of PSA velocity from pre-HIFU
1.29 to post-HIFU 0.12 ng/ml/year by treating only 25 % of the
prostatic volume. PCa diagnosis and consecutive watchful wait-
ing and active surveillance bears an imminent psychological
burden for the patient. The option of therapeutic efficacy, the
wish to avoid therapeutic side effects and to preserve potency
as well influences patients` decision for focal therapy with HIFU.A56
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Objectives
Bone is the third most common target organ that carcinomas
metastasize to after lung and liver. Bone pain induced by cancer
metastases contributes substantially to morbidity and mortality in
patients with malignant carcinomas. Magnetic Resonance guided Fo-
cused Ultrasound (MRgFUS) is considered as one of the most promis-
ing therapeutic modality for tumor ablation. But, not all patients
could obtain satisfied therapeutic efficacy. Some factors such as the
number of bone metastasis, KPS and NPVR score can affects the re-
sults. The purpose of this non-randomized study was to evaluate the
factors affecting the efficacy of the Magnetic Resonance guided Fo-
cused Ultrasound (MRgFUS) ablation for painful bone metastases
treatment, and the safety and efficacy of this new non-invasive treat-
ment modality.
Methods
One hundred and thirty one patients with painful bone metastases
were screened for this study from June 2014 to September 2015.
Seventy-one patients were finally enrolled in our study. All 71 pa-
tients underwent MRgFUS and none of them received radiotherapy
or chemotherapy for pain palliation in the past two weeks. The Nu-
merical Rating Scale for pain (NRS), the Brief Pain Inventory (BPI-QoL)
score, the karnofsky performance scale (KPS), morphine equivalent
daily intake dose (MEDID), and the adverse events (AEs) were re-
spectively recorded before and 1-week, 1-month, 2-month, 3-month
after the treatment.
Results
1) Seventy-one metastatic bone lesions in 71 patients were treated
by MRgFUS and the treatment data was as follows: the mean treat-
ment time was (83.94 ± 27.87) minutes, the mean sonication number
was (12.74 ± 7.30) minutes. 2) Adverse events included: pain in ther-
apy area in 3 patients and sciatica in 1 patient, which were obviously
reduced after physiotherapy. 3) The NRS before treatment and at 1-
week, 1-month, and 3-month after treatment was 6.70 ± 1.82, 4.37 ±
2.55, 3.96 ± 2.83, 3.70 ± 2.81 respectively. The NRS significantly de-
creased after treatment at all time points (P < 0.01). 4) The BPI-QoL
score before treatment and at 1-week, 1-month, and 3-month after
treatment respectively was 5.70 ± 2.09, 4.62 ± 2.36, 4.42 ± 2.60, and
4.42 ± 2.70. The BPI-QoL score significantly decreased after the treat-
ment at all time points (P < 0.01). 5) After treatment, at 3-month, the
mean ΔBPI-QoL score improvement in patients with solitary bone
metastasis was statistically superior to that in patients with multiple
bone metastases (P < 0.05). 6) At 1-week and 1-month, the mean
ΔBPI-QoL score improvement in patients with osteogenic bone me-
tastasis was statistically superior to other two groups (P < 0.05).
Conclusions
MRgFUS can be used as a non-invasive, safe, and effective method
for treating painful bone metastases. The patients with solitary bone
metastasis or osteogenic bone metastasis can achieve better thera-
peutic efficacy than those with multiple bone metastasis or osteolytic
bone metastasis.
A57
Can MRgFUS achieve local control of bone metastases?
Alberto Bazzocchi1, Alessandro Napoli2
1The “Rizzoli” Orthopaedic Institute, Bologna, Italy; 2Policlinico Umberto I,
University of Rome – La Sapienza, Rome, Italy
Journal of Therapeutic Ultrasound 2016, 4(Suppl 1):A57
Objectives
Magnetic Resonance Imaging guided Focused Ultrasound (MRgHIFU
or MRgFUS) treatment of bone metastases is effective and safe for
pain palliation. In a few circumstances, MRgFUS showed a partial or
Fig. 63 (abstract A58). Experiment timeline. Rabbits infused with
thermosensitive liposomal doxorubicin during 10 or 40 minutes of
MR-HIFU hyperthermia. At 3 hours post injection, animals were sacri-
ficed and tissues were harvested for doxorubicin quantification
Fig. 64 (abstract A58). Doxorubicin biodistribution in rabbits
following MR-HIFU hyperthermia mediated drug release
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of the work was to understand the efficacy of MRgFUS in terms of
local tumor control of bone metastases and to explore this opportun-
ity and the reasons for success or failure.
Methods
Patients with painful bone metastases were enrolled and sub-
mitted to MRgFUS (ExAblate 2100, InSightec Ltd, Israel), with
imaging (CT/MRI) before and 3, 6 and 12 months after treat-
ment. The primary endopoint was the number of lesions with
partial or complete response at 3 months according to MD An-
derson criteria.
Results
Out of 65 patients, 18 were lost and missed the 3-month imaging
check. Forty-seven patients with 49 lesions were evaluated. The
procedure was successful in terms of local control at 3 months in
24 lesions (49 %) – complete in 11, partial in 13. A stable disease
was observed in 20 lesions and a progression in 5. Lesions with
osteolytic (or mixed) pattern, with complete accessibility of the
margins to the ultrasound beam are perfect candidate for abla-
tion with the intent to control the lesion. Results were statistically
independent of histology (primary cancer), previous radiation
therapy (59 %), and size (up to 14 cm), though smaller lesions
were generally more associated with complete or wide accessibil-
ity. Body mass index, age and sex of patients did not influence
the outcome.
Conclusions
At present, MRgFUS for painful bone metastases may produce a local
control of the lesion. In the future, patients with bone metastases
should be selected for MRgFUS with three different intents, and the
target should be clearly established before the treatment according
to patient conditon, prognosis, symptoms and to the features of the
lesion: 1) palliation of pain; 2) palliation and local tumor control; or 3)
ablation / local control.
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Objectives
Localized drug delivery using MR-HIFU hyperthermia to trigger the
release of chemotherapeutic agents from thermosensitive liposomes
(TSLs) has the potential to increase the therapeutic ratio between an-
titumor effect and systemic toxicity. For doxorubicin (DOX), which is
active in many pediatric solid tumors, the late effects of cumulative
dose to the heart are treatment-limiting. In this study, we investigate
the effect of mild hyperthermia duration (10 vs. 40 minutes) on the
ratio of DOX deposited in heated tumors compared to cardiac
muscle, using a clinical formulation of TSL-DOX in a rabbit Vx2 tumor
model.
Methods
Rabbits had Vx2 tumor cells injected into each thigh 12 days
before therapy. For each rabbit, mild hyperthermia (10 or 40 mi-
nutes, 42 °C) was delivered to a 10 mm diameter region in one
tumor using a clinical MR-HIFU system (Sonalleve V2, Philips
Healthcare) incorporated into a 3 T MRI (Ingenia, Philips Health-
care). Feedback control of hyperthermia sonications was per-
formed by modified software designed for mild hyperthermia,
using MR thermometry data acquired in 6 slices every3.2 seconds. During heating, TSL-DOX (Thermodox, Celsion Cor-
poration) was administered intravenously at 2.5 mg/kg over 5-6
minutes. Rabbits were sacrificed and perfused with saline for
tissue harvest 3 hours after the start of TSL-DOX infusion
(Fig. 63). Tissue DOX concentrations were quantified using liquid
chromatography-mass spectrometry against a daunorubicin
standard following homogenization in cell lysis buffer and ex-
traction in silver nitrate.
Results
Vx2 tumors treated with 10 vs. 40 minutes of mild hyperthermia
(n = 10 per group) had largest dimensions of 24.3 and 29.9 mm,
and body temperatures of 36.6 °C and 36.6 °C before sonication.
Heating quality in the two groups was similar: target region tem-
peratures averaged 41.9 and 41.8 °C, respectively, with T90 of
41.1 and 41.0 °C, and T10 of 42.7 and 42.7 °C. The average dur-
ation that target region voxels exceeded 40 °C in the 10 and
40 min heating groups was 11.3 vs. 40.7 min.
In non-targeted organs (heart, lung, spleen, muscle) DOX concentra-
tions demonstrated no significant differences between the two heat-
ing groups (ANOVA with selected Bonferroni post-tests). This
indicates that systemic toxicity does not increase with heating dur-
ation (Fig. 64).
In both heated and unheated tumors, tumor DOX concentrations
were higher for 40 vs. 10 min (25.4 vs. 14.0 μg/g and 6.7 vs. 5.4 μg/g,
Fig. 65). Similarly, therapeutic ratio (DOX in tumor / DOX in heart) in-
creased with heating duration (3.9 vs 2.2 times). Heated tumors had
higher DOX concentrations and therapeutic ratios than unheated tu-
mors (p = 0.03, 2-way ANOVA with Bonferroni). Therapeutic ratio and
DOX concentration for heated tumors had a significant correlation
with duration above 40 °C.
Conclusions
Our results confirm the theory that longer heating duration in-
creases doxorubicin deposition in the targeted tumor without in-
creasing doxorubicin accumulation in critical structures such as
the heart. This will have an impact on hyperthermia protocols
used in clinical trials of MR-HIFU hyperthermia mediated drug
delivery.
Fig. 66 (abstract A59). Axial MR images of the right iliac bone
showing a T2 hyperintense permeative metastasis from lung cancer.
The lesion had been treated with radiation and was still causing
severe pain. b Multiple sonications (green oval) result in deposition
of thermal dose (blue) along the targeted bone contour. a Change
from baseline to 3 months in NRS score demonstrating a durable
halving of pain scores in the treatment arm of the Phase III study
Fig. 67 (abstract A59). a Subtracted contrast enhanced image of
the same patient as in Fig. 66 shows lack of perfusion of the treated
bone surface (black band), which is an immediate post-procedural
indicator of successful ablation of the periosteal nerves and b pre-
dicts subsequent pain relief. In this case in a), some of the cancer
within the bone was also treated
Fig. 65 (abstract A58). Therapeutic ratio of doxorubicin
concentration in tumor/heart in rabbits that underwent 10 or
40 minutes of MR-HIFU hyperthermia
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Objectives
Magnetic Resonance guided Focused Ultrasound (MRgFUS) has
proven to be effective in the treatment of painful osseous metas-
tases. The results of the phase III randomized clinical trial
comparing MRgFUS to sham treatment of bone metastases dem-
onstrated a 64 % response rate in the treatment group, com-
pared to a 20 % response rate in the sham arm (Fig. 66). We
hypothesized that this intention to treat analysis included
patients who were suboptimally treated. We reviewed images
from the patient procedures to identify imaging features that in-
dicated technically successful treatment, and assessed technical
parameters for predictors of pain relief.
Methods
All images were anonymized such that the reviewer was
blinded to the treatment outcome. Imaging features (size of
tumor, osteolytic vs blastic tumor, location of tumor, T2 signal
intensity, presence of edema around the tumor after treatment,
devascularization of the periosteum around the tumor, tumordevascularization, etc.) and technical parameters of the treat-
ments (number of sonications, total energy, average energy,
sonication time, type of anesthesia etc.) were documented for
each patient. After de-anonymization, imaging features and
technical parameters were then correlated with successful pain
relief (defined as at least a 2 point decline in pain score with-
out significant increase in analgesic medication).
Results
We identified an imaging feature that we call the black band (BB),
which represents devascularization of the periosteum around the
tumor, as best seen on subtracted contrast enhanced T1 weighted
fat saturated images obtained immediately after treatment (Fig. 67).
The presence of the black band correlated with response to treat-
ment (Odds Ratio of Complete or Partial Response with BB = 5.97;
95 % CI: 1.08 – 33.0; p = 0.041; sensitivity: 96 %, 95 % CI: 88-99 %;
specificity: 22 %, 95 % CI: 9 – 40 %). The presence of the BB after
treatment predicted a successful treatment (positive predictive
value = 72 %, 95 % CI: 61 – 81 %).
We also identified a simple technical parameter, the Energy Density
on Bone Surface (EDBS), which is the total energy delivered normal-
ized by the bone surface area. EDBS was the only parameter that in-
dependently correlated with the likelihood of achieving complete or
partial pain relief (OR of CR/PR with EDBS > 5 J/mm2 = 5.51; 95 % CI:
1.70 – 17.8; sensitivity = 57 %, 95 % CI: 44- 69 %; specificity = 81 %,
95 % CI: 61- 92 %). The black band was significantly correlated with
high EDBS (EDBSmean with BB was 5.7 ± 2.8 J/mm2; without BB was
2.7 ± 0.9 J/mm2, p < 0.001).
Conclusions
With a technically successful treatment (BB+, EDBS > 5), the posi-
tive clinical response rate was 86 %, higher than in the published
report. Those sites that had previous experience using MRgFUS
to treat bone metastases and that used deep anesthesia used
the highest mean EDBS (6.8 ± 3.1 J/mm2, p = 0.013), and also had
the highest response rate (88 %, p = 0.009, Table 3). We also
noted that the response rate (22 %) after suboptimal treatments
(BB-, EDBS < 5) was the same as in the sham arm of the trial. Util-
izing this information will help optimize MRgFUS treatment of os-
seous metastases.




No prior experience 70 % 36 % 58 %
(4/11) (14/20) (18/31)
Prior experience 48 % 88 % 73 %
(12/25) (36/41) (48/66)
Total 58 % 77 % 68 %
(26/45) (40/52) (66/97)
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Objectives
Osteoid osteoma (OO) is a benign bone tumor that causes dull, but
often debilitating pain, affecting mainly children and young adults. It
is most commonly treated with computed tomography (CT)-guided
radiofrequency ablation (RFA). However, RFA is invasive and CT guid-
ance requires exposure to ionizing radiation. These shortcomings
may be addressed through the use of Magnetic Resonance Imaging-
guided High Intensity Focused Ultrasound (MR-HIFU), which allows
non-invasive thermal ablation under real-time MRI guidance, with
high spatial precision and without ionizing radiation. MR-HIFU may
be used to reduce or eliminate pain through destruction of periosteal
nerves and the OO nidus, without need for incisions or drilling. In an
ongoing Phase I clinical trial, eight of the planned total of 12 children
with symptomatic OOs have been treated at the Children’s National
Medical Center (Washington D.C.). Herein we report on the technical
aspects, feasibility, safety, and preliminary efficacy of OO MR-HIFU
therapy.
Methods
Treatments were performed using the Sonalleve V2 clinical MR-HIFU
system (Philips, Vantaa, Finland). The system includes a 256-element
phased-array transducer, a positioning system with 5 degrees of free-
dom, and integrated MRI receive coils. Prior to therapy, patients were
anesthetized or sedated, and positioned on the HIFU tabletop using
gel pads, ultrasound gel, and degassed water for acoustic coupling.
T2w and T1w MR images were acquired as a 3D stack, and subse-
quently used for treatment planning. Sonications of 16-48 s duration
were performed at a frequency of 1.2 MHz, targeting regions 4-
12 mm in diameter with acoustic powers of 20-160 W. During sonica-
tions, real-time MRI temperature maps were acquired using a fast-
field-echo pulse sequence and the proton resonance frequency shift
method (3 orthogonal slices centered on the target region and an
additional slice in the near field). Post-therapy, T1w contrast-
enhanced MR images were acquired to report on ablated regions.
While complete follow-up is still pending, we assess technical aspects
of OO MR-HIFU therapy. Specifically, the following were evaluated:
patient positioning, sonication parameters, tissue temperature and
thermal dose, tissue perfusion changes, treatment times, and other
technical data.
Results
Patient positioning on the HIFU table was feasible in all eight cases,
with some modification to the shape of standard ultrasound standoff
pads to provide acoustic coupling to extremities. Lesion locations in-
cluded the tibia (n = 3), femur (n = 3), talus (n = 1), and the great toe
(n = 1). Distance between OO nidus center and skin ranged 1.1-7.7 cm, with estimated 43 ± 16 % power remaining at the bone sur-
face due to soft tissue attenuation. Average acoustic power was 50 ±
30 W per sonication and total energy deposition per therapy session
was on average 10 ± 7 kJ, resulting in complete lack of MR contrast
enhancement of the OO nidus on T1w-imaging in six of eight pa-
tients, and partial enhancement in two patients. Immediately after
the treatment, nonperfused volume extended 7 ± 4 mm into the
bone and 4 ± 6 mm into adjacent soft tissue. For seven of the eight
patients, complete or nearly complete resolution of OO-related pain
followed within days and all patients were able to cease using medi-
cation 28 days following treatment. Sonications, including cool-down
times, took 30-77 min, with 101-195 min of MRI suite time required.
The treatments required less than 4 hours of total anesthesia and/or
sedation and they were well-tolerated without any serious adverse
events.
Conclusions
With complete symptom resolution in all patients evaluated thus far,
MR-HIFU has the potential to offer a fast, safe, completely noninva-
sive, and radiation-free treatment option for children with painful
OO. Sonication parameters were chosen conservatively in this initial
clinical trial, and overall treatment quality may be improved and its
duration reduced through optimization of sonication power, dur-
ation, and frequency, as well as improved, or more specialized MRI
equipment.
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Objectives
MR-guided High Intensity Focused Ultrasound (MRgFUS) has recently
been applied to patients with bone lesions such as osteoid osteomas
(OO), which are painful benign tumours. While initial results are posi-
tive, there is much uncertainty about the ideal target location, effect-
ive thermal dose, overall bone heating and possible inadvertent
injury. Simulation of MRgFUS heat transfer within and around bone
can be used as a pre-treatment planning tool that could optimize
and improve the safety and efficacy of this therapy.
Methods
To address the uncertainties of MRgFUS treatment, a computer simu-
lator was developed. The simulator has three main components: 1)
an automatic bone segmentation tool; 2) an acoustic propagation
simulation to calculate the acoustic velocity distribution at the target;
and 3) a heat distribution model, calculated by the Pennes Bioheat
Equation, which simulates the temperature distribution at the target
location. Concurrently, a clinical pilot study is being conducted, to
treat OO patients with MRgFUS. The MR imaging and MRgFUS sonic-
ation data from the first four patients from this study was repro-
cessed with the simulator and the results were compared with the
measured clinical thermal results.
Results
Automatically segmented femurs were compared to the manually seg-
mented ones. The average volume overlap (VO) and sensitivity (S) be-
tween the automatic and manual segmentations were 92.2 % and
96.3 %, respectively. The calculations for VO and S are as follows: VO=
1-(FP + FN)/Vm and S = TP/Vm, were FP is the number of false positives,
FN is the number of false negatives, TP is the number of true positives
and Vm is the manually segmented volume. The average maximum
temperature difference between the simulation and clinical data at a
region near the sonication focus, after 20 seconds of sonication, was
1.4oC; after 40 seconds of cool down time, the difference was 7.3oC.
The max temperature is defined to be the average of the hottest 9 -
voxels. The average distance between ablation centroids was 2.9 mm.
Figure 68 represents the clinical MR thermometry distribution (left) and
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sonication in one patient. Figure 69 represents the max temperature
comparison over 60 seconds for this sonication.
Conclusions
The calculated segmentation validation metrics suggests that the
automatically segmented data is comparable to the manually seg-
mented data. The average difference between simulated and
thermometry data at peak temperature suggests that the simula-
tor can accurately predict the extent of ablation near the focus
during sonication. However, the average cool down temperature
difference suggests the simulation is consistently under-predicting
the temperature near the focus after 40 seconds of cool down.
The distance between ablation centroids suggests that the simu-
lator can predict the site of ablation to within 3 image voxels. A
robust MRgFUS bone thermal simulation platform has the poten-
tial to significantly improve efficiency, safety and outcomes of pa-
tients with bone lesions.Fig. 69 (abstract A61). Max temperature vs. time of simulated and
MR thermometry treatment data
Fig. 68 (abstract A61). Comparison of MR thermometry (left) with
simulated results (right)A62
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Percutaneous or surgical therapy can lead to non-negligible side-
effects and limited efficacy for paediatric population or young adults
with a benign, self-limiting pathology such as osteoid osteoma. Over
a period of 6- years we followed treated patients for at least 3-year
for clinical, imaging and rehabilitation process. The aim of the study
was to demonstrate that a completely non-invasive radiation-free
focal ablation of osteoid lesions with MRgFUS can be a safe, effective
and durable treatment option.
Methods
Patients were eligible for this dual-centre prospective development
study if they had both clinical and radiological diagnosis of non-
vertebral osteoid osteoma (typical nocturnal-worsening pain relieved
with NSAIDs, pain score [VAS] >4, CT and MRI specific findings), and if
they could safely undergo MRI, focalized US procedure and anesthetic.
Patients received non-invasive therapy using MRI guided high-intensity
Focused Ultrasound, delivered to all known osteoid lesions, identified
on MRI, CT, or both. Feasibility, patient safety (adverse events), and clin-
ical relevance profiles of MRgFUS were considered as primary out-
comes; tumour control at imaging was considered as secondary
outcome. Analyses were done on a per-protocol basis. This study is reg-
istered with ClinicalTrials.gov, number NCT02302651.
Results
Among 50 subjects recruited with both clinical and radiological diagnosis
of OO, 45 underwent MRgFUS treatment and were included in the ana-
lysis. After intervention, no complications related to treatment or anaes-
thesia occurred and every patient leaved our hospital within 12-24 hours.
Even during follow-up, no long-term complication related to treatment
was reported. Clinical benefit was effective in all patients and overall VAS
median value shifted from 8 (IQR 7-9) points before treatment to 0 at 1-
week, 1-month, 6-month, 12-month, 24-month and 36-month follow-up.
Similarly, VAS Scores median values for sleep disturbances, overall phys-
ical limitation, sport limitation and daily activities limitation dropped to 0
within the first month after treatment, and didn’t increase in subsequent
controls. Quality of Life, assessed with FACT-BP Score, rose from a median
value of 28 (22-34) before treatment to 55 at 1-week, 59 at 1-month, 60
at 6-month, 12-month, 24-month and 36-month follow-up. There was a
complete response (a zero pain score one month after treatment, without
recurrent symptoms, stable at follow up) in 80.00 % of cases. 4 patients
required a second line of intervention. Overall, patients who reached and
maintained a stable 0 VAS score during our 3-year observation with
MRgFUS treatment alone were 86.67 %. At final
Conclusions
MRgFUS has shown complete absence of adverse events, persistent
clinical efficacy and great tolerance profile. These strong features
may induce a change in the current paradigm of OO management,
making MRgFUS the treatment of choice, whilst CTgRFA role may
shift to a second-line intervention.
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Objectives
Osteoid osteoma (OO) is the most common benign bone tumor in chil-
dren. The vascularized, central nidus (Fig. 70) contains cells that produce
pain-inducing prostaglandin hormones. While pain can be managed with
non-steroidal anti-inflammatory drugs, many patients choose to undergo
CT-guided thermal ablation using radiofrequency or laser, the standard-
of-care for definitive treatment. Minimally invasive thermal ablation tech-
niques include risks from ionizing radiation, fracture, infection and trans-
mitted thermal damage along the needle. Non-target tissue injury is a
concern as temperature cannot be measured with CT, and the treatment
Fig. 71 (abstract A63). Representative MRI thermal imaging during
HIFU treatment from a 30 W, 20s exposure (axial and sagittal views).
Temperatures in the nidus reached >70 °C, indicating thermal
ablation of the lesion
Table 4 (abstract A63). Pain scores pre and post HIFU treatment (at
days 1, 2, 7, 14, 30 and 90) for all treated patients. Patient 4 could not
be treated, and exited the study. Only the data from the first treatment
of Patient 2 was used
Pre HIFU Post HIFU















16 60 8 1 1 0 0 0 0
HIFU-OO-
002
17 64 5 3 2 6 5 4 7
HIFU-OO-
003
8 24 7 4 0 0 0 0 0
HIFU-OO-
004
17 74 N/A N/A N/A N/A N/A N/A N/A
HIFU-OO-
005
10 58 10 6 5 0 0 0 0
HIFU-OO-
006
10 33 9 2 3 0 1 0 Pending
Average 13 52.2 7.8 3.2 2.2 1.2 1.2 0.8 1.8
SD 4.1 19.4 1.9 1.9 1.9 2.7 2.2 1.8 3.5
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nutes. Magnetic Resonance guided High Intensity Focused Ultrasound
(MRgHIFU) is an alternative modality to successfully treat OO. There is no
mechanical penetration of the bone, reducing the chance of pathologic
fractures and reducing the potential for infection. We present our initial
experience with OO MRgHIFU treatment in six pediatric pilot study
patients.
Methods
The study was performed to determine the impact of focused ultrasound
treatment on bone pain, medication usage and health-related quality of
life (HRQL). Standardized metrics, such as physical, emotional, social, and
school functioning were collected through the use of age-appropriate
and validated surveys (Pediatric Ouch, and PedsQLTM). An initial planning
MRI was performed to ensure lesion accessibility/patient eligibility. MR
thermometry (Fig. 71) was used during treatment to measure
temperature in the target and surrounding tissue to ensure patient safety.
Procedures were performed under general anesthesia or deep sedation.
Post procedure, contrast enhanced MRI, to assess the non-perfused tis-
sues that correspond to the ablated tissue volume (Fig. 70). Pain, HRQL
and drug usage surveys were recorded on days 1, 7, 14, 30, 90 and 180
post treatment. Clinical visits on days 30, 90 and 180 included physical
examination and diagnostic MRI of the target lesion.
Results
Between July 2014 and May 2016, 6 patients underwent 7 MR-HIFU
procedures. Subject 2 underwent MR-HIFU twice due to an inadequate
pain response after the first procedure. The average age of patients en-
rolled was 13 ± 4.1 years (range: 8 – 17) and weight was 52.2 ± 19.4 kg
(range: 24 – 74). During this period, a total of 12 patients were referred
for OO treatment. Reasons for exclusion from the study included acous-
tically inaccessible locations (proximity to nerve or growth plate) in 6
patients and patient refusal in 1. The overall technical success rate was
83 % (5/6 subjects). Subject 4 could not be treated due to poor acoustic
access to the lesion. Complete response (treatment success) was seen
in of 80 % (4/5) and partial response in 20 % (1/5) of the treated sub-
jects. Pain scores dropped from an average of 7.8 prior to treatment to
1.2 by day 7, as shown in Table 4. Prior to treatment, the time to fall
asleep was reported as 30-60 minutes. Following MR-HIFU, this de-
creased to 7-38 minutes. There were no significant adverse events.
Conclusions
This study shows that noninvasive MRgHIFU treatment of OO can be
used to successfully treat osteoid osteoma in pediatric patients. When
the cortex is intact, MR-HIFU heats the bone surface. Treatment of OO
lesions results from heat conduction through bone from the cortical
surface. In intact bone, MR-HIFU heats the cortical surface with deeper
areas being heated by conduction. Subjects 1, 3 and 5 had superficial
lesions and responded very well to MRgHIFU therapy. Subject 2 had a
large, sclerotic medullary lesion that presented a challenge for heat
conduction through the bone and required a second session with a
more aggressive MR-HIFU treatment. Further research is necessary to
define the optimal treatment parameters and limitations of MRgHIFU. A
prospective registry is currently being designed to compare MRgHIFU
with other types of thermal ablation.Fig. 70 (abstract A63). Representative pre and post HIFU sagittal
MRI of an osteoid osteoma lesion with gadolinium enhancement.
The lesion is fully enhanced before HIFU treatment, and shows non-
perfused regions following treatmentA64
Treatment of breast fibroadenoma with High Intensity Focused
Ultrasound: update of feasibility study IDE #G130252
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Objectives
Fibroadenomas are common in the United States and many patients
find their fibroadenoma bothersome, and thus opt for surgical
excision.
Study objectives are to evaluate the safety and feasibility of Ultra-
sound guided High Intensity Focused Ultrasound (USgHIFU) delivered
by the Echopulse device (Theraclion, Paris) for treatment of breast
fibroadenomas. General patient safety, cosmetic outcome, tumor re-
sponse, patient experience, physician/operator experience, and de-
vice performance are being assessed.
Methods
Twenty female patients diagnosed with palpable breast fibroaden-
omas 1 cm or larger were enrolled in a single arm study and
underwent treatment of their tumor utilizing a computer-driven, con-
tinuously cooled, extra-corporal HIFU probe mounted on an arm
moved by motors, and guided in real-time with an integrated ultra-
sound imaging scanner. The integrated probe is positioned by the
operator and the lesion is imaged. Treatment planning is automated
and presented for review and approval on an integrated computer
screen. Patients had tumors meeting the following criteria: Distance
from the skin of ≤ 23 mm to the posterior border of the
Journal of Therapeutic Ultrasound 2016, 4(Suppl 1):31 Page 41 of 113fibroadenoma, ≥ 5 mm from the anterior border of the fibroaden-
oma, and ≥ 11 mm from the focal point of the HIFU treatment. The
chest wall must be more than 1 cm from the posterior margin of the
tumor, and tumor volume must be between 0.3 cc and 10 cc.
Subjects are assessed immediately after treatment and at 3, 6, and
12 months.
Results
The study remains open to accrual, the following are PRELIMINARY
RESULTS, thus the denominators vary by data point: Enrolment at
the time of the writing of the abstract is16 patients. Six patients re-
main in follow-up. To date, there have been no grade 3 adverse
events, nor any skin burns, persistent changes in skin appearance,
nor other significant toxicities/morbidities observed in the patients
treated. Mean patient-rated pain score during treatment on a scale
from 0 to 100 was 17.8. One patient has reported persistent mild
pain at 6 months follow-up (2 on a scale from 0 to 100). The most
common toxicity observed was pain (reported by 9 of 16 patients).
Preliminary patient satisfaction was 4.65 on a scale of 1-5 (5 =most
satisfied), 10 of 11 patients reported they would undergo the proced-
ure again, and 11/11 reported they would recommend the procedure
to a friend or family member. Reduction in the size of the palpable
mass was reported by both the patient and evaluating physician in
almost all cases. Similar findings were found on ultrasound in the
majority of cases. Cosmesis can be excellent, and unchanged from
baseline in all cases to date.
Conclusions
To-date, USgHIFU, delivered by the Echopulse device for treatment
of breast fibroadenomas in the IDE G130252 study has been well tol-
erated by patients, resulted in minimal toxicity, and appears to have
been effective.A65
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Objectives
Breast fibroadenoma (FA) is the most prevalent benign tumor, ac-
counting for up to 70 % of benign breast lesions [1,2]. They affect fe-
males in the reproductive period with two peaks of incidence in the
third and in the fifth decade of life. During the follow-up, a minority
of FA decrease in size or disappear, more than half of them remain
unchanged, and some of them significantly increase [3].
Ultrasound (US)-guided high-intensity focused ultrasound (HIFU) is
the only non-surgical and non-invasive procedure, where thermal de-
struction is achieved by precisely delivered energy to the target,
without interrupting skin integrity. Recently, a multicentre study
established that US-guided HIFU treatment of 51 FA resulted in
72.5 % volume reduction at 1 year [4].
The purpose of our study was to compare the long-term efficacy and
tolerability of one or two HIFU treatments in patients with breast FA.
Methods
Twenty patients with 26 FA were selected for US-guided HIFU. The
therapy was performed with the system EchoPulse (Theraclion,
France) on an outpatient basis, in one or two sessions, under con-
scious sedation. FA volume was assessed before and followed up to
24 months after the last HIFU treatment. After each procedure, ad-
verse events were evaluated. Written informed consent was acquired
from all patients.
Results
In 19/26 FA (73.1 %) one HIFU was performed (group 1), whereas 7/26
FA (26.9 %) received second HIFU (group 2) 6-9 months (median,
7 months) after the first session. In group 1 and 2, FA volume
decreased significantly at 1-month (p < 0.001) and 3-month follow-up
(p = 0.005), respectively, and continued to reduce until 24-month
follow-up (p < 0.001 and p = 0.003, respectively). At 24 months,
mean volume reduction was 77.32 % in group 1 and 90.47 % ingroup 2 (p = 0.025). Mild subcutaneous oedema was observed in
4 patients and skin irritation in 3 patients.
Conclusions
US-guided HIFU represents a promising non-invasive method with
sustainable FA volume reduction and patient’s tolerability. Although
one treatment is highly efficient, the volume reduction can be in-
creased with second treatment.
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Objectives
Each year in the United States, over 60,000 women are diagnosed
with breast cancer. High-Intensity Focused Ultrasound (HIFU) holds
promise as a non-invasive and targeted therapeutic technique for
breast cancer patients. To facilitate its widespread translation to the
clinic, however, there is still a need for a real-time and cost-effective
device that can reliably monitor HIFU ablation. Harmonic Motion Im-
aging for Focused Ultrasound (HMIFU) is an all-ultrasound radiation-
force-based technique, which can be used for real-time HIFU ablation
monitoring by tracking relative stiffness change at the treated area
without interrupting HIFU.
Methods
Specimen collection and handling of post-surgical breast tissues
were approved by the Institutional Review Board (IRB) board of
Columbia University and informed consent was obtained from all en-
rolled patients. HMIFU was performed in 10 normal, 10 malignant
tumor (invasive ductal carcinoma, namely IDC) and one benign
tumor (fibroadenoma, namely FA) specimens. The HMIFU setup con-
sists of a 93-element, 4.5-MHz HIFU transducer and a confocally-
aligned 64-element, 2.5-MHz phased array imaging probe, which is
connected to an ultrasound imaging research system. All HIFU
elements were synchronously excited by a 25 Hz amplitude-
modulated signal to vibrate the tissue at 50 Hz. A GPU-based fast
image reconstruction method was used to monitor lesion develop-
ment in real-time.
Results
For real-time monitoring, the displacement map and lesion map
were streamed on the computer screen at a display frame rate of
2.4 Hz during treatment without interruption. Following a 2D raster
scan, 3D HMI displacement maps were reconstructed representing
the relative stiffness of the tissue (Fig. 72). The mean HMI displace-
ment within the ROI decreased by 60 % from 24.73 ± 10.97 μm to
9.83 ± 6.46 μm in normal breast tissue (n = 10, p = 0.0048), decreased
by 58 % from 12.77 ± 3.50 μm to 5.35 ± 2.74 μm (n = 10, p = 0.045) in
IDC and decreased by 20 % from 2.56 μm to 2.06 μm (n = 1) in FA.
There were statistically significant differences between before and
after HMIFU ablation in both the normal and tumor specimens.
Conclusions
HMIFU is shown to be capable of differentiating relative stiffness be-
tween normal and abnormal breast tissues prior to treatment. HMIFU
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sue in real-time.Fig. 72 (abstract A66). Gross pathology and 3D HMI displacement
images of normal breast tissue (a-c), IDC (d-f) and FA (g-i) before
and after HMIFU ablation. The brighter the color is indicates the
higher HMI displacement and lower relative stiffness, and vice versaA67
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Objectives
Desmoid tumors are benign but locally aggressive tumors derived
from fibroblasts. Surgery, chemotherapy, and radiation therapy have
historically been the mainstay of treatment but recurrence is com-
mon and side effects can result in significant morbidity. Desmoid tu-
mors of the thigh are particularly difficult to treat with conventional
approaches and have a higher recurrence rate. MRgFUS has increas-
ingly been used for management of desmoid tumors because of the
favorable side effect profile. In this case series we highlight our expe-
riences performing treatments in the thigh, including strategies for
optimizing ablation size and safety.
Methods
Since December 2014, 14 MRgFUS treatments for desmoid tumors
were performed at our institution in seven patients. 9 of these treat-
ments were completed in three patients with large tumors within
the posterior thigh. The first was a 7 year-old boy who had previ-
ously been treated with surgical resection, intraoperative radiation,
along with courses of vinblastine/methotrexate and sorafenib. The
second was a 21 year-old woman who had previously taken sulindac
and celecoxib but had no other therapy. The third patient was a
14 year-old girl with no prior treatment. Treatment efficacy was eval-
uated by calculation of post-contrast ablation volume immediately
following treatment and in diagnostic studies between treatments.
Side effects and complications were also documented for each
treatment.
Results
Case 1: Pre-treatment tumor volume 770 cc with 75 % non-
enhancing volume following the initial treatment. However, firsttreatment was complicated by a third degree burn along the far-field
skin. Despite the complication, the family and referring clinicians
wished to proceed with additional treatments. Enhanced safety mea-
sures were implemented to protect the far-field skin including water
bags and fiber-optic temperature probes, as well as interval skin
checks. The patient had four subsequent treatments over 14 months,
without complication, with non-perfused volume of 90 % most
recently.
Case 2: Pretreatment tumor volume 740 cc. Notably, the sciatic
nerve courses along the tumor’s anterior margin. Left lateral de-
cubitus position was used to minimize the amount of energy
through the sciatic nerve. Enhanced safety measures as above.
First treatment resulted in a relatively low non-perfused volume
of 30 %, likely related to a prominent fascial band. Second treat-
ment resulted in 75-80 % ablation of the target.
Case 3: Pretreatment tumor volume was approximately 440 cc. The
sciatic nerve was encased by the anteromedial portion of the mass.
Left lateral decubitus position and enhanced safety measures again
used. First treatment resulted in a relatively low non-perfused vol-
ume of 30 %, likely related to low energies. Second treatment re-
sulted in 70-80 % ablation.
Conclusions
MRgFUS is an effective treatment for desmoid tumors with a favor-
able side effect profile, allowing for repeated treatments if necessary.
Ablation size and safety can be improved by use of far-field coupling
devices, careful patient positioning, and optimized sonication
planning.
Consent to publish had been obtained from the patients and
guardians.A68
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Objectives
Benign thyroid nodules are prevalent among the general popu-
lation and some nodules may exhibit growth over time leading
to compression symptoms or cosmetic concerns. Although sur-
gery remains the treatment of choice for symptomatic thyroid
nodule, it is associated with a 2 %–10 % risk of complications
and requires a general anesthesia. The aims of the present
study were to assess the efficacy of a single treatment of High
Intensity Focused Ultrasound (HIFU) in reducing benign thyroid
nodule volume and to evaluate the changes in health-related
quality of life (HRQL) following a single HIFU treatment.
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After obtaining IRB approval, consecutive patients with symptomatic
thyroid nodule were assessed for eligibility. Inclusions were nodule(s):
1) without signs of malignancy (i.e. no suspicious clinical and ultra-
sonic features and benign cytology on fine needle aspiration); 2)
measuring ≥10 mm on ultrasound (USG) in three orthogonal dimen-
sions; and 3) menable to HIFU. Exclusions were nodule(s): 1) measur-
ing < 40 mm (by largest dimension); and 2) located <2 mm from
trachea, esophagus or recurrent laryngeal nerve (where ablation
might pose thermal injury). Eligible patients were offered a choice of
HIFU treatment, active observation or surgical resection. HIFU treat-
ment was conducted with the USG-guided Echopulse (Theraclion SA,
France). Primary outcome was a change in index thyroid nodule vol-
ume 6 months after HIFU. To have 80 % power and 95 % confidence
interval (two-sided) to detect minimal important difference of 20 %,
20 patients were needed. Assuming a 10 % incomplete and with-
drawal rate, 22 patients were required. Thyroid volume (mL) was
assessed at baseline (i.e. before ablation), 1-week, 3-month and 6-
month while HRQL was assessed by the Chinese version of the SF-
12v2 at baseline and 6-month. The HRQL measured by eight domain
scores and two summary scores (physical and mental component
summary) was then compared between those who received HIFU
and those who chose active observation (controls) at 6-month.
Results
Over this period, 22 (52.4 %) chose to receive a single course of HIFU
(HIFU group) while the other 20 patients chose to have active obser-
vation (controls). Among the HIFU group, the majority were females
(90.9 %) and the majority (77.3 %) had their index nodule as the
dominant nodule in a multinodular goiter. The mean base index nod-
ule volume was 6.48 ± 4.34 mL (range: 0.92 - 16.76 mL). At 6-month
following HIFU, the treated nodule volume decreased to 1.38 ±
1.31 mL (n = 22, p < 0.001). The average extent of nodule reduction
was 71.58 ± 11.81 % (range: 54.45 – 90.09 %). However, there was no
significant correlation between extent of 6-month volume reduction
and basal volume (r = 0.096, p = 0.806), total treatment time (r =
0.503, p = 0.168), total energy delivered (r = 0.122, p = 0755) or mean
delivered energy per treated volume tissue (r = 0.150, p = 0.700).
Compared with controls, the HIFU group achieved a significantly
greater improvement in four quality-of-life domains (17.57 ± 6.46, p =
0.009 for role physical; 18.01 ± 6.78, p = 0.011 for bodily pain; 24.77 ±
8.15, p = 0.004 for general health; 32.61 ± 8.93 for social functioning),
and physical component summary of the SF-12v2 ((7.89 ± 2.83, p =
0.001).
Conclusions
USG-guided HIFU ablation is not only an effective and safe treatment
option for patients with benign symptomatic thyroid nodules but
has the potential of improving the HRQL of patients who do not wish
to undergo surgical resection.
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Objectives
Thyroid nodules prevalence can reach 67 % on ultrasound (US)
examination. Although 95 % of them are benign, 1/3 show
continuous growth and should be treated because of clinical
symptoms or cosmetic concerns (1). Surgery is still the main
therapeutic strategy, in spite of the fact that it carries 2–10 %
risk of complications (2).
US-guided high-intensity focused ultrasound (HIFU) is a non-invasive
ablative technique, designed to decrease thyroid nodule size (3, 4).
The purpose of our work was to compare the long-term efficacy and
safety of one and two consecutive HIFU sessions for the ablation of
benign solid thyroid nodules.Methods
Twenty patients (mean age, 44.5 years) with euthyroid benign nodu-
lar goitre were treated with US-guided HIFU device (EchoPulse, Ther-
aclion, France) under procedural sedation and analgesia. US volume
measurement was performed at baseline, 3 and 12 months after the
final treatment. Three months after the first treatment, 12 patients
(group 1) continued the follow-up and 8 patients (group 2) received
second HIFU treatment. Adverse events were evaluated after each
HIFU procedure. Written informed consent was acquired from all
patients.
Results
Concerning the baseline nodule volume and the energy applied
per nodule volume, there was not significant difference between
group 1 and group 2 (5.04 ± 2.70 ml and 4.83 ± 2.74 ml, respect-
ively; 3.5 ± 1.4 kJ/mL and 4.1 ± 1.6 kJ/mL, respectively). At 12-
month follow-up the mean nodule volume decreased significantly
in both groups (2.35 ± 2.44 ml, p = 0.003, and 2.63 ± 1.85 ml, p =
0.017, respectively) with a maximal volume reduction of 95.4 %
and 66 %, respectively. The mean percent of volume reduction at
M3 after the first HIFU and at M12 after the final HIFU differed
significantly between group 1 and 2 (47.4 % ± 20.8 vs 24.2 % ±
15.8, p = 0.02 at M3, and 55.5 % ± 28.4 vs 46 % ± 22, p = 0.011 at
M12). In two patients, transient subcutaneous oedema and mild
skin redness were registered after the first HIFU procedure and
after the second procedure one patient developed transient Hor-
ner syndrom, which resolved in 6 months.
Conclusions
The long-term effect of one and two HIFU sessions in solid benign
thyroid nodules is comparable. Larger studies are needed to explain
the different thyroid nodule susceptibility to HIFU ablation.
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Objectives
To describe our experience with Magnetic Resonance-guided High
Intensity Focused Ultrasound (MR-HIFU) ablation of painful Osteoid
Osteoma (OO) in children.
Fig. 73 (abstract A73). Representative US B-mode images and color
Doppler images taken before and right after microtripsy thromboly-
sis treatment in an acute pig. a-d: Longitudinal sections of the fem-
oral vein. e-h: Cross sections of the femoral veins
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Nine children with OO (7 M, 2 F; 16 ± 6 years) underwent MR-
HIFU ablation through an FDA and IRB-approved safety and
feasibility clinical trial using the Sonalleve V2 MR-HIFU system.
Treatment feasibility, patient safety, and clinical response were
evaluated in all patients over 28 days. Additional follow-up was
performed to evaluate longer-term safety and durability of clin-
ical response.
Results
MR-HIFU therapy was feasible in all nine patients without any serious
treatment-related adverse events. Eight out of 9 patients reported
complete response in terms of pain resolution and cessation of medi-
cation usage and one out of 9 patients reported partial response. All
treatments were performed on an outpatient basis without overnight
admission.
Conclusions
These findings show that MR-HIFU ablation of OO is feasible
and safe in pediatric patients and offers clinical response rates
similar to those seen with radiofrequency ablation, the standard
of care therapy at most US hospitals. However, the completely
noninvasive and radiation-free nature of MR-HIFU is advanta-
geous over RFA, particularly in children and adolescents for
whom collateral damage and radiation exposure may cause
long-term morbidity.Fig. 74 (abstract A73). Histology of Femoral Veins. a-d: Right after a
free-flow treatment. e-h: Two weeks after a thrombolysis treatmentA73
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Objectives
Histrotripsy is a novel therapeutic technique that uses ultra-
sound generated from outside the body to create controlled
cavitation in a target tissue, and fractionates it into acellular
debris. We have developed a new histotripsy approach, termed
microtripsy, to improve targeting accuracy and to avoid collat-
eral tissue damage. This in vivo study evaluates the efficacy and
safety of microtripsy thrombolysis in a deep vein thrombosis
(DVT) model.
Methods
Acute thrombi were formed in the left femoral veins of pigs
(~35 kg) by occluding the vessel using two balloon catheters
and infusing with thrombin. Guided by ultrasound imaging,
microtripsy thrombolysis treatment was conducted in 14 pigs.
10 pigs were euthanized on the same day (acute) and 4 at
2 weeks (subacute). To evaluate the vessel damage, 30-min
free-flow treatment (no thrombus) in the right femoral vein was
also conducted in 8 acute pigs.
Results
Blood flow was restored or significantly increased after treatment
in 13 out of the 14 pigs (Fig. 73). One treatment was not effect-
ive due to a technical issue with clot formation. The flow chan-
nels reopened by microtripsy had a diameter up to 64 % of the
vessel diameter (~6 mm). The average treatment time was 16 mi-
nute per cm-long thrombus. Minor hemolysis was observed in
both thrombolysis and free-flow treatments. Histology showed no
vessel damage and only microscopic hemorrhage outside the
veins for the free-flow treatments with nothing abnormal ob-
served for the subacute treatments (Fig. 74).
Conclusions
Microtripsy is a safe and effective treatment for DVT in a por-
cine model. Further studies are warranted to study the role of
this promising noninvasive thrombolytic method in human
subjects.A74
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Objectives
Hypertension represents a critical health challenge for millions of
people and despite the availability of numerous pharmaceutical
agents, approximately 10 % of the patient population who are
currently taking three or more medications continue to have high
blood pressure and are identified with resistant hypertension.
Renal sympathetic nerves are key in initiating and maintaining
systemic hypertension. Many studies have demonstrated that per-
forming renal denervation (RD) using both catheter-based and
Focused Ultrasound have achieved significant decreases in blood
pressure. Mixed clinical trial results and the lack of an acute
metric that demonstrates successful RD highlight the need to find
alternative technologies and monitoring techniques that can con-
sistently result in RD.
This work evaluates using MRgFUS as a RD technique in a
normotensive rat model. Real-time MR monitoring, acute invasive
blood pressure probe measurements and histological results all
demonstrate the potential of using MRgFUS to control resistant
hypertension.
Methods
In this pilot study, both male and female (n = 6 treated/5 sham)
normotensive Sprague-Dawley rats underwent bilateral RD with
MRgFUS. All procedures were performed in a 3 T MRI scanner
(Siemens 3 T Trio) using a small animal MRgFUS system (f =
3 MHz, Image Guided Therapy). Sonications were applied along
the length of both renal arteries (8 points/animal, 2 W, 20s) and
monitored in real-time with 3D MR thermometry. Pre- and post-
RD procedure T1 maps were obtained evaluating the entire
insonified area. In 5 animals (36 total sonications), mean arterial
pressure (MAP) was monitored continuously using an invasive
fiberoptic blood pressure probe (SA instruments) inserted in the
Fig. 76 (abstract A74). H&E stain of ablated renal nerve region with
inflammatory cells, pyknotic nuclei and degraded nerve fiber
indicated. Scale bar = 50 μm
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nized and kidney medulla norepinephrine concentration, a
proven, robust metric of successful denervation, was obtained
using an ELISA (Rocky Mountain Diagnostics). Histological ana-
lysis was performed on both renal arteries and surrounding tis-
sues and kidney function, as measured by blood urea nitrogen
and urinary albumin secretion, was evaluated.
Results
Acute blood pressure response: A transient decrease in MAP
(>5 %) was observed during 11 of the 36 monitored sonications
(~30 %). The normalized MAP measurements obtained during
these 11 sonications are seen in Fig. 75. In all animals the effect
was dependent on sonication location. In addition, the change in
MAP occurred several seconds after the sonication start time indi-
cating it was an accumulated effect. Treatment efficacy: Kidney
medulla norepinephrine concentration was reduced by 36 % (p =
0.05) one-month post ablation when compared to the sham ani-
mals, indicating RD was successfully performed. Efficacy was fur-
ther confirmed by the presence of inflammatory cells, pyknotic
nuclei as well as degraded nerve architecture in the histological
results (Fig. 76). Treatment safety: Comparison of the treated and
sham RD animal’s blood urea nitrogen and urinary albumin/cre-
atinine ratio resulted in no significant changes indicating kidney
function was not affected by MRgFUS renal denervation. In
addition, mean T1 values in both kidneys did not significantly
change during the MRgFUS RD procedure. The peak mean
temperature rise measured by real-time MR thermometry in the
back muscle (Fig. 77) located in the near field of all animals
ranged from 15.5 to 25.0 °C, confirming energy delivery and tar-
geting accuracy.
Conclusions
Controlling resistant hypertension with renal denervation using
Focused Ultrasound has been demonstrated in this and other
studies to be a safe and potentially efficacious procedure. This
work indicates that an acute, systemic response that is a func-
tion of sonication position can be detected during MRgFUS ab-
lation of the renal sympathetic nerves. Future work will further
evaluate this response in a hypertensive animal model and as-
sess the effect of ultrasound parameters.Fig. 77 (abstract A74). Coronal MR thermometry image showing
the temperature rise measured in the back muscles (hollow arrows)
during a single sonication. The white arrow indicates the spine
Fig. 75 (abstract A74). Normalized mean arterial pressure response
for 11 sonications measured in 5 animals. Thick lines indicate the 20-
second sonication time
Fig. 78 (abstract A76). See text for description
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Objectives
Atrial fibrillation and ventricular tachycardia are currently treated with
catheter ablation using radiofrequency or cryoenergy. These endocar-
diac approaches are invasive and not fully satisfactory as the treat-
ments are often incomplete and can be associated with serious side
effects. The esophagus offers an excellent acoustic window to the heart
and transesophageal HIFU were proposed as an alternative strategy.
The present work describes the first attempt to perform thermal abla-
tion with trans esophageal HIFU in the heart of a non-human primate.
Methods
For that purpose, an endoscope integrating a 5 MHz 64-element com-
mercial transesophageal echocardiography (TEE) probe and a HIFU trans-
ducer was built. Anatomical configuration and numerical simulations
(Constanciel 2013) allowed setting the features of the HIFU transducer: 8
elements truncated at 14 mm, 3 MHz operating frequency and 40 mm
focal length. The focus could be steered electronically over a 15 to
55 mm range from the transducer. Circulation of water at 5 °C inside the
endoscope ensured cooling of the front face of the HIFU transducer and
acoustic coupling through the inflation of a latex balloon. The probe was
tested in vivo in a 30 kg-baboon after preliminary TEE and CT-scanner
demonstrated the acoustic access from the esophagus to the heart in this
animal model. HIFU were delivered to the interatrial septum, the inferior
wall of the left atrium and the upper posterior wall of the left ventricle
(LV). A multi channel amplifier allowed delivering a focal intensity (Ispta)
of 3000 W/cm2 applied 4 times for 16 s at each selected locations. B-
mode, shear-wave (SWE) and passive elastography were performed be-
fore and after HIFU with an ultrafast scanner. MR imaging (T1 mapping
and contrast) was performed one-day post HIFU. Animal experimentation
approved under agreement 04938.04.
Results
The endoscope was successfully inserted in the esophagus of the ba-
boon. The inflation of the latex balloon allowed acoustic transmission
from the esophagus to the heart and visualizing satisfactorily the car-
diac structures by TEE. HIFU could be delivered at the locations identi-
fied on the CT scans even though the heart was slightly shifted in the
chest due to different positions of the animal during CT and HIFU pro-
cedures. The ECG was not impacted by the treatments. No change in
echogenicity of treated zones could be evidenced after HIFU. SWE
showed a stiffening of the LV myocardial wall after ablation (two-fold
increase of the myocardial stiffness). Increase of stiffness could be ob-
served similarly in the beating heart on passive elastogram. MRI of the
atrial wall for detecting thermal ablation could not be achieved. A hypo
signal zone could be evidenced on T1 maps in the lateral wall of the LV
where one treatment was performed. Contrast MRI did not show local
fibrosis in the heart. Endoscopic examination did not reveal esophageal
damage. The baboon recovered properly from the protocol and no sig-
nificant side effect could be evidenced for one month after treatment.
Conclusions
This experiment was a first attempt to perform thermal ablation in the
heart with a trans esophageal probe in vivo in a non-human primate.
While the procedure was safe and lesions seemed to be induced in the
heart, developments will be necessary in order to 1- Deliver more power
locally by HIFU, to compensate for motion and heat sink by blood circula-
tion and to generate more pronounced lesions, 2- Improve the perform-
ance of monitoring techniques for the atrium (sensitivity and resolution)
and for the ventricle (difficult to generate shearwave farther than 50 mm
from the esophagus).A76
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Objectives
Currently, no non-invasive cardiac pacing device acceptable for pro-
longed use in conscious patients exists. The main approach is invasive,
employing intravascular catheters, which has associated risks. Focused
ultrasound can be used to perform remote pacing using reversibility of
electromechanical coupling of cardiomyocytes. This technique might
be useful in the short term in the clinical settings in various conditions:
temporary pacing for bradycardia or any clinical condition with risks of
asystole; terminating or examining the inducibility of tachyarrhythmia;
screening and optimization of cardiac resynchronization therapy. Here
we described an extracorporeal cardiac stimulation device and study its
efficiency and safety.
Methods
Ex vivo acoustic stimulation threshold was determined performing 756
sonications in 10 pig beating hearts. In vivo non-invasive stimulation was
performed using 314 sonications in 4 anesthetized pigs. The animals
were injected with ultrasound contrast agents. Experiments were per-
formed using a Focused Ultrasound device (256 elements, 13/13 cm
aperture/focal, operating at 1 MHz) under MR-guidance. At the end of
each in vivo experiment, a navigated delayed inversion-recovery 3D Flash
sequence was performed. Masson’s staining was performed to assess
acute damages screening from acoustic stimulation of both ex vivo and
in vivo experiments.
Results
Using HIFU it was possible to perform ventricular continuous pacing
(Fig. 78a) or to induce ventricular tachycardia (Fig. 78b). Consecutive
stimulations of different heart chambers with a single ultrasonic probe
was shown, allowing to modify the resulting atrio-ventricular delay
(Fig. 78c-d). The results of the 756 stimulation sites performed in the
right atrium, and the left and right ventricles in 10 ex vivo beating
hearts from pigs were processed to determine stimulation threshold for
pulse duration ranging from 30 μs to 10 ms. Two different pressure
thresholds were highlighted: one around 4 MPa peak negative for HIFU
pulse durations above 1 ms and one around 6 MPa peak negative for
HIFU pulses ranging from 50 μs to 1 ms (Fig. 78e). The same setup was
used in vivo in 4 pigs to show clinical potential (Fig. 78f). Electrophysio-
logical changes were also confirmed by arterial pressure modifications
(Fig. 78g). The maximal peak negative pressure was estimated to be
around 2 MPa at focus during in vivo experiments, due to the limited
acoustic window. At this pressure level, stimulation of the LV was ob-
served but with an insufficient success rate. Using ultrasound contrast
agents, consistent cardiac stimulation was achievable for up to 1 hour
sessions in 4 different animals. No damage was observed in the 4
animals.
Conclusions
To the best of our knowledge, this study is the first ex vivo and
in vivo proof of feasibility of controlled non-invasive ultrasound-
based cardiac stimulation in large animals. Preliminary safety results
showed that this novel technology offers good prospects for clinical
developments.
Fig. 79 (abstract A77). Contains the results from the LDPI studies
at 7 weeks post surgical ligation of the external iliac artery demonstrating
clear differenes in perfusion in the lower extremities for the saline
control, pFUS and MSC alone groups versus the (pFUS +MSC)x3 group.
Figure 79a is a graph of the ratio of measured perfusion in the ischemic
limb/contralateral limb. The only group that showed an increase in
perfusion starting 2 weeks after intervention with pFUS with our without
MSC or MSC alone is the cohort of mice that received both treatments.
The pFUS +MSCx3 group of mice had approximately 60 % recovery of
perfusion to the hind limb compared to the other cohorts of animals.
Figure 79b contains representative sections from the hamstring muscle
stained for CD31+ endothelial cells (brown cells) clearly showing an
increase in vascular density in the (pFUS +MSC)x3 group of mice
compared to the other groups (Fig. 79c)
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Objectives
Critical limb ischemia (CLI) is associated with a 5 year mortality rate
in excess of 70 % with limited effective therapies. The goal of this
study was to determine if pulsed Focused Ultrasound (pFUS) would
enhance homing of mesenchymal stromal cells (MSC) to CLI in an
aged mouse model and reestablish perfusion compared to pFUS or
MSC alone.
Methods
CLI model was created by cauterizing the external iliac artery
(EIA) on C3H mice (age = 10-12 months). Laser Doppler perfusion
imaging (LDPI) was perform of lower extremities to confirm sur-
gery and subsequently performed for weekly for 7 weeks post
surgery. At 14 days post surgery, mice were divided into 4
groups: saline (n = 8), pFUS (n = 8), MSC (n = 8), and MSC + pFUS
(n = 17). Mice received either 3 consecutive days of saline, pFUS ,
MSC, or MSC + pFUS starting on day 14 post surgery. 106 human
MSC were administered IV. CLI mice (n = 3/group) were eutha-
nized after one dose of either MSC + pFUS or MSC alone to de-
termine if there was increased cell homing to ischemic muscle.
pFUS exposures was performed with VIFU 2000 with a 1 MHz
transducer; at 4 MPa; pulse repetition frequency, 1 Hz; DC 5 %;
100 pulses per point. Histology for vascular cell density from
ischemic limb was performed at 7 weeks post EAI. Fluorescent
microscopy was performed for human vascular endothelia growth
factor (VEGF) and interleukin (IL) 10 one day after treatment with
MSC alone or MSC + pFUS to determine if pFUS improved the po-
tency in CLI.
Results
LDPI demonstrated significant (p < 0.01) differences between
(MSC+ pFUS) versus saline, pFUS, and MSC groups when treat-
ment was delayed 2 weeks after CLI (Fig. 79). Perfusion signifi-
cantly increased with the MSC + pFUS treatment out to 7 weeks
compared to other cohorts. Histological examination of muscle
revealed significant increase (p < 0.05) in CD31+ cells and vascu-
lar density treated with MSC + pFUS compared to other groups
(Fig. 79b,c). Mice were euthanized on day 15-post surgery and
human cells were counted in CLI muscle to determine if MSC +
pFUS would enhance homing of infused cells in CLI model.
Following IV MSC alone, MSC detected in the ischemic limb
101.0 ± 67.4 compared to mice that received pFUS + MSC, MSC
in the ischemic limb was 306 ± 175 (p < 0.01 for MSC alone vs.
pFUS + MSC). We also observed ~4-6 fold increases (p < 0.05) in
human VEGF and IL10 expression in MSC + pFUS compared MSC
alone groups.
Conclusions
This study demonstrates that pFUS enhanced homing of IV MSC
to targeted muscle resulting in reperfusion and neovasculariza-
tion in CLI model compared to MSC alone. pFUS precondition-
ing effects in the ischemic muscle stimulated local molecular
changes in the tissue microenvironment that when combined
with MSC infusion increased stem cell numbers and potency by
producing increased amount anti-inflammatory faction that lead
to increased perfusion compared to MSC alone. The ability of
pFUS to modulate the molecular microenvironment in chronic
diseased tissue opens the possibilities for enhancing cellular
therapies in regenerative medicine and potentially improves
clinical outcomes in patients suffering from CLI.A78
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Objectives
Hypertension affects 1.2 billion people worldwide. A novel method
to address this need is ablation of the renal (kidney) sympathetic
nerves which run along the renal arteries (“RDN”). In contrast to
catheter-based RDN, which relies on intravascular delivery energy
through the wall of the artery to ablate renal nerves, the Kona Med-
ical Surround Sound™ system delivers non-invasive Focused Ultra-
sound energy from outside the body.
Methods
Surround Sound® System is a fully-integrated, self-contained system
which can be used in virtually any exam room in a hospital, office or
clinic, and does not require a catheterization lab. The system adminis-
ters focused therapeutic ultrasound to the renal nerve complex using a
custom therapeutic transducer array with a unique shape consisting of
205 individually phased elements that can provide more than 800 W
peak acoustic power. The clinical dose includes 14 lesions delivered
over a 2.8 minute period. A separate ultrasound imaging probe is used
to identify the renal artery position and an optical tracking system
transforms the target location position via the imaging array to a motor
that steers the therapy array to the selected target. A fully automated
image tracking algorithm corrects for target motion while interleaved
imaging and therapy pulses provide monitoring during the entire treat-
ment. Beamforming and target motion tracking utilize fast, GPU com-
putation to incorporate robotic, closed-loop motion control for 3D
energy delivery, focusing, and positioning in real-time.
Results
69 patients with uncontrolled hypertension were treated in the first 3
clinical trials (WAVE I, II and III) using the Kona Surround Sound™ sys-
tem. 64 out of 69 subjects have completed at least one year follow up
with an average systolic and diastolic blood pressure reduction of
23.8 mmHg/10.3 mmHg at one year. No devices related unanticipated
serious adverse events occurred. This data suggests that externally de-
livered ultrasound appears to be safe with an encouraging efficacy sig-
nal. A blinded, randomized, sham-controlled clinical trial (Wave IV; 132
patients) is currently enrolling at leading health care institutions in the
Fig. 80 (abstract A79). T1w MR localize ultrasound for (a) point, (b)
circle, (c) grid ablation. MR thermometry following (d) 20 s point, (e)
60 s circle ablation. Autoradiography 48 hours after (f) point, (g)
circle, (h) grid ablation. (i) Survival plot for all animal groups
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81 eligible study participants have been treated to date.
Conclusions
The Surround Sound system, which is developed to provide a one-
time, non-invasive procedure to treat hypertension, has the potential
to greatly reduce cost, lower risk, and improve access to millions of
hypertension patients worldwide who are not adequately controlled
by drug therapy. The initial clinical data have shown that ablation of
renal nerves using Surround Sound system can result in profound
and lasting reduction in blood pressure. The technology platform in
which the system targets specific tissue while automatically tracking
movement and continuously enabling therapy delivery through a
custom shaped high power therapeutic phased array, could be easily
adapted and used in other clinical applications.
A79
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Objectives
Magnetic Resonance-guided Focused Ultrasound (MRgFUS) ablation is a
noninvasive method for treating solid tumors. However, ablation of the
entirety of the tumor may not be possible due to constraints imposed by
surrounding tissue, resulting in a small rim of viable tumor following ther-
mal therapy. Therefore, augmentation of MRgFUS with chemotherapeu-
tics such as liposomal doxorubicin may be necessary. These formulations
reduce systemic toxicity by encapsulating non-bioactive copper-
doxorubicin crystals which dissociate in the low pH of the tumor micro-
environment. Our ultimate goal is to use Focused Ultrasound (US) within
curative protocols in the mouse and in human medicine.
Methods
All studies were approved by the UC Davis Institutional Animal Care
and Use committee. Tumors were generated in FVB/n mice expressing
an activated form of ErbB2/neu, a system modeling human HER2 amp-
lified breast cancer. These tumors were then transplanted into the
mammary fat pads of wild type FVB/n mice. The results were validated
in another mammary carcinoma model (4 T1 in BALB/c mice).
US ablation was accomplished under Magnetic Resonance (MR) guid-
ance via either a 20 s insonation at a single point or a 60 s insonation
in a circular pattern (16 element annular array with a 3 MHz central fre-
quency, 3.1 MPa peak negative pressure (PNP)). Both protocols induced
temperatures >65 °C and CEM43 > 5000. Hyperthermia (41 °C) was in-
duced using a 192-element transducer with 128 therapeutic elements
operated with a center frequency of 1.5 MHz and 1.1 MPa PNP, under
US guidance and a needle thermocouple for temperature monitoring.
Temperature-sensitive and long-circulating doxorubicin liposomal for-
mulations (Dox-TSL and Dox-LCL, respectively) were evaluated in
combination with each ablation protocol. Accumulation of 64Cu-
labelled liposomes was assessed with positron emission tomography
(PET) and autoradiography following each of the ablation protocols.
Results
Ablation enhanced accumulation of 64Cu-LCL in the remaining rim of vi-
able tumor (Fig. 80), with a 5-fold increase in nanoparticle and 50-fold in-
crease in local drug concentration. With the combination of a 5 mm
circular ablation region and Dox-LCL, tumors were eliminated in all mice
and recurrence was not observed within 180 days. Integrating this sphere
of ablation with Dox-TSL achieved a durable response with 4 treatments
in 75 % of mice treated. Alternatively, preapplication of hyperthermia to
enhance release of Dox-TSL prior to the application of the spherical re-
gion of ablation produced durable response in 100 % of mice within 4
treatments.
Conclusions
In conclusion, initial results for the combination of hyperthermia, abla-
tion and liposomal doxorubicin in a fully immunocompetent aggressive
syngeneic model demonstrated multiple opportunities to achieve a
durable response in local disease.A80
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Objectives
The Nanoporation project set out to explore specific solutions to over-
come the current challenges of targeted drug delivery (TDD) to tumours
using Magnetic Resonance Imaging guided Focused Ultrasound
(MRgFUS) to cavitate microbubbles (MBs) for increasing cell permeability
and to open ‘drug nano-capsules’ to release proven active anticancer
drugs directly to the tumour site with reduction of systemic drug dosage
needed for the desired therapeutic effect. The work reported here aimed
to develop novel nano-carriers for existing anticancer drugs, by establish-
ment of human cancer cell models to evaluate the carriers’ encapsulation
efficiency in vitro and in vivo, by using animal models and a clinical
MRgFUS system to investigate the carrier-drug vehicles’ in vivo distribu-
tion and localised drug release / cellular drug uptake.
Methods
A novel γ-cyclodextrin (γ-CD) based carrier for encapsulation of doxo-
rubicin (DOX) was synthesised and fully characterized (Figs. 81 and 82).
The encapsulation efficiency was assessed under various temperatures
and pH levels by both chemical analysis and in vitro human cancer cell
modeling with KB and HCT116 cells. A computer-controlled high-
throughput in vitro FUS device facilitating exposure to High Intensity
FUS fields in a standard 96-well plate was designed and applied. It al-
lows maximum flexibility in choosing experimental parameters in com-
bination with carrier-DOX inclusion. SonoVue® MBs was used to
investigate TDD in cell monolayers. An extensive in vitro study had
been carried out to investigate both mechanical and thermal effects of
ultrasound. An unique MRgFUS system compatible anmial house were
designed and built to allow ex vivo and in vivo experiments by using
small rodents (Fig. 83). Ex vivo and in vivo trials were carried out with a
clinically approved ExAblate MRgFUS system (InSightec, Israel) to estab-
lish a safe and efficient clinical TDD protocol on small rodents (Fig. 84).
Results
The desired γ-CD based carrier greatly reduced DOX’s toxicity and the
carrier-DOX inclusion was highly stable under physiological temperature
conditions as well as under a wide range of acidic conditions (pH 1.0 ~
7.0); the encapsulated DOX is slowly released under hyperthermic condi-
tions (up to 50 °C). In the presence of MBs, application of FUS with low
mechanical indexes, under which no thermal effect was observed,
enhanced the drug uptake into tumour cells for both encapsulated and
free DOX. Optimal setups of MR parameters and FUS parameters were
identified ex vivo and in vivo, allowing application of MRgFUS treatments
to 4 live mice bearing tumours (human colorectal carcinoma, up to
1059.71 mm3) under anaesthesia with full recovery.
Fig. 84 (abstract A80). MRgFUS ex vivo study
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The study demonstrated the possibility of translation of the constructed
γ-CD derivative to potential clinical use as a delivery vehicle for DOX
using combined thermal and mechanical release mechanisms by clinic-
ally applicable MRgFUS– triggered TDD with the potential for cancer
therapy. it provides better understanding of the mechanism of and po-
tential for this novel delivery approach: MRI-guided, ultrasound-
mediated, site-specific drug delivery assisted by MB contrast agents.
The chemical modifications and in vitro, ex vivo and in vivo preclinical
studies discussed here represent only a glimpse into the future of clin-
ical application. It is likely that this novel technology will enter the clin-
ical arena in the near future, based on the ever-increasing scientific
contributions from researchers.Fig. 82 (abstract A80). AFM cell surface morphology of KB cells
after sonication with and without MBs
Fig. 83 (abstract A80). MRgFUS compatible small animal house for
ex vivo and in vivo study
Fig. 81 (abstract A80). γ-CD based drug delivery vehicleA81
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Objectives
Thermosensitive liposomes (TSLs) have been reported to accumu-
late and deliver an effective therapeutic to tumours with the ap-
plication of hyperthermia. However there is limited understanding
of the effect of pharmacokinetics, the time frames and the dur-
ation of hyperthermia applications. For instance, the timing be-
tween drug injection and application of focused ultrasound (FUS)
needs to be optimised considering nanoparticle biodistribution in
the tumour and drug release. Near-Infrared Fluorescence (NIRF)
imaging offers an easy and sensitive method to follow the biodis-
tribution of dye-labelled theranostic nanoparticles and drug re-
lease in real time and could act as a useful preclinical surrogate
for other forms of imaging to help understand the mechanism of
drug kinetics in the tumours. In the present study we examined
the biodistribution of novel dual MRI and NIRF-labelled thermo-
sensitive liposomes (image guided; iTSLs), and we modulate their
distribution with hyperthermia induced by a high intensity fo-
cused ultrasound transducer (FUS).
Methods
We have synthesized lipids that can be used for imaging in mice
by MRI and NIRF. We have prepared iTSLs with the optimum con-
centration of imaging lipids for thermally triggered release and
we developed them in combination with a FUS treatments regi-
men (thermal dosing). Labeling of liposomes for imaging can pro-
vide substantial information of the mechanism of tumor uptake
(post injection) and provide insight on the reasons why this up-
take is more enhanced in FUS treated tumors. We prepared iTSLs
to encapsulate the anticancer drug topotecan (Hycamtin®), a che-
motherapeutic agent which when released in vivo can be moni-
tored by its intrinsic drug fluorescence. We have optimized drug
encapsulation for maximum fluorescence signal difference (before
/after release) for both in vitro and in vivo. FUS (TIPS Phillips)
was applied using temperature feedback via subcutaneously
placed fine-wire thermocouples to maintain hyperthermic temper-
atures. NIRF imaging was performed using multispectral analysis
bioimaging (Maestro EX) following the emission of the NIRF lipid
and topotecan. FUS was applied using imaging as guidance. FUS
was applied 30 min post injection and the tumors were moni-
tored. In a separate group of animals FUS was applied at 30 and
90 min post injection. MRI imaging confirmed observations ob-
tained with NIRF imaging.
Results
iTSL tumour accumulation was detected using NIRF imaging im-
mediately after liposome administration, this is due to the en-
hanced permeability and retention effect. Mice were bearing
tumours at both flanks allowing one tumour to act for control
(no FUS treatment). FUS-induced hyperthermia (3 min at 42 oC,
30 min post i.v.) greatly enhanced liposomal uptake as seen by
imaging. A co-localised, enhancement of topotecan fluorescence
emission was also observed immediately after application of
hyperthermia indicating rapid thermally triggered drug release
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cer drug model and its intrinsic fluorescent properties allow to
easily follow thermal drug release. The phenomena of increased
iTSL accumulation and concomitant topotecan release appeared
to be amplified by a second mild hyperthermia treatment applied
1 hour after the first. NIRF imaging detected the signal coming
from the liposomes (NIRF incorporated lipid) indicating that lipo-
somes accumulated in tumours post injection. This accumulation
was substantially enhanced after each application of FUS. Topote-
can fluorescent appeared transient in the tumour indicating phe-
nomena of cell uptake and DNA binding. MR imaging also
confirmed enhanced iTSLs uptake due to the FUS treatments in
the same animals that were imaged using NIRF imaging (Fig. 85).
Conclusions
In this study we have formulated a theranostic novel dual MRI/
NIRF labeled thermosensitive liposome (iTSL) that encapsulates
the anti-cancer agent topotecan and enables real time/diagnostic
imaging, making use of pre-clinically and clinically relevant im-
aging modalities. Image-guidance in turn enables the application
of brief, moderate intensity FUS treatments that greatly increase
iTSL tumor uptake and set up the possibility for substantial FUS
triggered topotecan release within the tumor volume. FUS hyper-
thermia applied during the half-life of the iTSL in plasma pro-
motes iTSL accumulation in the tumors and takes advantage of
the high concentration of the liposomal drug in plasma seen
immediately after injection. Should these effects be translated to
the clinic, this suggests substantial benefits to cancer patients
and improvements of the standard of the chemotherapy treat-
ments for both primary and metastatic tumors.Fig. 85 (abstract A81). NIRF and MRI imaging after dual FUS application
Fig. 86 (abstract A82). TIPS focused ultrasound (FUS); (left) overview
of the equipment showing the water-filled transducer chamber, the
thermocouple interface, and the control PC; (right) schematic of the
in vivo configuration with the transducer (a) raised such that the
ultrasound biconic (b) focuses just above the skin surface over the
tumour (c). The mouse is surrounded with warmed, degassed ultra-
sound gel (d) and placed on an ultrasound absorbing mat (e) to
prevent reflections off the table. Temperature monitoring is via two
or three fine-wire thermocouples (f) implanted around the tumourA82
Near infrared fluorescence imaging for Focused-Ultrasound
mediated local drug delivery of doxorubicin
Miguell Centelles1, Mike Wright1, Wladyslaw Gedroyc2, Maya Thanou1
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Objectives
High-intensity Focused Ultrasound (FUS) is valuable clinical
technique for non-invasive thermal tissue ablation. Its capability
for localised drug delivery has also been investigated recently,
with application to cancer therapies. The ability of thermosensi-
tive liposomes (TSLs) to accumulate and deliver a therapeutic
drug to tumours under application of hyperthermia has been
well reported but there is limited understanding of the time
frames and kinetics involved. For instance, the optimal delay (if
any) between injection of the therapeutic and application of
heat. Near-Infrared Fluorescence (NIRF) imaging offers a sensitivemethod to follow the biodistribution of dye-labelled theranostic
nanoparticles in near real time and acts as a useful preclinical
surrogate for other forms of imaging (such as PET or MRI).
Methods
Our iTSLs (imageable TSL) containing doxorubicin (0.8 mg/mL)
were formulated with different molar ratios of key lipids, and a
dye-labelled lipid - XL750-DSA. In vitro studies were performed to
characterise the temperature-triggered doxorubixin release by
measuring changes in its intrinsic fluorescence. In vivo experi-
ments were performed on SHO mice bearing subcutaneous MDA-
MB-231 tumours on both flanks. For bioimaging experiments,
iTSLs were injected i.v. with and without any hyperthermia in-
duced by FUS (TIPS, Philips) and controlled by three thermocou-
ples placed around the tumour (Fig. 86). TSLs and doxorubicin
were respectively monitored by recording the emitted fluores-
cence in the NIR and the blue regions of the spectrum. Finally,
tumour sizes were measured by calliper for 3-4 weeks following
treatment.
Results
In vitro release studies showed minimal leakage of the drug at
37oC over a 10 min period, while the release was almost immedi-
ate when the temperature was raised to 41oC. In vivo, a first
hyperthermia event (3 min at 43oC) was applied on one of the
two tumours before iTSLs administration. After 30 min, the iTSLs
were injected i.v. (tail vein) and their tumour accumulation was
monitored by tracking the NIRF signal. A second hyperthermia
treatment (3 min at 42 oC) was then applied 45 min later in
order to release the doxorubicin. As a consequence of this regi-
men, the mice showed a very significant NIRF intensity increase
in the treated area. At the same time, doxorubicin release was
observed but only for a short period of time. The combination of
this protocol & doxorubicin-iTSLs showed a significant impact on
tumour growth, including tumour eradication in some cases
(Figs. 87 and 88).
Conclusions
NIR fluorophores carried by the iTSLs allowed the monitoring of
the liposomes’ biodistribution over a period of several weeks
post-injection in our mouse model. Mild hyperthermia applica-
tions on the tumour greatly favoured nanoparticle uptake. The
hyperthermia also had the effect of releasing encapsulated
doxorubicin, therefore improving the drug delivery to the
tumour. Finally, a strong correlation between thermal dosing
and tumour targeting was observed with an increase of the
NIRF signal in the heated area with a subsequent enhanced
therapeutic effect.
Fig. 88 (abstract A82). Histology (H&E). The tumours were excised
48 hours after the treatment. Four micrometer H&E slices of MDA-
MB-231 tumors untreated and treated. The arrows indicate the large
necrotic areas only found when the combination of drug and hyper-
thermia was applied
Fig. 87 (abstract A82). Treatment efficacy: Mice were injected i.v.
with F5-XL750 (6 mg/kg) and were treated twice by FUS hyperther-
mia applied to the right side
Journal of Therapeutic Ultrasound 2016, 4(Suppl 1):31 Page 51 of 113A83
Interleaved mapping of temperature and longitudinal relaxation
rate monitor drug delivery from temperature sensitive liposomes
during MR-HIFU induced hyperthermia
Esther Kneepkens1, Edwin Heijman2, Jochen Keupp3, Steffen Weiss3,
Klaas Nicolay1, Holger Grüll2
1Eindhoven University of Technology, Eindhoven, Netherlands; 2Philips
Research, Eindhoven, Netherlands; 3Philips Research, Hamburg, Germany
Journal of Therapeutic Ultrasound 2016, 4(Suppl 1):A83
Objectives
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Ultrasound ablation transiently increases accumulation of small
molecule gadoteridol within the ablated volume
Brett Fite, Andrew Wong, Yu Liu, Azadeh Kheirolomoom, Lisa Mahakian,
Sarah Tam, Josquin Foiret, Katherine Ferrara
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Objectives
Magnetic Resonance guided Focused Ultrasound (MRgFUS)
ablation is a nonvasive method to deliver a precise, and lethal,
thermal dose to solid tumors. During thermal ablation, tissue
temperature typically exceeds 50-60 °C and results in rapid
coagulative necrosis. Such ablation often results in “heat fixing”
of the tissue which is thought to restrict the diffusion of mole-
cules into and out of the ablated region. In this study we used
gadoteridol (MW 558D) to evaluate the extent to which small
molecules could be delivered to tissue following thermal
ablation.
Methods
All studies were approved by the UC Davis Institutional Animal Care
and Use committee. MRgFUS ablation of syngeneic murine mammary
carcinoma (FVB/n mice expressing an activated form of ErbB2/neu)
was accomplished via a 60 s insonation in a circular pattern (16
element annular array with a 3 MHz central frequency, 3.1 MPa PNP).
This ablation protocol resulted in temperatures >65 °C and CEM43 >
5000.
Animals were injected with intraperitoneal gadoteridol either
immediately before or after treatment (0.05 mmol/kg) or with
intravenous gadoteridol before or after treatment. Mice were
then imaged with a T1w scan (TE/TR = 12.5/750 ms, FOV =
3.2 cm × 3.2 cm, MTX = 256 × 256, ST/SI = 1/1 mm, and 9 slices)
at 0.5, 1.5, 3, 6, 20, and 48 hours following ablation. The ab-
lated region and quadriceps were then manually segmented
and the tumor-to-muscle (T/M) ratio measured. In addition, two
control groups of mice were also imaged with T1w MRI, a set
treated with circle pattern MRgFUS and but no gadoteridol and
a set not treated with ultrasound, but injected with intraperito-
neal gadoteridol.
Results
Immediately following ablation, the T1w signal of the ablated
volume increased, beginning with the rim. The T1w T/M signal
ratio progressively increased until 1.5 hours post-ablation where
it peaked (Fig. 89). The T/M ratio remained elevated compared
to pre-ablation values for up to 6 hours post-ablation. Control
animals treated with the same ablation protocol without
gadoteridol injection did not exhibit an increase in T1w signal
post-ablation. At 20 and 48 hours post-ablation, the T1w signal
had decreased to pre-ablation levels and re-injection of
gadoteridol at these time points had no effect on tumor T1w
signal.
Thus, the small molecule gadoteridol accumulated within the tumor,
specifically within the ablated volume, for several hours following
ablation.
Conclusions
The results suggest that there is a window of time post-ablation
when small molecule drugs can be successfully delivered to ablated
tissue.
Fig. 90 (abstract A85). MSC better improve AKI with pFUS to
increase renal IFNg and MSC IL10 expression. MSCs with reduced
IL10 or IFNg-deficient mice to not see AKI benefit from pFUS +MSC
Fig. 89 (abstract A84). a T1w images of a tumor prior to, and
0.5 hours, 1.5 hours, 3 hours, and 6 hours following MRgFUS
ablation. Control tumors that received ablation but no gadoteridol
did not show regions of increased T1w signal. b Tumor to muscle
ratio of T1w signal
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Pulsed Focused Ultrasound to kidneys induces Molecular changes
that potentiate mesenchymal stem cells to further improve acute
kidney injury
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Objectives
Pulsed Focused Ultrasound (pFUS) enhances homing of IV-infused
mesenchymal stem cells (MSC) to kidneys during cisplatin (CIS)-in-
duced acute kidney injury (AKI). pFUS serves as a neo-adjuvant to
MSC therapy where sonicating kidneys with IV MSC leads to better
AKI outcomes than MSC therapy alone. Nearly twice as many MSC
home to pFUS-treated AKI kidneys, but >10 times as much interleu-
kin (IL)-10 is produced by MSC that home to pFUS-treated kidneys.
This result suggests that pFUS sonications modify the renal micro-
environment to increase potency of MSC that home to pFUS-treated
kidneys. Interferon-g (IFNg) increases MSC potency and is upregu-
lated in kidneys by pFUS. This study investigates pFUS-induced IFNg
expression in kidneys as an activator of MSCs that improves their
therapeutic efficacy during AKI.
Methods
C3H or IFNg-ko mice received CIS (15 mg/kg ip), kidney pFUS
(4 MPa; 5 % duty cycle) and/or MSC (106 human MSC). IV MSC
injections were performed 3-4 hr post-pFUS. siRNA was used to
knockdown IL-10 in some experiments. Experimental groups in-
cluded AKI only, AKI + pFUS, AKI + MSC, AKI + pFUS + MSC, and
healthy mice. Mice received CIS on Day (D)0 and pFUS/MSC on D1.
Mice were euthanized on D4. One-way analysis of variance used Bon-
ferroni post-hoc with p-values <0.05 considered significant.
Results
Following pFUS to the kidneys of IFNg ko mice, more MSC homed to
sonicated kidneys (~2 fold) but did not lead to improved AKI [serum
blood urea nitrogen (BUN) or serum Creatinine (SCr)] outcomes com-
pared to mice that received MSC injections alone (Fig. 90). Levels of
BUN and SCr, as well as expression of kidney injury molecule 1
(KIM1), were all significantly reduced by MSC treatment alone, but
not further reduced by combination pFUS/MSC treatment like was
previously observed in wild-type mice. Furthermore, the production
of IL-10 by MSC seen in wild-type mice treated with pFUS +MSC was
absent in IFNg-ko mice. Lastly, the improved AKI outcomes using
pFUS +MSC in wild-type mice were erased when mice were given
MSC that had been pretreated with siRNA to knockdown IL-10.
Conclusions
pFUS creates a molecular zip code in AKI kidneys that enhances MSC
homing. While MSC infusions alone improve AKI in IFNg KO mice,
pFUS +MSCs did not replicated the additional improvements in out-
comes seen in wild-type mice. While pFUS-independent mechanismsof AKI repair by MSCs do not require renal IFNg, the pFUS-
dependent mechanism that yields improved recovery does depend
on preconditioning of the parenchyma. IFNg upregulated by pFUS
mediates the neoadjuvant function of pFUS. Furthermore, the IFNg
upregulated by pFUS serves to enhance MSC function by increasing
MSC production of IL10, which has previously been shown to im-
prove AKI. These data demonstrate that an IFNg/IL10 molecular axis
is activated by pFUS and critical for improved AKI outcomes. More-
over, these results provide justification in incorporating pFUS as a
treatment to improve MSC therapy during AKI, which often has lim-
ited clinical therapeutic options.A86
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Objectives
Focused ultrasound not only causes lesions in biological tissue, but
can effectively push the medium in the focal region. This effect, asso-
ciated with the ability of ultrasound to remotely deliver and trans-
form momentum to an absorbing or scattering target, is called
radiation force. Until recently, therapeutic applications of this effect
did not exist, although it has been employed in ultrasound imaging,
e.g. shear wave elasticity imaging. Previously, our team developed a
technology to reposition kidney stones with radiation force. In a clin-
ical trial, the technology was used to transcutaneously facilitate pas-
sage of small stones and to relieve pain by dislodging larger
obstructing stones. While successful, the trial revealed a need for
optimization of the ultrasound beam structure, frequency, and inten-
sity to make it more effective.
Methods
Two aspects of the kidney stone repositioning were studied. First, we
investigated the optimal ultrasonic beam diameter vs. stone size. Nu-
merical modeling was performed to calculate the force acting on an
elastic sphere in liquid from a focused beam. Simulations were
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beam width to the diameter of the stone. The second study investi-
gated the feasibility of trapping and moving a stone in a direction
transverse to the beam axis. Toward this goal, vortex beams were
considered that produce a ring-like intensity distribution in the focal
region with zero on-axis intensity. Theoretical modeling was per-
formed using a previously developed algorithm. Acoustic trapping
and manipulation of kidney stones in water was investigated using
both a single-element transducer (combined with a sector-shaped
phase plate) and sector arrays with operating frequencies 0.3–
1.5 MHz. Human stones approximately 3–5 mm, as well as glass and
aluminum beads, were displaced in a water bath.
Results
The numerical modeling indicated that pushing a kidney stone is
strongest when the beam width is slightly wider than the stone
diameter. This can be explained by more effective generation of
shear waves inside the stone resulting from their effective coupling
with the acoustic waves in liquid at the stone edges. During expo-
sures with the vortex beams, stones could be drawn to the beam
axis and then controllably translated along the surface in any direc-
tion transverse to the beam. The phase between sector elements
could be used to control the vortex size and thus adjusted for trap-
ping different-sized stones.
Conclusions
The intensity distribution in the focal region significantly influences
the ability to manipulate kidney stones using radiation force. To
achieve the strongest force with a predetermined acoustic power, it
is necessary to select a mode in which the focal waist diameter
slightly exceeds the stone diameter. For transverse confinement, it is
convenient to use vortex beams radiated by sector arrays or single-
element sources with an attached phase plate. In such an approach,
the beam diameter can be controlled by choosing a proper phase
distribution on the source surface.
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Modulated Focused Ultrasound for treatment of de-myelinating
axons in multiple sclerosis lesions — pilot animal studies
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Objectives
Multiple sclerosis (MS) is a debilitating disease of the central nervous
system whose symptoms arise from de-myelination of axons within
brain and spinal cord tissue. De-myelination can lead to loss of cen-
tral and peripheral function, including vision and muscular problems.
There currently exists no cure for multiple sclerosis. In this explora-
tory study, we seek to induce re-myelination of axons de-myelinated
by an MS model using pulsed Focused Ultrasound (pFU). There exists
a rich history targeting the use of ultrasound to temporarily and
non-destructively activate central neural circuits. Our own work has
shown that pFU can induce detectable electroencephalography (EEG)
signals in the brain. Recent work by Gibson et al. (2014) who showed
increased myelin thickness of neurons that had been activated by
laser light in an optogenetic mouse model. It seems plausible, there-
fore, that ultrasound induced neural activation could affect myelin
growth and thickness.
Methods
We hypothesize that pFU activation of axons within MS lesions in a
rodent model will decrease de-myelination and increase re-
myelination. To test this, we selected the cuprizone model for MS,
which causes de-myelination in the corpus callosum of the mouse
brain and is reversible, allowing us to assess the effects of ultrasound
during the phase of disease progression and during the phase of
disease recovery. Rodents undergoing the MS model received five
consecutive days of pFU therapy and underwent EEG monitoring. We
applied pFU at two different time points, first during the demyelin-
ation process and second (in separate groups of animals) during re-
covery from demyelination. The pFU therapy protocols were inspired
by the optogenetic stimulation protocols of Gibson et al (2014), and
consisted of 30 seconds of pFU application followed by 90 secondsof rest, repeated 15 times. We tested three different pFU transducers
with center frequencies of 0.65 MHz, 1.09 MHz, and 2.0 MHz, all with
Ispta of 1.2 W/cm2*s. For each of those frequencies, we verified that
each pFU protocol could activate brain. We collected Magnetic Res-
onance (MR) images at three time points and collected the brains for
histological analysis at the end of the study.
Results
Initial results show that mice undergoing the MS model exhibit
different shapes in their pFU-induced EEG signals than normal
healthy mice. Further results of the therapeutic pFU treatment fol-
lowing analysis of MR and histological results will be presented.
Conclusions
If successful, this non-invasive therapy may lead to rapid advance-
ments in the treatment of MS and other de-myelinating neurological
disorders.
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Objectives
The leading technique to treat peripheral neurological disorders is
currently through implantation of electrodes along the peripheral
nerve and stimulating the nerve with electrical current. Recently,
Focused Ultrasound (FUS) has been shown to elicit modulation of
both brain and peripheral neurons. While the effects of the FUS brain
stimulation experiments have been shown in vivo, the majority of
the peripheral nerve stimulation studies have been in vitro, or only
investigating the effects of FUS stimulation on the nerve itself. Thus
far, there have been no studies determining if non-invasive stimula-
tion of peripheral nerves with FUS can elicit physiological effects
in vivo.
Methods
Peripheral nerve stimulation was conducted on both hind limbs of
13 mice under general anesthesia (pentobarbital 65 mg/kg). Both the
imaging and stimulation transducers were mounted interchangeably
on a 3-DOF positioning system with 1-mm resolution. Targeting of
the sciatic nerve was achieved using a 1282element imaging probe
with a center frequency of 18.5 MHz. A single element transducer
(3.57 MHz center frequency, 90 % duty cycle, 1 kHz PRF, 5-10 ms son-
ication duration, 3.65 x 0.45 mm focal area) was used for stimulation
of the sciatic nerve. Evoked EMG activity in the Tibialis Anterior
muscle was recorded via two stainless steel electrodes sampling at
2 kHz. Gross pathology was used to assess safety of the procedure.
Behavioral testing occurred an hour before, and 24 hours after FUS
stimulation. Electrophysiology experiments were used as positive
controls with electrodes directly stimulating the sciatic nerve while
recording EMG from the Tibialis Anterior muscle. Negative controls
were conducted via administration of 5 mg/kg lidocaine to the
stimulation region as well as clipping the nerves downstream from
stimulation.
Results
Stimulation of the sciatic nerve was successful eliciting both
muscle movement and EMG activity. Two distinct responses to
stimulation were observed, a fast and slow activation (2.1 ±
2.6 ms and 18.8 ± 5.5 ms average delay following onset of FUS
stimulation). The fast activation was accompanied by an average
higher peak-to-peak EMG response than the slow responses (0.86
± 0.87, 0.19 ± 0.63 mV respectively). EMG spike duration for both
responses were similar and not significantly different (6.9 ± 2.6,
7.1 ± 2.2 ms respectively). Administration of lidocaine IM to the
target region eliminated EMG responses from FUS stimulation. An
hour following lidocaine administration EMG responses were de-
tected again with FUS stimulation of the nerve. Electrical stimula-
tion resulted in similar EMG spike durations to FUS stimulation,
although at significantly higher peak-to-peak responses (7.3 ±
1.6 mV average). Gross pathology and behavioral testing revealed
no significant damage (no red blood cell extravasation, significant
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FUS stimulation at the powers used for stimulation.
Conclusions
In this study, we show physiological effects of in vivo FUS stimulation
of peripheral nerves in the mouse for the first time. FUS stimulation
can safely elicit muscle activation with no short-term behavioral ef-
fects. Positive controls verified EMG responses similar to that of elec-
trical stimulation while negative controls verified FUS was stimulating
the nerves and not the muscle tissue. These results support the fur-
ther investigation of FUS-based techniques for the treatment of per-
ipheral neurological disorders.Fig. 91 (abstract A89). pFUS-induced MSC homing is blocked by
inhibiting mechano-stretch receptors or in TRPC-ko miceA89
The mechanosensitive TRPC1 channel is activated by pulsed
Focused Ultrasound to induce stem cell homing
Scott Burks, Matthew Nagle, Ben Nguyen, Michele Bresler, Saejeong Kim,
Blerta Milo, Joseph Frank
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Objectives
Stem cell therapies are promising regenerative medicine approaches.
Pulsed Focused Ultrasound (pFUS) induces microenvironmental
changes in normal and diseased tissues that enhance homing
and efficacy of intravenously-infused mesenchymal stromal cells
(MSC) to further improve disease outcomes. pFUS/tissue interac-
tions that induce molecular changes is unclear. Mouse muscle
and kidneys were sonicated at increasing powers while passive
cavitation and tissue displacement were measured. Tissue was
measured for cyclooxygenase-2 (COX2) to correlate with ultra-
sound effects, as COX2 signaling is critical for MSC homing. To
test that mechanotransduction causes the necessary molecular
changes, inhibitors of mechanosensitive channels were given be-
fore pFUS as well as pFUS to TRPC-knockout mice, as TRPC can
function as a mechanosensitive receptor.
Methods
C3H or TRPC-ko mice received hamstring or kidney pFUS from a
VIFU 2000 system. pFUS was at 1 MHz, 5 Hz pulse repitition fre-
quency, 5 % duty cycle, and varying transducer output powers
(ranging from 10-80 W). A built-in hydrophone passively detected
cavitation. Mice were euthanized 4 hr post-pFUS and COX2 ex-
pression was measured by ELISA. GdCl3 (0.04mmoles/kg) or ru-
thenium red (RR) (0.01mmoles/kg) was given by intravenous
injection before pFUS. One-way analysis of variance using Bonfer-
roni post-hoc with p-values <0.05 were considered significant.
Results
Statistically significant increases in COX2 were measured at 20, 40,
60, and 80 W compared to untreated muscle. Mean tissue displace-
ment correlated with COX2 expression. Statistically significant in-
creases in cavitation were only observed at 60 and 80 W. At 40 W,
pFUS-induced COX2 increases and MSC homing were blocked in
TRPC-ko mice or when Gd or RR were administered to wild-type mice
before sonication (Fig. 91).
Conclusions
Mechanical pFUS forces interact with the mechanostretch recep-
tor TRPC1 to drive molecular changes in tissue that are critical to
stem cell homing processes. We have previously determined that
COX2 expression is an acceptable proxy for molecular outcomes.
At lower powers (20 and 40 W), cavitation from the sonications
was not detectable, suggesting that cavitation-independent mech-
anical forces (i.e., acoustic radiation forces) drive COX2 expression
and thus cell homing. At higher powers (60 and 80 W), cavitation
was detectable and COX2 expression was elevated compared to
sonications at 20 and 40 W. It is unclear whether cavitation at
these elevated powers drives the additional COX2 expression, or
if it is the result of increased acoustic radiation forces at higher
powers. Regardless, 40 W was maximum power we previously de-
termined not to cause detectable tissue damage and from the
point of view of pFUS use in regenerative medicine, would be
the maximum power.A90
Low-intensity ultrasound prolongs lifetimes of transplanted
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Objectives
Mesenchymal stem cells (MSC) are currently the most clinically ap-
plicable stem cell type for transplantation. Transplanted MSCs act as
“drug-pumps” by continually releasing cytokines, chemokines, and
trophic factors (CCTF) that reduce host inflammation and stimulate
endogenous regeneration mechanisms. MSCs have shown promise
for a wide range of diseases from ischemic events to graft-versus-host
disease. While MSCs are considered immune privileged and evade
immune surveillance to some extent, they typically do not engraft
into host tissue and usually die within 3-10 days post-transplantation.
Efforts to extend the lifetimes of MSCs previously have involved
chemical or genetic manipulation of MSCs prior to transplantation,
but these approaches are not readily translatable. We have found
that pulsed Focused Ultrasound interacts with host tissues to upregu-
late a variety of anti-apoptotic, pro-mitotic factors that could increase
the lifespan of transplanted MSCs. In this study we tested the hy-
pothesis that the application of daily unfocused therapeutic
ultrasound
Methods
106 human LMSCs were intramuscularly transplanted into each ham-
string of C3H mice. MSCs were transfected with renilla luciferase
using lentoviral vectors and expressed under the EF1 promoter. Be-
ginning on the day of implantation (D1), mice received daily TUS
sonication to one hamstring (1 MHz US, 2 W/cm2, 10 % duty cycle
[1 ms “on”/9 ms “off”], 10 min total exposure time). After TUS, mice
were subjected to bioluminescence imaging for 10s after receiving
an intraperitoneal injection of D-luciferin (150 mg/kg). Mice were eu-
thanized on D6. Temperature measurements were obtained in differ-
ent group of mice using an implanted thermocouple.
Results
TUS exposures result in a combination of mechanical and thermal ef-
fects. TUS raised hamstring temperature from 36 to 41 during the
10 min exposure. Total bioluminescence in treated and control legs
decayed each successive day, but decay was slower in the TUS-
treated hamstrings. Accordingly, by D6, bioluminescence was nearly
undetectable in untreated legs, while still imageable in TUS-treated
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nearly 10 times greater than in contralateral muscle.
Conclusions
The application of TUS to skeletal muscle containing transplanted
MSCs extends the resident time of live MSCs in tissue by slowing
MSC death/clearance rates. This has profound implications for a wide
range of MSC therapies because TUS is noninvasive, safe, and inex-
pensive. Therefore, such a routine and uninvolved procedure to ex-
tend the survival of transplanted MSCs could easily and dramatically
improve clinical cell therapies, extending the functional lifetimes of
transplanted cells and reducing the number of transplantations/injec-
tions required for disease treatment.Fig. 92 (abstract A90). BLI signal decreases in control hamstrings
(left) over 6 days while BLI signal in TUS-treated legs (right) is better
preserved. Experimental timeline shown belowA91
Red blood cells as ultrasound-triggered drug delivery vehicles:
Activation via perfluorocarbon nanodroplets, targeting and
photoacoustic imaging
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Objectives
Red blood cells (RBC), when modified to operate as drug carriers,
combine the biocompatibility of a patients’ own cells, long circula-
tion time, large volume to sequester the drug, and ability to accumu-
late at the target sites (e.g., tumor vasculature) via molecular
targeting. Recently point-of-care devices for RBC drug encapsulation
have received CE approval mark in Europe. However, triggered re-
lease of the drug at the desired site is still complicated; therefore, we
present in this study ultrasound-triggered release of entrapped mate-
rials from RBCs, by the preparation of RBC decorated with super-
heated perfluorocarbon (PFC) nanodroplets, and subsequent rupture
of RBC membrane with contents release.
Methods
Fluorescent dyes, calcein and indocyanine green (ICG) and magnetic
nanoparticles were loaded inside RBCs via hypotonic loading. After
incubation in hypotonic media, the loaded RBCs were resealed by
PIGPA buffer (adenine, glucose, inosine and pyruvate). Unincorpor-
ated material was removed by centrifugation (1000 g, 5 min). Nano-
particles made of decafluorobutane and dodecafluoropentane were
prepared by sonication followed by the repeated Nuclepore filtration
under elevated pressure; they were stabilized with a positively
charged lipid shell, made of PEG stearate, DSPC and distearoyl tri-
methylammonium propane. Nanoparticles were attached externally
to the membranes of dye-loaded RBCs. For molecular targeting, RBCs
were decorated with biotin or alphaVbeta3-specific peptide cyclo-(RGDfK), via insertion of the molecules anchored to the cell mem-
brane via a PEG spacer. To characterize the efficacy of ligand attach-
ment, fluorescein-PEG-lipid was used as a model. Magnetic sensitivity
of iron oxide-loaded RBCs was confirmed with a N52 neodymium
magnet. Peptide-mediated targeting was confirmed in a solid phase
binding system, where RGDfK-PEG-DSPE RBCs were incubated with
polystyrene dishes carrying recombinant alphaVbeta3, or control al-
bumin surface. Photoacoustic imaging of ICG-loaded RBCs was per-
formed with a custom-built apparatus (Verasonics Vantage mated
with a SpectraPhysics laser). Ultrasound-triggered contents release
was monitored by fluorescence microscopy: dye-loaded RBCs carry-
ing perfluorocarbon nanodroplets were subjected to insonation.
Results
Fluorescent dyes were loaded into RBCs with good stability (minor
leakage over many hours). Fluorescent PFC nanodroplets demon-
strated stable adherence to the RBC membrane. Upon a single ten-
cycle 10 MHz ultrasound pulse, dye leaked from the RBC within a
fraction of a second. Specific adhesion (~65-fold over control) of tar-
geted RBCs to alphaVbeta3-coated surface was observed. Magnetic
targeting demonstrated efficient pulling of magnetic RBCs in a tube
and phantom, confirmed by photoacoustic imaging of ICG-loaded
RBCs. RBC-nanodroplet complexes remained in the bloodstream for
at least two hours following intravenous injection, as determined
with Cr-51-radiolabeling.
Conclusions
Red blood cells decorated with perfluorocarbon nanodroplets rapidly
release entrapped fluorescent dye after a short ultrasound pulse. As
a drug carrier, modified RBCs stay in the bloodstream for extended
time; they can be targeted by molecular or magnetic means, and
monitored by photoacoustic imaging. Overall, PFC-RBCs may be an
ideal drug carrier system for ultrasound-triggered drug delivery.
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Objectives
Chronic non-healing wound infections require long duration anti-
biotic therapy, and are associated with significant morbidity and
healthcare costs. This results in both systemic and local infection to
deeper tissues (e.g bones), thereby requiring long duration treatment
(generally >6 weeks), resection of tissues, and emergence of drug re-
sistance. Novel approaches for efficient, readily-translatable targeted
and localized antimicrobial delivery, as well as targeted ablation of
pathogens are a critical clinical need. The objectives of this study
were to: 1) develop low temperature-sensitive liposomes (LTSLs) con-
taining an antimicrobial agent (ciprofloxacin) for induced release at
mild hyperthermia (~42 °C) (Fig. 93), 2) characterize in vitro ciproflox-
acin release, and efficacy against Staphylococcus aureus plankton
and biofilms, and 3) determine the feasibility of localized ciprofloxa-
cin delivery in combination with MR-HIFU hyperthermia in a rat
model.
Methods
LTSLs were loaded actively with ciprofloxacin, and their efficacy was
determined using a disc diffusion method, MBEC biofilm device, and
scanning electron microscopy (SEM). Ciprofloxacin release from LTSLs
was assessed in a physiologic buffer (serum and PBS), and in vivo in
a rat model using MR-HIFU by fluorescence spectroscopy.
Results
Results indicated that > 95 % loading of ciprofloxacin was achieved. Fur-
ther, < 5 % was released from the LTSL within 15 min at baseline (25 °C)
and body (37 °C) temperature, while > 95 % was released at 42 °C. Sonic-
ation of rat muscles resulted in accurate and homogeneous temperature
Journal of Therapeutic Ultrasound 2016, 4(Suppl 1):31 Page 56 of 113control within the heated ROI (42.0 ± 0.2 °C), with a 90th percentile (T10)
and 10th percentile (T90) of 43.2 ± 0.3 °C and 41.0 ± 0.3 °C respectively
Precise hyperthermia exposures in the thigh of rats using MR-HIFU
during IV administration of the LTSLs resulted in a 4-fold greater local
concentration of ciprofloxacin compared to controls (free ciprofloxa-
cin + MR-HIFU or LTSL alone). The biodistribution of ciprofloxacin in
unheated tissues was fairly similar between treatment groups.
Triggered release at 42 °C from LTSL achieved significantly greater S.
aureus killing and induced membrane deformation and changes in
biofilm matrix compared to free ciprofloxacin or LTSL at 37 °C.
Conclusions
This technique has potential as a method to deliver high concentra-
tion antimicrobials to chronic wounds.Fig. 93 (abstract A92). Development of low temperature sensitive
liposomes for HIFU guided localized delivery of antimicrobial against
chronic woundA93
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Objectives
MR-guided Focused Ultrasound surgery (MRgFUS) has been recently
demonstrated as a promising tool for pain alleviation of painful bone
metastases (pBM) and lumbar facet joint pain. The mechanisms of pain
alleviation are believed to be most likely local denervation of the noci-
ceptors at the ablated area using the Focused Ultrasound. However,
few previous studies have suggested an assessment method to esti-
mate the denervation. Peripheral nociceptive sensitization resulting inbone metastatic pain and osteoarthritic pain is thought to make pain
on pressure (tenderness) at the lesion sites too sensitive. Therefore, our
hypothesis is that MRgFUS treatment of the sensitized tender points
could improve the refractory chronic pain in patients with bone metas-
tasis or osteoarthritis (OA). The aim of the present study is to clarify
changes in the tenderness and the worst pain intensity at the lesion
treated with MRgFUS.
Methods
We have conducted MRgFUS treatments using ExAblate® system
(InSightec Ltd, Haifa, Israel) for 8patients (mean age; 64 years old)
with pBM, 9 patients (72 y.o.) with chronic lumbar facet joint osteo-
arthritic pain (LFP), and 11 patients (78 y.o.) with chronic knee osteo-
arthritic pain (KP). Patients with the worst pain intensity (worst) ≥ 4
on the Numerical Rating Scale (NRS) and tenderness at the lesion site
were enrolled. Treatments were applied to the bone surface of the
most painful tender point of the metastasis in pBM group, the dorsal
area of these joints which selected on the basis of 70 % reduction of
pain with diagnostic block in LFP group, the bone surface around
osteophyte of medial femorotibial joint tenderness in KP group. We
assessed pressure pain threshold (PPT) using an electronic pressure
algometer to evaluate tenderness at the lesion sites, and the subject-
ive local worst pain intensity with NRS. PPT is defined as the minimal
amount of pressure where a sensation of pressure first change to
pain. We evaluated changes in the PPT on the treated site and at the
contralateral non-treated site as a control and NRS before and 1 week,
1 month and 3 months after the treatments.
Results
PPTs at the treated sites were significantly increased from 107 kPa
[40-432] (median [min-max]) at the baseline to 271 kPa [94-534] at
the final follow-up in pBM group, 280 kPa [66-427] to 462 kPa [207-
818] in OALFJP group, and 156 kPa [50-249] to 246 kPa [1146-427] in
OAKP group. At the control sites, the PPTs were significantly higher
than at the treated sites and there was no significant difference of
PPTs between before and after the treatment in all groups. The NRS
were significantly decreased from 6.5 [4-8] to1 [0-3] in pBM group, 8
[4-9] to 1.5 [0-7] in LFP group, and 6 [5-9] and 3 [1-6] in KP group.
The treatment responder, defined as reduction of 2 or more in the
NRS without increase analgesic intake in pBM, and a 50 % or greater
decrease in the NRS in OA group, were all patients in pBM group, 14
of 20 patients in OA group. In OA group, the PPTs at the treated sites
were significantly increased from 223 kPa [50-427] to 326 kPa [184-
731] at 1 week after the treatment in responders, but there were no
significant differences in non-responders.
Conclusions
These results illustrate the excellent pain-relieving effects of MRgFUS
treatment for the tender points in patients with painful bone metas-
tasis or with chronic osteoarthritic pain. Significant increase of PPTs
speculated successful denervation effect on the nociceptive nerve
terminals of the treated area. PPTs measurement is a useful tool for
quantitative evaluation after MRgFUS and might be a useful param-
eter for assessing a treatment’s effect.
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Objectives
MRI provides outstanding soft-tissue contrast and ability to map
temperature which are ideal for monitoring of Focused Ultrasound
therapy. However, at the high intensities required for ablation acous-
tic cavitation may be nucleated, leading to an enhancement in
ultrasound-mediated heating. The likelihood of cavitation may also
vary significantly between adjacent tissue regions, which has frus-
trated efforts to control ablation over large volumes. As the onset of
cavitation is accompanied by characteristic acoustic emissions,
Fig. 95 (abstract A94). a Passive acoustic mapping (PAM) and MR-
derived temperature rise over time. b MRI temperature map and (c)
acoustic map for cavitation-enhanced focal heating
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information that may used for control of ultrasound output to
achieve ablation of entire tumors. Previous work has shown that such
monitoring is feasible within an MR scanner using post-processed
ultrasound data. The objective of the current study was to optimize
ultrasound data acquisition and processing to allow rapid real-time
display of acoustic mapping data alongside MR thermometry.
Methods
An ultrasound imaging array was aligned with the focus of a
1.5 MHz HIFU transducer (Fig. 94). The two components were
clamped together, immersed in degassed water, and connected
to a MR-compatible positioning stage. Rabbits with subcutaneous
VX2 tumors were anaesthetized and placed on a platform with a
cutout for ultrasound propagation and acoustically coupled using
a bag filled with degassed water. A receive-only MR surface coil
was placed in the air gap between the water and animal plat-
form. The entire setup was placed within a clinical 3 T MR scan-
ner (GE Signa Excite). The HIFU transducer was then driven from
a waveform generator via a power amplifier. During sonication
the MR scanner performed temperature mapping while an ultra-
sound research platform (Verasonics) performed B-mode and pas-
sive acoustic mapping (PAM) using the array. Temperature maps,
B-mode and passive acoustic images were displayed in real time.
The process was repeated in rabbits injected with phase-shift
nanoemulsions (PSNE) to promote cavitation or saline as a con-
trol under a range of ultrasound conditions.
Results
Real time passive acoustic mapping was successfully implemented
using a rapid frequency-domain beamformer and employed sim-
ultaneously with MR thermometry for imaging of tumor ablation.
Illustrative results are shown in Fig. 95. Over 50s (40s sonication,
10s baseline and cooling time) 477 frames of ultrasound data
were acquired, processed and immediately displayed at an aver-
age frame rate of 10 fps. MR temperature maps were also ac-
quired and displayed every 2.3 s (0.4 fps). Comparison of the two
modalities (Fig. 95a) shows accelerated temperature rise following
the onset of cavitation (30s) and decline thereafter as the ampli-
tude of cavitation dropped (40s), perhaps due to depletion of
cavitation nuclei or changes in tissue structure. MR temperature
maps (Fig. 95b) and passive acoustic maps (Fig. 95c) show that
heating and cavitation activity were both well localized to the
intended focal region. Extraction of tumors after sonication
showed lesions were successfully produced in the tumors.
Conclusions
These results show that rapid, real-time passive acoustic im-
aging coupled with PSNE for nucleating cavitation locally may
be applied simultaneously with MR thermometry for enhancing
Focused Ultrasound ablation. Future work will apply the method
for optimization and control of PSNE enhanced ablation of
whole tumors.Fig. 94 (abstract A94). Setup for multi-modality imaging of focused
ultrasound ablationA95
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Objectives
With the rapid advancement of MR-guided HIFU clinical applications,
calibration of HIFU pressure fields is an urgent need to ensure con-
sistent and safe treatment outcomes. Few studies have been re-
ported on the characterization of acoustic pressure fields of clinical
MR-guided HIFU outside the MR scanner. To date, no study has been
reported on acoustic field calibration inside the MR scanner, owing
to combined effects of strong magnetic field and limited space in
the MR bore that makes it difficult to perform the measurements in-
side the MR scanner. In this study, we present a method of acoustic
field calibration and results for a clinical MR-HIFU system both inside
and outside a clinical MR scanner.
Methods
For hydrophone measurement outside the MR scanner (Ingenia 1.5 T,
Philips), the HIFU patient table with an integrated 256-element trans-
ducer (Sonalleve V2, Philips) was moved outside the magnet room. A
fiber-optic hydrophone (HFO-690, Onda) attached to a 3D motor
stage was used for pressure field measurements in a deionized and
degassed water tank placed above the transducer. A Matlab® pro-
gram was developed to control the 3D stage, capture the hydro-
phone signals, and synchronize the data acquisition with the HIFU
pulses. For measurements inside the MRI, an MRI-compatible water
tank, a 20-meter long optical fiber was used for the hydrophone
measurements and it was visualized in MR imaging (Fig. 96). The
HIFU transducer was moved in 3D space while keeping the optical
fiber fixed. The HIFU transducer was operated at a frequency of
1.2 MHz, a pulse length of 40 cycles and pulse repetition frequency
of 10 Hz. The nominal acoustic power was varied from 50-650 W.
Hydrophone measurements were performed in planes parallel and
perpendicular to the beam path. The acoustic parameters such as
peak positive/negative pressures (p+, p-), temporal and pulse aver-
age intensities (ITA, IPA) at the HIFU focus, and the full-widths of the
pressure distribution along and perpendicular to the bean path were
calculated.
Results
Outside MRI Scanner: The HIFU focus was identified approximately
6.8 cm away from membrane (when the transducer was at the hom-
ing position and without steering) by scanning the hydrophone in
planes parallel and perpendicular to the beam path (Fig. 97; left-
hand side). The acoustic parameters p + (3.4 - 65.8 MPa), p- (3.1 -
13.2 MPa) (Fig. 98), ITA (0.06 - 6.2 W/cm2), IPA (78.5-20159 W/cm2) at
the focus were measured with respect to nominal acoustical power
(50-650 W). The FWHM of pressure profiles at the focus was 1.0 mm
in the lateral direction and 9.5 mm in the axial direction (Fig. 97;
right-hand side).
Inside MRI scanner: The acoustic pressure measurements inside MR
scanner were found consistent with the outside measurements. The
motor step-size of the HIFU transducer was 0.1 mm which allowed
Journal of Therapeutic Ultrasound 2016, 4(Suppl 1):31 Page 58 of 113high spatial resolution scanning of the acoustic field inside the MR
scanner.
Conclusions
In conclusion, HIFU pressure field measurements both outside and
inside an MRI scanner provides a systemic method for ensuring safe
and consistent treatment in a clinical MR-guided HIFU system. More-
over, the proposed inside MR scanner calibration method allowed
characterization of the acoustic fields of a clinical MR-guided HIFU
system without the need of moving the HIFU table outside of MR
scanner, which is not feasible for most clinical systems.Fig. 96 (abstract A95). The location of fiber tip inside the water
tank in the MR scanner was identified precisely with the help of MR
imaging and the HIFU transducer was moved to the corresponding
location for the acoustic field calibration
Fig. 97 (abstract A95). Results of pressure field measurements in
YZ (along) (top left) and XY (perpendicular) (bottom left) planes
to beam paths and right hand side plots are the normalized
pressures with respect to distances to find the FWHM of the
pressure distribution
Fig. 98 (abstract A95). Peak positive and negative pressures at the HIFU
transducer focus with respect to acoustic power between 50-650 WA96
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Objectives
To evaluate the endometrial integrity after MR-HIFU ablation for sub-
mucosal uterine fibroids based on MRI findings and to know the risk
factors associated with endometrial injury
Methods
A total of 117 submucosal uterine fibroids (diameter: 5.9 ± 3.0 cm,
1.0-12.9 cm) in 101 women (age: 43.6 ± 4.4 year, 33-55 year) treated
with volumetric MR-HIFU ablation between November 2010 and De-
cember 2015 were retrospectively analyzed. Endometrial integrity
was assessed with contrast-enhanced T1WI of immediate (n = 101), 3-
month (n = 62), and 12-month (n = 15) follow-up. Endometrial injury
was classified into one of grade 0 (continuous involved endometrial
lining), grade 1 (pin-point, full-thickness discontinuity of involved
endometrium), grade 2 (between grade 1 and 3) and grade 3 (full-
thickness discontinuity of involved endometrium over 1 cm in size).
Potential risk factors for endometrial injury (age, duration from LMP,
history of full term delivery, GnRH agonist pretreatment, FIGO grad-
ing of endometrial protrusion, T2 signal intensity and perfusion de-
gree of fibroid, and average acoustic power) were assessed with a
generalized estimating equation (GEE) analysis.
Results
Among 117 fibroids, endometrial injury was of grade 0 in 66 (56.4 %),
grade 1 in 29 (24.8 %), grade 2 in 16 (13.7 %), and grade 3 in 5 (4.3 %)
at immediate follow-up (Fig. 99). Among 37 fibroids of which endomet-
rium was injured and underwent follow-up studies, 30 (81.1 %) showed
improvements at 3- and/or 12-month follow-up. Among 14 fibroids in
which endometrium was injured and followed-up till 12 months, 12
(85.7 %) were completely normalized (Fig. 100). GEE analysis revealed
that the degree of endometrial protrusion were significantly associated
with severer endometrial injury (p < 0.0001, B = -0.687).
Conclusions
After MR-HIFU ablation of submucosal uterine fibroids, endometrium
is preserved or minimally injured in majority of the cases. Injured
endometrium which is more frequently encountered after treating in-
tracavitary fibroids usually recovers spontaneously.
Fig. 100 (abstract A96). Follow-up results of endometrial injury
after MR-HIFU ablation for submucosal uterine fibroids
Fig. 99 (abstract A96). Follow-up results of endometrial injury after
MR-HIFU ablation for submucosal uterine fibroids
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Objectives
To evaluate changes in MR findings of uterine fibroids after using
GnRHa as a pretreatment of MR-HIFU ablation and to know the influ-
encing factors for favorable changes to MR-HIFU ablation
Methods
From August 2012 to March 2016, 60 women (age: 43.6 ± 5.7 years,
26-54 years) with 127 uterine fibroids (diameter, 5.9 ± 3.0 cm; volume,
121.1 ± 162.3 mL) underwent GnRHa injections as a pretreatment of
MR-HIFU ablation (1-4 cycles; 5 women with 10 fibroids, 8 women
with 17 fibroids, 40 women with 87 fibroids, and 7 women with 13 fi-
broids, respectively) and retrospectively analyzed. Fibroid volumes
and T2 signal intensity ratios relative to skeletal muscle were com-
pared between before and 2-3 weeks after the last GnRHa injection.
Potential factors (age, BMI, history of full term delivery, multiplicity of
fibroids, number of GnRHa injections, volume, T2 signal intensity ra-
tio, and semiquantitative perfusion MR parameters of fibroid) were
evaluated for the association with greater volume and T2 signal in-
tensity changes. All statistical tests were performed using with model
analyses.
Results
While fibroid volume significantly reduced after GnRHa therapy (vol-
ume reduction ratio = 74.8 ± 25.3 %, p < 0.001), T2 signal intensity ra-
tios did not show a significant difference (T2 signal change ratio =
102.0 ± 32.2 %, p = 0.257). Increased number of GnRH injection (B
= -0.067, p = 0.028), greater T2 signal intensity ratio (B = -0.014, p =
0.028) and greater wash-in rate (B = 0.0006, p = 0.012) were revealedto be independently significant for greater volume reduction of fi-
broids. However, no factor turned out to be associated with T2 signal
intensity change.
Conclusions
After using GnRHa as a pretreatment of MR-HIFU ablation, uterine fi-
broids with higher T2 signal intensity and/or greater wash-in rate in
semiquantitative perfusion MRI show greater volume reduction, of
which effect is strengthened with an increased number of GnRHa cy-
cles. T2 signal intensity does not show a significant change after
GnRHa therapy.
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Objectives
Type 3 uterine fibroids are considered highly perfused and/or to
have a high extracellular fluid content and are known to have poor
treatment outcome in terms of non-perfused volume (NPV), volume
reduction, symptom relief and an increased risk of adverse events.
Type 3 fibroids have therefore been excluded form HIFU treatment
at our institutionfor the last two years. However, a novel approach
using higher acoustic power to precisely target the feeding vessels
might result in vessel occlusion rendering the bulk tissue less per-
fused and more susceptible to ‘lower’ powers, which in turn might
lead to better treatment outcomes. Therefore, the aim of this re-
search is the feasibility and safety of high power targeted vessel ab-
lation of type 3 fibroids with MR-HIFU.
Methods
In this study 10 patients with a type 3 fibroid will be included. Screen-
ing MR scans include a T2w-scan to determine fibroid type, a dynamic
contrast enhanced (DCE) series to assess perfusion, and a time-spatial
labeling inversion pulse (TimeSLIP) sequence to visualize the vascula-
ture without using a contrast agent. Areas of blood inflow are deter-
mined based on the DCE and TimeSLIP and are marked. The TimeSLIP
is repeated prior to treatment, spatially matched with the screening
DCE and TimeSLIP sequence, and used for planning of the high power
(450 W) sonications. A Philips Sonalleve V2 system with skin cooling
(water temperature ~ 15C) is used. After sonicating the inflow areas
with high power cells the bulk volume is treated with ‘low power’ soni-
cations (£300 W). NPV is assessed on contrast-enhanced T1w-images.
Follow-up MRI is performed after three months.
As a preparation a patient with a type 2 fibroid was treated in a simi-
lar manner except that all sonication were at a power £300 W. Philips
software was used to determine areas with a high wash-in rate (WIR)
indicating the areas of early inflow and these regions were treated.
Results
The WIR map of the type 2 fibroid showed areas of higher inflow
(Fig. 101). These regions were targeted with 12/14 mm sonications
(maximum power of 230 W, 42-55 s). The resulting NPV was larger
than the planned treatment volume (PTV) (Fig. 102).
So far, one type 3 fibroid has been treated. Two inflow areas were de-
termined (Fig. 103) and seven treatment cells (4 mm) were planned in
each of these areas. Sonications were completed successfully. Hereafter,
8/12 mm volumetric feedback cells (max. 250 W) were used. Two NPVs
corresponding to the two high-power clusters were observed post
treatment (Fig. 104). Small NPVs (2-3 mm) could be observed in the
bulk tissue volume. However, no confluent NPV similar in volume to
the PTV could be observed. Three-month follow-up has not yet been
performed. No adverse events occurred during treatment.
Conclusions
The results of the type 2 fibroid treatment using MR-HIFU showed
the potential of targeted vessel ablation. A similar strategy was used
for type 3 fibroids. Based on the first treatment the high power soni-
cations might result in a non-perfused volume in type 3 fibroids.
More data are expected soon and are needed to draw conclusions
on the feasibility and safety of this approach.
Fig. 103 (abstract A98). Dynamic contrast enhanced image
showing the fibroid in the red circle and one of the targeted blood-
inflow areas in the white circle
Fig. 102 (abstract A98). Left: coronal view Right: sagittal view of
the treatment cells overlaid on the contrast-enhanced T1w-image
showing the NPV (dark region). The NPV is much larger than the
planned treatment volume most likely due to vessel occlusion by
the sonications
Fig. 101 (abstract A98). Wish-in-rate map shown in a coronal view.
The lower (caudal) part of the fibroid shows higher inflow rates
Fig. 104 (abstract A98). Contrast enhanced T1w-image showing
the two non-perfused volumes created by the twp clusters of high
power sonications
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Objectives
The efficacy of MRgFUS treatment of uterine fibroids is evaluated
post-operatively by measuring the non-perfused volume (NPV) on
post-contrast images as an estimate of the ablated region. NPV is not
a direct measurement of ablation but rather of non-perfused tissue.
This may lead to an underestimate of the ultimately ablated volume,
as some cell death may be delayed, or to an overestimate of the
treatment effect, for example, in cases where temporary vasocon-
striction contributes to the non-perfused volume (Fig. 105a,b). In
addition, this can be confusing in cases where non-targeted tissue
appears non-perfused; since there is no thermal dose predicted in
these regions, it may be unclear whether the tissue is actually
ablated.
A hypointense contour, which we call the Black-Line Volume (BLV), is
present around the margin of fibroids on non-contrast images ob-
tained at follow-up (Fig. 105c). Our aim was to quantitatively com-
pare the BLV to the NPV.
Methods
Five patients with follow-up imaging after treatment were in-
cluded in this study. Four of them had a second treatment
within 7 to 14 days either because the fibroid was too large for
a single treatment, or it appeared incompletely ablated. Patient
2 had no additional treatment. In three of the retreated pa-
tients, a reperfused volume was noted on follow-up images in
regions that the NPV indicated as non-perfused at the end of
the first treatment
The NPVs obtained at the end of each treatment (NPV1 and NPV2)
and the reperfused volumes were measured and compared by multi-
plying slice-by-slice measurements of the manually contoured area
by the slice thickness. Using the same methodology, the BLV was cal-
culated using EPI thermometry magnitude images acquired during
each sonication in follow-up images.
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The results are provided in Table 5. In these patients, the BLV con-
tour is not present prior to treatment, but is reliably visualized on
follow-up imaging obtained 7-43 days after treatment. Quantitation
of the BLV demonstrates that it is very similar to the NPV. In cases
where the BLV was less than NPV1, the discrepancy is explained by
reperfusion (Fig. 105d).
In three cases, at the end of a second treatment, portions of the fi-
broid that were part of NPV1 were seen to have reperfused. In these
cases, BLV consistently identified the reperfused volume, which was
outside of the BLV.
Conclusions
These results show that BLV correlates well with the ablated region,
and the non-perfused volume. In cases in which NPV1 overestimated
the truly ablated volume, as defined during the follow-up imaging,
BLV was a better predictor because it excluded the reperfused vol-
ume. Thus, BLV may prove to be a powerful tool to disclose inad-
equately treated regions during the planning session of a second
treatment, allowing more tailored targeting of the area to ablate and
preventing under-treatment.
We are currently assessing how soon after the initial treatment the
BLV becomes visible. If further research demonstrates a BLV at the
end of the first treatment, then it may be used to identify untreated
parts of the fibroid and guide further, more complete treatment
without contrast administration.Table 5 (abstract A99). Comparison of non-perfused volume after first










1 412 14 419 none
2 42 43 42 none
3 314 14 295 16
4 257 7 208 88
5 85 14 82 5
Fig. 105 (abstract A99). Comparison of a) NPV1 and b) NPV2
demonstrates an area of reperfusion (green outline). The BLV
contour (c, pink), matches the NPV2 contour (d, pink), and excludes
the reperfused contour (green) in Patient 3A100
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Objectives
Adenomyosis is the common gynecologic disorder that in the pres-
ence of endometrial glands and stroma deep within the myome-
trium. Treatment of diffuse Adenomyosis has always been difficult,
especially for patients who desire subsequent pregnancy. GnRH-a is
a ovarian suppression drug that has been effectively used for Adeno-
myosis, while as long time use will result in symptoms of low estro-
gen, it is not recommended for use more than 6 months. In previous
reports, symptoms recurred after stopping the drugs, therefore
GnRH-a is often used as an adjuvant prior to or after the surgery.
MRgFUS is safe and feasible for the treatment of focal Adenomyosis,
while it showed limited efficacy in the treatment of diffuse Adeno-
myosis. In this study, the preliminary clinical effects of combined
MRgFUS and GnRH-a therapy in the treatment of diffuse Adenomyo-
sis will be evaluated, and the fertility and pregnancy outcomes for
patients who desired pregnancy will be investigated.
Methods
9 patients with diffuse Adenomyosis were treated in Harbin MRgFUS
Center between April 2015 and May 2016. Including, 7 patients (1 pa-
tient has fertility requirements) received MRgFUS treatments only,
while the rest 2 patients (1 patient has fertility requirements) re-
ceived 3 months of GnRH-a prior to MRgFUS treatment. The treat-
ment response was evaluated by the symptom severity score (SSS, 0-
100), visual analogue scale score for assessment of pain (VAS, 0-10)
and Pictorial Blood Loss Assessment Chart (PBAC). The questionnaires
were evaluated on treatment day as well as before, 3 and 6 months
after treatment. Uterine volume reduction was recorded before and
6 months after the treatments.
Results
During the 6-month follow up, 89 % (8/9) of the patients showed sig-
nificant symptomatic relief (based on SSS and PBAC) and 67 % (6/9)
of the patients experienced pain reduction (based on VAS). The stat-
istic uterine volume reduction was 14.5 ± 1.2 % in patients treated
with MRgFUS only. On the contrary, uterine volume reduction of
20.3 ± 1.8 % was observed in patients treated with MRgFUS com-
bined with GnRH-a. 1 patient underwent single session of MRgFUS
treatment had relapse 6 M after MRgFUS and enlarged uterus was
found on FU and MR exam. Up to now, the 2 patients that desired
fertility are still not pregnant, this study will extend the follow up
period to 24 months.
Conclusions
MRgFUS combined with GnRH-a can potentially prevent recurrences
after solely GnRH-a analog therapy, and can also enhance the treat-
ment efficacy of MRgFUS for diffuse Adenomyosis. MRgFUS is
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hence may reduce the length of duration before pregnancy.
MRgFUS is a very promising technique for Adenomyosis patients
who desired fertility, while its short and long term impacts in
the fertility and pregnancy outcomes are still required.Fig. 107 (abstract A102). T2-weighted MRI image showing
placement of endoluminal applicator in porcine stomach and
alignment for treatment of pancreatic tissue
Fig. 106 (abstract A102). Prototype endoluminal ultrasound
applicator assemblyA102
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Objectives
While conventional treatments remain limited, thermal ablation has
been demonstrated to provide pain palliation and survival benefit to
patients with advanced pancreatic cancer. In light of the anatomical
challenges that limit safe and effective thermal ablation to the pan-
creas, endoluminal ultrasound may serve as a minimally invasive op-
tion for treating pancreatic tumors adjacent to the gastrointestinal
(GI) tract, and could be compatible with MR-guidance for target con-
firmation and real-time thermometry. This study’s objective was to
perform a preliminary investigation of endoluminal placement and
heating performance of prototype ultrasound applicators and
temperature monitoring capabilities in MR-guided in vivo porcine
pancreas ablations.
Methods
A family of MR-compatible endoluminal applicators were fabri-
cated and characterized using radiation force balance and
hydrophone measurements. Each applicator possessed a distinct
two-element transducer array (~3.2 MHz) covered by a cooling
balloon at the tip of a flexible catheter assembly, as shown in
Fig. 106. Three transducer geometries were considered: 10x10
mm (planar), 8x10 mm with 20 mm radius of curvature (ROC)
along the short dimension (lightly-focused curvilinear), and
9.3x11.4 mm with 25 mm ROC along the long axis (strongly-fo-
cused curvilinear). In each in vivo porcine experiment, an appli-
cator was orally introduced and positioned in the stomach
adjacent to the splenic lobe of the pancreas. Sonications were
performed through the luminal wall into the pancreas for abla-
tion, at durations ranging from 3-16 minutes and applied inten-
sities of 5-7 W/cm2. MR-guidance techniques were developed
and evaluated for anatomical target identification, tracking/
placement of the applicator, and PRF-based MR temperature im-
aging (MRTI), implemented in the real-time RTHawk software
environment.
Results
Placement of the endoluminal applicators in the stomach adja-
cent to pancreatic tissue, as demonstrated in Fig. 107, was
achieved in all porcine studies (n = 5). In vivo MRTI-guided heat-
ing trials demonstrated capability of ~15-20 °C temperature
elevation in pancreatic tissue at 1-2 cm depths using the planar
and lightly-curvilinear applicators (6-16 mins, 5-7 W/cm2).
Strongly-focused curvilinear applicators were capable of reach-
ing higher temperature elevations of ~25-35 °C at 2-3 cm
depths and more spatially localized lesions in shorter treatment
durations (3-5 mins, ~5 W/cm2), as shown in Fig. 108. Dimen-
sions of thermal lesions in excised pancreas ranged from 9-
28 mm, 3-10 mm, and 5-10 mm in length, width, and depth, re-
spectively, as verified through histopathological analysis oftissue sections (Fig. 109). Multiple-baseline reconstruction and
respiratory-gated acquisition were effective in suppressing mo-
tion artifacts and improving temperature precision for multi-
slice MRTI in the in vivo studies.
Conclusions
This study demonstrates the technical feasibility of generating
volumetric ablation in porcine pancreatic tissue using endolum-
inal ultrasound applicators positioned in the GI tract, with inte-
grated MR-guidance for target identification, device positioning/
alignment, and MRTI treatment monitoring. Future applicator de-
velopment will involve incorporating endoscopic steering capabil-
ities to enhance control over endoluminal placement, fixation,
and coupling to the gastric wall to improve positional accuracy
and luminal sparing.
Fig. 109 (abstract A102). H&E staining of a section of excised
pancreatic tissue following endoluminal ablation, showing regions of
coagulative necrosis (CN) and the transition zone (TZ) to untreated
tissue (UT)
Fig. 108 (abstract A102). MRTI temperature map for in vivo
porcine pancreatic ablation using an endoluminal ultrasound
applicator with strongly focused curvilinear elements, at 6 W/cm2
applied intensity
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Objectives
Traditional stereotactic RF thalamotomy has been used with success in
medication refractory tremor-dominant Parkinson’s disease. Recently,
transcranial MR guided Focused Ultrasound (MRgFUS) has been used
to successfully perform thalamotomy for essential tremor. We designed
a double blinded, randomized controlled trial to investigate the effect-
iveness of MRgFUS thalamotomy in tremor-dominant PD.
Methods
Patients with medication refractory, tremor-dominant Parkinson’s dis-
ease were enrolled in the two center study and randomized 1:2 to re-
ceive either a sham procedure or treatment. After the 3 month blinded
phase, the sham group was offered treatment. Outcome was measured
with blinded CRST and UPDRS ratings. The primary outcome compared
improvement in hand tremor between the treatment and sham pro-
cedure at 3 months. Secondary outcomes were measured with UPDRS
and hand tremor at 12 months. Safety was assessed with MRI, adverse
events, and comprehensive Neurocognitive assessment.
Results
Twenty-seven patients were enrolled and six were randomized to a
sham procedure. For the primary outcome assessment, there was a
mean 50 % improvement in hand tremor from MRgFUS thalamot-
omy at 3 months compared to a 22 % improvement from the sham
procedures (p = 0.088). The 1 yr tremor scores for all 19 patients
treated with 1 year follow up data (blinded and unblinded) showed
a reduction in tremor scores of 40.6 % (p = 0.0154) and a mean re-
duction in medicated UPDRS motor scores of 3.7 (32 %, p = 0.0326).
Sham patients had a notable placebo effect with a mean 21.5 %
improvement in tremor scores at 3 months. Twenty seven patients
completed the primary analysis, 19 patients completed the 12 months
assessment, 3 patients opted for DBS, 3 were lost to follow up, 1 patient
opted for no treatment, and 1 is pending 12 m evaluation.
Conclusions
Transcranial MRgFUS demonstrates a trend towards improvement in
hand tremor, and a clinically significant reduction in mean UPDRS. A
significant placebo response was noted in the randomized trial.
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Objectives
Glioblastoma (GBM) is remarkably difficult to treat with systemically
administered therapeutics because the blood brain/blood tumor bar-
rier (BBB/BTB) blocks their diffusion from the bloodstream, while the
bioadhesive and nanoporous ECM hinders their tissue dispersion. In
addition, GBM is characterized by genetic complexity, molecular
adaptability, and multiple deregulated pathways, all of which mark-
edly limit conventional therapies. Here, we address these obstacles
by combining Focused Ultrasound (FUS)-mediated disruption of the
BBB/BTB with brain-penetrating non-viral gene vectors (DNA-BPN)
bearing the plasmid for miRNA-34a, a miRNA that is downregulated
in human GBM and predicted to regulate multiple tumor suppressive
pathways.
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U87 malignant glioma cells were injected into the brains of athymic
nude mice. Five days later, anesthetized mice were coupled to an
MRI compatible 1.14 MHz FUS system. T1 contrast MR imaging was
used to visualize and target tumors. miR-34a plasmid-bearing DNA-
BPN that had been densely PEGylated to permit brain penetration
were i.v. co-injected with microbubbles. FUS was applied to tumors
with a 0.5 % duty cycle for 2 minutes at either 0.4 or 0.5 MPa peak
negative pressure (PNP). Immediately after sonication, additional con-
trast MR images confirmed BBB/BTB opening. Untreated mice and
mice that were i.v. injected with miRNA-34a BPNs and MBs without
FUS application served as controls. At 7 days and 15 days after treat-
ment, corresponding to 12 and 20 days after tumor implantation,
tumor volumes were determined from 7 T MR images.
Results
Figure 110a shows representative pre- and post-FUS T1-weighted
contrast MR images when using PNPs of 0.4 and 0.5 MPa. Enhanced
signal in the post-FUS images indicates increased leakage of gadolin-
ium contrast agent across the vasculature due to FUS-mediated BBB/
BTB disruption. Note that BBB/BTB disruption appears to be further
enhanced at 0.5 MPa when compared to 0.4 MPa. Figure 110b shows
representative 7 T images of U87 tumors for each group taken at 12
and 20 days post tumor implantation. These images were used to
quantify post-treatment tumor volume (Fig. 110c). At Day 20, mice
treated with 0.5 MPa FUS +MB +miRNA-34a BPN (n = 3) showed a
marked and statistically significant (p < 0.05) decrease in tumor vol-
ume when compared to the untreated (n = 5), miRNA-34a BPN +MB
(n = 4), and 0.4 MPa FUS +MB +miRNA-34a BPN (n = 4) groups. For
all groups, T2* MRI (not shown) confirmed that there was no leakage
of blood products across the BBB/BTB.
Conclusions
We show that a single MR image-guided treatment, entailing the
FUS (1.14 MHz; 0.5 MPa) mediated delivery of brain-penetrating
non-viral miR-34a gene carriers across the BBB/BTB, can signifi-
cantly inhibit glioma growth in mice. To the best of our know-
ledge, this represents the first time that therapeutic miRNA
plasmid has been complexed into a non-viral gene nanocarrier
and delivered using Focused Ultrasound for treatment of gliomas.
Ongoing studies are centered on optimizing miRNA-34a expres-
sion levels, verifying changes in miRNA-34a oncogenic target
protein expression, and assessing tumor cell apoptosis and
proliferation.Fig. 110 (abstract A104). a Pre- and Post-FUS contrast MR images
of U87 tumors (yellow arrows). b 7 T contrast MR images of U87
tumors (yellow arrows) at 12 and 20 days after tumor implantation. c
U87 tumor volumes. P < 0.05 vs. all other groups at Day 20A105
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Objectives
Current Central Nervous System (CNS) drug delivery techniques are
confined to either targeted but invasive or to non-targeted and non-
invasive. Focused Ultrasound (FUS) coupled with the systemic admin-
istration of microbubbles has been proven to open the Blood-Brain
Barrier (BBB) locally, transiently and non-invasively, thus facilitating
the diffusion of neurotrophic factors. IV injection of Neurturin, a
member of the glial derived neurotrophic factors (GDNF) family has
been demonstrated to activate the downstream signaling pathway
following BBB opening. The promising previous findings set the mile-
stone for investigating the effect of Neurturin on the depleted dopa-
minergic neurons in vivo. The aim of the current study was thus to
investigate the neurorestorative effects of single and triple delivery
sessions of the neurotrophic factor Neurturin in a Parkinsonian
mouse model.
Methods
For this study a single control group was employed and three groups
per treatment cascade; single and triple. Wild type mice (12 months
old) were infused with sub-acute dosages of MPTP causing apoptotic
degeneration in the nigrostriatal pathway. After stabilization of the
MPTP lesions and the decontamination period, the treatment groups
were sonicated on the left hemisphere targeting twice the Caudate
Putamen region (CPu) and once the Substantia Nigra region (SN)
while one received an IV injection of 0.5 mg Neurturin. The survival
period after the last treatment was equal to 28 days allowing the
neurotrophic factor to develop its restorative effects followed by cor-
onal sectioning for tissue processing. The brain slices of both the SN
and the CPu were stained for tyrosine hydroxylase positive cells (TH
+) with a custom protocol. Brain sections were imaged to count the
TH+ nerve cell bodies on the SN while the dendritic and terminal
areas were quantified by a custom MATLAB algorithm by computing
the percentage of the relative difference (RD) between the two hemi-
spheres as for each mouse the contralateral side was compared to
the ipsilateral side to eliminate across-mice variation in the number
of nuclei and projections.
Results
Comparison between the neuronal cells on the contralateral side and
the ipsilateral side revealed an increase in the cell number on the
treated side only for the group that received Neurturin with FUS. The
RD was found to be significantly higher in the SN region for the groups
that received Neurturin, both in the cases of single and multiple treat-
ments. An increase in RD for the group that received multiple treat-
ments with Neurturin compared to the single administration group was
not observed. On the other hand, significant increase in the RD was
only found in the case of the triple-treatment group in the CPu region.
Conclusions
The increased RD at the SN region revealed the immense potential of
the current treatment and the necessity of expanding the study into
multiple administrations of Neurturin. The comparable findings in den-
dritic density at the SN region between the two treatment regimens
pointed towards the direction of examining the treatment effect at the
CPu region. The significantly increased CPu terminal density could be ex-
plained as the restoration of the neuronal processes through collateral
sprouting. Finally, despite the increase in neuronal cells on the ipsilateral
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ance with our knowledge of Neurturin restoring impaired neurons and
not regenerating them. The presented findings are essential considering
the therapeutic effect of multiple treatments with FUS enhanced drug
delivery in patients.Fig. 111 (abstract A105). Substantia Nigra: a Atlas 3D representation
of the nigrostriatal pathway and the involved structures, Substantia
Nigra (SN) and Caudoputamen (CPu). b Coronal section at a cross-
section of the SN in increasing magnification. c Fluorescent im
Fig. 112 (abstract A106). a T1wGd, T2w, T2*w MRI (3.0 T), and b
T2*w and DTI MRI (9.4 T) of a representative brain after 6 weekly
sonicationsA106
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Objectives
The objective of this study is to use advanced Magnetic Resonance
Imaging (MRI) techniques to characterize the long-term effects of
pulsed Focused Ultrasound (pFUS) and microbubbles (MB) in the rat
brain. We evaluated the effects of single and repeated Blood-Brain
Barrier (BBB) disruptions (D) on morphology in the rat striatum and
hippocampusas monitored by MRI and histology over 12 weeks.
Methods
Female Sprague Dawley rats (n = 6/group) received either pFUS +MB
once (Group A) or six weekly exposures (Group B) to the striatum and
the contralateral hippocampus along with 100 μl of intravenous MB
(OptisonTM, GE Healthcare). Prior to the first sonication rats received 3
daily doses of 300 mg/kg 5-Bromo-2′-deoxy-uridine (BrdU, Sigma Al-
drich) intraperitoneally to label proliferating (neurogenesis) cellsin vivo.
0.3-0.5 MPa acoustic pressures were applied in 10 ms burst length and
1 % duty cycle (9 focal points, 120 sec/9 focal points – striatum, 120 sec/
4 focal points – hippocampus) using a single-element spherical FUS
transducer (center frequency 589.636 kHz; FUS Instruments). T2w, T2*w
and Gadofosveset (Gd)-enhanced T1w images were obtained by 3.0 T
MRI (Philips) and T2w, T2*w, diffusion tensor imaging (DTI) was per-
formed by 9.4 T MRI (Bruker). Animals were euthanized 6 or 12 weeks
after the first pFUS treatment. Histological evaluation of brain and track-
ing of BrdU tagged cells was performed and compared to untreated
contralateral brain.
Results
In groups A and B, contrast enhancement on T1w images was de-
tected post sonication in the striatum and the hippocampus. Gd-
extravasation, T2 and T2* abnormalities were not seen in the brain
1 day post pFUS +MB at 9.4 T MRI. Approximately 50 % of Group A
and 100 % of Group B rats had hypointense voxels appeared on
T2*w 3 T MRI 2-3 weeks post pFUS +MB (Fig. 112a) consistent with
microhemorrhages or influx of metallophagocytic cells from the
spleen within the parenchyma. Fractional anisotropic (FA) changes in
white matter fiber structure- and gray matter-abnormalities on DTI
MRI were detected in regions with the T2* abnormalities suggestive
of increased astrogliosis and transient axonal damage along with
increased cell density. Group B also demonstrated ventriculomegalyand meningeal abnormalities (Fig. 112a, b). Histologically, increase in
numbers of Nissl positive cells along with activated microglia and
BrdU labeled cells were detected in both cortex and hippocampus in
greater amounts in Group B compared to Group A rats, consistent
with multiple episodes of induced sterile inflammatory response (SIR)
within the parenchyma.
Conclusions
We have observed a complex graded molecular and cellular SIR with
increase in the brain up to 24 hrs after pFUS +MB. However, little
has been reported on using advanced imaging techniques at high
magnetic field strengths on the long-term effects of single and re-
peated pFUS +MB in the brain. Based on changes in FA, DTI MRI
demonstrated low degree of structural injury at the location of both
single and multiple sonication exposures. Multiple pFUS +MB expo-
sures resulted in increased ventriculomegaly and numbers of acti-
vated microglia, Nissl positive cells and BrdU in both striatum and
hippocampus. Increased numbers of BrdU+ cells would be consistent
with the stimulation of neurogenesis indicative of increased damage
secondary to repeated SIR episodes in the parenchyma.A107
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Objectives
Activatable nanotherapeutics are attractive since the toxicity of chemo-
therapeutics can be constrained to a small region; combining such a
strategy with immunotherapy is the goal of this study. We have previ-
ously shown that administration of CpG-ODN as an adjuvant, together
with local release of doxorubicin from temperature sensitive liposomes
(TSL) resulted in regression of directly-treated tumors, suppressed growth
of contralateral tumors and reduced chemotherapeutic-mediated toxicity
in a murine breast cancer model.
Methods
The following is the protocol explored for the addition of anti-PD1:
immune intact FVB/n mice with bilateral invasive neu deletion syngen-
eic transplanted tumors were treated with a combination of anti-PD1
(aPD-1, 200 μg, i.p.) and intratumoral administration of CpG-ODN
(100 μg, i.t.) on days 0, 7, 14 and 0, 3, 7, 10, 17 and 24, respectively.
Doxorubicin TSL were prepared from DPPC:MPPC:DSPE-PEG2k, 86:10:4
in the presence of copper (II) gluconate and triethanolamine at 0.2 mg-
drug/mg-lipid and administrated i.v. at 6 mg doxorubicin/kg body
Fig. 113 (abstract A108). In-vivo T2w (84 ms/900 ms) image of
porcine lung, right ventilated, left flooded lung
Fig. 114 (abstract A108). Ex-vivo T1w GRE (5 ms/244 ms) image of
flooded human lung lobe with
hyperintense NSCLC-Adenocarcinoma
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rubicin and copper was created to enhance the circulation and stability
of TSL and to reduce systemic toxicity. To trigger drug release, hyper-
thermia was induced in the primary tumor with ultrasound (peak ultra-
sound pressure of 1.1 MPa at a frequency of 1.5 MHz) at 42 °C for
5 min prior to and 20 min post drug injection with a variable duty
cycle. Immediately afterwards, 100 μg of CpG-ODN 1826 was adminis-
tered intratumorally to the insonified tumor.
Results
Upon treatment with this combination of locally-released doxorubicin,
local administration of CpG-ODN and systemic aPD-1, 100 % of treated
and contralateral tumors regressed by at least 80 %; further, all of the
directly-treated tumors and 50 % of the contralateral tumors were elim-
inated without recurrence. Thus, a 50 % complete response rate was
achieved, with tumor regression observed immediately after the incorp-
oration of the doxorubicin treatment. By contrast, administration of
CpG-ODN and systemic aPD-1 alone resulted in regression of 66 % of
treated and contralateral tumors.
Conclusions
We demonstrate for the first time that blocking of the programmed
death-1 (PD-1) pathway in conjunction with immunogenic cell death
induced by CpG-ODN and activatable nanodelivery of doxorubicin
can generate curative responses in both primary and contralateral tu-
mors. Increases in cytotoxic CD8+ T lymphocytes and a reduction in
regulatory T cells and myeloid-derived suppressor cells were ob-
served in both directly treated and contralateral tumors. This com-
binatorial approach was curative for directly-treated tumors and
overall survival was significantly extended, however, the contralateral
tumor returned in all treated mice.
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Objectives
One-Lung flooding (OLF) enables HIFU application under sonographic
guidance in lung. Additionally MRgFUS is superior for non-invasive ab-
lation under thermal dose monitoring. FUS treatment of lung tumours
requires complete gas- liquid exchange in the treated lung section,
which will likely affect also imaging modalities. MRI is seldom used for
diagnosis and staging of thoracic tumours because of low proton dens-
ity with short T2* and field inhomogeneities in ventilated lung. So far
no data is accessible for MR imaging of lung in flooded condition and
therefore its use for FUS guidance on lung tumours. This study was
aimed to investigate in vivo OLF in MR environment and to evaluate
the capabilities of MR imaging on lung tumours (NSCLC).
Methods
OLF was performed on six pigs (female 35-60 kg) in 3 T MR (Prisma,
Siemens AG, Germany). After narcosis, mechanical ventilation was per-
formed with an ICU respirator (Servo 900, Siemens AG, Germany)
through a 39 Ch double-lumen tube (Mallinckrodt, Ireland). After venti-
lation with FIO2 = 1.0 for 30 min the left lung wing was flooded with
isotonic saline (0,9 %@ 35 °C). Ventilation of the right lung was main-
tained for 60-90 min, followed by re-ventilation for 30 min. MR imaging
was performed with spine and body array coils in lateral position using
T2 HASTE, and T1 weighted GRE sequences. As a cancerous ex vivo
model, MR imaging was performed on ten human lung lobes contain-
ing lung cancer (NSCLC). Lobes where flooded immediately after resec-
tion with saline (35 °C) and imaged using GRE and T2 HASTE sequences
in 1,5 T MR (Achieva, Philips, NL).
Results
OLF was successfully performed in MR environment on all animals
(6/6). Flooded lung appears hyperintense in T2 weighted images(Fig. 113) and hypointense in T1w. Bronchial wall and vascular struc-
tures in flooded lung clearly appear as hypointense structures in T2
weighted image at high level of detail. GRE phase images show a
homogenous phase in bronchial and alveolar tissue of the flooded
lung wing. NSCLC tissue appear in flooded lung as strongly hyperin-
tense lesions in T1 (Fig. 114) and hypointense in T2 weighted images
with clear demarcation from lung parenchyma.
Conclusions
This study shows that in vivo OLF is operable in MR environment, all
animals survived the procedure. The absence of susceptibility
changes in GRE phase images suggests a complete gas to saline ex-
change in the flooded lung wing. For FUS guidance a demarcation of
tumor to parenchymal structures is essential. In T1w images the lung
tumour appears bright hyperintense to surrounding lung in all tu-
mours. Further in T2w images a good demarcation between bron-
chus and parenchyma can be used for anatomic orientation. It can
be concluded that MR imaging based on general fast GRE and TSE
sequences is sufficient for FUS guidance on lung cancer during OLF.
Further research investigating nodule size detection limits and the
use of PRFS thermometry in flooded lung is required.
Fig. 115 (abstract A109). Generated scattering model for
Hounsfield Units of a) 301-400 and b) 801-900. Bone is represented
as yellow, while porous material is represented as green and
simulated as marrow. Blue is water. The transducer is to the left
and focused in the water
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Objectives
In transcranial HIFU treatments, scattering that occurs in the porous
skull can contribute to a significant portion of the ultrasonic attenu-
ation. In many acoustic models, scattering is neglected or consid-
ered homogenous across the skull. However, significant variations
in skull anatomy may require patent-specific models of scattering
for treatment planning. These patient-specific models are based on
clinical CT scans that do not have high enough resolution to re-
solve many of the scattering sites. In this work, we relate the scat-
tering properties of the skull, as simulated using a high-resolution
microCT scan, to quantitative Hounsfield Units (HU) as measured by
a clinical CT.
Methods
A high-resolution (23.6 micrometer isotropic) microCT scan was
obtained of an ex vivo human skull section in a holder and
thresholded into cortical bone and pores. The same skull was
imaged with a clinical-resolution (0.23 x 0.23 x 0.4 mm) CT scan.
The images were registered using hand-selected correspond-
ence points. A database of pores was created from the microCT
scan via connected components analysis and associated with
the corresponding HU values in the clinical CT scan based on
the center of mass. Additionally, the ratio of cortical bone ver-
sus porous material in the microCT was calculated for each as-
sociated HU range in the clinical CT. Models for various HU
ranges were constructed by randomly selecting hole shape and
sizes associated with the HU range and placing them in uniform
bone until the ratio of cortical bone to porous material was the
same as measured for the HU range. Simulations were then per-
formed using the Hybrid Angular Spectrum1 technique assum-
ing no absorption. The ratio of power at the focus compared to
the input power at the face of the model is representative of
scattering and reflections.
Results
Figure 115 shows example models for 301-400 and 801-900 HU
ranges respectively. For simulations, the transducer is to the left
of the model with the focus in the water to the right. These
representative models clearly show the differences in shape dis-
tribution of the pores as well as overall density of the different
HU ranges. Figure 116 shows the ratio of power at the focal
plane compared to the power input to the simulation as a func-
tion of HU range. The power lost is due to both scattering and
reflections.
Conclusions
The work presented here is the first step towards patient-specific
models of acoustic scattering. The models created represent the dif-
ferences in scattering and reflections for various HU ranges. Future
work will be focused on applying these results in simulations at a
clinical resolution to validate the method.Fig. 116 (abstract A109). The ratio of the power at the focal plane
to the power input for various models representing different
Hounsfield unitsReference
1. U. Vyas and D. Christensen, “Ultrasound beam simulations in
inhomogeneous tissue geometries using the hybrid angular spectrum
method,” IEEE Trans. Ultrason. Ferroelectr. Freq. Control,
2012 59(6):1093–1100.
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Objectives
Over 95 % of useful therapeutically molecules cannot penetrate to the
brain parenchyma in central nervous system due to the Blood-Brain
Barrier. In recent years it has been developed a promising ultrasound
assisted technique for noninvasive, targeted and safe BBB disruption
for drug delivery. This technique employs a transcranial focused ultra-
sound beam focalized on targeted BBB areas to disrupt. However, there
are many limitations of the technique: the skull shows very high acous-
tic absorption, the acoustic impedance of the skull bone is highly differ-
ent than the inner brain and outer media and the shape of the skull
produces aberrations in the acoustic field generated by focused acous-
tic beams that cause unexpected targeted focal areas. The aim of this
work is to study the transcranial targeting of whatever part of the brain
taking into account normal skull surface incidence, in order to find the
best incidence zone which generates less beam aberrations.
Methods
A 500 KHz focused transducer (aperture = 100 mm; radius = 140 mm)
was simulated with K-Wave Matlab toolbox, which is based on the k-
space pseudospectral method. A 3-D fluid media was considered with
CT-based acoustic maps of the skull. Geometrical algorithms were devel-
oped to select the position of the transducer normal to the skull from oc-
cipital to frontal areas and from temporal to parietal; and several physical
criteria have been applied to quantify the aberration level by comparing
the focal area of the beam when it propagates with and without skull.
Results
Refraction has proven to be one of the most important effects in the
propagation through the skull. Figure 117 shows the effect of the
skull shape in the focus of the single element transducer simulated,
both in a XY plane and in the YZ plane. We provide an evaluation of
the aberration of the focus of the beam in each plane following a
plath from the occipital to the frontal areas. Aberration in each plane
are different, and more important in the occipital area, were irregu-
larities of the skull shape affects the propagation due to the refrac-
tion phenomenon. Here, also, the existence of muscle adhered to the
bone increases the refraction of the beam.
Conclusions
The shift in the location of the focus respect to the propagation of
the free ultrasonic beam changes when the beam targets different
areas of the skull. It can be also affected by the presence of muscles
attached to the bone, and of course, when not normal incidence is
considered. The best target areas to minimize aberration in the beam
have been selected and characterized.Fig. 117 (abstract A110). Occipital incidence of the ultrasonic beam.
The focus suffers a higher deviation in the XY plane than in the XZ oneA111
Bilateral thermal capsulotomy with Focused Ultrasound for treatment-
refractory obsessive-compulsive disorder: 1-year follow-up
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Objectives
We investigated the efficacy and safety of bilateral thermal lesioning of
the anterior limb of internal capsule (ALIC) using magnetic resonance-
guided focused ultrasound (MRgFUS) in patients with treatment-
refractory obsessive-compulsive disorder (OCD).
Methods
Eleven patients with treatment-refractory OCD were included. Clin-
ical outcomes were evaluated using the Yale-Brown Obsessive-
Compulsive Scale (Y-BOCS), Hamilton Rating Scale for Depression
(HAM-D), and Hamilton Rating Scale for Anxiety (HAM-A) at 1 week
and 1, 3, 6, and 12 months following MRgFUS. Neuropsychological
functioning, Global Assessment of Functioning (GAF), and adverse
events were also assessed. This trial is registered with ClinicalTrials.
gov number, NCT01986296.
Results
After bilateral thermal lesioning of the ALIC using MRgFUS, Y-BOCS
scores significantly decreased across the 12-month follow-up period
(median Y-BOCS score, 34 vs. 22, p < 0.001). HAM-D and HAM-A
scores also significantly decreased (median HAM-D score, 19 vs. 6, p
< 0.001; median HAM-A score, 20 vs. 6, p < 0.001). GAF score also
significantly improved (median GAF score, 35 vs. 48, p < 0.001).
Wechsler Adult Intelligence Scale-Korean version and Memory Quo-
tient scores significantly improved after MRgFUS, and Controlled Oral
Word Association Test, Stroop Test, and Digit Span Test scores were
unchanged. Adverse events were mild and transient, including head-
ache, nausea, and anxiety during sonication.
Conclusions
The results of this pilot study suggest that bilateral thermal lesioning
of the ALIC using MRgFUS may improve obsessive-compulsive, de-
pressive, and anxiety symptoms in treatment-refractory OCD patients
without serious adverse events
A112
Development of an optically-guided system for transcranial
Focused Ultrasound
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Objectives
Focused ultrasound is a promising method for non-invasive neural
stimulation therapies in the brain. Early animal and human studies
have shown that neurological conditions such as essential tremors
can be effectively treated with ultrasound ablation therapy, while
sub-thermal neuromodulation has therapeutic effects that could
benefit a variety of neurological diseases, including manic depressive
disorder, Alzheimer’s and epilepsy. Ultrasound treatments typically
occur using image-guidance within a magnetic resonance imaging
(MR) system, but working outside the MR environment is often desir-
able. Conventional image-guided surgery can be used to enable
ultrasound neurosurgery outside the magnet by using preoperative
MR data registered to the physical patient, fixing tracked markers to
the ultrasound probe and registering the tracked space to pre-
acquired images. The accuracy of this system is determined by cali-
bration between the tracked markers and acoustic focus. Here, we
present a pulse-echo based method of calibration and characterize
its accuracy using MR thermometry.
Methods
We localized the tip of an optically-tracked stylus relative to the HIFU
transducer (Sonic Concepts H-115, center frequency 250 kHz) by
using the transducer in pulse-echo mode, while simultaneously track-
ing a rigid target attached to the transducer (Fig. 118a). A standard
optical tracking system (NDI Polaris, Waterloo, ON) was used to
Journal of Therapeutic Ultrasound 2016, 4(Suppl 1):31 Page 69 of 113record the transducer and probe locations during pulse-echo acquisi-
tion. The stylus was mounted to a 3D translation stage to function as
an echo target, and near-infrared reflectors with well-characterized
geometry were affixed to the transducer with custom mounting
hardware to make a rigid body for registration. We acquired loca-
tions of the rigid bodies as the probe was moved in 3-directions to
maximize the echo signal, providing an estimate of the ultrasound
focus position in optical coordinates. Next, multi-modal fiducials (vis-
ible via MRI) were attached to the transducer, and their positions
measured with the Polaris system. Finally, the transducer and a sonic-
ation phantom were placed in the MR scanner. The thermal focus
position was measured with MR thermometry, and the fiducial loca-
tions in MR coordinates were used to register the focus position to
optical coordinates. The difference of MRI-derived thermal focus and
the pulse-echo focus was the target registration error (TRE).
Results
MRI (green stars) and optically tracked fiducials (red triangles) were regis-
tered to coincident locations (Fig. 118b), yielding a fiducial registration
error of 2.8 mm. After registration, the mean TRE between the pulse-echo
focus and thermal focus across three phantoms was 5.7 +/- 1.5 mm
(Fig. 118c). This error is comparable to published methods, but work is
ongoing to achieve better results by optimizing placement of optical
tracking targets on the HIFU transducer. The TRE of this method in the
context of trans-cranial sonication is currently being evaluated.
Conclusions
Optical tracking allows prediction of FUS focal zone location. Future
experiments will assess the target registration error by performing
optically-guided transcranial ablation of a brain-equivalent phantom
and assessing the lesion location in a post-procedural MRI.Fig. 119 (abstract A113). Schematic (a) and picture (b) of the
calibration setup with the hydrophone positioned over an ex vivo
cranial specimen. c A picture showing a rat positioned with its brain
near to a known pressure calibration location within the skull
Fig. 118 (abstract A112). a Optically track calibration target (right) and
FUS transducer (left) operated in pulse-echo mode. b Iso-surface of the
phantom+ transducer scan showing registration of multi-modal fiducials.
c Results comparing thermal scan maximum and pulse-echo maximum,
with the displacement between representing total registration errorA113
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Objectives
MR-guided Focused Ultrasound (MRgFUS) has been used for many non-
invasive mechanical and thermal therapies throughout the body. One of
the most promising applications in the brain is the use of MRgFUS for
safe, local, and transient Blood-Brain Barrier (BBB) disruption.
Current transcranial MRgFUS therapy is performed using a hemi-
spherical, 1024-element transducer. For thermal therapy, this designis warranted as a large aperture is required to obtain enough gain
for focal heating without overheating the skull. For low duty cycle
and low pressure applications like BBB disruption, it may be possible
to use smaller-aperture transducer arrays like those found in clinical
body MRgFUS systems. The goal of this study is to characterize a
clinical body MRgFUS system in regards to ultrasound transmission
through a human cranium and in an application to disrupt the BBB
in vivo in rats.
Methods
A clean, degassed human cranium was mounted in a bath of degassed
water over a 14 cm, 256-element clinical body transducer (Sonalleve
V2, Philips). Short, 40 cycle ultrasound bursts at 1 MHz were transmitted
through the skull, and acoustic pressures were measured using a
hydrophone mounted to a positioning stage (Fig. 119). Three different
skull orientations were evaluated at 3-4 different sonication depths,
along with evaluating the sensitivity of ultrasound transmission to small
transducer translations.
Six anesthetized rats were shaved and positioned supine on an
acoustic window with their brains at the location of prior pressure
calibration. MR imaging was used for targeting. Microbubbles
(0.02 mL/kg, Definity) were injected concurrently with sonications
(0.4-0.6 MPa in situ based on hydrophone calibration, 10 ms bursts at
1 Hz pulse repetition frequency for 120 s). Gadolinium was adminis-
tered (0.2 mL/kg, Magnevist) and follow-up T1-weighted imaging
was performed to evaluate BBB disruption. Three brains were further
examined with histology to look for damage.
Results
Hydrophone measurements demonstrated a great deal of variation
in ultrasound transmission with change in skull orientation, though
the change was gradual. Attenuation ranged from ¬ 3.7 dB to 9.3 dB
(11 % to 43 % transmission). For a single skull orientation, the aver-
age variation in transmission was 3 % for a 5 mm transducer transla-
tion in-plane.
Contrast enhancement in the brain indicated focal BBB disruption
(Fig. 120). The error in the disruption location perpendicular to the
ultrasound beam was 1.0 +/- 0.5 mm, (Fig. 121). The error in the dor-
sal/ventral direction was 2 +/- 2 mm. The Lilliefors normality test did
not reject the null hypothesis that these samples were drawn from a
normal distribution (p < 0.05). In each animal, enhancement in-
creased with in situ sonication pressure, though there was a large
variation.
Conclusions
Transcranial MRgFUS is feasible with a smaller-aperture transducer
for BBB disruption. The accuracy of sonication was 1 mm in plane
and 2 mm out of plane without any corrections for the skull. For clin-
ical feasibility and safety, however, the attenuation of the skull must
be taken into account so as to apply appropriate pressures to disrupt
the BBB without causing damage.
Fig. 120 (abstract A113). Axial (a) and sagittal (b) contrast-enhanced
T1-weighted MRI scans indicating focal BBB disruption with intended
targets overlaid in blue. From the top-left and clockwise in (a), the four
targets had in situ pressures of 0.4, 0.5, 0.45, and 0.55 MPa
Fig. 121 (abstract A113). In-plane error of BBB disruption location.
Different symbols represents a different animals
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Objectives
Real time MR thermometry, usually based on the proton-resonance
frequency shift, is a key aspect of MR-guided ultrasound procedures.The desire to monitor the entire insonicated volume has led the field
towards the development of rapid, 3D methods; however, acquiring
fully sampled 3D volumetric data to monitor heating is time consum-
ing, and so fast methods must be developed in order to meet the
spatial and temporal requirements for adequate monitoring of ther-
mal therapy. Spiral k-space trajectories have higher data acquisition
efficiency than the traditional Cartesian scanning so that they are an
attractive way to improve temporal resolution while maintaining
spatial resolution in MR thermometry. Furthermore, temporal redun-
dancy can be exploited with real-time reconstruction models such as
the Kalman filter to further accelerate the scan without sacrificing
the real-time tracking capabilities. The purpose of this study was to
implement the 3D spiral thermometry sequence on a real-time plat-
form to demonstrate its effectiveness.
Methods
A non-accelerated 3D retraced spiral-in/out (RIO) thermometry se-
quence was implemented on the RTHawk platform (HeartVista, Inc.) to
enable real-time sequence control and monitoring of a FUS insonica-
tion. RTHawk interfaced with a GE Discovery MR750T 3 T scanner at the
UVA Focused Ultrasound Center, where an Insightec ExAblate 650 fo-
cused ultrasound transducer was used to induce focal heating. Three
Yorkshire pigs were used for initial sequence evaluation. Non-ablative
power settings were used to compare the temperature measured by
the 3D sequence to those measured by the standard 2D GRE thermom-
etry sequence provided by Insightec. Maximum temperature, measured
by the single hottest pixel, and mean temperature, measured as the
average of the 9 pixels centered at the hottest pixel in a single plane,
were recorded. After FUS, the animals were moved into a head coil
array for high quality post-ablation assessment, which induced T2-,
Diffusion, and T2*-weighted imaging using standard sequences.
To explore the acceleration technique, a Kalman filter model was de-
veloped given as:
x kð Þ ¼ x k‐1ð Þ þ w k‐1ð Þ
z kð Þ ¼ U kð ÞFx kð Þ þ v kð Þ
in which x(k) is the target image, z(k) is the measurement from
undersampling pattern U(k) and Fourier transform matrix F. The
model can give optimal estimation of x(k) based on undersampled
measurement and previous images.
Results
Sequence parameters for 3D RIO thermometry were: FA = 5-10°, TR/
TE = 22.0/12.8 ms, readout length = 8 ms, interleaves = 24 over a FOV
of 280 mm2 for an in-plane resolution of 1.5 mm2. 3D phase en-
codes = 12 with through-plane resolution of 3 mm so that the
through-plane FOV was 36 mm. Total acquisition time per volume
was 6.3 seconds. Sequence parameters for the 2D thermometry
method were: TR/TE = 27.6/12.8 ms, pixel bandwidth = 44 Hz/px,
matrix size 256 x 128 over a FOV of 280 mm2 for a resolution of 1.1
x 2.2 mm2, slice width of 3 mm, and update interval 3.5 seconds.
Real-time in vivo thermometry images using the non-accelerated 3D
RIO thermometry sequence are shown in Fig. 122. The hot spot is
resolved in volumetric space, albeit with lower SNR with the spiral
3D sequence, due in part to reduced voxel size. The maximum tem-
peratures measured by the 3D sequence correlate well with those
measured by the 2D sequence (Fig. 123). The mean temporal stand-
ard deviations of the 2D and 3D sequences were 0.8 °C and 1.3 °C,
respectively.
Conclusions: The efficiency of spiral readouts supports rapid gener-
ation of 3D temperature maps. In vivo, we have successfully moni-
tored the entire ablation with adequate spatial resolution to
qualitatively compare the ablation area with temperature. The tem-
poral resolution of the 3D sequence can be further improved with
the application of the Kalman filter model to match that of the
standard 2D Cartesian sequence. If this combination performs well
in vivo, the result will be a self-training 3D real-time thermometry
method with excellent temporal resolution and no focal spot shift.
Fig. 122 (abstract A114). In-plane error of BBB disruption location.
Different symbols represents a different animals
Fig. 123 (abstract A114). 2D/3D correlations between the
maximum (left) and mean (right) measured hot spot data
Fig. 124 (abstract A115). The T2 weighted (upper) and diffusion
kurtosis (lower) images after 1 min ultrasound exposure are shown.
The employed power from left to right is 1 W, 1.5 W, 2 W, 2.5 W and
3 W, respectively
Fig. 125 (abstract A115). With 3 W acoustic power for 1 min,
recorded temperature from MRgFUS system is shown, in which the
maximum temperature rise was found to be 15 °C
Fig. 126 (abstract A115). Acoustic pressure field from simulations
using the bio-heat equation (left), and tissue temperature changes
after taking into account the skull and tissue characteristics (right)
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Objectives
Focused ultrasound (FUS) for neuro-internventions is gaining popularity
not only for ablating tissues as in the case of the treatment of essential
tremors and Parkinson’s disease, but also to study the effects of
neuromodulation, and temporary opening of Blood-Brain Barrier non-
invasively. However, the biological effects of such low level exposure
on the brain tissue are less understood especially at locations that are
removed from the focal spot. In this study, we used in vivo diffusion
kurtosis imaging (DKI) to measure brain water diffusion changes in vivo
in rats at varying FUS exposure levels at the focal spot and away from
the focal spot.
Methods
To systematically understand the rain structural, functional, and bio-
chemical changes from focused ultrasound intervention, rats (n = 5;
300 ~ 400 g) were exposed to various FUS energies. Prior to FUS ex-
posure, rats were imaged using an MR scanner (Bruker, Germany) for
small animals. The rats were then subject to various levels of MR
guided FUS exposure ranging from 1-3 W using an eight array trans-
ducer from IGT, France. Localization for the exposure was determined
using ARFI technique. Once the focal spot was identified, each ani-
mal was subject to exposure at a specific energy level. Temperature
monitoring was performed during the exposure to identify no over
exposure or cavitation occurs in other areas of the brain. Following
the exposure, high-resolution images similar to the pre-exposure
were obtained within two hours after FUS. The axial temperature dis-
tribution of the focal spot was visualized with MRI during ultrasound
exposure. To acquire the coronal temperature distribution of the
focal spot, a k-space time-domain method was employed to simulate
the acoustic field during the exposure by solving the full Westervelt
equation. Temperature simulation was estimated by solving inhomo-
geneous Pennes equation of heat conduction.
Results
The T2 weighted and diffusion tensor images after a minute of ultra-
sound exposure with varying energy are shown in Fig. 124. As anexample, recorded temperature with 3 W acoustic power is shown in
Fig. 125, in which the maximum temperature rise was found to be
15 °C. This was also confirmed from the simulations using the bio-
heat equation which also takes into consideration of the skull and tis-
sue map from CT images. The tissue temperature distribution from
the simulation over the exposure time was also found to be about
15 °C (acoustic power is 3 W; base temperature is 37 °C) as well
(Fig. 126). With increasing acoustic power, increased mean kurtosis
(MK) and reduced mean diffusion (MD) were observed both at the
focal spot and away from the focal spot (Fig. 127). Increased MK typ-
ically means that there is increased heterogeneity in the tissue micro-
structure suggesting increased astroglial reactivity associated with
the rise in temperature. These results suggest that at even low ex-
posure rates and away from the focal spot, where the pressures
reaches ~400-500 kPa, water diffusion changes occur that can be de-
tected by diffusion tensor imaging in the absence of any visible dam-
age observed on T1 or T2-weighted image.
Conclusions
We hypothesize that these water diffusivity changes induced by fo-
cused ultrasound are mainly due to shearing forces exerted on the
brain tissue that have an effect on the tissue environment if only tem-
porarily. Ultrasound simulations could provide information on the pres-
sure distribution and temperature distribution throughout the brain to
enable correlation with water diffusion changes. In the future we will
be studying the long term effects of such low level exposure to under-
stand if such changes are similar to those observed on animals with
mild traumatic brain injury follow exposure to blast pressures.
Fig. 127 (abstract A115). Increased acoustic power leads to a
decrease in mean diffusivity (MD) and increased mean kurtosis (MK)
in the focal area
Fig. 128 (abstract A116). Pulse signal acquired by eight on board
PCDs. The signal from channel 2 was abended because it seems not
recording the cavitation signal. The signal on channel 4 and channel 8
were also excluded to the cavitation localization because its higher
sensitivity may cause different pattern on time domain signal compare
to others. A large unknown signal was frequently appeared at the
begging of the recorded signal on channel 5. The signal from channel 1,
3, 6 and 7 shows similar pattern and carried for further cavitation
localization process
Fig. 129 (abstract A116). Time domain signal of one pulse. The large
signal represents the cavitation activity and we assume the first peak of
the large signal group as the initiation of the cavitation activity
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Objectives
Since cavitation is a potential risk factor that must be monitored and lim-
ited, the power measurement and frequency response of the acquired
signal through passive cavitation detectors (PCDs) are utilized to detect
cavitation activity. Currently, the sonication system was designed to auto-
matically shut down when the power of the cavitation signal exceeds a
certain threshold. However, cavitation caused by the bubbles on the skin
could also contribute to the appearance of large broad band signal
resulting in unexpected stop of sonication. Localizing the cavitation
source may improve the monitoring of the cavitation activity at the focal
area and provide more reliable sonication with known cavitation location.
The purpose of this study is to localize cavitation near the focus using on-
board PCD set without change of a current clinical system setup and to
try to distinguish if the cavitation is activated in region of interest.
Methods
In order to generate the cavitation intentionally, high power sonic-
ation was targeted on the geometrical center in tap water with and
without a human skull. Eight PCDs on a 220 kHz hemispherical trans-
ducer (ExAblate Neuro system, InSightec) were synchronized with
the pulse sonication. The PCD signals were recorded each sonication
and saved into a log file. One of the pulse signal (4096 sample points
with 2 MHz sampling rate) acquired by eight the PCDs are shown in
Fig. 128. The relatively large signals are from cavitation and we as-
sume the first peak (marked with red arrow in Fig. 129) of this large
signal train as initiation of the cavitation activity. The mean value of
the first 200 samples and a constant value was used as a threshold
to track the first arrived signal. A trilateration, which is normally uti-
lized as a standard localization method on global positioning system
(GPS), was modified to localize the cavitation spot. The cavitation sig-
nals from 4 PCDs were read in MATLAB software to implement the
cavitation localization. The distance between tracked location and
sonication location was calculated to verify the localization error.
Results
We found time shifting of the cavitated signals through a skull com-
pared to the data without skull. As shown in Fig. 130, the red arrow de-
notes the arriving time on tap water data (without skull) and green
arrow shows the shifted signals through the skull. And the strong signals
pointed by yellow arrow is the reflected signals from skull. The simula-
tion signals using a k-wave model result in cavitation localization with
an initial errors of 3 ± 3 mm. Implementation of this localization algo-
rithm to experimental data made the cavitation localization with larger
errors of 49 ± 21 mm in tap water (without skull) compared to the water
with skull (20 ± 4 mm shown in Fig. 131). It may be because of the signal
patterns of the skull embedded data containing aforementioned
discernible-vertical line (marked with white arrow in Fig. 130) and has
higher SNR near the arriving time.
Conclusions
In conclusion, the cavitation localization could be possible with an
error range of 20 ± 4 mm with skull with some limitations. So far, weverified the localization algorithm based on the experimental data
targeted at the geometrical center only, and more off-centered data
are required to confirm the robustness of this localization algorithm.
Fig. 130 (abstract A116). The sampled signals on one passive
cavitation detector (PCD) in tap water with and without skull. The x
axis denotes the sample points and y axis denotes the pulse number,
and the brighter color represent the larger amplitude of the signal
Fig. 131 (abstract A116). Tracking of the signals of cavitation
initiation for 4 PCDs and the corresponding localization errors. (a) to
(d) denotes the tracking result of the cavitation signals from 4 PCDs
marked with white dots. The error distances between the known
source positions and localized ones with a modified trilateration
algorithm are shown in (e)
Fig. 132 (abstract A117). a Placement two frontal EEG electrodes
with ground and reference electrodes. b The normalized
percentage of total power in delta, alpha, and gamma frequency
bins. c SEF 95 % and MPF indexes were calculated from
each period
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Anesthetic depth challenges for ultrasonic neuromodulation: An
electroencephalographic index monitoring
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Transcranial application of low-intensity focused ultrasound (FUS) for
brain stimulation has proven to be powerful tool to manipulate brain
activity with a few millimeters of spatial resolution while keeping it
completely non-invasive (Yoo et al., 2011). Until recently, however,
transcranial FUS-mediated brain stimulation conceded some room for
variability and inconsistency in exerting its neuromodulatory effects; it
is unclear how different types of anesthetic drugs and varying
anesthetic depth intervene in the process of ultrasonic neuromodula-
tion. For these reasons, it is necessary to discover the effective time
window for neuromodulation. The purpose of the present study is to
monitor the anesthetic depth with electroencephalogram (EEG) to
optimize the working parameters for neuromodulation in different
anesthetic periods.
Methods
Sprague-Dawley rats (female, n = 8) were induced to anesthesia with
5 % of isoflurane, and sustained anesthesia by intraperitoneal injec-
tion of 0.1 ml/100 g ketamine/xylazine cocktail. Power spectra of two
EEG channels were obtained from prefrontal cortex (Fp1, Fp2), and
one ground electrode were placed at midline of the cerebellum
(Fig. 132a). We adopted 350 kHz of fundamental frequency, 50 % of
duty cycle, 1 kHz of pulse-repetition frequency, 0.5 ms of tone-burst
duration, and 300 ms of sonication duration, and acoustic intensity
of 3.3 W/cm2 Ispta (spatial-peak temporal-average intensity) as the
sonication parameters for inducing the tail movement (Kim et al.,
2014). EEG was recorded approximately for an hour until the animal
wakes up, and each experimental recording was divided into 6 con-
secutive periods to calculate the depth of anesthesia. From EEG
spectrum analysis, SEF 95 % (spectral edge frequency), MPF (median
power frequency), and vigilance index, and other spectral parameters
were used to estimate the depth of anesthesia.
Results
At the 3thperiod, EEG delta and alpha activity were strongly suppressed
while gamma activity was significantly enhanced during the time
(Fig. 132b), which indicate rapid eyeball movement (REM) sleep like
EEG activity (Ferri et al., 2001). At this stage of anesthesia, even at the
intensity level above the previously confirmed excitation threshold did
not elicit any tail movement as stimulating the motor cortex. This may
be translated as the results of REM stage characteristics where the ex-
ternal stimuli are strongly inhibited. During the 5th and 6th periods,
SEF 95 % and MPF repeated increasing tendency (Fig. 132c) from
briefly deepened 4thanesthetic period after 3th period (REM stage) im-
plying lightened anesthetic depth (Kortelainen et al., 2012).
Conclusions
We observed voluntary whisker movements at 5th and 6th
period which is a typical sign for superficial depth of anesthesia
(Brecht et al., 2004), and the ultrasound induced tail movement
success rates accompanying the whisker movements were higher
at both periods than the rest of the anesthetic stages.A118
The effect of skull model resolution on phase aberration correction
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Fig. 134 (abstract A118). Coronal beam profiles at each skull
model resolution. A different set of phases was calculated at each
resolution, and the resulting beam was simulated using the full
resolution CT model
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Skull bone is heterogeneous and distorts ultrasound waves. This al-
ters the location, shape, and itensity of the beam’s focus. To compen-
sate for skull distortions, phase corrections may be applied to each
element - these corrections are estimated using simulations of the
patient skull.
Traditionally, models of the patient skull are derived from high reso-
lution computed tomography (CT) images. However, there is a move
towards ultra-short echo time (UTE) magnetic resonance imaging to
reduce patient exposure to ionizing radiation.
UTE cannot achieve the same resolution as CT, therefore it is unclear
whether simulations based on UTE-derived skull models will yield ac-
curate phase corrections. To determine the feasibility of the lower reso-
lution UTE-based simulations, we investigate the trade-offs between
skull model resolution and characteristics of the corrected beam. In this
study, we use CT images to create skull models of varying resolution.
Methods
We performed 3D simulations using the hybrid angular spectrum (HAS)
method at 680 kHz. Skull models were generated by down-sampling
high resolution skull CT images with cubic convolution interpolation.
Isotropic resolutions of 0.5 mm to 3 mm (in 0.5 mm steps) were used.
To compensate for phase distortion introduced by the skull, the
phase of each transducer element was estimated at the intended lo-
cation. We applied the conjugate of this phase to achieve a phase
correction. A different set of phases was calculated at each reso-
lution, and the resulting beam was simulated using the full resolution
CT model.
We define a global efficiency metric as the ratio of focal spot intensity
to total intensity in the brain; this metric detects the presence of large
sidelobes or multiple focal spots.
Results
With decreasing resolution, full width at half maximum and sidelobe
level increase whereas focal intensity and global efficiency decrease
(Fig. 133). There is minimal blurring of the focal spot for resolutions
0.5 mm to 1.5 mm. However, the focal spot quickly degrades as the
voxel size exceeds 1.5 mm (Fig. 134).
Conclusions
Focal intensity, sidelobe level, and global efficiency worsen at resolu-
tions 2 mm and below. Even though computation time is drastically
shorter, the deterioration of the focal spot is unacceptable.
To avoid frequency aliasing in the HAS method, the minimum reso-
lution should be 1.1 mm (assuming 680 kHz frequency and 1500 m/s
speed of sound). The 1.5 mm and 2 mm resolutions will thus lead to
aliasing. The 1.5 mm option, however, appears to yield similar results to
the higher resolution options. This may be plausible considering that
the acoustic wavelength in bone is approximately 3.4 mm (assuming
2300 m/s speed of sound). 1.5 mm would satisfy the resolution require-
ment in the skull, which is the dominant contributor to phase aberra-
tions. Therefore, a resolution cutoff is suggested at around 1.5 mm,
with additional work recommended to determine the minimum effect-
ive resolution.Fig. 133 (abstract A118). Metrics used to characterize trade-offs
between skull model resolution and characteristics of the corrected
beamA119
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Objectives
This study investigated the impact of oxygen versus medical air as a
carrier gas for isoflurane anesthesia on Blood-Brain Barrier (BBB) disrup-
tion, a method under investigation that can enable and target the de-
livery of drugs to the brain.
Methods
In experiments in mice (N = 7), four brain targets were sonicated in
combination with administration of Optison microbubbles (100 μl/
kg) under isoflurane anesthesia. A 690 kHz focused ultrasound trans-
ducer applied 10 ms bursts at 1 Hz for two minutes at applied peak
pressure amplitudes of 0.51-0.54 MPa (N = 2) or 0.34-0.36 MPa (N =
5). After sonication of two locations in one hemisphere, the carrier
gas for the anesthesia was changed from oxygen to medical air, or
vice versa, and the sonications were repeated in the contralateral
hemisphere. Acoustic emissions were recorded during each sonic-
ation, and the resulting BBB disruption was assessed using contrast-
enhanced MRI.
Results
Example findings are shown in Fig. 135. BBB disruption, as mea-
sured by MRI signal enhancement after Gd-DTPA administration,
was significantly greater (P < 0.001) in animals breathing medical
air (Fig. 136b). MRI signal enhancement was detected in 13/14 lo-
cations sonicated in animals breathing medical air, but only in 7/
14 locations with oxygen. Harmonic emissions were also greater
with medical air (P < 0.001), and the decay rate of the harmonic
emissions was 1.5 times higher with oxygen (Fig. 136b). A good
correlation (R2: 0.46) was observed between MRI signal enhance-
ment after Gd-DTPA administration and harmonic emissions
(Fig. 136c). At 0.51-0.54 MPa, both the occurrence and strength
of wideband emissions with greater with medical air. However, at
0.34-0.36 MPa, the strength and probability for such emissions
was higher with oxygen. Little or no effects were observed in
histology at 0.34-0.36 MPa.
Conclusions
The use of oxygen as a carrier gas has a profound impact on BBB
disruption. These findings are consistent with earlier work compar-
ing ketamine/xylazine versus isoflurane and oxygen anesthesia on
BBB disruption as well as imaging studies showing increased clear-
ance rates of ultrasound contrast agents in animals breathing oxy-
gen. The increase in wideband emissions at the lower exposure
levels with oxygen without significant BBThis work was supported
by NIH grants R01EB003268, P01CA174645B disruption is an inter-
esting finding that should be pursued further. Overall these find-
ings are important for comparing results from different research
groups and should be taken into account in translation to clinical
trials.
Fig. 135 (abstract A119). Example MRI contrast enhancement (left)
and acoustic emission spectra (right) in 2 mice. Only animals
breathing medical air showed detectable BBB disruption and large
harmonic emissions (arrows)
Fig. 136 (abstract A119). a Mean MRI signal enhancement vs time
for 0.34-0.36 MPa sonication. b Mean harmonic emission strength
(relative to recordings obtained without microbubbles) vs time for
0.34-0.36 MPa sonication. c MRI enhancement vs harmonics for
all sonications
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Objectives
Previous experiments with histotripsy has shown that it can be used
to generate targeted lesions through the skullcap without aberration
correction. However, before therapy is applied, one would like be
sure that the focal point of the transducer through the skullcap is
within the confines of the treatment volume. The results from this
study demonstrate how ray tracing can be used to predict the loca-
tion of the focal point in a transcranial setting.
Methods
Histotripsy pulses for the experiments were delivered through hu-
man skullcaps using a 256-element 500 kHz hemispherical phased
array transducer. Three excised human skullcaps were used for the
experiments. During experiments, measurements of pressure profiles
and focal shifts of the transducer through the skull were acquired
using a needle hydrophone. The pressure profiles were measured by
scanning the hydrophone along 2 cm long lines across the axial and
transverse directions with respect to the origin of array. The experi-
ments were performed without aberration correction. 3D surface
scans of the excised skullcaps were acquired for the simulations. Dur-
ing simulations, straight line rays from each transducer element of
the array were propagated through the skull. Calculations of ray tra-
jectories based on Snell’s law, the time of flight of the rays, and
losses due to attenuation as the rays propagated through the skull
were made during simulations. The rays were then simulated as
plane waves that propagated across the origin of the array to calcu-
late the pressure field about origin. The results from the simulations
were then compared to the results from the experiments.
Results
Experimental results revealed that the focal point of the transducer
remained confined to less than 1 mm of the geometric origin of the
array. The experiments also revealed that the propagation direction
of acoustic pulses from each element of the transducer were not sig-
nificantly altered when traveling through the skull. The simulations
using ray tracing were able to accurately predict the overall shape of
the pressure profile measured experimentally and the focal position
of transducer through the skullcap.
Conclusions
The focal location of the transducer was not significantly affected by
the skull even when the skullcap was moved within the array. Ray
tracing was able to accurately predict the major features of the pres-
sure profile and focal locations through the skull.A121
Bilateral anterior capsulotomy with MR-guided Focused Ultrasound
for refractory obsessive-compulsive disorder: 1 year follow-up results
Chang Kyu Park1, Sang Man Park1, Na Young Jung1, Min Soo Kim1, Won
Seok Chang1, Hyun Ho Jung1, Jin Woo Chang2
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Objectives
Obsessive-compulsive disorder (OCD) is a chronic and debilitating
psychiatric condition. Traditionally, anterior capsulotomy was an
established procedure for treatment of patients with refractory OCD.
However, despite the potential benefits of these surgical procedures,
patients show significant surgery-related complications. Previously,
we demonstrated that bilateral thermal capsulotomy using magnetic
Fig. 137 (abstract A122). Experimental setup (top) for shear-mode
transcranial transmission and functions (bottom) based on the skull
density for longitudinal and shear speed of sound, and longitudinal
and shear attenuation. Tx refers to the transducer
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nique with surgical precision for thermal ablation, is a safe and effective
therapy for patients with refractory OCD. In the present study, we in-
vestigated the long-term outcome of the patients who underwent
MRgFUS for refractory OCD.
Methods
Eleven medically intractable OCD patients who underwent MRgFUS
bilateral thermal anterior capsulotomy from February 2013 to June
2014 were included in this study. Pre- and post-operative (1 week,
1 month, 3 months, 6 months, 12 months) Yale-Brown Obsessive-
Compulsive Scale (Y-BOCS), Hamilton Depression Scale (HAMD) and
Hamilton Anxiety Scale (HAMA) scores were recorded. Brain MRI was
performed pre-operatively, 1 week, 1 month, 3 months and 6 months
after the operation to assess the effect of the operation.
Results
There was a 36 % improvement in Y-BOCS at 12 months after MRgFUS.
The HAMD and the HAMA were showed 54 % and 62 % improvement
compared to pre-operative score. The improvement according to time
had shown statistical significance (all p value was less than 0.001, re-
peated ANOVA test). There was a marked difference in MRI findings be-
fore and 6 months after the operation. Moreover, there were no
neurological, psychological complications with the exception of mild
headache and nausea.
Conclusions
The optimal treatment for refractory OCD has been unclear; however,
in this study, MRgFUS was an effective and safe treatment for refrac-
tory OCD. Thus, MRgFUS may be an effective treatment modality for
refractory OCD in high risk surgery patients.
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Prediction of shear-mode conversion for transcranial ultrasound
using a viscoelastic model for sound propagation: First
experimental results
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Objectives
The skull barrier represents the main limitation for many therapeutic
applications of High Intensity Focused Ultrasound (HIFU) in the brain
tissue. A better understanding and modelling of this barrier facilitates
an optimal design of transcranial HIFU applications. An important
aspect not yet fully explored in transcranial ultrasound is the use of
shear-mode conversion, which in principle can result in less defocus-
ing effects caused by the skull barrier.
However, there is not yet a well-established modeling method that
can take into account both longitudinal and shear waves in the skull
bone. In this study we present our first results on the validation of a
sound transmission model based on the viscoelastic wave propaga-
tion adapted for the case of transcranial ultrasound. We compared
the predictions obtained with this model with measurements in human
calvaria where shear mode conversion was present in the transcranial
sound transmission.
Methods
Characterization of transcranial acoustic transmission. Human skull
caps were immersed in degassed water and put under vacuum at
−0.7 MPa for 8 h prior to measurements. A transducer (diameter of
5 cm and a focal length of 10 cm) was used to send 15 ultrasound
pulses with a frequency of 270 kHz. A stereoscopic fixation system
was used to ensure an incident angle of ultrasound of 40°. The skull
was located 12 cm from the transducer. Measurements were per-
formed in the presence of the skull and in water-only conditions using
a 2 mm-diameter hydrophone over a scan plan of 35 mm x 35 mm
with a spatial step of half-wavelength and located 15 cm from the
transducer.
Viscoelastic wave propagation modeling for transcranial ultrasound
transmission. The propagation model is based on a staggered grid
scheme (Geophysics, 1986; 51(4): 889-90). We included refinements to
the original model to consider transmission between fluids and solids
(Computers & Geosciences, 2002; 28(8): 887-99) and attenuation effects(Geophysics, 1995; 60(1): 176-184). The equations were solved using a
Finite Difference Time Difference (FDTD) solution using approximations
of second order in time and fourth order in space.
Results
Figure 137 shows a scheme for the experimental setup and the
relationships in function of the skull density of the longitudinal
and shear speed of sound, and longitudinal and shear attenu-
ation, which were used for this feasibility study. The simulated
delay DS on the scan plane between water-only and skull mea-
surements was compared to the corresponding experimental
delay DE. Negative values of delay indicated that signals in the
presence of the skull arrived before their respective water-only
counterparts. Comparison was done in ten measurement locations
from three different skull samples.
Figures 138 and 139 shows an example of experimental and simu-
lated results where shear-mode conversion was clearly observed.
Each figure shows the delay and normalized pressure maps. Also,
plots of the acoustic signals at the center of scan plane are shown
in water conditions, in the presence of the skull and in the pres-
ence of the skull plus the calculated delay. All measurements com-
bined, seven of ten measurements showed shear-mode conversion
(negative delay) while three others (all from skull #3) still showed
that longitudinal transmission dominated (positive delay). The lin-
ear regression analysis (Fig. 140) of DS versus DE indicated that
viscoelastic model predicted accurately the delay for all cases with
R2 = 0.97 and a significance of p < 1e-5.
Conclusions
The proposed model represents a significant progress for a more
accurate prediction of transcranial ultrasound transmission. The
comparison with experimental results indicated that the model is
adequate to predict sound propagation when either shear or longi-
tudinal transmission dominates. In our tests, two of three skull sam-
ples clearly showed shear-mode conversion while the other did
not. Closer inspection of skull #3 indicated a less differentiated cor-
tical bone layer and a density 20 % lower compared to the other
two specimens. As a result, the average longitudinal speed of
sound of skull #3 was slower compared to the other two speci-
mens, implying that its critical angle for shear-mode conversion
should be higher than 40°. These results indicated how important
can be the degree of differentiation among different subjects. An
adequate modelling that considers the skull bone as a viscoelastic
medium will be an important asset to better design and execute
transcranial HIFU therapy.
Fig. 138 (abstract A122). Example of experimental maps of delay
and pressure amplitude for skull location showing shear-mode
conversion. Average of delay was calculated in the isoregion of 50 %
or more (contour showed in maps) of the maximal pressure in the
water measurement
Fig. 140 (abstract A122). Linear regression of experimental and
simulated delay
Fig. 139 (abstract A122). Corresponding simulation of maps of
delay and pressure amplitude for skull location showing shear-mode
conversion. Average of delay was calculated in the isoregion of 50 %
or more (contour showed in maps) of the maximal pressure in the
water measurement
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biophysics predicts cell-type-selective stimulation
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Objectives
US can noninvasively suppress or excite central nervous system (CNS)
activity using different combinations of stimulation parameters. While
applications are already emerging, the underlying biophysics remains
unclear regarding the relative contribution of possible mechanisms:
extracellular bubble cavitation, thermal effects, acoustic radiation pres-
sure and US-induced intramembrane cavitation within the bilayer mem-
brane (the bilayer sonophore or BLS model). Interestingly, temperature
transients, radiation pressure and intramembrane cavitation can induce
plasma membrane capacitance changes. Here, we use detailed predict-
ive modelling and find that only intramembrane cavitation can explain
all the observed aspects of ultrasonic neuromodulation.
Methods
We analyzed the relevant experimental literature using modified
Rayleigh–Plesset intramembrane cavitation BLS biomechanics and
acoustic radiation pressure gradients (RPG) - induced membrane dynam-
ics. By coupling these biomechanical models to biophysical membrane
models we predict dynamical biophysical responses of artificial bilayer
membranes, and of three common neocortical single cell Hodgkin-
Huxley type models: i) Regular Spiking (RS) cortical pyramidal neuron, ii)
Fast Spiking (FS) cortical inhibitory neuron and iii) Low Threshold Spiking
(LTS) cortical inhibitory neuron, RS-FS-LTS Hodgkin- Huxley based net-
work model and CNS axon model. In addition, live brain tissue RPG sub-
jected areal strains were evaluated in a viscoelastic brain model. To
explore high intensity US-related thermal effects on membranes’ bio-
physics a Gouy-Chapman-Stern-based model was developed.
Results
Only the Neuronal Intramembrane Cavitation Excitation (NICE) models
were able to explain US-induced action potential generation through
BLS-type pulsating nano-bubbles inside the bilayer plasma membrane:
the leaflets’ periodic vibrations induce US-frequency membrane capaci-
tance and potential oscillations, leading to slow charge accumulation
across the membrane (on a time scale of tens of milliseconds), until ac-
tion potentials are generated. In contrast, the analysis of RPG-induced
membrane capacitance variations associated with membrane area
changes explain artificial membrane results, but were found to be highly
unlikely sources for neural excitation, when considering the areal strains
expected to form in brain tissue during normal sonication. Further, the
NICE-LTS inhibitory neurons show a much higher relative sensitivity to
sparse ultrasonic stimulation compared to the other neurons, resulting
from their T-type voltage gated calcium channels. This model-based pre-
diction was found to explain the results of a significant body of suppres-
sion and excitation experimental studies, including in humans. Finally, a
rigorous analysis of thermal effects using Gouy-Chapman-Stern theory
reveals that an elevation in membrane capacitance coupled with surface
charge-related thermal processes can be associated with high intensity
US’s temperature transients.
Conclusions
This study provides a unified theoretical framework for a large body of
experiments in multiple preparations across the field of US neuromodu-
lation, lending further support to the hypothesis that intramembrane
cavitation is responsible for ultrasonic neuromodulation. They could
thus pave the way towards new CNS therapeutic protocols, using the
only method that currently allows targeted non-invasive neuromodula-
tion with millimeter spatial resolution essentially anywhere in the brain.
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Current clinical systems for Focused Ultrasound (FUS) brain surgeries
are not designed to precisely or accurately deliver a desired thermal
dose to a target in brain tissue. This study attempts to modulate the
power applied during sonications to maintain a target temperature
in order to accumulate thermal dose in a predictable and control-
lable fashion, allowing researchers and clinicians to prescribe a deliv-
ered thermal dose.
Methods
The regular gating and control of an MRI-guided FUS brain system
(ExAblate 4000 Neuro 650 kHz system, InSightec) was bypassed and
fed into a proportional-integral-derivative (PID) control loop, and em-
pirically tuned during sonications of gel phantoms with a propor-
tional gain of 5 and an integral gain of 1.5. The system was then
used for an animal trial with pigs in vivo, performing thalamus abla-
tion following a craniectomy.
Results
Trials in gel phantoms demonstrated the effectiveness of PID
temperature control with the brain system, with different settings for
proportional and integral gain affecting the time to reach the target
temperature and the magnitude of the temperature overshoot. When
used in vivo, the system was able to deliver a desired thermal dose
within 10 CEM, with lower temperatures demonstrating a lower rate
of accumulation of dose.
Conclusions
In conclusion, PID temperature control is possible to implement in
current FUS brain systems, and can be used to deliver a desired ther-
mal dose with the principle limitations of uncertainty in starting
temperature and the low signal to noise ratio of the MRI-
thermometry.
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Objectives
Ultrasound treatment of the brain is typically performed using large-
aperture submegahertz-range sources of a hemispherical shape to
achieve better energy concentration. Heat deposition at the focus
depends on the frequency content of the ultrasound wave that can
be different from the source single-frequency signal due to nonlinear
generation of harmonics on the way to the focus. Several theoretical
models exist for simulating generation of higher harmonics for
weakly or moderately focused waves. In this case the acoustic field
can be considered as a directed beam. In the case of the hemispher-
ical sources this assumption is no longer valid, so different strategies
are needed.
Methods
Theoretical methods are proposed for evaluating the amplitude level
of the second harmonic generated in hemispherically focused fields.
Two approaches are used: 1) a simplified nonlinear 1D model; and 2)
a more accurate model that accounts for the combined effect of dif-
fraction and nonlinearity. In the first approach, the nonlinear propa-
gation is studied by considering a spherically converging nonlinear
wave for which an exact solution of the generalized Burgers equation
can be obtained [R.V. Khokhlov et al., Acustica 14 (1964)]. The solu-
tion is used to predict the degree of nonlinear effects when the wave
arrives to the focal region. In the second approach, the calculation
consists of several steps and employs the successive approximations
method. First, the linear acoustic problem is solved for a hemispher-
ical source using a spherical harmonics series expansion [O.A.
Sapozhnikov and T.V. Sinilo, Acoust. Phys. 48 (2002)]. Then the vol-
ume sources for the second harmonic generation are calculated
based on the solution to the linear problem. Finally, these sources
are used for obtaining an analytic solution for the second harmonic
amplitude at the focus.Results
The developed methods were applied to study the acoustic field of
the ExAblate 3000 clinical system (InSightec, Haifa, Israel). This source
has the following parameters: 512 equal area elements, hemispher-
ical shape of 30 cm diameter, working frequency of 670 kHz, and
acoustic power of several hundreds watts [K. Hynynen et al., Europ. J.
Radiology 59 (2006)]. The spherical harmonics expansion approach
shows that the linear field can be accurately calculated using the
Rayleigh integral. Calculations by both models predict that nonlinear
effects are weak even for the free-field focusing in water at the
acoustic power up to approximately 1 kW. Around this power level, a
noticeable waveform distortion, with 10 % of the wave power being
transferred to the higher harmonics, is predicted at the focus. The
focal pressure in this regime is on the order of tens of MPa.
Conclusions
Typical hemispherical sources of submegahertz frequencies (ExAblate
3000) operate in almost linear regime up to the acoustic power levels
of several kilowatts. In clinical applications, even less effect of nonlin-
earity is expected, as the effective power is much lower due to losses
in the skull and brain tissue.A126
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Objectives
Recent years have seen intensifying scientific and clinical interest in
US neuromodulation of CNS circuits, and relevant empirical data is
rapidly accumulating. To date, studies in this field, and in particular
rodent studies, employed single-element transducers. The introduc-
tion of wavefront engineering techniques based on phased ultra-
sonic arrays could open up new vistas for this field, including the
generation of multi-focal patterned stimulation.
Methods
We adapted an Insightec prostate phased array (986 phase elements
over 2.5x4 cm^2, 2.3 MHz center frequency) to interface with several
custom holders for either in vitro and in vivo work. For in vitro record-
ing we coupled the transducer to a 256-channel planar multi-
electrode array (Multichannel systems) and recording system (Ripple
Technologies). For in vivo work we designed custom couplers and
calibration procedures for operating the system over head-fixed ro-
dents, allowing high-accuracy targeting of the sub-mm focal spot
using either marker-based or MR-guidance in a 9.4 T small-animal
MRI (Bruker). For generating accurate distributed acoustic phase ho-
lograms we applied our recent mathematical framework, based on
adaptations from optical computer-generated holography.
Results
The system generates steerable foci whose dimensions are 0.6 x 0.8
x 3 mm (FWHM) in an open water bath, and 0.7 x 0.9 x 4.5 mm
through the top portion of a mouse skull, with a sub-mm targeting
accuracy. Excitation foci and holograms can be flexibly generated
and switched every 100 ms.
We observed and characterized stimulus-locked neuronal responses
in extended-duration US pulses to different neural systems. In iso-
lated mouse retinas, we observed highly structured off-responses
from retinal ganglion cell single-units. In live rats and mice we ob-
served motor responses of the animal’s limbs and distributed BOLD
responses to cortical stimulation.
Conclusions
Our early results and the system’s versatile ability to steer and pattern
acoustic fields on a sub-mm scale may open new vistas in the study of
causal US neuromodulation in relevant small animal models. These
abilities can possibly help advance multiple aspects of US neuromodu-
lation, including target optimization and dissecting the underlying
biophysical mechanisms.
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Objectives
Histotripsy is an ultrasound therapy that generates cavitation bubble
clouds to fractionate soft tissue using short duration, high-amplitude
ultrasound pulses. Previous studies have shown that histotripsy is
capable of producing lesions through the skullcap using aberration
correction. The goals of this study are to demonstrate the ability of
histotripsy to generate targeted, precise single lesions through the
skull without using aberration correction and to show that larger le-
sions of arbitrary shapes and sizes can be generated through the
skull using either mechanical or phased array steering without aber-
ration correction. We also plan to establish the treatment location
envelope, e.g. proximity to the skull surface, over which lesion gener-
ation may be accomplished using histotripsy through the skull with-
out aberration correction.
Methods
Histotripsy therapy was delivered using a 500 kHz, 256-element hemi-
spherical phased array transducer with an aperture diameter of 30 cm
and a focal distance of 15 cm fabricated in our lab. This transducer is
capable of producing estimated peak rarefactional pressures in the free
field in excess of 200 MPa with pulse durations of <2 acoustic cycles.
For the single lesion generation study, targeted single lesions were
generated in red-blood cell (RBC) tissue phantoms through three ex-
cised human skulls using histotripsy pulses delivered at a PRF of 1Hz,
with estimated peak rarefactional pressures in the focal zone through
the skull of 31-38 MPa. Lesions were examined by optical imaging dur-
ing treatment. During the treatment envelope and large lesion studies,
histotripsy pulses were delivered at a PRF of 200Hz using a combin-
ation of electrical focal steering and mechanical steering to target vol-
umes with characteristic dimensions up to 50 mm, extending up to the
skull’s interior surface, at locations near the front, back, top, side, and
base of the skull. During these experiments, the skull’s volume was
filled with RBC phantom, and lesion generation was evaluated follow-
ing treatment via MR imaging. No aberration correction was used.
Results
Histotripsy was able to generate precise, single lesions with radii
≤1 mm in the RBC phantoms without using aberration correction
through all skull samples tested. Lesion generation was consistently
observed at the geometric focus of the transducer even as the pos-
ition of the skullcap with respect to the transducer was varied. Dur-
ing large lesion studies, lesions with characteristic dimensions up to
5 cm were generated. Treatment envelope studies revealed that le-
sion generation was consistently possible at depths of 5-10 mm from
the interior skull surface at all locations targeted.
Conclusions
These results show that histotripsy may be used to generate tar-
geted, arbitrarily shaped lesions through intact human skulls without
using aberration correction. They demonstrate that both mechanical
and phased array steering strategies may be used for lesion gener-
ation, and that the treatment envelope for lesion generations ex-
tends to within as little as 5 mm from the skull’s interior surface.
Such capability has the potential to greatly simplify and expand the
target window of transcranial ultrasound therapies for non-invasive
transcranial applications.
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We aim to develop novel methodology to non-invasively deliver
neurotransmitter chemicals to spatially localized brain regions for
modulation of neuronal activity. In this approach, focused ultrasound
in conjunction with microbubble injection is used to transiently open
the Blood-Brain Barrier (BBB) in a localized region of the rat brain.
Neurotransmitter chemicals, such as GABA or glutamate, are then
systemically injected such that they leak out and have an effect on
neuronal activity only at the site of BBB disruption.
We have previously used electrophysiology measurements to demon-
strate functional blockade via BBB disruption and GABA administration.
The current study will use resting state functional MRI (rs-fMRI) to evalu-
ate the effects of GABA delivery to the rodent thalamus on resting state
networks.
Methods
5 - 10 Sprague-Dawley rats will be imaged under resting state condi-
tions using a 2x2 factorial design with conditions of BBB Open vs
BBB Closed and GABA Injected vs No GABA Injected. The case of BBB
Closed and No GABA Injected will be considered the baseline state.
The other three cases will be compared against this baseline for
changes in activation patterns.
BBB opening: Right thalamus targeted. Microbubbles injected (Optison,
200 μl/kg), 690 kHz transcranial FUS with 10 ms bursts applied at 1 Hz
for 60 seconds.
GABA delivery: Systemic tail vein injection of 20 mg/kg bolus
followed by 5 mg/kg/min infusion.
rs-fMRI: Images acquired on a Bruker 7 T scanner with a single shot
EPI sequence (TR = 1.5 s, TE = 18 ms, 18 slices, 280 images). Continu-
ous infusion of Dexmedetomidine used for anesthesia to ensure light
anesthetic state. rs-fMRI temporal correlation analysis performed as
described by Pawela et al (MRM 2008).
Results
This is a prospective study to be carried out by Jessica Cahill during
her summer internship at the Focused Ultrasound Laboratory. We
hypothesize the following: 1) that we will see robust resting state
network activation in the baseline case; 2) that the resting state net-
works seen for the cases of BBB Open and No GABA Injected, and BBB
Closed and GABA Injected will show little to no differences relative to
the baseline; 3) that the resting state networks seen for the case of BBB
Open and GABA Injected will be significantly different than the baseline
case. We will not speculate on how these differences will manifest.
Conclusions
Resting state fMRI consistently shows that BOLD signal fluctuations are
temporally correlated in brain regions that make up functional net-
works, such as the visual or sensorimotor systems. Demonstrating that
non-invasive targeted delivery of GABA via FUS-mediated BBB opening
can alter the activation patterns seen in these networks will be convin-
cing evidence that the approach can modulate brain function.
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Objectives
Clinical trials for neurological disorders are ongoing using MR guided
Focused Ultrasound (MRgFUS) on adult patients. Pediatric patients have
a thinner skull and could highly benefit from this new technique. How-
ever, the acoustic properties of their skull have not been reported ex-
tensively in the literature. Patient growth affects the structure and
shape of the skull. Designing an MRgFUS system dedicated to pediatric
patients requires a full understanding of the evolution of the skull with
the age of the patient. Acoustic characterization of ex vivo pediatric
skulls is ongoing but specimens are rare and cannot represent the en-
tire population. Creating a library of skull phantoms based on CT or
Journal of Therapeutic Ultrasound 2016, 4(Suppl 1):31 Page 80 of 113MRI scans could offset the lack of ex vivo specimens. The aim of this
study was to compare two pediatric skull phantoms to their corre-
sponding ex vivo skulls to validate the material properties and the
manufacturing process.
Methods
A neonate ex vivo skull and an 8-year old (8-y.o.) ex vivo skull were
scanned using a micro-CT scanner and a clinical CT scanner, respect-
ively. Skull phantoms were manufactured, based on these CT data-
sets, using a bone-mimicking material previously described (Wydra
and Maev, 2013), and in turn CT scanned. Variations in the compos-
ition of the material were used to mimic purely cortical bone but also
mixte cortical and trabecular bone structures. The 2 skulls and their
phantoms were acoustically characterized using a clinical MRgFUS
system (Philips Sonalleve V1) and a needle hydrophone at 1.2 MHz.
Using the 256 elements of the transducer, a mapping of the Time-
Of-Flight (ToF) delays after insertion of the skull was obtained. The
thickness of the skulls and the phantoms was estimated using the CT
datasets. The average speeds of sound (SoS) of the phantoms were
compared to the SoS of the real skulls.
Results
Visually, phantoms and ex vivo skulls were similar. The neonate phan-
tom even featured a fontanelle made of an ultrasound-transparent
material. CT dataset comparisons showed a discrepancy between the
thickness of the real skulls and the phantoms. The neonate phantom
was on average 100 % thicker than the ex vivo skull. The 8-y.o. skull
phantom was 50 % thicker than the ex vivo skull. The ToF delays ob-
tained reflected these differences with an average of -0.4 μs for the
neonate phantom vs -0.15 μs for the ex vivo skull and an average of
-1.1 μs for the 8-y.o. skull phantom vs -0.7 μs for the ex vivo skull. The
average SoS of the neonate phantom was 2250 m.s-1 vs 2080 m.s-1 for
the ex vivo skull. The average SoS of the 8-y.o. skull phantom was
2500 m.s-1 vs 2300 m.s-1 for the ex vivo skull.
Conclusions
The bone-mimicking phantoms are a good alternative to rarely avail-
able ex vivo pediatric skulls. The thickness of the phantoms will be
further adjusted in order to better mimic the real skulls. Future work
will focus on the attenuation properties of these phantoms.
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Objectives
The therapeutic potential of glial cell-line derived neurotrophic factor
(GDNF) for treating Parkinson’s disease (PD) has been limited thus far
by its inability to cross the Blood-Brain Barrier (BBB). We have previously
shown that intranasal administration of PEGylated lysine 30-mer
(CK30PEG10K) DNA nanoparticles (NPs) encoding hGDNF, developed
by Copernicus Therapeutics, Inc., can transfect brain cells in vivo, induce
transgene expression, and provide neuroprotection of substantia nigra
(SN) dopamine neurons in the rat 6-hydroxydopamine model of PD.
We have also shown using double-label immunohistochemistry that
transgene expression in the rat brain occurs primarily in cells lining the
vasculature, most likely pericytes. Although intranasal administration al-
lows large biomolecules to bypass the BBB, it is a low efficiency route
and results in widespread distribution with no means of targeting spe-
cific brain regions. Here we investigated whether focused ultrasound
(FUS) combined with circulating microbubbles can enhance intranasal
delivery of pGDNF NPs to the brain.Methods
The first goal of our current study was to assess the duration of
transgene expression after intranasal administration of DNA NPs. We
used a reporter plasmid (pUGG), which produces an eGFP-GDNF fu-
sion protein. All rats received 90 μg of pUGG NPs, a dose that we
previously showed yields significant eGFP expression throughout the
rat brain 1 week after intranasal administration. Groups of 8 rats were
sacrificed at 1 week, 3 months and 6 months after intranasal dosing.
Separate groups received intranasal saline and were sacrificed at the
same time points.
Our second goal was to evaluate whether FUS can be combined with
intranasal administration of pUGG NPs, as well as the naked plasmid,
to yield greater overall delivery, improved tissue penetration, and en-
richment of transgene expression in the desired location(s) in brain.
To date, we have conducted a pilot study in 3 rats given 180 μg of
naked pUGG DNA intranasally. FUS bursts (32 msec bursts at 4 Hz for
100 sec) at 274 kHz were applied during infusion of Optison micro-
bubbles to one brain hemisphere before intranasal delivery, and re-
peated 1 hour later at a caudal location on the same side after
intranasal delivery. The rats were sacrificed 1 week later.
Expression of eGFP was assessed throughout the brain by eGFP-ELISA.
Results
In the time course study, ELISA revealed that whole brain eGFP ex-
pression (above background in saline-treated controls) was highest
at one week, and persisted at ~30 % of maximal expression at both
the 3 and 6 month time points (p < 0.05 for 1 week versus 3 and
6 months). These results provided evidence that intranasal delivery
of Copernicus’ pDNA NPs results in significant and prolonged trans-
gene expression in rat brain, with highest levels at 1 week and con-
tinued expression over at least 6 months.
Results from the pilot study in rats which received naked plasmid in-
tranasally, in conjunction with FUS and microbubbles, indicated that
the amount of transgene expression was increased on the sonicated
versus the unsonicated side of the brain, and overall whole brain
eGFP weighted averages were significantly increased in the sonicated
rats. These results suggest that FUS with microbubbles may increase
the overall delivery of DNA NPs to the sonicated brain regions.
Conclusions
In conclusion, FUS may enable agents with poor capabilities of crossing
the BBB, e.g. neurotrophic factors, and viral and non-viral vectors en-
coding them, to become disease-altering therapies by a non-invasive
route of administration. Our ongoing studies are examining the effect
of FUS on transgene expression in the sonicated regions, and will
assess tissue penetration and cell types transfected after intranasal
administration of our DNA NPs.
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Objectives
Melanoma has a 5-year survival rate of <10 %, primarily due to thera-
peutic resistance and immune tolerance. Durable responses to ther-
apy of metastatic melanoma are enhanced when the anti-tumor
immune response is activated. FUS is an emerging non-invasive
treatment modality for localized treatment of cancers. Damaged
tumor cells have been shown to release endogenous danger signals,
which could stimulate an immune response, implying that the pa-
tient’s dying cancer cells serve as a therapeutic vaccine that stimu-
lates an anti-tumor immune response. Specifically, we hypothesize
that FUS will augment tumor antigen release and danger signals to
mediate rejection of both FUS treated and untreated tumors. We be-
lieve that this approach will increase the percentage of patients who
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immune response. However the optimum parameters to simulate
this response is mostly unknown. Therefore we conducted a prelim-
inary experiment to compare different FUS parameters with bio-
logical responses.
Methods
Studies using C57BL6 mice inoculated subcutaneously with B16 mel-
anoma cells were approved by the institutional animal care and use
committee. When tumors became palpable, mice received FUS treat-
ments (two sites per tumor) using a 1.14 MHz transducer (FUS Instru-
ments, Canada). FUS treatment was applied either in pulsed (group-1:
44 W, 10 ms pulse duration, 1 s intervals, 60s total duration at 7 MPa or
group-2: 44 W, 14 ms pulse duration, 0.5 s intervals, 120 s total duration
at 7 MPa or in continuous mode (group-3: 15 W, 10s, 4 MPa or group-4:
44 W, 3.5 s, 7 MPa). The temperature maps were generated for treated
tumors. Following FUS treatment, necrosis, and apoptosis were mea-
sured. Standard H&E staining was performed to evaluate histological
changes that may have occurred as a result of the FUS exposures. The
detection of apoptotic cells was performed using staining for Caspase-3.
Results
We observed that the temperature rise for tumors treated in continu-
ous mode (group-3) were in the range of 55-65 °C and temperature of
pulsed tumors (group-1 and 2) were approximately ~40 °C. We were
unable to measure the temperature of group-4, due to the tumor
movement as result of FUS treatment. We observed increase in both
necrosis and apoptosis with FUS treatment (group-1, 2 and 3) when
compared to untreated tumors.
Conclusions
Our data shows that FUS parameter used in the group-4 cannot be
adopted due to technical difficulties that arise due to movement of the
tumor. However our data shows that group-3 conditions give rise to in-
crease in temperature when compared groups-1 and 2. Additional
mouse studies are currently underway to confirm these results and to
characterize and compare the immune response elicited in the group-1,
2 and 3.
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Objectives
One challenge in MRgFUS ablation of bone tumors is extending the
depth of the ablation beyond the cortical surface, which rapidly at-
tenuates sound. Anecdotally, providers will lower ultrasound fre-
quency or increase sonication duration, in order to achieve better
penetration. The purpose of this study was to evaluate the effect of
longer versus shorter sonication durations on the size of the post-
ablation appearance in a swine model of MR guided Focused Ultra-
sound ablation of bone, for a given total energy.
Methods
Experimental procedures received approval from the institutional
committee on animal research. MRgFUS was used to create two abla-
tion foci (distal and proximal) in the left femoral diaphysis of 6 pigs.
The spacing of sonications was equivalent between the two foci. Both
targets were subjected to six sonications with 400 J of energy each: the
distal targets were dosed with 20 W for 20 seconds (standard time) and
the proximal targets were dosed with 10 W for 40 seconds (long
duration). The hypoenehanced ablation zone was then measured on
post-contrast MRI sequences in three dimensions.
Results
w?>MRgFUScreated focalhypoenhanced lesionsat thedistal andprox-
imal targets. Interestingly, the use of the conventional 20 second
duration sonication resulted in the largest depth of the transverseintramedullaryhypoenhancedzoneandthecraniocaudaldimensionof
theablations,whichmeasuredup toanaverageof7.3mmand26.7mm,
respectively. By comparison, the mean ablation measurements for the
40 second long duration sonication group were 4.5 mm and 21.0 mm:
these differences reached statistical significance (paired t-test, p =
0.026 and 0.006). There was no significant difference in the anteropos-
teriormeasurementsbetweenthetwogroups.
Conclusions
While different techniques can and should be used to maximize the
size of the ablation zone in MRgFUS of bone lesions, these results sug-
gest that increasing the sonication duration, while concomitantly de-
creasing the acoustic power to maintain a given total energy, is not an
effective technique and may be counterproductive. These results can
be used to achieve more complete MRgFUS ablations of bone lesions.
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Objectives
Since advances in systemic treatment have led to improved overall
survival in patients with metastatic breast cancer obtaining optimal
local control of the primary tumor has become more important. Fur-
thermore, various studies have suggested that as a consequence of
effective locoregional treatment, survival can further be improved.
Doxorubicin is an effective drug in breast cancer treatment and is in-
cluded in most chemotherapy regimens today. At present, the achiev-
able dose of doxorubicin to the primary tumor is limited by its systemic
effects.
Based on pre-clinical investigations we hypothesize that, doxorubicin
loaded thermos-sensitive liposomes (ThermoDox) in combination
with MR-HIFU induced local hyperthermia can be safely substituted
for free doxorubicin in the AC regimen for treating metastatic breast
cancer without compromising systemic toxicity and efficacy. Here,
we present the design of the i-GO study that aims to investigate the
safety and tolerability of this combination.
Methods
Patients with stage IV, HER2-negative breast cancer at diagnosis, who
have not received any breast cancer therapy, will be included. For each
cycle, six in total, patients will receive a combination of ThermoDox and
HIFU-induced hyperthermia followed by cyclophosphamide. All MR-HIFU
experiments will be performed on a dedicated breast MR-HIFU system
(Philips Healthcare, Vantaa, Finland) integrated with a clinical 1.5 T MRI
scanner (Achieva, Philips Healthcare, Best, The Netherlands) [6, 7]. Four
to six weeks after finishing the last cycle of chemotherapy the patients
will undergo surgery. From here on subjects receive standard of care
treatment for metastatic breast cancer. The primary endpoints of this
study are safety and tolerability. The secondary objectives are to assess
the pathologic response of the primary tumor and the clinical objective
response of metastases and primary tumor.
Results
We anticipate increased shrinkage of the primary tumor when free
doxorubicin is substituted by ThermoDox combined with local HIFU-
induced hyperthermia, because this approach leads to a higher drug
deposition in tumor tissue. At the same time, we expect that the
control of distant disease is maintained, because the systemic effect
of ThermoDox is similar to free doxorubicin.
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Establishing whether ThermoDox combined with local HIFU-induced
hyperthermia is safe and tolerable, is the first step towards potential
future replacement of surgery in a selected group of high-risk, primary
breast cancer patients.A134
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Objectives
Liver cancer treatments range from radical surgery to minimally-
invasive treatments like radiofrequency ablation. Severe side effects
of liver surgery limit its use to possibly curable patients, while inad-
equate precision and monitoring of image-guided minimally-invasive
methods limit their effectiveness. These methods also carry the risks
of ionizing radiation, infection, and inadvertent off-target treatment.
Shortcomings of current therapies may be addressed with MR-HIFU,
which permits exacting, non-invasive tumor ablation without ionizing
radiation. Following recent advancements in organ motion tracking
and treatment approaches to MR-HIFU treatment of highly perfused
organs, a need exists to define eligibility criteria for liver MR-HIFU.
However, patient suitability for liver MR-HIFU is currently not well de-
fined. Factors including the degree of underlying liver dysfunction,
tumor extent, and anatomic accessibility may inform MR-HIFU inclu-
sion and exclusion criteria. This study seeks to identify suitable candi-
dates for MR-HIFU and its possible combination therapies based
solely on HIFU beam access to tumor.
Methods
We assess the theoretical suitability of patients for MR-HIFU by retro-
spectively evaluating the medical and treatment-planning records of
patients with liver tumor. All patients were enrolled at the Center for
Interventional Oncology at the Clinical Center in National Institutes of
Health between January 2015 and January 2016 and have had known,
non-MR-HIFU treatments. The institutional review board approved this
retrospective chart review study and informed consent was waived. All
medical records were anonymized and de-identified. A blinded clinician
segmented computed tomography (CT) scans with thin slices using
3DSlicer. Segmented volumes were exported to MatLab where a semi-
automated algorithm evaluated whether the tumor(s) would be access-
ible by an MR-HIFU platform. Treatment feasibility was evaluated on
both a clinical tabletop HIFU system (Sonalleve V2, Philips, Vantaa,
Finland) and a freely positionable extracorporeal mock HIFU transducer.
Patients were categorized into the following treatment groups: 1) full
ablation of the tumor; 2) combination of HIFU and trans-arterial che-
moembolization (TACE); 3) full or partial sonication of tumor for im-
mune response evaluation; and 4) HIFU mediated targeted drug
delivery. The categorization of patients into these therapeutic arms was
based upon size, volume, number, and distribution of disease.
Results
Data for 250 patients with liver mass were analyzed, and suitability for
HIFU therapy evaluated. We aim to report patient and tumor character-
istics, percentage of patients eligible for MR-HIFU, and the distribution
of non-HIFU treatments the patients received. Data analysis is pending.
Conclusions
MR-HIFU may improve existing treatment algorithms by offering
patients a precise, non-invasive choice in both curative and palliative
settings. Randomized control studies are required to evaluate thetrue potential of HIFU as a therapy modality. To better inform patient
enrollment strategies, our retrospective study aims to define charac-
teristics of a suitable candidate for MR-HIFU liver therapy.
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Objectives
MR-guided Focused Ultrasound (MRgFUS) has the potential to be
used as a non-invasive breast cancer therapy. Clinical feasibility has
been demonstrated in multiple studies and hardware development
has progressed in addressing the challenges of treating the breast. It
has been demonstrated in a simulation study that phase aberration
caused by the patient-specific heterogeneous anatomy of the breast
may decrease the efficiency of MRgFUS breast treatments by causing
unwanted heating when using a small phased-array transducer (256-
element, 1-MHz, 14.4 x 9.8-cm aperture). The purpose of this work is to
develop tissue-mimicking heterogeneous breast phantoms in which
the simulated effects of phase aberration and phase aberration correc-
tion techniques can be experimentally verified.
Methods
Phantom: A heterogeneous phantom was constructed that mimics
the breast anatomy and adequately replicates the acoustic properties
of breast fibroglandular and fat tissue. The phantom consists of 250-
bloom gelatin with a 1 to 1 mixture of water and evaporated milk.
Six latex balloons (diameter = 1.5-2.0 cm) filled with canola oil were
dispersed throughout the phantom. The phantom was mounted in
our breast MRgFUS system and 3D MR images were obtained to cre-
ate a numerical model of the phantom (3D 2-point Dixon). MRgFUS
experiment: To assess the effect of phase aberrations, two MRgFUS
heating schemes were tested: a single-point sonication (23 W, 30 s)
and a 9-point raster-scanned trajectory (2-mm spacing, 32 W, 20 s/
point, no cooling). Both heating schemes were performed with occlu-
sions in the near field. To evaluate different acoustic windows, these
sonications were repeated at two different transducer locations. MR
thermometry was used for real-time monitoring (3D seg-EPI GRE).
Simulations: Using the hybrid angular spectrum method applied to
the generated numerical model, simulated pressure patterns were
obtained both with and without applying a phase correction tech-
nique. Temperature response was modeled with a finite-difference
implementation of the Pennes bioheat equation.
Results
Figures 141, 142 and 143 show the comparison of experimental and
simulated results for the single sonication case. In all cases the
temperature map is overlaid on the phantom’s magnitude image or
the numerical model, and the transducer (not shown) is located to the
left for all images. The experimental temperature response is shown in
an oblique slice in Fig. 141. The focal spot is clearly aberrated and
resulted in low temperatures (peak of 9.5 °C) at the desired focus.
Figures 142 and 143 show the simulated temperature maps for a single
sonication at the same location without and with phase aberration cor-
rection, respectively. The simulation of the focal spot after phase correc-
tion is applied shows a dramatic improvement in energy delivery. The
aberrated focal spot resulted in a much lower temperature rise (scaled
to match experimental) when compared to the focal spot with phase
correction applied (peak of 27.6 °C). Also, the peak temperature was
3 mm in front of the desired focal location for the single sonication
without phase correction and at the desired location with the correc-
tion applied. A similar trend for the peak temperatures and focal loca-
tion accuracy was seen for the 9-point trajectory.
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This work presents a heterogeneous anatomy-mimicking breast phantom
that produced aberrations both experimentally and in simulation. The
correction of these aberrations in simulation demonstrated an increased
temperature rise and more accurate focal location. Work is ongoing to
apply the phase correction technique experimentally. Additional hetero-
geneous aberrating breast phantoms are under construction to further
validate this technique.Fig. 143 (abstract A135). The simulation on the segmented
numerical model obtained from the same aberrating phantom as
shown in Fig. 141 is shown with temperature maps overlaid with
phase correction applied. The white scale bar represents 5 cm
Fig. 142 (abstract A135). The simulation on the segmented
numerical model obtained from the same aberrating phantom as
shown in Fig. 141 is shown with temperature maps overlaid for
uncorrected phases. The white scale bar represents 5 cm
Fig. 141 (abstract A122). A coronal oblique slice of the
heterogeneous aberrating breast phantom is shown with the
experimental MR temperature map (PRF-shift method) overlaid on a
T1-weighted image. The white scale bar represents 5 cmA136
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Objectives
Magnetic Resonance Imaging-guided High Intensity Focused Ultra-
sound (MR-HIFU) has recently been suggested as an alternative treat-
ment modality, for pancreatic cancer patients in cases where surgery
is not an option. MR-guidance allows to monitor temperature for
feedback control, however using proton resonance frequency shift
(PRFS) based thermometry is challenging, because of unpredictable
motion (peristaltic) and the presence of air in the digestive tract near
the head of the pancreas. This can lead to changes in the magnetic
volume susceptibility distribution resulting in artifacts in the temperature
maps. Solutions have been proposed to this end, and even if it is tempt-
ing to transfer methods from one organ to another it is not necessarily
straightforward.
In this study, we propose an approach aimed at reducing susceptibil-
ity heterogeneity by filling the stomach and duodenum with fluid,
and evaluate its effect on PRFS based temperature mapping using
different known methods for respiratory compensation.
Methods
Experiments were performed on a 1.5-T MRI scanner (Achieva, Philips
Healthcare, The Netherlands) equipped with a clinical MR-HIFU sys-
tem. Experiments were executed twice on healthy volunteers (n = 7),
first, without any special preparation. Then during a different exam,
volunteers were asked to ingest 2 ´ 500 mL of fluid with favorable
relaxation times (pineapple juice) to fill the tract, 5 hours and 2 to 5 mi-
nutes prior to scan, respectively. A breathhold 3D fat suppressed T1-
weighted scan was acquired for planning. For temperature mapping, a
dynamic gradient echo series consisting of 3 coronal slices covering
the pancreas was acquired. Scan parameters: TR = 100 ms, TE = 19 ms,
Fig. 145 (abstract A136). Percentage of coverage of the pancreas
at +/-2 °C precision for our different respiratory compensated and
filling methods. Preparation without liquid (white bars) is compared
to preparation with juice (grey bars). Respectively borders of each
bar graph represent different respiratory compensation strategies, in
red gating, green multibaseline and blue referenceless
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400 ms, 500 dynamics.
Statistical analysis: Datasets were analyzed offline using three tech-
niques, viz. gating2, multibaseline4, and referenceless6. The temperature
standard deviation (TSD) over time was calculated voxel-by-voxel. As ref-
erence the whole pancreas was semi automatically segmented on the
T1 image and used as ROI for statistical analysis. For each technique the
volume of pancreas under the threshold value of 2 °C precision was
compared to the total pancreas volume in our images leading to a per-
centage of coverage at 2 °C.
Results
Figure 144 shows an example of the juice filling effect in one of the
volunteer. Without juice the TSD varied from 2 to 10 °C, within our
three methods. After juice intake, the TSD range went down to
values between 1 to 2 °C and the spatial distribution became clearly
more homogeneous.
In Figure 145, preparation without liquid is compared to preparation
with juice, for every technique the coverage of the pancreas with a
precision under 2 °C is increased by 25 % in average. It allows to
reach values, up to 80 % with multibaseline and gating.
Conclusions
In all volunteers, oral ingestion of pineapple juice for patient prepar-
ation reduced the range of values in the TSD leading to an increase of
the precision coverage in the pancreas. Filling the digestive tract in this
way could be an attractive solution for more precise temperature moni-
toring during MR-HIFU therapy in the pancreas.Fig. 144 (abstract A136). Standard Deviation maps computed with
our different respiratory compensated methods, overlayed on
anatomical image of the same volunteer (contour of the pancreas is
outlined in white, the head and a part of the body is always shown).
Volunteers were imaged without or after intake of 2 times 500 mL
of pineapple juiceA137
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Objectives
Tissue mechanical properties are altered both in disease states and
following ablative, or other, therapy. Changes in mechanical tissue
properties are manifested in changes to the speed of a shear wave
propagating through the tissue. Transient shear waves can be in-
duced in tissue via application of short bursts of focused ultrasound
(US). Imaging the propagating shear wave with MR confers the bene-
fits of that modality’s excellent soft tissue contrast, 3D visualization,
and the ability to assess tissue immediately following US ablation.
Here, we quantify tissue elasticity using constructive multi-pulse
transmission under MR and US guidance and validate with mechan-
ical testing.
Methods
MR measurement of transient shear wave (SW) propagation was per-
formed using a 7 T MRI (Bruker Biospin, Germany) and a 3 MHz 16-
element annular array (IMASONIC SAS, France, 48 mm diameter,
35 mm radius of curvature, 0.5 × 0.5 × 2 mm3 focal volume at -6 dB),
controlled by an embedded MR-compatible 2D positioning and US
system (Image-Guided Therapy, France). Three foci (3 MHz, 450 ms
pulses with 4.5 mm spacing between transmit foci, 12.5 MPa PNP)
were sequentially excited along the beam axis creating a planar SW
which was imaged with MRI (Fig. 146a, TR/TE/FA = 500 ms/26.1 ms/
180°). A series of images was acquired with different propagation
times, varying from 0.45 ms to 4.05 ms and the shear modulus was
estimated using the time-of-flight (TOF) method. The US-based SW
measurement was performed with a Vantage 256 (Verasonics, WA,
USA) and a Phillips L7-4 probe. To generate the SW, 4.3 MHz, 10 MPa
PNP, 100 μs pulses were transmitted with 5 mm spacing between
transmit foci. US images were obtained with a 5.2 MHz center fre-
quency and 10 kHz PRF and the local inversion method (LIM) was
used to estimate the shear modulus. Phantom cylinders (9.7 mm in
diameter and 8.5 mm
Results
The propagating SW was visualized with both MRI (Fig. 146a) and US
(Fig. 146b) and quantitative elasticity maps (Fig. 146c) were gener-
ated. Using multi-pulse transmission, the shear modulus in a 1.5 %
agar and 1.5 % gelatin phantom was estimated as 27.3 ± 2.3 kPa with
MR and 28.2 ± 2.3 kPa with US, which agreed with 32.3 ± 1.8 kPa
yielded by compressive testing (Fif. 1D).
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In conclusion, the shear modulus in tissue-mimicking phantoms was
accurately estimated using the combination of an MR shear imaging
sequence and multi-pulse transmission.Fig. 146 (abstract A137). Elasticity maps from a MR and b
ultrasound. c Strain-stress results based on mechanical testing. e The
estimated shear moduli were 28.2 ± 2.3, 27.3 ± 2.3 and 32.3 ± 1.8 kPa in
US, MR and mechanical testing, respectivelyA138
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Objectives
Our ultimate goal to initiate the present study is to develop a novel
approach for treating prostate cancer with improved efficiency while
reducing normal tissue toxicities. In this treatment approach, the drug
is delivered into the tumor via encapsulation inside an ultrasound-
sensitive, drug delivery system (nanodroplets). Once the system
reaches tumor, MR-guided pulsed High Intensity Focused Ultrasound
(MRg-pHIFU) is applied to the tumor to help activate the release of the
drug from nanodroplets inside the tumor, thus increasing the bioavail-
ability of the drug.
The purpose of the present work is to study the biodistribution of
paclitaxel-loaded nanodroplets in vivo in nude mice. We consider our
present study to be of high impact because it tries to answer specif-
ically for the first time an important question of appropriate timing
to apply tumor-targeted focused-ultrasound for activating release of
drug from these drug carriers for effective prostate cancer treatment.
Methods
Poly {ethylene oxide}-co-poly {D, L-lactide} (PDLA) nanodroplets
loaded with fluorescently labeled-paclitaxel (F-PTX) were synthesized
using solid dispersion technique. Human prostate cancer, LNCaP cells
were implanted orthotopically in prostates of male nude mice.
Tumor-bearing mice (n = 3) were injected with 0.1 % F-PTX, 2 %
PDLA nanodroplets using tail vein. At chosen time points (30 min;
2 h; 4 h; 6 h; 12 h; 24 h) animals were anesthetized, blood was col-
lected by eye bleed, animals were sacrificed, tumor and vital organs
(liver, spleen, kidney lung and heart) were excised, cut and weighed.
Then the organ was homogenized, incubated in lysis buffer and centri-
fuged. The lysates were read using fluorescence spectrophotometer
(Excitation- 496 nm, Emission– 524 nm). Fluorescence readings
were compared with values from the standard calibration curve.
Tumor-bearing mice (n = 3) were also injected with 0.1 % F-PTX so-
lution (fluorescent drug in free form).Results
Quantitative analysis showed 20 % of the injected drug-loaded nano-
droplets in the tumor, 30 min after systemic injection; which in-
creased to 30 % after 2 h; 35 % after 4 h; then decreased to 27 %
after 6 h; 11 % after 12 h and 5 % after 24 h. When drug in free form
was injected, drug accumulation in the tumor was 7 % within 30mnt;
8 % within 2 h; 10 % within 4 h; 9 % within 6 h, 3 % within 12 h and
2 % within 24 h. Liver showed major drug accumulation for drug-
loaded nanodroplets while heart and lung showed less. For drug in
free form, liver and spleen showed maximum drug concentrations
while heart showed concentrations similar to that in tumor.
Conclusions
Treating prostate cancer with MRg-pHIFU mediated drug-delivery
using ultrasound-responsive, drug-delivery vehicle (nanodroplets) is
innovative and aims at minimizing toxic effects to healthy tissues, as
caused by chemotherapeutics drugs and maximizing better treat-
ment efficacy. Present bio-distribution indicates that the optimum
time for applying focused ultrasound is after 4 h of systemically
injecting drug-loaded nanodroplets. Using this optimum time point,
In vivo experiments in nude mice are being carried out to test the ef-
ficacy of combined MRg-pHIFU exposures and chemotherapeutic
agents encapsulated nanodroplets for prostate cancer therapy.
A139
From research to clinics: an example of clinical translation of MR
guided FUS treatment of the liver
Sabrina Haase1, Stephan Zidowitz1, Andreas Melzer2, Tobias Preusser1,3
1Fraunhofer MEVIS, Bremen, Germany; 2University of Dundee, Dundee,
UK; 3Jacobs University Bremen, Bremen, Germany
Journal of Therapeutic Ultrasound 2016, 4(Suppl 1):A139
Objectives
There are many groups around the world working on MR guided
FUS research topics to enhance the treatment for patients and to ad-
vance the technologies. The main goals of the research is to provide
faster and more accurate algorithms and tools while ensuring the
clinical safety, efficiency and effectiveness. In the European funded
TRANS-FUSIMO project (www.trans-fusimo.eu), the consortium is cur-
rently developing a quality assured treatment system for MR guided
Focused Ultrasound in moving abdominal organs which will be vali-
dated and pre-clinically tested. The target of the project is to enable
a clinical study using the developed technologies. Here we will dis-
cuss the quality assurance that is needed for translation of a research
tool towards a clinical study.
Methods
If newly developed features or technologies from research shall be
translated to clinical use, there are many obstacles on the way. In
particular if the research system shall be used in a clinical study it
has to comply with high quality standards. It is also possible to per-
form clinical studies without a CE mark but the medical device must
have a quality status that is CE mark ready. The most important norm
is 93/42/EEC which is the European medical devices directive. This
directive also asks for an underlying quality management system
which can be EN ISO 13485. This means that the parties, which are
responsible for this medical device have to be qualified according to
EN ISO 13485. If a software tool is the critical part of the clinical de-
vice, its development and implementation has to conform to IEC
62304, which is the international standard for medical device soft-
ware. Furthermore, a risk management for the medical device ac-
cording to ISO 14971 has to be performed. Only if development and
validation are conducted according to these standards authorities
can approve a clinical investigation of the medical device.
Results
In the work presented here, we are translating software, which is
able to communicate with an MR device as well as an HIFU device.
Both MR device and HIFU system have CE marks or are at least CE
mark ready for their intended use, the new research communication
software not, still it shall be used in a clinical trial. The software shall
have the ability to follow the breathing motion of the patient and
steer a focal spot in the liver accordingly. Since this software without
CE mark shall be used in a clinical study we must follow the above
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components is developed according to the EN ISO 13485 norm and
also the preclinical in vitro and ex vivo validation is performed ac-
cording to this quality management system. Furthermore, since the
software acts as the control system of the HIFU device it is a critical
part of the system and thus the development and implementation
has to conform to IEC 62304. Finally, a risk management for the med-
ical device according to ISO 14971 was created.
Conclusions
If a clinical investigation is anticipated, CE mark status is necessary. The
example presented in this work shows how to use a non CE marked
software tool in conjunction with existing qualified hardware. Also a
preclinical validation is mandatory in order to ensure the safety, effi-
ciency and effectiveness for the patients during the treatment.
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Objectives
Bone metastasis represents one of the major causes resulting in cancer
pain. Traditionally, conventional radiotherapy serves as the standard
treatment for painful bone metastasis. Recently, magnetic resonance-
guided focused ultrasound (MRgFUS) has been demonstrated as an al-
ternative therapy for pain palliation of bone metastasis. Therefore, this
phase IV study was conducted to evaluate the long-term safety and ef-
ficacy of MRgFUS treatment for patients with painful bone metastasis.
Methods
Current ongoing single-institute phase IV study has enrolled 20 pa-
tients at Taipei Cancer Center, Taipei Medical University in Taiwan
since Nov 15th, 2014. The MRgFUS is delivered by ExAblate 2000 sys-
tem (InSightec Ltd., Israel) which integrates a high-intensity focused
ultrasound compartment for hyperthermia treatment with a magnetic
resonance imaging scanner for real-time position and temperature
monitoring. The treatment response is evaluated by the interval change
of numerical rating scale (NRS) before and after treatment. Pain relief is
defined as a reduction of 2 points or more on NRS pain scoring system
without increasing analgesics use. Patient’s quality of life is assessed by
the Brief Pain Inventory (BPI-QoL) score. The adverse event is also
documented.
Results
The median age of the 20 treated patients (12 male and 8 female)
was 62 years old (range, 40–83). Each patient underwent MRgFUS
treatment for single painful bone metastasis. Sixteen targeted lesions
were located in the pelvic bone, whereas 3 at rib cage and 1 at scapula.
At a median follow-up duration of six months, none of the patients ex-
perienced treatment related adverse events above grade 2 according
to Common Terminology Criteria for Adverse Events version 4.0. Signifi-
cant improvement of NRS pain score and BPI-QoL score is observed
after treatment.
Conclusions
The initial results of current study demonstrate the safety and effi-
cacy of MRgFUS in treating painful bone metastasis. MRgFUS has the
potential to serve as a first-line treatment in selective patients with
painful bone metastasis.
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Utilizing magnetic Resonance-guided Focused Ultrasound Surgery
(MRgFUS) to treat metastatic bone tumor is an advance therapy for
palliative pain control. MRgFUS system performs High Intensity Fo-
cused Ultrasound (HIFU) with real-time MRI monitoring and results in
local high temperature hyperthermia. In this study, we applied qual-
ity assurance concepts to endorse accuracy of thermal dose and pos-
ition stability. Furthermore, this research tried to share experience of
calibration protocol, and to provide permissible criteria according to
cases treated so far. Moreover, the goal is to establish standard oper-
ating procedure of examining accuracy of focal spots, in order to
provide patients a more qualified treatment.
Methods
In this research, we measured focusing error distances between focal
spots and real heating spots from 31 cases in Taipei Medical Univer-
sity Hospital to identify the effectiveness of Daily Quality Assurance
(DQA) for preventing focusing error in MRgFUS. MRgFUS applies
Magnetic Resonance Imaging (MRI) to locate metastatic bone tumors,
uses heating technique of focused ultrasound to convey ultrasound
energy to painful bone area. The energy would heat the area up to
60 degrees Celsius and ablate nerve fibers on the surface of bone to
achieve the purpose of palliative pain control. Advantages of this
treatment include non-invasive, non-irradiative, and long-term pain
relief in single treatment.
Results
Comparing the differences before and after quality assurance, focusing
errors in DQA group were observed consistent diminutions, which
reached statistical significance (p-value < 0.01). Nevertheless, DQA pro-
cedures also benefited heating accuracy in practice. The 95 % confident
interval of accuracy were reported from 1.73 ± 0.43 mm (Pre-DQA
groups) to 0.43 ± 0.12 mm (DQA groups).
Conclusions
In summary, a comprehensive DQA standard guarantees treatment
accuracy and patient safety. As a suitable calibration procedure, DQA
was evaluated its advantages to reduce focusing errors and unex-
pected heating spots. Therefore, DQA procedures were highly recom-
mended to adjust each distance between focal spot and real heating
spot within 1 mm before treatment.
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Objectives
High intensity focused ultrasound (HIFU) has been reported for its non-
invasive heating capability in tumour treatment. As an advance applica-
tion, magnetic Resonance guided focused ultrasound (MRgFUS) system
performs High Intensity Focused Ultrasound (HIFU) with real-time MRI
monitoring and results in local high temperature hyperthermia. How-
ever, despite correct delivery of thermal dose to treatment area within
a short period, to protect nearby critical organs real time temperature
should also be monitored. Since local temperature over 56 °C heat
shock may lead to thermal tissue necrosis. In this study, gold based
micro particles were designed as an enhanced for ultrasound energy
absorption in tumor lesions. Through our thermal dose simulation, we
found that intra-artery micro enhancer is able to improve thermal dose
response during routine HIFU treatment. Furthermore, we tried to share
experience of thermal necrosis, and provided a feasible strategy to es-
tablish novel treatment.
Methods
ExAblate 2000 system (Insightec, Israel) installed in Taipei Medical
University and was used to treat bone metastasis for severe pain pa-
tients. This system contented a 1.5 T GE magnetic resonance system
and a phase array transducer with 208 independent HIFU sonication
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(Thermoway co., Taiwan) to detect true temperature and compared
with PRF temperature. Based on this HIFU system, SAS human oral
cancer cell xenograft in nude mouse (National Laboratory Animal
Center, NLAC, Taiwan) served as the animal model in this experi-
ment. 6 weeks old nude mice were injected SAS cancer cells in both
hind legs and formed about 1 cm tumor. Micro particles conjugated
polyethylene glycol (PEG) were inject via intraportal injection and
conducted higher affinity with tumor. The ablation target was lo-
cated in the center of pathology tumor volume (PTV) and sonicated
by 300 J energy. Statistical analysis distinguished significant differ-
ences for various dose of particles and PRF temperature. Moreover,
multiple regression and Matlab models validated correlation of dose
bias.
Results
It is observed that micro particles promote both MR image resolution
and focused ultrasound absorption in target soft tissue. As was
shown by man MR signal, that photon intensity (PD) calculated
within pathology tumor volume (PTV) in particle injected group (PD
= 71.2) was higher than that of sham group (PD = 47.7) and blank
group (PD = 67.8).
After HIFU sonication, via implementation of PRF algorithm,
temperature distribution at target treatment area was observed to in-
crease form 58.1 ± 3.6 °C (control group) to 63.5 ± 6.3 °C (particle
injected group), with statistical significance from Wilcoxon rank-sum
test (p = 0.03) between control group and particle group. In addition,
from imagine evaluation, post sonicated tissue also shown a dark
area in the center of tumor which indicates thermal necrosis of abla-
tion, implying thermal damages that block blood circulation in tumor
vessel.
Conclusions
In summary, a comprehensive simulation has demonstrated that en-
hanced tumor necrosis in local lesions generated benefit effects for
deep tumor controlling. Nevertheless, we also discovered that micro
enhancer is able to improve thermal energy absorption during rou-
tine HIFU treatment. This finding indicated that enhanced thermal
dose distribution within solid tumor is feasible for first line tumor
treatment.Fig. 147 (abstract A143). Average T1 values from the heated tumor
ROI and a background (control) ROI in a homogenous medium
surrounding the tumor (either agar gel or pork loin) pre- and post-
ablation (n = 16)A143
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Objectives
A current interest in the field of clinical MR-guided HIFU tumor
treatments is the ability to acutely assess the extent of tumor ne-
crosis. Previous studies have investigated MR-derived multi-
parametrics such as the apparent diffusion coefficient and contrast-
enhanced T1 and T2 maps as indicators of cell death within mi-
nutes of ablation. In the field of radio-frequency ablation, investiga-
tors have used the non-contrast T1 mapping technique, modified
look-locker inversion recovery (MOLLI) to predict areas of complete
thermal ablation in cardiac tissue. The following study investigates
the use of this quantitative T1 imaging technique as a single-
parametric predictor of thermal dose achieved in human breast
cancer tumors injected in mice.
Methods
T1 maps were acquired using the MOLLI method pre- and post- partial
thermal HIFU ablation of human breast cancer tumors grown in NOD-
SCID mice. Cell suspensions (1 x 106 cells) of one of two human-derived
triple negative breast cancer cell lines, HCI002 and, were surgicallyinjected into the mammary fat pads of 16 female NOD-SCID mice (n = 8/
cell line), and grown to an average volume of 1609 mm2 or 558 mm2
(HCI002, HCI019, respectively). After localization, a single slice pre-
ablation T1 map was acquired (MOLLI). For HIFU treatment, four to nine
ablation points (8.3-14.9 W, 30 s) were applied to the center region
of each tumor with a small animal MR-compatible HIFU system
(Image Guided Therapy, f = 3.0 MHz, FWHM = 1x3 mm), while
temperature rise was measured with MR temperature imaging (seg-
mented EPI GRE). Finally a post-ablation T1 map was acquired post-
ablation at 20 or 120 s post-ablation (HCI002, HCI019, respectively).
Thermal dose of the total treatment was calculated using the
CEM@43 °C metric from the MR temperature data, assuming a
tumor baseline temperature of 30 °C. ROIs for T1 maps were se-
lected via manual registration with temperature imaging DICOMs
(Osirix).
Results
As shown by Fig. 147, there is a consistent trend of increased T1
values in the heated region of the tumors post-ablation. In contrast,
the background (control) signal remained relatively constant. Add-
itionally, a small ROI in a region of each tumor not directly heated
with HIFU was selected for comparison to the heated regions
(Fig. 148). Calculating the percent change in T1 values resulted in P-
values of 0.0709 and 0.0136 between the heated and non-heated
tumor and control ROIs, respectively. The less significant difference
between the heated and non-heated ROIs may be due to the large
variance in local tumor changes for both groups, as well as a limited
ability to select non-heated regions distant (>3 mm) from the heated
regions, since the diffusion of HIFU heating likely contributed to local
T1 changes. Finally, the correlation between thermal dose and T1
change is shown (Fig. 149). While there is a correlation between ther-
mal dose and T1 value for the HCI019 cohort, which accumulated
higher thermal dose levels and also at a later time post-ablation, the
HCI002 cohort, which accumulated a lower thermal dose, shows no
correlation.
Conclusions
Preliminary results of this breast cancer xenograft study shows that
localized changes in quantitative T1 maps can be observed as a re-
sult of HIFU ablation within two minutes of treatment completion.
Additionally, T1 values were not shown to significantly decrease with
increased cooling time, indicating presence of a T1 effect independ-
ent of temperature change (data not shown). Finally, the observed
T1 change may be correlated with achieved thermal dose, particu-
larly if time after treatment is increased to two minutes or at high
thermal doses. Histology for directly determining cell viability in
these tumors is ongoing.
Fig. 150 (abstract A144). Combine thermal and immune effect to
enhance effect of HIFU
Fig. 149 (abstract A143). Percent change in average T1 values
plotted as a function of maximum thermal dose reached in each
animal. R-squared values refer to the linear regression applied to a
logarithmic scale of thermal dose (x-axis)
Fig. 148 (abstract A143). Average percent change in T1 value
between pre- and post-ablation in the heated tumor ROI, the non-
heated tumor ROI, and the background control ROI, with error bars
representing the standard error (N = 16)
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Objectives
HIFU is a method which cures local tumor by thermal effect of ultra-
sound. But Cancer is systemic disease. Even the local cancer is re-
moved, the rest of the cancer cells will still be transferred to other
parts, resulting in the lesion of other parts. How to further improve
the treatment effect is still a problem.
This paper discusses how to improve immunity by HIFU, to further kill
the metastasis of cancer cells by immune system, and improve the ef-
fect of HIFU. Immune system can kill some of the cancer cells. It can
prolong the patients’ life and improve the quality of life (Fig. 150.).HIFU immune function has been mentioned for many years, but
there is no specific program. This paper put forward a method to ac-
tivate the immune function of the human body, and kill tumor cells
by immune function. The specific method is that controls the
temperature 46 °C for half an hour at the tumor edge.
Methods
The method of this paper is based on the production of magnetic res-
onance imaging guided HIFU. The MRI guided HIFU device use MRI as
positioning system and HIFU to treat cancer. This is a new generation
of HIFU device, MRI image is much clearer than the ultrasound scanner
as the positioning system. At the same time, because the MRI can
measure temperature. So the device can measure temperature by MRI
and generate heat by HIFU, in order to achieve the treatment method
of this program.
The HIFU is focused on the center of the tumor. When temperature
is near 46 °C, the dose is reduced to maintain the temperature. This
paper uses improved PID arithmetic to control temperature and dis-
cusses a lot of experiments in vitro, to verify the specific method.
Results
The device has achieved the HIFU immunotherapy of control the
temperature of tumor edge which is in line with the intended purpose
of the design. For irregular margin tumor, the error of the temperature
will be increased. For the position of the vessel, the error of temperature
will be further increased.
Conclusions
The immunotherapy can increase the effect of HIFU. So we should
research this method further. Next step is to do clinical trials to verify
the efficacy and safety of HIFU immunotherapy.A145
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Objectives
Trans-fusimo Treatment System (TTS) (Fraunhofer MEVIS) aims at apply-
ing Magnetic Resonance guided Focused Ultra Sound (MRgFUS) ther-
apy to ablate liver tumours under respiratory motion through the rib
cage. Sonicating of a moving target is a very challenging task. TTS con-
trols the Conformal Bone System (CBS) transducer of ( ExAblate 2100,
Insightec, Ltd, Tirat Carmel, Israel) for ablation of human tissue while
monitoring using the 1.5 T GE MR Scanner. TTS is classified as high risk
software as it controls high energy levels emitted by the CBS transducer
Fig. 152 (abstract A145). Schematic view of experimental set up
for sonication duration
Fig. 153 (abstract A145). Measurement of sonication deviation
actual versus planned (20 mm distance planned)
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clinical validation of the software is mandatory. Preclinical valid-
ation is divided into two parts; first static case and as next step
based on the working evidence of the first part, moving case sce-
narios. Specs were set with tolerance levels for delivered acoustic
power, sonication duration, thermometry and sonicating to a
planned position
Methods
To validate TTS , novel protocols were designed and feasibility
studies were completed for each spec. Acoustic power measure-
ments were completed using the radiation force balance; follow-
ing the standard IEC 61161(Fig. 151). Results were cross validated
against the measured acoustic power delivery of ExAblate 2100
(Insightec, Ltd, Tirat Carmel, Israel). Sonication duration measure-
ments were completed using the hydrophone for measuring the
duration of actual sonication deviation from the planned, and the
delay after the emergency stop (Fig. 152). Thermometry measured
by TTS was validated against measurements of ExAblate 2100.
Sonication positioning experiments were completed using of poly-
acrylamide (PAA) egg white phantom by measuring the position
of the scar after grid surface sonication’s. Measurements were
completed both using external calliper (Fig. 153) and grey scale
DICOM images. Each of these described protocols were repeated
by two independent operators for 30 times for repeatability pur-
poses. The Quality Management System ISO13485 has been ap-
plied to provide the required documentation for the approval for
labelling the new system
Results
For safe usage of the system, delivery of acoustic power should be
within the tolerance level of efficiency (70 %-90 %). TTS can deliver
the acoustic power reliably in a controlled way within this specs
(75 % and 80 %) as well as ExAblate 2100 (75 % and 83 %). Actual
sonication deviation from the planned sonication duration was
maximum -0.17 (Std 0.33) seconds meeting the spec being less
than 1 seconds. Maximum sonication stop delay was 0.14 ms (0.16).
Measured temperature values by TTS were relatively lower than
ExAblate but still efficient enough to provide a scar for coagulation
process to measure the deviation. Grey scale images were able to
provide better resolution for distance measurement when com-
pared to external calliper, maximum deviation being less than
1 mm. Results show that for static validations TTS successfully
meets the criteria for the defined specs
Conclusions
Due to regulatory requirements, it is mandatory to provide pre-
clinical validation before any tests on animals take place. Designed
protocols were able to provide traceability of the input and the out-
put in a controllable way. Repeatability studies provide statistical evi-
dence for the reliability of the static application of TTS software in
pre-clinical settings. Based on these results, motion validation proto-
cols are planned as a next step.Fig. 151 (abstract A145). Experimental set up for acoustic power
measurements by using weight scale holder assembly for the
application of power measurement protocolA146
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Objectives
The novel Trans-fusimo Treatment System (TTS) (Fraunhofer MEVIS) is
designed for the purpose of applying Magnetic Resonance guided
Focused Ultrasound (MRgFUS) therapy to ablate liver tumours
trhough the rib cage. Application of sonication under breathing mo-
tion to a moving target is a very challenging task. TTS is classified as
a high-risk software as it controls the Conformal Bone System (CBS)
transducer (Exablate 2100, Insightec, Ltd, Tirat Carmel, Israel) for abla-
tion of human tissue as well as the MRI tracking and temperature
mapping. For this reason, it requires preclinical validation. The first
step in pre-clinical validation of TTS required static validation. Static
validation was completed by cross-validating against ExAblate 2100
Fig. 155 (abstract A146). Land marks detected by Transfusimo
Treatment Software for tracking for the application of treatment by
using the improved planning scan set up under EPI imaging
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the set of specifications for delivering acoustic power, sonication dur-
ation, thermometry and sonicating to a planned location by using
the designed protocols for validation in pre-clinical settings. The next
step after
Methods
A novel phantom, providing both temperature information and
detecting sufficient amount of landmarks for tracking algorithm
was developed. For measuring thermometry and observing coagu-
lation procedure, the middle part of the phantom consisted of
polyacrylamide (PAA) egg white material surrounded by 2 % agar
and samphire to replicate the vein structure of liver. Echo Planar
Imaging (EPI) was used during sonication to provide real time
thermometry information using 1.5 T GE Scanner. To replicate
breathing motion, phantom was moved within 20 -30 mm range
by using the INNOMOTION Robotic arm (IBSMM, Prague). A special
phantom holder was designed to provide the linear motion with
the robotic arm while sonicating using the transducer of CBS. The
experiment setup is as shown in Fig. 154. With this designed phan-
tom holder, dual flex MR coils were positioned at a closer distance
to each other for better image quality. Sonication was planned for
100 W and 30 seconds to observe the sonication scar. The Quality
Management System ISO13485 has been applied to provide the
required documentation for the approval for labelling the new
system
Results
Initial results show that samphire can replicate the vein structure for
tracking algorithm in EPI scanning, without using any contrast
agents. TTS can detect the vein structure as landmarks (Fig. 155) and
sonicate to a planned location, by leaving a permanent scar to ob-
serve coagulation. The distance of coils to each other play important
role in pre-clinical validation, due to noise problem caused by air in
between the coils, which is not supposed be a problem in clinical
settings. Designed phantom holder to place coils at a near location
(16 cm in between distance) led into the successful application of
tracking algorithm for sonication to a planned location. TTS can
monitor the prescribed range of motion provided by the robotic arm
during sonication, replicating the breathing motion for abdominal
organs
Conclusions
Pre-clinical validation is the mandatory step in qualifying a software
controller TTS of MRI and the FUS system a class 3 device. Initial re-
sults show that TTS can function to track land marks and provide
thermometry information in real-time in pre-clinical settings. As a
next step, repeatability experiments are planned in more detail to
provide statistical evidence and prepare the first in human trial.Fig. 154 (abstract A146). Experiment set up showing the phantom,
phantom holder, dual flex MR coils and the INNOMOTION Robotic
arm (IBSMM, Prague) to provide 1 Dimentional range of motionA147
Effect of transducer ground plane configuration on Magnetic
Resonance radio-frequency coils and corresponding significance
on image SNR during MRgFUS treatments
Emilee Minalga, Allison Payne, Robb Merrill, Dennis Parker, Rock Hadley
University of Utah, Salt Lake City, Utah, USA
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Objectives
In MRI, the highest signal-to-noise ratio (SNR) is achieved by placing
the radio-frequency (RF) coils as close to the region of interest as
possible. In MRgFUS treatments, the transducer is often within the
volume that would contain the ideal RF coil placement. In addition, if
the transducer has a single, continuous ground plane, eddy currents
can reduce the SNR in the region of interest. This study compliments
the previous work that has been done to reduce gradient induced
eddy currents. Using a similar approach this work investigates effects
of ground plane eddy currents on RF coils by quantifying the result-
ing reduction of SNR. Finally, design strategies are outlined that are
required to reinstate the diminished SNR.
Fig. 157 (abstract A147). Coronal SNR plots of a homogenous
phantom under different transducer ground plane configurations.
No transducer present (Left) and a Solid transducer 1x1 ground
plane configuration (Right)
Fig. 158 (abstract A147). Coronal SNR plots of a homogenous
phantom with a 3x3 transducer ground plane configuration (Left)
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A rectangular radio-frequency coil (20 cm x 13 cm) was built on a
homogeneous cylindrical phantom (12 cm x 11 cm). The transducer
ground plane was simulated by placing copper tape on the face of a
3-D printed plastic transducer (aperture: 13 x 10 cm, 10 cm radius of
curvature). The ground plane was then broken into multiple copper
patch elements by removing different numbers of thin copper strips
(1 mm) in the short and long axis directions (Table 6 and Fig. 156).
For each ground plane configuration, the RF coil loop was tuned and
matched with the ground plane in position at 123 MHz with an inser-
tion loss better than -35 dB. Active and preamp detuning were better
than -35 dB and -20 dB, respectively. Using a Siemens 3 T MRI scan-
ner (PrismaFit), SNR measurements were made using standard gradi-
ent echo sequences (TR/TE/FA/FOV = 500 ms/10 ms/90°/256 mm, 256
x 256 mm matrix). The homogenous cylindrical phantom was imaged
with the single loop using each of the variations of the ground plane.
SNR was calculated in the center of the phantom as well as near the
transducer face using a sum of squares calculation.
Results
SNR results of various ground plane conditions are shown in Figs. 157
and 158. Quantitative SNR values measured in the center of the
phantom and at the transducer’s face are plotted in Fig. 159. SNR
was reduced by 57 % at the transducer face when comparing the
single element ground plane case to the no ground plane case. By
segmenting the ground plane, the SNR was nearly recovered (95 %)
while still maintaining a ground plane.
Conclusions
In general, increasing the segments in the ground plane increased
the normalized SNR both at the center of the phantom and at the
transducer face, as seen in Fig. 159. By incorporating this design
principle into transducer ground plane design, eddy current effects
could be reduced allowing for increase image SNR that would posi-
tively enhance both temperature and anatomic imaging during
MRgFUS treatments.Fig. 156 (abstract A147). Left image showing imaging setup with
mock transducer (white) radio-frequency coils (copper) phantom
holder (gray) on the right is a mock transducer with 1x3 ground
plane configuration
and 1x2 transducer ground plane configuration (Right)
Fig. 159 (abstract A147) Plot of number of ground plane segments
versus the normalized SNR in the phantom (center Xs and
Transducer face Os)
Table 6 (abstract A147) Description of ground plane conditions
Ground plane element configuration
No ground plane 4x1 1x4 3x3 3x2 2x3 3x1 1x3 2x2 2x1 1x2 1x1
Total number of ground plane segments
No segments 4 4 9 6 6 3 3 4 2 2 1
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Improving intercostal HIFU through a novel transducer design: a
numerical evaluation
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Objectives
Not released for publication
Methods
Not released for publication
Results
Not released for publication
Conclusions
Not released for publication
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Objectives
Nonalcoholic Fatty Liver Disease (NAFLD) is a chronic liver disease
which is manifested by steatosis, steatohepatitis, cirrhosis, and hepato-
cellular carcinoma. Patients with Nonalcoholic Steatohepatitis (NASH),
which is a subset of NAFLD, have high risks of progressive liver disease
and in need of effective treatment.
Methods
High-intensity Focused Ultrasound also known as HIFU can be deliv-
ered with precision resulting in necrosis of hepatocellular carcinoma
(HCC) without a dysfunction liver. HIFU has some important advantages
such as non-invasion and non-ionization. The heating effect produced
by a focused ultrasound transducer should be checked by using a posi-
tioning system. Sonoelastography is a way to quantify fibrosis and it
might be useful for predicting liver histology. To obtain more efficient
results HIFU Simulation has been used in MATLAB software. In addition,
in vitro cases has been examined.
Results
The results of this simulation indicated that with thermal analysis,
according to tissue accoustic parameters in different frequencies, the
desired temperature can be achieved for the destruction of cancer
tissues and also the destruction of tumors.
Conclusions
The aim of this research was to evaluate the safety and efficacy of
High-Intensity Focused Ultrasound therapeutic ablation of HCC as pri-
mary tumors in liver lesion that is in difficult location s such as main
blood vessels, the heart, the gallbladder and bile ducts, or the stomach.
A150
A real-time data processing framework for steered FUS
Michael Schwenke1, Jan Strehlow1, Daniel Demedts1, Christine Tanner2,
Sven Rothluebbers1, Tobias Preusser1,3
1Fraunhofer MEVIS, Bremen, Germany; 2ETH Zurich, Computer Vision
Laboratory, Zurich, Switzerland; 3Jacobs University Bremen, Bremen,
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Objectives
FUS in moving organs can be realized by updating the focal spot pos-
ition to follow the target motion (steered FUS). A key feature of such a
system is the ability to predict the target motion for the treatment time.Real-time 2D imaging enables capturing some of the organ motion,
which is quantified by consecutive tracking of anatomical features in
the image stream (observation). All occurring delays need to be com-
pensated for by introducing a spatio-temporal prediction of the poten-
tially unobserved target region and surrounding structures. The final
step in the processing pipeline is the update of the FUS control param-
eter values derived from the prediction (control). A common problem is
the tight coupling between observation and control loop.
Methods
While the observation rate is restricted by the update frequency of
the imaging device, it is desirable to update the FUS focal spot pos-
ition as often as possible to achieve the best possible approximation
of the target trajectory given the hardware constraints.
We propose an approach for decoupling observation and control
loop by inserting an asynchronous motion model between the two
loops. The motion model is continuously updated using tracking in-
formation while an independently running control loop queries the
model for target position predictions and controls the FUS device.
The system continuously measures the delays caused by all compo-
nents (imaging, processing, FUS hardware upload) of both loops to cal-
culate the time between the observed target motion and the actual
arrival of FUS energy at the target (time of action). A spatio-temporal
prediction is then calculated using the motion model for the time of ac-
tion to compensate the delays.
Results
We propose a concept for decoupling observation and control in a
steered FUS system. This enables the use of multiple imaging modal-
ities with varying update rates to observe target motion. Further the
update rate of the focus position is thereby limited only by the FUS
hardware and not by the imaging update rate.
Conclusions
Our System may enable a better compensation of the target motion
by the steered FUS system. All delays between observation and con-
trol are measured continuously by the system and are being com-
pensated for.
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Library sorting for real-time multi-baseline thermometry
Jan Strehlow1, Ruben Stein1, Daniel Demedts1, Michael Schwenke1, Sven
Rothluebbers1, Tobias Preusser1,2
1Fraunhofer MEVIS, Bremen, Germany; 2Jacobs University Bremen,
Bremen, Germany
Journal of Therapeutic Ultrasound 2016, 4(Suppl 1):A151
Objectives
MRgFUS is typically monitored by MR thermometry, where
temperature differences are calculated from phase differences with
respect to a baseline-scan. For periodically moving scenarios, such as
FUS in liver treatments, a popular method is the so-called multi-
baseline method, where a set of baseline images covering the whole
motion cycle (library) is acquired prior to heating. For a given moni-
toring image, temperature differences are then calculated with re-
spect to the most similar phase-image within the library. Sparse
sampling of the motion cycle will thus lead to error in temperature
estimation, dense sampling on the other hand leads to another prob-
lem: Searching through hundreds of library-images, acquired over
several motion cycles, to find the most similar baseline image is com-
putationally expensive and impedes real time applicability. We
propose a library sorting method that reorganizes the library-images
acquired over several motion cycles to represent a single, but tem-
porally densely sampled motion cycle.
Methods
In our method baseline library-images I_i, acquired over several mo-
tion cycles, are sorted into a single motion cycle by a three step
pipeline: First, a motion cycles extreme position I_e is identified by
computing an image similarity (S) between the first library image I_0
Journal of Therapeutic Ultrasound 2016, 4(Suppl 1):31 Page 93 of 113and all other images and choosing the most dissimilar I_e = ARG-
MIN_i (S(I_0,I_i)). In the second pass all library-images are labelled
with their similarity to I_e: S_e(i) = S(I_e,I_i). A peak detection is used
to find peaks and valleys in S_e. Library-images between a valley and
a peak are tagged ascending, images between peak and valley are
tagged descending. All ascending and all descending images can
then be grouped and sorted according to S_e. Appending the sorted
ascending to the sorted descending images yields the sorted library.
With a sorted library the search for the best fitting library image can
be narrowed down, e.g. by taking the time between successive mon-
itoring images into account.
Results
The proposed method is work-in-progress and currently evaluated on
data of several FUS experiments in moving phantoms and an animal
experiment.
We expect to considerably lower time to find the most similar baseline
image as compared to search over an unsorted library.
Conclusions
The method accounts for hysteresis in the motion cycle and may
increase robustness of multi baseline thermometry. It may enable the
real time use of big libraries that densely sample the motion cycle.A152
Training and learning software in the field of Focused Ultrasound
therapy of the liver
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Objectives
Currently, non-invasive treatment using MR guided Focused Ultrasound
(FUS) is an emerging technology. Especially in the field of moving ab-
dominal organs there are ongoing developments to compensate for
breathing motion while targeting a certain location in a liver tumor.
Furthermore, up to our knowledge there is currently no product on the
market which could perform such treatments. Within an EU FP7-funded
project (TRANS-FUSIMO), a treatment software was developed capable
of compensating for breathing motion during FUS. The presented work
serves as a possibility to train the usage of the software without being
dependent on MR or FUS hardware. In addition, the training and learn-
ing software enables the operator to review previously stored cases
from a case database which was also implemented in the course of
these developments. Furthermore, also trainees can learn from previous
procedures to perform safe, efficient and effective treatments in the
future.
Methods
A modified version of the TRANS-FUSIMO treatment software is pre-
sented that acts as training and learning system. Since the TRANS-
FUSIMO treatment system has a modular software architecture with
respect to several parts like motion compensation, MR image acquisi-
tion, and FUS beam steering, components may easily be exchanged
without changing neither core functionality nor user interface of the
software. For the training and learning system, MR image acquisition
and FUS beam steering components were exchanged by emulating
software pieces. Images are then loaded from a database instead of
being acquired by a real MRI whereas FUS beam steering commands
are either just logged or used for a real-time simulation of temperature.
This way operators can train to use the software in a safe and effective
way. If also trainees will perform such FUS treatments it is important to
learn from previous procedures about, i.e., cooling effects by the ves-
sels. A secure case database with encrypted communication has been
developed and access to it is possible with the training and learningsystem. That enables querying of cases which can then be reviewed or
trained on. This approach also enables storing data which was not
processed with the TRANS-FUSIMO treatment software.
Results
A training and learning system is a necessary part when introducing
new and complex software tools to be used in clinical studies. It en-
ables the operator to work with the software before treating a patient
while using the same interface and functionality like in the real world
scenario. To guarantee these requirements, our software implementa-
tion is based on the same code as the actual TRANS-FUSIMO treatment
software. However, only the connection to the hardware components
are replaced by emulated hardware components. In the future, this
training and learning system can be extended in such a way that the
system itself learns from the previous procedures and provides treat-
ment proposals for the actual cases. However, from the quality assur-
ance point of view, there should be no direct connection between the
training and learning system and the TRANS-FUSIMO treatment
software.
Conclusions
In the course of the TRANS-FUSIMO project a training and learning
system was developed to train the clinical personnel performing the
anticipated clinical studies using a database of previously performed
interventions. The main goal is to provide training and knowledge
about the used TRANS-FUSIMO treatment software to ensure a safe,
efficient and effective focused ultrasound treatment for the patient.A153
Optical flow based motion tracking in the abdomen: Ultrasound
vs. MRI; A direct comparison
Jeremy Tan, Cornel Zachiu, Pascal Ramaekers, Chrit Moonen, Mario Ries
University Medical Center – Utrecht, Utrecht, Netherlands
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Objectives
High-intensity focused ultrasound (HIFU) therapies in the abdomen
usually employ motion tracking to ensure that sufficient thermal
dose is delivered while minimizing collateral damage. Previous work
proposed optical flow based tracking schemes using either ultra-
sound (US) or magnetic resonance (MR) imaging for this purpose.
While MRI has thereby the advantage of superior soft tissue contrast,
ultrasound imaging can achieve higher frame-rates. However, HIFU
guidance with US penalizes the image quality by the requirement to
perform standoff-imaging. This study directly compares the accuracy
and precision of motion tracking of real-time MRI and standoff-US
imaging using a hybrid imaging setup that can observe with both
modalities simultaneously.
Methods
Simultaneous US-MR imaging was performed using an MR-compatible
128-element phased-array US imager installed adjacent to the HIFU
transducer of a Philips Sonalleve MR-HIFU system. Two data sets were
acquired: one on a phantom undergoing a known motion pattern and
a second one on the abdomen of a healthy volunteer. Tracking was
performed separately on the US and MR images using an optical flow
algorithm. The precision and accuracy of the displacements estimated
on the US data were then evaluated relative to the injected motion pat-
tern for the phantom dataset and relative to the displacements esti-
mated on the MR data for the in vivo case.
US acquisition was performed at 4 MHz with tissue harmonic im-
aging while the MR Echo Planar Imaging (EPI) sequence employed
the following parameters: TE = 9.0 ms, TR = 33 ms, matrix size =
176x176, FA = 25°, voxel size = 2x2x7mm3, EPI-Factor = 13. A total of
500 images were acquired for both phantom and in vivo studies. US-
MR synchronization was achieved via a TTL pulse generated by the
MR-scanner.
Fig. 162 (abstract A153). Average displacement of phantom within
an ROI, estimated on the MR (green) and US (red) datasets. The blue
curve corresponds to the injected motion pattern
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Figures 160 and 161 respectively illustrate, for the healthy volunteer
dataset, an example of raw and overlapped images of both modal-
ities. Precision and accuracy evaluation of the US and MR motion es-
timates were restricted to a region of interest (ROI), for both the
in vivo and phantom scenarios. Figure 162 displays the average dis-
placements estimated for the phantom dataset. Relative to the
injected motion pattern, an accuracy and precision of 0.71 mm and
0.32 mm respectively were achieved for the MR data, and 1.26 mm
and 0.85 mm respectively for the US images. Figure 163 shows the
average motion in a ROI defined on the in vivo images. Relative to
the MR estimates, the accuracy and precision of the US displace-
ments are 1.57 mm and 0.42 mm respectively.
Conclusions
This investigation validates the accuracy and precision of optical flow
in standoff US imaging. Phantom and in vivo experiments show that
sub-pixel performance can be achieved (<2 mm). As such, standoff
US imaging is a viable alternative to MR tracking and can allow more
flexibility in MR protocol design for additional scans or optimization.
It can also be a powerful tool for triggering dynamic switching in MR
scans. Further work includes optimization of US parameters and real-
time applications of this dual modality system.Fig. 163 (abstract A153). Average displacement, for the healthy
volunteer dataset, within an ROI (see blue outline in Fig. 161),
estimated on the MR (green) and US (red) images
Fig. 160 (abstract A153). Sagittal images of the liver and the upper
intestinal tract of a volunteer with T2*-weighted MRI on the left and
tissue harmonic imaging ultrasound on the right
Fig. 161 (abstract A153). MR (green) and US (red) images
overlapped in the same coordinate system. The blue ROI outlines
prominent features tracked by the optical flow algorithmA154
Trans-pulmonary FUS ablation of liver using lung flooding, aspects
of lung penetration and diaphragm motion
Frank Wolfram1, Daniel Güllmar2, Harald Schubert3, Thomas G. Lesser1
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Objectives
Several patient studies investigated HIFU treatment of liver tumours. Its
location and respiratory induced motion affects the ability to treat. The
surrounding lung inhibits extracostal HIFU penetration and respiration
induced motion requires compensational guiding and thermometry
techniques. It has been shown that One-Lung Flooding (OLF) is safe
and originates a superior acoustic path for FUS ablation of lung cancer.
FUS treatment in liver could benefit from a direct trans-pulmonary HIFU
path and a stable target fixation. Therefore the effects of OLF, enabling
a direct transpulmonary HIFU liver ablation and reducing diaphragm
motion were investigated.
Methods
One-Lung flooding was performed using a porcine model (female, 30-
60 kg). Ultrasound guided HIFU was applied transthoracic, transpulmon-
ary into liver on three animals. HIFU exposure (SU102, Sonic Concepts)
Fig. 165 (abstract A154). Merged MR images at endex-inspration
after edge detection, diaphragm position in ex- (green) and inspiration
(red), ventilated (1) and flooded (2) lung
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times into the upper liver dome. During autopsy, examination of in-
duced ablation zones in liver was performed as well as on lung and dia-
phragm tissue out of the beam path.
For diaphragm motion, MR imaging on five animals was performed dur-
ing OLF under mechanical ventilation at the ex-inspirational endpoints.
Images based on T2w HASTE (TE84ms/TR900ms) sequence was merged
after edge detection and the diaphragmatic deviation in cranial direc-
tion was extracted.
Results
Fifteen of fifteen (100 %) thermal lesions were generated by trans-
pulmonary HIFU sonication in liver. After HIFU exposure the focal
zone appeared bright in B mode (Fig. 164). Makroskopically the le-
sions appeared elliptical with a mean length of 11.3 mm and 3.8 mm
width. Histology showed no signs of diaphragm and lung tissue dam-
age. On MRI examinations the largest diaphragm movement (35 mm)
was measured in the latero-posterior diaphragm on the ventilated side.
The movement wanes towards the flooded side down to 15 mm in the
central area. At the lateral edge of the flooded side diaphragmatic
movement becomes deterred (Fig. 165).
Conclusions
OLF provides a direct transpulmonary acoustic pathway for HIFU
ablation in liver. Therefore the therapeutic window for transcostal
FUS can be enlarged, which increases the ablation speed and en-
ables treatment of liver tumors in the proximity to lung. Further,
the reduced diaphragm and therefore liver motion simplifies tar-
geting strategies. Alternatively pleural effusion has been reported
for acoustic coupling of the upper liver dome during FUS treat-
ment. But OLF might comprise several advantages to pleural effu-
sion. So a lower invasivity, a position independend diaphragma
location and the mentioned reduced target motion. It needs to be
discussed whether the advantages for a transcostal - transpulmon-
ary FUS ablation of liver would justify the increased procedural ef-
forts of OLF.Fig. 164 (abstract A154). B-mode image after transpulmonary HIFU
exposure during OLF showing a strongly hyperechoic lesion within
the liver. The yellow dashed line indicates the HIFU beam path,
diaphragm and liver cystA155
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Objectives
Hypertrophic Obstructive Cardiomyopathy (HOCM) is characterized
by abnormal thickening of the ventricular walls leading to dynamic
outflow obstruction. Existing intervention techniques are invasive
and present risks, such as complete heart block or arrhythmias due
to scarring. Histotripsy is used to perform mechanical fractionation of
tissue and has been proven effective in the creation of atrial septum
defect on animals. When applied in bulk tissue, the lesions obtained
are in a liquid state and can stay inside the lesion to be reabsorbed
by the surrounding tissue. Thus, the creation of several, relatively
small histotriptic lesions is hypothesized to potentially contribute to
the reduction of myocardial volume non-invasively and with minimal
scarring and risk of thrombus formation, relieving HOCM.
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A boiling histotripsy feasibility study was conducted on ex vivo tissue
using a clinical MR-guided HIFU system (Sonalleve V1, Philips Health-
care) to determine the optimal sonication parameters and to study
the guidance and monitoring capabilities of MRI for this application.
Sonications of beef steaks and heart and pig heart were performed
at 1.2 MHz using duty cycles (DC) varying from 0.3 % - 2 %, power
from 200 W to 850 W and sonication duration from 20s to 70s.
Results
The MR-guided HIFU system was effective at delivering shocks suffi-
cient to create lesions of 3 - 5 mm in diameter without causing vis-
ible thermal injury (see Fig. 166a). Optimal results were reached at
0.5 - 0.7 % DC, 50 seconds of sonication duration and power output
between 550 - 750 W. MRI was proven efficient for guidance and
could be used for lesion assessment for DC more than 0.5 % and
power output more than 300 W (see Fig. 166b).
Conclusions
Boiling histotripsy was proven feasible in ex vivo cardiac tissue under
MRI guidance and MRI monitoring. Preliminary results also showed
that thermometry data could be of value in predicting lesion aspect
(see Fig. 166c). Further research is needed to evaluate the feasibility
of in vivo ablation through transthoracic application of HIFU.Fig. 166 (abstract A155). See text for description
Fig. 167 (abstract A156). (a and b) Reconstructed from T2w
images demonstrating hyperintensity in the apex of heart that is
consistent with edema following pFUS at 8 MPa. Fluorescent image of
left ventricle showing EBD extravasation into the apex of left ventricle.
(c and d) H&E stain of treated and SHAM control myocardium showing
no difference in muscle morphologyA156
Proteomic and histological analysis of the rat myocardium
following MR-guided pulsed Focused Ultrasound
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Pulsed focused ultrasound (pFUS) has been shown to alter molecu-
lar microenvionment of kidney and muscle and has the potential to
enhance homing permeability and retention of intravenously (IV)
administered mesenchymal stem cells (MSCs) to target tissue. In
this study, we examined the mechanotransductive induced prote-
omic and histological changes following MRI-guided pFUS on rat
myocardium.
Methods
Female Sprague Dawley rats (8-10 weeks old) were imaged on a 3 T
clinical MR scanner (Philips) and T2-weighted MR images were ac-
quired with 8.9 ms repetition and 4.5 ms echo time in 1 mm slice
thickness. The images were used as guidance for pFUS to target
heart apex (1 MHz; 0 to 8 MPa; 10 ms bursts; 1Hz PRF; RK-100, FUS
Instruments). Post-pFUS changes were evaluated ex vivo using 7 T
MR microimaging system (Bruker) with 7,000 ms TR and 50 ms TE in
250 μm slice thickness followed by fluorescence immunohistochemi-
cal (fIHC) analysis of albumin, Evans-blue dye (EBD) extravasation and
haematoxylin and eosin (H&E). Proteomic analysis was performed
using ELISA kits (Rat Cytokine 24-plex, Bio-Rad, US) and cardiac injury
markers (cardiac troponin I (cTnI), pro b-type natriuretic peptide (pro-
BNP) and heart fatty acid-binding proteins (hBAFP)).
Results
Targeted pFUS resulted in interstitial edema in the myocardium
based on 3D reconstructed T2w MRI. Significant EBD extravasation
and fIHC staining for rat albumin was observed in the left ventricular
apex. H&E staining showed no morphological changes in myocar-
dium in pFUS targeted region (Fig. 167). Temporal proteomic analysis
revealed that pFUS treatment significantly elevated pro-inflammatory
cytokines consistent with sterile inflammatory response with the
levels returning to baseline after 24 hours post pFUS. Cardiac injury
markers, cTnI, pro-BNP and hBAFP, demonstrated no significant dif-
ference compared to non-pFUS treated SHAM.
Conclusions
Noninvasive attempts to the repair of heart diseases as part of a re-
generative medicine strategy has been slow. Recent studies suggest
that targeted pFUS in combination with IV administered MSCs has
the potential to modulate inflammatory response and improve clin-
ical outcomes. In this study, the mechanotransductive effects of
pFUS treatment triggered transient increases in pro-inflammatory
and anti-inflammatory cytokines (TNF-a, IL1a IL1b, IL10 and IL13)
consistent with sterile inflammation without histological damage to
myocardium or changes in cardiac injury markers. Histology reveals
leakage of plasma albumin and edema into pFUS targeted myocar-
dium in absence of microhemorrhages or muscle damage. pFUS in
combination with MSCs maybe used as non-invasive technique for
regenerative medicine for delivering stem cells in myocardial
diseases.
Fig. 168 (abstract A157). a Single axial slice of 3D T1–w VIBE
image used for segmentation. b Segmentation process using Seg3D.
Simulated power deposition (scale bar from 0 to 1.5x107 W/m3) for
the model using (c) heterogeneous and (d) artificially homogeneous
acoustic parameters
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Objectives
Approximately 30 % of adults in America are affected by hyperten-
sion. Because of the established role the sympathetic renal system
has in hypertension, renal sympathetic denervation (RSD), disruption
of the renal nerves found in the arterial wall and perivascular soft tis-
sue, has emerged as a potential treatment for hypertension. The
feasibility of using magnetic resonance guided focused ultrasound
(MRgFUS) to non-invasively perform RSD has been demonstrated in
both pre-clinical and clinical studies. A porcine animal study was re-
cently done to test the efficacy of MRgFUS in performing RSD. The
efficacy of the procedure was determined through assessing kidney
medulla norepinephrine in 24 pigs. Using the MRI data obtained dur-
ing these procedures, 3D models of the treated animals were created
and acoustic simulations are underway to correlate the simulated
pressure patterns to the experimental efficacy results and determine
the effects of phase aberration.
Methods
Segmentation: For each of the 24 animals, a T1-weighted VIBE
(T1w Volumetric Interpolated Breath hold Examination) image
series is used to perform the segmentation (Fig. 168a). Segmenta-
tion is done using Seg3D (Fig. 168b), a volume segmentation and
processing tool (Center for Integrative Biomedical Computing at
the University of Utah). Twelve tissue types are segmented and a
correction algorithm is used to prepare the resulting models for
acoustic simulations.
Acoustic Simulations: Each tissue type is assigned an attenuation,
speed of sound, and density value consistent with the literature.
Using the Hybrid Angular Spectrum (HAS) method, pressure patterns
for each experimental sonication treatment location are obtained.
The global maximum pressure as well as the maximum pressure
achieved within 5 cm of the intended focal point is identified. Add-
itionally, a phase spread metric (PSM) is calculated to quantify the
heterogeneity of each model. A PSM value of 0 indicates no phase
spread while a value of 1 denotes full phase spread. For comparison,
simulations are also performed for a homogenous model where all
tissue types are assumed to be uniform (an average value of all 12
tissue types).
Results
At the time of submittal, simulations have been completed for 7/24
animals. Initial results demonstrate that phase aberration due to
the heterogeneous anatomical structure of the pig decreased the
maximum pressure achieved at the focal location by 36 % when
comparing the heterogeneous to artificially homogeneous seg-
mented models. Additionally there is an average 10 % increase in
the PSM, indicating that the heterogeneity of the segmented
models increases the phase spread. The distance between the
intended focal point and maximum pressure location was also af-
fected by the heterogeneity of the model. The mean average dis-
tance between intended focal point and maximum pressure
location was found to be significantly larger (p < 0.001) when com-
paring the heterogonous (18.4 mm) and artificially homogeneous
models (5.6 mm).
Conclusions
These initial results indicate it would be beneficial to perform phase
aberration correction when performing RSD with MRgFUS in order to
increase the accuracy and efficacy of the procedure.A158
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Objectives
Nearly 30 million people in the United States suffer from kidney stones.
For these patients, shockwave lithotripsy (SWL; litho-: “stone”, -tripsy:
“crushing”) is a first-line treatment, in which extracorporeally generated
acoustic waves are focused on the stone to fragment it. Despite the ex-
tensive clinical use, SWL is to some extent still a “black box” to the
treating urologist: the in-depth mechanisms of stone fragmentation
and tissue injury are still unclear; and there is no rational approach to
Fig. 171 (abstract A159). Computational setup of a shock-bubble-
stone interaction problem
Fig. 170 (abstract A159). A shock-bubble-stone interaction problem
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study towards a better understanding of the stone fragmentation
process. Specifically, we apply a novel multiphase fluid-solid coupled
computational framework to investigate the interaction of a kidney
stone immersed in liquid with a lithotripter-generated shock wave and
a gas bubble near the stone. The main objective is to elucidate the ef-
fects of a bubble in the shock path to stone fracture.
Methods
The computational framework used in this work couples a three-
dimensional (3D) finite volume two-phase computational fluid dy-
namics (CFD) solver with a three-dimensional finite element (FE)
computational solid dynamics (CSD) solver. The surface of the stone
is represented as a dynamic embedded boundary in the CFD solver.
The evolution of the bubble surface is captured by solving the level-
set equation. The interface conditions at the surfaces of the stone
and the bubble are enforced through the construction and solution
of local fluid-solid and two-fluid Riemann problems. The computa-
tional analysis reported in this presentation are performed on the
BlueRidge supercomputer at Virginia Tech, using 200 to 400 proces-
sor cores.
Results
The first step in this study is to verify the computational frame-
work. To this end, we present a 1D multi-material Riemann
problem, and two 3D problems on shock-stone and shockbub-
ble interactions. For all the three problems, our numerical solu-
tion is in close agreement with the reference (Fig. 169). Next,
we present a series of 3D shock-bubble-stone coupled simula-
tions (Figs. 170, 171 and 172).
Conclusions
Our computational analysis suggests that the dynamic response of
a bubble to an LSW, as well as its impact to the stone, heavily de-
pends on the initial size of the bubble. Bubbles smaller than a cer-
tain threshold implode within 1 s after the passage of LSW;
whereas larger bubbles do not. For a specific (and realistic) setting,
we find this threshold, in terms of bubble radius, to be 0:12
0:02 mm. Moreover, our results suggest that a non-imploding bub-
ble imposes a negative effect on stone fracture, as it shields part of
the LSW from the stone. The effect of an imploding bubble is a bit
more complex: it may promote fracture on the proximal surface of
the stone, yet hinder fracture from stone interior.Fig. 169 (abstract A159). A shock-bubble interaction problem:
comparison of the present result (left) and the previous result pre-
sented in Johnsen et al. (2008) (right) for the time history of hydro-
dynamic pressure at three sensor locations
Fig. 172 (abstract A159). Snapshots of numerical solutions at four
time instances. R0 denotes the initial bubble radius. t0 denotes the
time instance when the lithotripter-generated shock wave reaches
the front surface of the stone
Fig. 174 (abstract A160). X-ray image of the perfused porcine
kidneys
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Objectives
One of the main challenges during FUS treatment of abdominal or-
gans is organ motion due to respiration. If motion is ignored, the
thermal dose spreads over a larger area, leading to insufficient heat
for ablative necrosis. The current FUS treatment systems lack com-
pensation of breathing motion. Research requires ex vivo moving
organ models with appropriate perfusion. The work reports prepar-
ation of a ‘perfused, breathing kidney phantom’ using fresh and pre-
served porcine kidneys.
Methods
Fresh ex vivo porcine kidneys are prepared carefully to remove
excess fat and to make the ureters, artery and vein clearly visible.
The vessels are then flushed out repeatedly using saline water to
remove blood. The process is then continued using ‘Thiel’ pre-
serving fluid and then the prepared tissue is immersed in the
preservation fluid for up to one week. This process will leave the
tissue re-usable for months and thus making it suitable for re-
peated sonication and testing. The vessels in the kidneys are
then attached to connectors to allow perfusion. The preserved
kidneys with the connected connectors are embedded between
two layers of agar phantom. The agar block with the embedded
kidneys were attached to balloons to mimic breathing motion as
seen in Fig. 173. Heart-lung machine is used for perfusion. The
inflow from the heart-lung machine is connected to the renal ar-
tery and the outflow from the kidney is taken back to the heart-
lung machine from the renal vein. Two balloons each side of the
phantom are filled with water and air respectively and one of
the balloons connected to the ventilator to mimic the breathing
motion.
Results
The perfusion of the kidneys was imaged using x-rays (Fig. 174) and
it showed very good circulation in the kidneys. The blood flow vol-
umes can be controlled from 100 ~ 300 ml/minutes. The phantom
was scanned with real time MRI under respiratory motion. The re-
spiratory motion range along superior-inferior direction could be ad-
justed within 10 ~ 40 mm. Meantime, the motion speed was adjusted
according to different applications as well.
Conclusions
A perusable, breathing kidney phantom was prepared using ex vivo
porcine kidneys. The circulation was images using x-rays and the
breathing motion was accomplished using the ventilator. This phan-
tom uses Thiel preserved ex vivo kidneys accounting for its increased
longevity.Fig. 173 (abstract A160). Respiratory perfused kidney schematicA161
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Objectives
The use of MR-HIFU to deliver mild hyperthermia (40-45 °C for 10-60
minutes) requires stable MR temperature mapping for long durations.
While this can be achieved in the extremities, for targets in the pel-
vis, abdomen, chest, and neck, respiratory motion causes magnetic
field variations that induce unacceptably large temperature mapping
errors. Pediatric MRI examinations are routinely performed under
general anesthesia with mechanical ventilation, where forced breath
holds of 1-2 minutes interrupted by 20-30 seconds of hyperventila-
tion. Our goal is to investigate the use of forced breath holds to de-
liver mild hyperthermia to pediatric solid tumors. In this study we
evaluate the precision of MR thermometry acquired in phantoms
near a moving structure and in pig back muscle near the lungs.
Methods
Experiments were performed using a 3 T MRI (Ingenia, Philips Health-
care) equipped with a clinical MR-HIFU system (Sonalleve V2, Philips
Healthcare). Temperature maps were acquired over 10-20 minutes
and optical temperature sensors (Neoptix T1) were embedded to val-
idate MR thermometry.
In phantom studies, breathing motion was simulated using an MRI-
compatible motion platform programmed to move an aluminum
block along a sinusoidal one-dimensional trajectory. Gating was sim-
ulated by halting the motion at the furthest distance away from the
phantom.
In vivo experiments were performed in ventilated, anesthetized pigs
lying with their back muscles above the acoustic window of the MR-
HIFU system. The lungs and diaphragm were outside of the imaging
field of view, but close enough to trigger the motion artifacts. Sterilized
temperature sensors were embedded in the muscle adjacent to the tar-
get region. Breathing was controlled at 20-24 breaths per minute. End
expiration breath holds of 40-60 seconds were implemented by switch-
ing off the ventilator, during which mild hyperthermia with a target
Fig. 177 (abstract A161). Temperature measured with MR
thermometry in pig with HIFU enabled. Heating above 41 °C was
achieved within the target region for 11.6 minutes, confirming the
feasibility of breath-hold mild hyperthermia treatment
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recovery period of 20-40 seconds with HIFU disabled was performed
after each breath hold. This cycle continued for 10 minutes hyperther-
mia and another 10 minutes of cooling.
Results
In phantoms next to a moving structure with a large relative suscep-
tibility, MR temperature measurements acquired during a series of
motion holds demonstrated a precision of 0.8 °C, compared to mea-
surements acquired while the structure was moving had a precision
of 1.6 °C (Fig. 175).
In pig back muscle with no HIFU heating, precision during breath
holds was 0.9 °C compared to 2.0 °C during ventilation (Fig. 176).
MR-HIFU hyperthermia delivered during intermittent breath holds
over a 10 minute duration heated the 18 mm diameter target region
above 41 °C for 11.6 minutes, demonstrating the feasibility of breath-
hold MR-HIFU hyperthermia (Fig. 177).
Conclusions
The use of forced breath holds enables precise control of MR-HIFU
hyperthermia in targets near moving structures, and may allow MR-
HIFU hyperthermia to be extended to pediatric solid tumors of the
pelvis, abdomen, chest, and neck.Fig. 175 (abstract A161). Temperature measured with MR
thermometry and optical temperature probe in phantom motion
study. The temporal precision is 0.8 °C during motion holds
compared to 1.6 °C during free motion
Fig. 176 (abstract A161). Temperature measured with MR
thermometry and optical temperature probe in pig without heating.
The temporal precision is 0.9 °C during breath holds compared to
2.0 °C during ventilationA162
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Objectives
Leg length discrepancy is an orthopaedic problem that usually ap-
pears in childhood. Without treatment, the patients will have notice-
able limp, back pain and other symptoms. Traditional treatment
includes surgically injuring the growth plate to shorten the longer
leg. While effective, this procedure is invasive and associated with
the risks of surgery. MR-guided high-intensity focused ultrasound
(MR-HIFU) could provide a non-invasive approach for growth plate
ablation. The hypothesis of this study was that exposure of the
growth plate to HIFU would achieve a reduction in limb growth, as
an alternative to surgical destruction. To test this hypothesis, we
adapted a pre-clinical small animal MR-HIFU system to perform
growth plate ablation treatment in rodent models.
Methods
Experiment were performed with a 3 T MRI (Ingenia, Philips Health-
care) with a preclinical HIFU system (RK 100, FUS Instruments).
Growth plate ablation treatment was performed on young animals in
the growth phase of their limbs (Sprague Dawley rats, male, 4-6
weeks old, n = 8). All in vivo experiments were approved by UT
Southwestern Institutional Animal Care and Use Committee. Anaes-
thetised animals were stabilized on the HIFU platform, with one side
of the thigh facing the acoustic window. The target region was se-
lected as the growth plate of the proximal femur, with the contralat-
eral leg acting as a control. Approximately 3 W of acoustic power
was delivered to the bone for 20-30 seconds for the ablation.
Temperature was measured with MR thermometry within the target
region during the treatment. The animals were allowed to recover
and were observed for 8 weeks. Contrast-enhanced MR images were
acquired on the day of sacrifice. Femurs on both sides were collected
and micro-CT images were obtained to evaluate the treatment effect
on bone growth.
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A localized temperature increase was observed in the targeted re-
gion and appeared to cover the entire region of the growth plates
(Fig. 178). All animals recovered quickly and did not exhibit any defi-
cits in gait or function during the 8-week observation period. An
average length difference of -6.4 ± 6.2 % (p = 0.02, paired t test,
Fig. 179a) between treated and control femur was observed from the
micro-CT images. Post-treatment MR contrast imaging (n = 8 animals)
showed a signal increase of 16.7 ± 12.1 % (p < 0.01, paired t-test,
Fig. 179b) in the exposed region, suggesting residual scar tissue in
the region of exposure.
Conclusions
In this study, we have confirmed that growth plate ablation treatment
in rodent models can be achieved with a pre-clinical MR-HIFU system.
The procedure was safe and resulted in a reduction in the growth rate
of the exposed leg. These results support further investigation of HIFU
as a non-invasive treatment for pediatric leg length discrepancy.Fig. 179 (abstract A162). 8-weeks post treatment evaluation by
contrast-enhanced MR images and micro-CT scans
Fig. 178 (abstract A162). MR thermometry during the treatment
and temperature measurement within the target region
Fig. 180 (abstract A163). Coronal T2 fast spin echo images
demonstrating the two set-ups used during this experiment, one
with and one without a waterbag at the far field air interface
Fig. 181 (abstract A163). Comparison of temperature curves over
time for each experimental set-upA163
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Objectives
One challenge in using magnetic resonance focused ultrasound
(MRgFUS) in the extremities is heating of the tissue at the far field
skin-air interface where reflection of sound waves occurs. Heating in
this region can be difficult to detect by MR thermometry and can po-
tentially result in high grade skin injuries.
In clinical practice, clinicians will sometimes use a water bag or gel pad
device coupled to the far-field skin in order to prevent excess heating in
this region. The purpose of the current study was to determine the
amount of heating prevented in the far field by use of a coupling device,
as a function of time to temperature rise and maximum temperature
reached.Methods
MRgFUS was used to perform sonications on a tissue mimicking gel
phantom (ATS Labs Inc, Bridgport, CT) in two experimental scenarios.
In the first scenario, the phantom was sonicated directly without a
coupling device attached to the far field of the phantom. In the sec-
ond scenario, a room temperature water bag was attached to the far
field of the phantom.
In both scenarios, two fiber-optic temperature probes were placed ap-
proximately 1 cm below the far field air-phantom interface, 5 cm above
and distal to the planned level of sonication, with the tip of both
probes at approximately the center of the phantom’s cross-sectional
surface area (Fig. 180). The probes provided continuous thermal read-
ings. A mock flat circular target of 5 cm was prescribed 4 cm from the
base of the phantom on planning images. A small amount of degassed
water was placed at the near field interface in both scenarios.
Each phantom was sonicated a minimum of 15 times, and additional
sonications were performed if necessary to produce a 10 °C temperature
rise. Maximum temperature rise following each sonication was recorded.
Results
In the first scenario (no water bag coupling device), the temperature
began at 19.6 °C and rose to a maximum of 32.4 °C after 15 sonica-
tions (Fig. 181). An increase of 10 °C was seen after 12 sonications.
Intermittent temperature spikes were also noted, most strikingly after
sonications 5, 9, and 12. In the second scenario (with water bag
coupling device in the far field) the temperature began at 18.4 °C
and rose to a maximum of 26 °C after 15 sonications. Additional soni-
cations were performed and an increase of 10 °C was seen only after
18 sonications, rising to a temperature of 28.4 °C. No temperature
spikes were seen in the second scenario with a relatively smooth/
gradual increase in temperature noted.
Conclusions
This experiment demonstrates that a water bag coupling device in
the far field significantly delays the rate of heating and maximum
heating in this region during MRgFUS. These results suggest that this
type of device can both allow for more complete treatments and
help minimize risk of far field skin injury.
Fig. 182 (abstract A164). a Generalized schema of the exposimetry
system for LIPUS delivery at calibrated intensity exposures to
damaged rat-tail discs in vivo; b focused with integrated housing
and mylar membrane to position focus; c US energy penetrating tail
Fig. 183 (abstract A164). a Positioning platform and p-FUS system
for disc exposure with sectioned rat tail; b hydrophone scanning
setup without absorbers; and beam plots of (c) no tail and (d) tail
demonstrating penetration through the IVD as targeted
Journal of Therapeutic Ultrasound 2016, 4(Suppl 1):31 Page 102 of 113A164
Low Intensity Pulsed Ultrasound (LIPUS) for the treatment of spinal
disc degeneration — ultrasound exposimetry system and in vivo
implementation in a rat tail model
Chris Diederich1, Vasant Salgaonkar2, Peter Jones1, Matthew Adams1,
Arda Ozilgen1, Peter Zahos3, Dezba Coughlin1, Xinyan Tang1, Jeff Lotz1
1University of California San Francisco, San Francisco, California, USA;
2University of California San Francisco, Sunnyvale, California, USA;
3University of California San Francisco, Napa, California, USA
Journal of Therapeutic Ultrasound 2016, 4(Suppl 1):A164
Objectives
Discogenic back pain presents a major health issue, with current
therapeutic interventions limited to short term symptom relief
without providing regenerative remedies for diseased interverte-
bral discs (IVD). LIPUS or non-thermal pulsed focused ultrasound
(p-FUS) offers a potential treatment option, where ultrasound
mechanical energy targeted to a damaged IVD may produce a fa-
vorable biological response to modify, stall and even reverse IVD
degeneration in a non-invasive manner. LIPUS has been shown
clinically to be an effective noninvasive method for the stimula-
tion of bioactivity and favorable tissue remodeling, such as
wound and fracture healing. Recent in vitro studies have shown
that LIPUS stimulation can induce desirable effects within cul-
tured intervertebral disc cells such as an increase in extracellular
matrix metabolism, upregulation of proteoglycan synthesis, stimu-
lated collagen synthesis, and induction of anti-inflammatory fac-
tors. The objective of our “work in progress” presented herein is
to develop a LIPUS exposimetry system specific to targeting
degenerated
Methods
Ultrasound exposimetry systems were devised and fabricated
specific to delivering LIPUS to damaged caudal discs in the rat
tail (Fig. 182). The two configurations consisted of 2.5 cm diam-
eter spherically focused PZT4 transducers (1.0 MHz, f = 1;
1.6 MHz, f = 3.8), integrated within a water-filled 3D printed plas-
tic housing with a mylar window w/ cross-hairs, designed as an
acoustic standoff to place the focus within the targeted rat tail
disc. The applicators/apparatus were evaluated with comparative
beam plot measurements with/without insertion of sectioned rat
tails ex vivo (Fig. 183a, b). In vivo studies using the disc damage
model are performed following standard procedures approved
by UCSF IACUC, with stab incisions applied within 16 Sprague-
Dawley rats to generate damage/inflammation in tail discs. Five
daily p-FUS exposures (ISPTA120 mW cm-2) are to be applied to
stab discs and compared to stab only and normal controls. Hist-
ology and microarray gene analysis are performed at 5 days and
28 days after injury, also assessing changes to cartilage, fibrous
tissue, and bone.
Results
Intensity measurements and radiation force observations with and
without the tail sections (Fig. 182c, 183c) demonstrate the focused
systems can deliver LIPUS (at 30-50 % of mylar surface intensity)
through the skin and connective tissue, to the center of the narrow
~1.5 mm x 5 mm rat tail disc, while reducing exposure to significant
portions of the adjacent bone and negligible temperature elevation.
The LIPUS exposimetry to damaged rat tail discs, and subsequent
histological and microarray analysis are currently ongoing and will be
presented.
Conclusions
This study demonstrated the technical feasibility of delivering ultra-
sound isolated to a targeted rat tail disc for studies of LIPUS expos-
ure. In summary, this LIPUS exposimetry apparatus and disc damage
model can be implemented for further study in vivo to demonstrate
potential of ultrasound to increase cellularity, reduce inflammation,
and improve remodeling to acute or degenerative disc-related back
injury.A165
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Objectives
Chronic low back pain (CLBP) is a leading cause of work disability. In
15-30 % of CLBP patients, the source is the dysfunction of the Sacro-
iliac Joint (SIJ). [1] One method providing therapeutic effectiveness is
radiofrequency ablation (RFA), however this invasive and laborious
procedure has seen slow clinical adoption, limiting effective treat-
ments for SIJ pain.[2-3] HIFU could provide a non-invasive alternative
by creating a continuous lesion lateral to the sacral foramina
(Fig. 184). The main risk of using HIFU for SI joint ablation is dam-
aging adjacent neural structures. A pilot study in swine demon-
strated that MR-guided HIFU (MRgHIFU) ablation of SIJ is feasible,
and lateral branch nerves can be ablated without damaging adjacent
nerve roots. [4] The anatomy of human sacral foramina, however, is
not identical to that of swine (Fig. 185). Hence, translating preclinical
safety results into human patients may be prone to risk and further
evaluation is needed.
Methods
Phantom: Images from an adult pelvic CT scan will be used to segment
the sacrum bone from adjacent muscle tissue. The segmented model
will be manufactured in a 3-D printer using (Acrylonitrile Butadiene
Styrene) ABS plastic.[5] The muscle tissue will be mimicked by a high-
temperature hydrogel matrix (gellan gum) combined with different
sizes of aluminum oxide particles and other chemicals.[6]
Experiment: MR-HIFU experiment will be performed using a clinical
HIFU system (InSightec, Ltd., Israel) installed in a 1.5 Tesla MRI scanner
(GE Healthcare, USA). HIFU beam will be applied as shown in Fig. 184.
Temperature will be monitored using MR thermometry and four fiber-
optic temperature sensors (Luxtron, USA) inserted into a foramen.
Results
For L5 to S3 vertebral levels, we will determine the range of the
acoustic parameters (focal spot size and position) and HIFU beam
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without causing thermal damage inside the sacral foramina.
Conclusions
Detailed investigation of the safety of HIFU of SIJ using human-
sacrum-mimicking phantom will inform future studies aimed at ap-
plying MR-HIFU clinically to treat sacroiliac low back pain.
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2011;58(7):1397-1405.Fig. 185 (abstract A165). Axial CT images of human and porcine
sacrum. White arrows point at the sacral foramen
Fig. 184 (abstract A165). Schematic of approach to MR-HIFU
treatment of SIJ. A. Oblique axial view of patient in supine position.
HIFU beam (orange) aimed nerves (yellow) at SIJ B. Oblique coronal
view of sacrum showing HIFU ablation targets (orange), lateral
branch nervesA166
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Currently, there is no feasible way to measure bone heating in vivo.
Tissue close to bone can be monitored and temperature models can
be used to determine when it is safe to apply another burst of ultra-
sound energy. However, a noninvasive MR-based bone thermometry
method would be useful to directly monitor bone heating during
FUS treatment.
Because of its short T2/T2*, the popular PRF shift thermometry tech-
nique cannot be performed in bone. A method proposed by Miller
and further demonstrated by Han uses UTE imaging to detect signal
changes in bone caused by changes in the relaxation rates due to
heating. Here, we have used a 3D spiral-based UTE sequence to rap-
idly collect UTE images and detect signal changes in bone as it cools
down inside the bore of the scanner. Furthermore, we have used this
sequence in a proof-of-concept UTE skull imaging experiment using
a human volunteer.
Methods
A 3D spiral UTE sequence was used for rapid UTE imaging. Briefly, a
3D stack-of-spirals acquisition was modified to achieve very short
echo times by beginning each spiral readout immediately after the
through-plane phase-encoding gradient waveform is complete. This
results in a variable TE in the through-plane direction. For the center
of k-space where the PE gradients are small (or nonexistent), the
minimum TE achievable is approximately 50 μs (Fig. 186).
A room-temperature bone sample was first placed into the scanner
and the spiral UTE sequence was used to acquire volumetric images
every 75 seconds for 12.6 minutes. Following this acquisition, the
bone was placed into a 55 °C water bath for 5 minutes, then imaged
again with the same protocol. After imaging, cortical bone was
manually segmented and the mean signal intensity recorded at each
time point.
To demonstrate the sequence’s potential for human skull imaging, a
volunteer was scanned with parameters set to achieve a 67-second
acquisition time with an in-plane resolution of 2.5 mm2. A second
volumetric image was obtained with a TE of 5.1 ms (to preserve fat/
water phase) to provide late-TE comparison images. No heating was
performed in this experiment.
Results
In Fig. 187, the early and late TE images from the bovine tibia experi-
ment are shown, along with the subtraction image of the two.
Cortical bone signal is only visualized with the early TE configuration.
Figure 188 shows the mean signal of the heated sample increasing
as the bone cools in the bore of the magnet over a 12-minute time-
span. In contrast, the sample that remained at room temperature
shows no change in signal. Figure 189 shows whole-head spiral UTE
images alongside late-echo images to illustrate the difference in con-
trast achievable with this sequence. Direct subtractions as well as
scaled subtractions are shown, highlighting the bone signal. SNR,
measured in a region of the frontal bone, is 54 in the minimum-TE
image, 23 in the direct-subtraction image, and 43 in the scaled-
subtraction image.
Conclusions
This work shows the feasibility of temperature monitoring for bone
across potentially large fields of view; however, the small phantom
size and number of experiments presented here call for further
study. Volumetric UTE sequences have typically required scan times
of about 10 minutes, which may preclude their use in focused ultra-
sound procedures; by comparison, the 3D spiral UTE sequence can
acquire large volumetric data in about one minute. The ultimate goal
is to monitor the entire skull and skull base between therapeutic
insonications, which are typically separated by a few minutes.
Fig. 186 (abstract A166). Variable TE 3D spiral pulse sequence
diagram. Very short TEs are achievable near the center of k-space,
where the through-plane PE gradients are small (or nonexistent)
Fig. 187 (abstract A166). Spiral UTE of bovine tibia. a Minimum TE.
b Late TE. c) Subtraction, highlighting cortical bone (and connective
tissue surrounding the sample). One slice is shown from the 3D
volume. Cortical bone is only detectable in the minimum TE image
Fig. 188 (abstract A166). Mean signal difference of cortical bone,
referenced from final time point. The signal of the heated sample
increases as the bone cools in the bore of the magnet over a 12-
minute timespan. The unheated sample shows no signal change
Fig. 189 (abstract A166). Whole-head UTE images acquired in
67 seconds. While visible in the subtraction image, the skull is better
visualized with a scaled subtraction
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A versatile ultrasound system for in vitro experiments on cells
Gaetano Barbato, Gian Luca Scoarughi, Cristiano Corso, Alessandro
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Objectives
One of the most difficult tasks to achieve with available instrumenta-
tion used to study the interaction between ultrasound (US) and cellu-
lar model systems is to design an experiment, where the effects of
only one physical parameter is evaluated, while all the others are
kept constant. The set-ups are usually custom made, often use instru-
ments intended for a different purpose. The outcome are results not
always well reproducible, and rarely comparable with those obtained
with techniques considered standard in molecular and cellular biol-
ogy. Sterility, as well as temperature, are not well controlled. All these
considerations translate into poor reproducibility of US in vitro data,
leading to standard deviations which are often larger than the values
themselves. We present US experiments performed on cell samples
with our designed bench-top US apparatus versatile to be adapted
for several in vitro experiments and show easy and robust reproduci-
bility and low Standard Deviations data, using standard set-ups for
the cell samples.
Methods
One main feature of our bench-top US system is that it has been
designed in order to minimize interferences and degradation of the
acoustic energy using the standard plasticware that are commonly
used in molecular biology labs, ensure temperature controls and ster-
ility conditions needed in the field. We present a set-up where the
simultaneous use of a set of transducers operating at different fre-
quencies on the same plate, allows the comparison of the deposition
of the same acoustic pressure, while evaluating the effect of fre-
quency alone on the readout of the cell experiments. The apparatus
modular design allows also to use a set of transducers operating at
the same frequency, in experiments where the throughput is a rele-
vant factor. We show that it is possible to define the position of the
target within all the achievable areas of the acoustic field with sub-
millimetric accuracy.
Table 7 (abstract A168). Simulation material properties
Apt-Flex Coupling Gel Ceramic Air
Density (kg/m3) 1010 1050 3800 1.21
Speed of sound (m/s) 1500 1500 9900 330
Attenuation (Np/m) 330 2.5x10-3 2.5x10-3 18.9
Specific heat (J/kg*K) 1800 4200 775 0.001
Thermal diffusivity (mm2/s) 0.091 0.086 0.13 0.21
Thermal conductivity (W/m*K) 0.165 0.38 39 0.026
Fig. 190 (abstract A168). Measured pressure in x-z plane and
computed x-y plane pressure
Fig. 191 (abstract A168). Time required for observable DQA color-
change at different driving electrical power levels
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have been carried out by varying the acoustic parameters such as
the power, the frequency range, the sonication time and the duty
cycle, all controlled within robust protocols executed in automation.
Results
We show data that demonstrate that it is possible to perform
in vitro experiments for different purpose (i.e. drug or gene delivery
via cellular sonoporation, tissue regeneration, neuronal cell stimula-
tion, bacterial growth etc.) keeping constant the relevant physical
parameters of sonication, for instance acoustic pressure, but varying
one at the time the others parameters (i.e. frequency, pulse length
or duty cycle etc).
Conclusions
We show that with our apparatus it is possible to obtain robust and
reproducible results on cellular experiments using all the standard
devices that are commonly available in biological labs. The improve-
ment on the side of reproducibility and portability of the experi-
ments allows a straightforward comparison between our results and
those obtained with other techniques.
A168
Stability of a low-cost thermochromic quality assurance phantom
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Objectives
A simple phantom was designed, constructed and tested for daily
quality assurance (DQA) of ultrasound therapy transducers. Regular
checking of the therapeutic transducer is indeed a key safety test
as differences in power output can either result in harm to the pa-
tient or ineffective treatment. We introduced recently a DQA phan-
tom which allows the user to determine if the power output of a
transducer has changed after calibration through visual inspection.
We present here repeated experiments over 6 months on a thermo-
chromic material-based phantom, with two identical transducers, in
order to investigate the repeatability and the stability of the DQA
phantom. The phantom is made of an attenuating ultrasound ab-
sorber (AptFlex F28, Precision Acoustics Ltd, Dorchester, UK) with a
surface layer of thermochromic liquid crystals (TLCs) (R35C5B, LCR
Hallcrest LLC, Glenview, USA). The TLC changes color when
temperature exceeds 35 °C
Methods
Two phantoms made from the same sample of AptFlex F28 were
tested respectively with two high-power 1.1 MHz transducers (Sonic
Concepts, Bothell, USA). A waveform generator (DG1022, Rigol, Bea-
verton, USA) supplied a 1.1 MHz sinusoid to a power amplifier
(100A100, Amplifier Research Corp., Souderton, PA, USA). The ampli-
fied signal was monitored by an oscilloscope (TDS2001C, Tektronix,
Beaverton, OR, USA) and connected to the input of a Sonic Concepts
matching network and ultrasound transducer. Measurements of the
time until first TLC material color change were recorded to across a
0.4-11 W range of power in ten sessions spanning over a six-month
period.
In addition, the pressure field of the transducers was measured in a
water tank (AIMS III, Onda Corp., Sunnyvale, CA, USA) and used as in-
put to a time-domain finite difference simulation of the bio heat
equation to simulate the thermal rise in the absorbing material. Sim-
ulations were performed with an in house Matlab code (Mathworks,
Natwick, USA) operated on a laptop. Table 7 provides material prop-
erties used in the simulation. The time required to achieve a color-
change temperature of 35 °C is recorded, and the simulation is re-
run across electrical intensities ranging between 0.5 and 12 W, based
on 85 % efficiency.
Results
Transverse and longitudinal maps of the pressure fields are displayed
on Fig. 190. All measurements of time to see a thermal change onboth DQA phantoms are plotted in Fig. 191 as a function of electrical
power, as well as the corresponding simulated curve. Good agree-
ment is observed between simulation and experimental results. For
optimal sensitivity, it is recommended to select an electrical power of
1.5 – 2.0 W. Here, DQA assessments are complete within 20 seconds,
and the typical user (with reaction time of 0.5 s) can detect a 10 %
deviation in acoustic power output.
Conclusions
Long term (6-month) testing of two DQA phantoms on two identical
transducers proved to be stable enough to compile all measure-
ments on a single graph (Fig. 190). This system is a cheap and effect-
ive way to produce DQA phantoms, both because of the ease of use,
and because the use of TLC makes visual changes in the phantom re-
versible and reproducible over a long period of time. Next steps in-
volve refining the simulation methods used to better validate the
DQA design and deploying custom-mounted DQA phantoms to end
users and iterate upon the design based on their scenario-specific
experiences.
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Objectives
High intensity focused ultrasound (HIFU) is a non-invasive therapeutic
technique currently used in the clinic to thermally ablate tissues, How-
ever, there exists a likelihood for significant collateral tissue damage
and/or incomplete treatment. Alternate HIFU regimes such as cavitation
histotripsy (CH) utilize microsecond-long pulses, low duty cycles, and
high acoustic pressures to mechanically fractionate tissue. This ap-
proach could help disrupt tissues while sparing nearby critical struc-
tures from thermal effects and increase the clinical applicability of HIFU.
To understand the effect of CH parameters on lesion volumes, we ex-
plored a wide range of sonication parameters, such as acoustic power,
total sonication time, number of cycles/pulse (pulse width), and pulse
repetition frequency (PRF). The goal of this work was to quantify lesion
volumes in tissue-mimicking phantoms for various CH sonication
parameters.
Methods
Sonications were performed on a clinical MR-HIFU system (Sonalleve
V1, Philips, Vantaa, Finland) with a 256-element, phased-array trans-
ducer (focal length = 12 cm, f-number = 0.94, frequency = 1.2 MHz).
Different sonication parameters were tested in polyacrylamide tissue-
mimicking gel phantoms, which were placed in a custom 3D-printed
holder within a deionized and degassed water bath. A pattern consist-
ing of 27 foci separated by 1 mm, in a 3x3x3 matrix was produced.
Sonication parameters were: acoustic power 300 W to 800 W in steps
of 100 W, pulse length 200-1200cycles/pulse in steps of 200, total sonic-
ation time 270 to 1630 seconds, and PRF 10 to 60Hz in 10Hz incre-
ments. Post sonication, 3D ultrasound (X6-1, iU22, Philips, Bothell, WA)
was used to obtain the lesion volumes.
Results
CH sonications produced varying lesion volumes in the tissue-
mimicking phantoms. Increasing the peak acoustic power from 500
to 800 W linearly increased the lesion volumes from 790 to
2780 mm3(R2 = 0.83). On the other hand, 300 W did not produce a
visible lesion and 400 W produced a lesion that was visible to the
naked eye, but not spatially resolvable using a 6 MHz ultrasound
imaging transducer. A linear increase in lesion volume from 600 to
2711 mm3 (R2 = 0.76) was also observed for the tested range of
number of cycles/pulse. When increasing total sonication time from
271 to 1630s, lesion volume increased from 1392 to 1500 mm3.
Varying PRF from 10 to 60Hz also increased lesion volumes (1688-
1802 mm3). Both 0.17 and 0.33 % duty cycle sonications produced
small lesion volumes (<0.5 cm3), while sonications at higher duty
cycles produced lesion volumes greater than 2 cm3.
Conclusions
Cavitation histotripsy was performed on a clinical MR-HIFU system
and resulting lesion volumes in tissue-mimicking phantoms were
quantified across a broad range of sonication parameters. Results in-
dicate that acoustic power and number of cycles/pulse strongly
affect lesion volume, while total sonication time and PRF do not. This
study informs future CH work in tissue-mimicking phantoms as well
asex vivo and in vivo studies. The use of a commercial, clinical HIFU
system may speed up clinical translation of histotripsy compared to
custom-built, preclinical HIFU systems.A170
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Objectives
High intensity focused ultrasound (HIFU) is a non-invasive therapy
modality, offering a unique method of tumor thermoablation. HIFU
treatment of hepatic tumors requires intercostal transmission of suffi-
cient energy while minimizing rib and adjacent tissue heating. As-
sessment and experimental validation of beam-shaping methods and
numerical models may aid in clinical translation of HIFU for hepatic
tumor therapy. The objective of this study was to develop and pro-
duce a tissue-mimicking thermochromic phantom (TMTCP) with em-
bedded rib-mimics to characterize sonications and evaluate beam-
shaping methods for transcostal HIFU therapy.
Methods
3D-printable ribcage was based on rib renderings from computed
tomography. Rib-mimics were manufactured using 3D-printed UV-
curing photopolymer with acoustic properties comparable to
human ribs. Phantoms were produced by fixing a rib-mimic within
a plastic container and then filling it with TMTCP gel. Before HIFU,
rib-mimic was visualized on T2-weighted MRI and manually
segmented. During sonication, MR images were acquired and
temperature was calculated using the PRFS method. Beam-
shaping was performed by projecting the ribs onto the transducer
surface by ray tracing from the focal point. Transducer elements
shadowed by ribs were disabled, while power for active elements
was compensated accordingly. Locations 3 cm behind the ribs
were targeted with all elements enabled or by using beam-
shaping. Temperatures within the targeted region and around rib-
mimic were assessed. Phantoms were sonicated by electronic
steering (target = 8 mm) at 1.2 MHz frequency and 80 W power
for 60s under MRI guidance using a clinical MR-HIFU system
(Sonalleve V2, Philips, Finland). Post-HIFU, TMTCP enabled evalu-
ation of temperature distribution within the targeted location and
at the rib-mimic. Moreover, acoustic pressure measurements were
performed in water by scanning a hydrophone within: 1) focal
plane behind rib-mimics, 2) same location with beam-shaping,
and 3) plane at the rib-mimic level.
Results
TMTCP material with embedded rib mimics was developed and
produced. Real-time MRI temperature monitoring at the targeted
location and around the rib-mimic was successful. Qualitative and
quantitative assessment of temperature was also obtained by
phantom color change. Temperatures over the rib-mimics were
reduced using beam-shaping, i.e., selectively disabling transducer
elements whilst maintaining equivalent acoustic power. Acoustic
pressure fields were evaluated using a hydrophone (results
pending).
Conclusions
TMTCP rib phantom was developed and applied in characterization
of intercostal HIFU sonications. The utility of beam-shaping tech-
niques to minimize temperature rise on the ribs while maintaining
focus quality during transcostal sonications was demonstrated by moni-
toring heating patterns. This phantom may be useful in characterization
and validation of intercostal HIFU sonication methods and numerical
models.
Fig. 192 (abstract A172). Microscopic images of the 3D model.
Bladder cancer cells are embedded into collagen type-I. left, 50
microL; middle 100 microL; right 200 microL
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Objectives
Not released for publication
Methods
Not released for publication
Results
Not released for publication
Conclusions
Not released for publication
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Objectives
Multi-modality treatment for muscle invasive bladder cancer aims se-
lective organ preservation with favorable outcome. Cisplatin-based
chemotherapy has a survival benefit in combination with radiother-
apy. Local delivery of cisplatin may improve local disease control and
survival rates. Ultrasound triggered microbubble cavitation enhances
chemotherapeutic agents including cisplatin both in vitro and in vivo.
However, it is not fully elucidated whether the enhancement is re-
lated to cisplatin concentration in tumor cells. The purpose of this
work is to clarify the relation between enhanced cisplatin effect and
cellular cisplatin concentration in a 3D culture system.
Methods
Human urinary bladder cancer cells were mixed with collagen type-I
and were seeded into a culture dish at the volume of 50, 100, and
200 microL (Fig. 192). The gel mixture was exposed to non-focused
ultrasound (center frequency 1 MHz, duty factor 50 %, intensity
0.9 mW/cm2, time 1 min) in the presence of cisplatin and microbub-
bles. For platinum measurement, cells were harvested from the gel
right after the sonication and were separated from the dissolved gel.
Cisplatin concentration was determined by measuring 195Pt with an
inductively coupled plasma mass spectrometer. For assessing cell via-
bility, cells were culture for 4 days in the gel after the sonication;
thereafter cells were harvested and counted manually.
Results
The combination of ultrasound and microbubbles increased the cel-
lular platinum concentration at all tested gel volume. Ultrasound
alone did not significantly increase the cellular platinum concentra-
tion. Sonication did not increase the platinum concentration of the
dissolved gel (i.e. without cells). The platinum concentration of the
dissolved gel increased with the gel volume. The enhanced cytotoxic
effect was observed at the gel volumes of 50 and 100 microL.
Conclusions
This study shows the feasibility of our culture model for assessing
the relation of the intracellular delivery and the cytotoxic effect. With
our ultrasound parameter, ultrasound-triggered microbubble cavita-
tion has a potential to deliver cisplatin to cancer cells. Meanwhile,
the results of this study suggest cisplatin in the extracellular matrix
gradually enters cells and shows the cytotoxic effect even without
ultrasound. Because cisplatin is a small molecular hydrophilic drug, it
rapidly diffuses and may remain in the collagen. The thicker gel
retained the higher platinum concentration. Further studies on ultra-
sound parameter may improve efficiency of the intracellular delivery
and contribute to the local delivery of cisplatin in bladder cancer
treatment.A173
Model predictive control algorithm for large-area regional
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Objectives
Hyperthermia has been shown in clinical trials to strongly enhance
therapeutic efficacy of radio- and chemotherapy. Main challenge in
hyperthermia is to achieve temperatures between ca. 41-43 oC for
ca. one hour. While current RF-based hyperthermia devices allow
heating of larger volumes, they cannot heat specific subvolumes that
are colder due to perfusion. HIFU has been used in preclinical and re-
cently also in a clinical study for hyperthermia applications. The typ-
ical approach is to scan the focus point through the tissue using a
real-time MRI thermometry feedback for temperature control (MR-
HIFU). Here, we are currently developing a new regulatory algorithm
based on Model Predictive Control (MPC) for stable HIFU-hyperthermia,
which is designed to predict the temperature evolution under the influ-
ence of perfusion and diffusion inside the tissue and to plan a power
application pattern, which will keep the temperature distribution within
a predefined set of parameters.
Methods
The MPC algorithm aims to heat the target tissue to a predefined
temperature profile using a heating model derived from the bioheat
equation. A system of partial differential equations (PDE) is generated
by transferring the heat equation to the Fourier domain. This PDE
system is then used by the MPC algorithm to calculate the temperature
distribution in the next timestep. The actual MR temperature readout
functions as feedback for controlling the heating power (Fig. 193).
The control objective is to minimize the cost function of the soft con-
straints imposed on the temperature distributions. Their violation occurs
if the modeled temperature doesn’t fit in between the temperature pro-
files representing the maximum and minimum desired temperatures
(Fig. 194). The algorithm was implemented with the Python interface of
Gurobi.
To test the model, the predicted heating pattern was compared with
MR-thermometry data acquired during sonications performed in a
polyacrylamide phantom using the following HIFU-parameters: cell
diameter 14 mm, time 45 s and power 30 W. A pixel-wise compari-
son was made between the acquired sagittal temperature maps and
the modeled temperature per time step.
Results
First, the temperature diffusion terms of the PDE system were deter-
mined by fitting our model to the cooling curve of a test measurement.
The pixel-wise temperature difference between the measurement
temperature profile in the phantom and the model’s prediction are
shown in Fig. 195 as a boxplot in time, enabling us to see tendencies
of over- or underestimation in the predictions. The whiskers were
chosen to represent the range in which 90 % of the measurements lie.
The upshifted boxes reveal that the model slightly overestimates most
of the temperature values for the subsequent temperature distribution
during the heating phase. Comparing the reach of the upper and the
lower whiskers, we also see that under-estimations mostly stay below
0.4 °C, while over-estimations mostly stay below 0.8 °C. It follows that
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a tendency to under-treat rather than to cause immediate thermal
damage. It also reveals that the algorithm would benefit from a refined
mechanism for online-adjustment of the heating estimation.
Conclusions
We have implemented the basic functionalities of a MPC-based algo-
rithm for hyperthermia using HIFU. Given a treatment region and a
safety margin, it computes a HIFU treatment sequence which meets
the minimum required treatment temperature while respecting a
given maximum temperature to avoid thermal damage. Using the
model in its current implementation, the algorithm will likely have a
tendency to under-treat rather than causing thermal damage as
temperature estimation errors are more extreme in over-estimations.
We have yet to prove the viability of the algorithm in an experiment
which uses the algorithm to steer the transducer. The good agreement
between a real temperature development and the used model’s predic-
tion, however, gives us reason to believe that we will be able to present
the working prototype of an MPC-based HIFU hyperthermia system in
the near future.Fig. 194 (abstract A173). Scheme of Temperature thresholds given
to the algorithm (black) and one possible temperature distribution
outcome (red). Heatmap inset shows reading line for temperature
profile displayed in graph and possible application points
Fig. 195 (abstract A173). Boxplots of pixel-wise differences between
experimental data and the model’s prediction as boxplot versus the
measurement time. Whiskers show the 90th percentile
Fig. 193 (abstract A173). The information of the MR-thermometry
image is used as feedback for the control algorithm to plan a heating
pattern. The first of these heating steps is applied to control the
temperature and a new measurement is takenA174
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Objectives
In MRgFUS applications with movable transducers it is a common
problem to establish a connection between scanner- and transducer-
coordinate systems (spatial calibration). Vendor calibration tools are
often only available in proprietary software and not accessible in re-
search applications. Thus, transducer position and orientation are
often prescribed in a tedious and error prone manual process. The
current work presents an image-based spatial transducer calibration
method that transforms a transducer model automatically into a
given setup. Our method is based on the idea, that the water sys-
tems tubes are typically well visible in MR imaging and attached to
one side of the transducer, giving information on the transducers
position and orientation. An MR image of the transducer and its per-
iphery can thus be used for an automatic calibration method.
Methods
Inputs for the method are an MR image of the transducer in a given
setup and a transducer model. A transducer model consists of all
relevant transducer information (such as e.g. transducer center, trans-
ducer orientation, or relative element positions) and a corresponding
MR image. Note that this transducer model has to be established
only once and can afterwards be used on any given setup. Both
model- and setup-image should contain the transducer and its direct
periphery, slice orientation should be roughly parallel to the trans-
ducer surface.
The transducer calibration is implemented as two-step process: An
initialization is used to coarsely align setup and model image, a sub-
sequent image registration aligns the images precisely. The accumu-
lated transformation can then be used to map from transducer to
MR coordinates and vice versa.
The initialization is a series of image registrations that subsequently align
transducer to skin coupling, transducer center, and cable orientation.
Fig. 196 (abstract A176). a Image of mouse with Philips Small Flex
Coil. b Image of mouse with custom RF coil. Images performed on a
3 T Achieva system with identical parameters. c Custom RF coil
tested at SickKids (Toronto, Ontario, Canada)
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image registration.
Results
After setting up a transducer model once, the proposed method can
be used to automatically determine transducer position and orienta-
tion from a single MR scan within 2-4 seconds. The method was used
in a several validation experiments as a suggestion to the user. In
most cases the proposed calibration was accepted, only a few times
minor adjustments were necessary. We currently evaluate the
method on the basis of manual ground-truth and with different
transducer models.
Conclusions
A hardware- and vendor-independent, image based transducer cali-
bration may be useful in a variety of research applications. Our
method was implemented with publicly available modules in MeVi-
sLab and can be provided for research purposes.
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Objectives
Human Thiel embalmed cadavers have a number of advantages over
traditional formalin embalmed cadavers. Properties such as flexibility,
tissue tone and a patent vascular system provide the basis for an
anatomically accurate model. Researchers at University of Dundee
have developed techniques to provide extracorporeal perfusion to
the cadaver vascular system, facilitating multimodal imaging tech-
niques such as CT, Xray, Ultrasound and MR. Model complexity is fur-
ther improved by the addition of respiratory motion, produced by
mechanical ventilation. Applications for perfused cadaveric models in
the development and validation of Focused Ultrasound Technologies
have been demonstrated.
Methods
Input and output (if required) connections are placed into the cadav-
eric target vessels and secured. Connections are made to a heart
lung bypass machine to provide extracorporeal flow into the vessels,
with flow conditions input to mimic the native flow expected. The
fluid selected during perfusion is dependent upon the imaging mo-
dality, for example vascular ultrasound requires contrast therefore, a
specific blood mimic solution is used. X ray, CT and MRI can success-
fully use a variety of fluids, with contrast being delivered to target
vessel as bolus dose, mimicking clinical practice. Respiratory motion
is created by intubating the cadaver with ET tube and ventilating
with a mechanical ventilator.
Results
Exemplar images from all imaging modalities demonstrate the appli-
cation of multi modal imaging techniques within Thiel embalmed
human cadavers. The perfused cadaveric model has been used
within the preclinical development and validation of Focused Ultra-
sound therapies targeting liver and kidneys.
Conclusions
The perfused Thiel embalmed human cadaver can be imaged in mul-
tiple modalities, CT, fluoroscopy, angiography, MRI and Ultrasound. It
offers a robust and versatile model, ideal for development and evalu-
ation of advanced technologies such as focused ultrasound therapy
in moving organs.
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Objectives
Magnetic-Resonance Guided High Intensity Focused Ultrasound (MR-
HIFU) is a minimally-invasive treatment modality that is gaining clinicaluse. It is used to non-invasively ablate tissue or disrupt the Blood-Brain
Barrier. Translation of this technique can be accelerated by facilitating
animal experiments, and the development of ergonomic platforms can
achieve this purpose. MR-HIFU exposure is performed under water re-
quiring unique engineering solutions to waterproof and tune RF coils.
Custom radiofrequency (RF) coils are necessary to obtain optimal
signal-to-noise ratio (SNR) in this setting. Without careful tuning and
matching of RF coils, targeting, temperature monitoring and thermal
dose assessment may not be accurate enough.
The purpose of this study is to provide an engineering solution to
treat mice using MR-HIFU using custom RF coils submerged in water
with sufficient SNR that allowed for accurate thermal mapping.
Methods
An MR-HIFU animal treatment system was designed so that:
SNR was increased compared to commercial coils
Tissues were acoustically coupled while the animal remained
appropriately anesthetized and warm
HIFU beam could pass-through window to target
The animal could be placed for treatment with good reproducibility
The developed system was compared to the Small Flex Coil (Philips,
USA). An ex vivo mouse was imaged to compare systems. Two
parameters were used to determine quality of new system: SNR of
targeting images and temperature stability from thermal mapping.
The system was tested at two different locations, TBRHSC (Thunder
Bay, Ontario, Canada) and Sickkids (Toronto, Ontario, Canada) to con-
firm reproducibility.
Results
An ergonomic treatment bed was designed with a waterproofed coil
embedded. After first tuning, RF coils experienced significant loading
from the surrounding water, with a frequency shift as high as
7.3 MHz when submerged in water. A tunable matching circuit was
added on the circuit to achieve further fine tuning.
Figure 196 shows a comparison between the Flex coil and the devel-
oped coil. SNR of the in-house developed coil was 28 and 23.5 com-
pared to an SNR of 6 from the Small Flex coil during TBRHSC and
SickKids tests respectively. (Gradient Echo, TE = 4 ms, TR = 8 ms, FOV
= 50 mm x 50 mm, 2.5 mm slice thickness NEX = 4, FA = 10o.
Figure 197 shows a 1D thermal calculation over time for both coils.
The custom coil showed a stable temperature where the Flex coil re-
corded a decrease over time for the temperature.
Figure 198 shows the device used to ergonomically hold mice for fo-
cused ultrasound exposure.
Conclusions
We successfully designed an ergonomic treatment bed designed for
HIFU exposure that can be used underwater while providing sufficient
SNR for targeting and thermal mapping. This treatment bed will further
facilitate research for focused ultrasound small animal experiments.
Fig. 197 (abstract A176). Thermal Calculation of Custom RF Coil (red)
and Philips Small Flex Coil (blue). Temperature calculation are based on
the proton frequency shift method and averaged over a region of
interest for 300 seconds. Reference temperature was set at 22 °C
Fig. 198 (abstract A176). Device used to ergonomically hold mice
for focused ultrasound exposure
Fig. 199 (abstract A178). a In vivo MRI of uterus with hypointense
T2wSI fibroids (asterisks). Ex vivo perfusion model. c Photos of
Fig. 199. the excised uterus before and after perfusion. (d) MR T2
maps: fibroids are hypointense relative to myometrium (star). (e) Ex
vivo TWIST MRI
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A unique tissue preparation for characterizing uterine fibroid
tissue properties for MRgFUS thermal therapies
Christopher Dillon, Margit Janát-Amsbury, Allison Payne
University of Utah, Salt Lake City, Utah, USA
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Magnetic resonance-guided focused ultrasound (MRgFUS) has re-
peatedly been demonstrated as a safe, non-invasive therapy for
uterine fibroids. However, the treatment response of fibroids with
high T2-weighted signal intensity (T2wSI) on pretreatment MRI is
poor. While blood flow and cellularity have been hypothesized to
play a role, there is a lack of research investigating the cause of
poor outcomes in high T2wSI fibroids. This abstract presents an
innovative excised, perfused human uterine fibroid model de-
signed to address this clinical challenge. Implementation of this
model will allow for characterization of the MR, physiological,
thermal, and acoustic properties of uterine fibroids and clarify the
reason for variable efficacy in MRgFUS fibroid treatments.
Methods
In this study, women undergoing hysterectomy due to symptom-
atic fibroids receive a preoperative MRI (Siemens 3 T Trio). Imme-
diately following surgical removal, both uterine arteries are
cannulated, and the specimen is perfused and immersed in a
Modified Krebs Henseleit Buffer maintained at a temperature of
37 °C. Tissue pH, temperature, and interstitial pressure are moni-
tored throughout. This setup keeps tissue viable up to 8 hours
post surgery, during which time, the preoperative MRI protocol is
repeated on the ex vivo uterus. Comparing in vivo and ex vivo
images reveals how/if MR tissue properties and organ perfusion
have changed. Additional property measurements include thermal
diffusivity and conductivity, acoustic properties of density, speed
of sound, and attenuation, and histological examination of vessel
density, cellularity, and fibrosis.
Results
Figure 199a shows an in vivo coronal MRI identifying two fibroids
with hypointense T2wSI. The ex vivo model (Fig. 199b) includes
heated water baths and fiberoptic probes for temperature control,
perfusion-line manometers, and bubble traps; it is MR-compatible
and integrated with the MRgFUS system. Photos of the excised
uterus before and after perfusion (Fig. 199c) demonstrate effective
clearing of blood. While the fibroids’ T2 values increase slightly
ex vivo (Fig. 199d, TrueFISP MRI), they remain hypointense relative to
the myometrium.
Figure 199e shows an ex vivo T1 TWIST MRI where contrast agent
does not extravasate into the fibroids, indicating the low vascularity
of these fibroids. Thermal diffusivity and thermal conductivity of the
fibroid tissue were 0.173 mm2/s and 0.431 W/m/°C, respectively. Par-
ticipant recruitment and data collection are ongoing.
Conclusions
This unique setup for the characterization of fibroid properties has
great potential for explaining the variable treatment response of fi-
broids, for improving MRgFUS planning, monitoring, and control, and
for identifying the patient population most likely to benefit from
MRgFUS therapy.
Fig. 201 (abstract A179). A) Printed array wrapped around gel
phantom submerged in water inside head transducer. B) Scan of
phantom with (i) body coil and (ii) 4-channel array. Lines highlight
where SNR was calculated. C) SNR comparison of printed array and
body coil
Fig. 202 (abstract A179). a Scan of phantom on a fibroid
transducer. b Heating point inside of phantom (i) without and (ii)
with the array present. c) Phantom inside head transducer D. (i)
Coronal and (ii) axial scans of heating point in phantom tracked
with array
Fig. 203. (abstract A179). a Location of array wrapped around 3D
printed skull containing bovine brain/gel submerged in water in
head transducer. b Sagittal of brain phantom showing heating
tracked with array. c Axial scan of skull and brain phantom from
4-channel array
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Objectives
In MR imaging, a surface coil array is most sensitive to tissue close to it.
So for MR guided HIFU, placing the array between the transducer and
the patient gives the highest signal-to-noise ratio (SNR), and in turn the
best quality images to track the heating. During therapy, the transducer
is moved in the water bath, which would pass acoustic energy directly
through different parts of an array between patient and transducer.
Ultrasonic energy easily scatters and attenuates in the materials com-
monly used in array construction (Fig. 200a). As a result, lower SNR
body or non-fitting arrays are used during therapy. This limits the SNR
for accurate temperature estimation and resolution compared to specif-
ically designed surface arrays. We address this by creating a surface
array using ultra-flexible low attenuation materials that allow it to be
placed in the beam path of an ultrasonic transducer with negligible at-
tenuation and signal distortion.
Methods
We used additive manufacturing techniques to print very thin receive coils
making our array nearly transparent to the acoustic energies common in
HIFU (~650Khz-1Mhz). In printing, coils are fabricated layer-by-layer creat-
ing the conductors and capacitors needed for tuning (Fig. 200b).
A water resistant 4-channel array was fabricated using 75 μm of PEEK
(polyether ether ketone) film encapsulated in 75 μm polytetrafluoro-
ethylene film with 20 μm Dupont 5064H conductive ink (Fig. 200c). The
SNR of our array was compared to the SNR of the body coil of a 3 T
scanner on a gel phantom inside the head transducer (Fig. 201).
To characterize acoustic attenuation, an area inside a gel phantom was
heated with an in-table system (Insightec ExAblate 2100) with and
without the array present (Fig. 203a and b). Temperature increase was
tracked with the body coil of a 3 T MR scanner (General Electric) in both
cases. For beam distortion characterization, a spot was heated in a
phantom in a brain system (InSightec Exablate 4000) and tracked with
the 4-channel array (Fig. 202c and d).
For system proof-of-concept, our array tracked the heating of a bo-
vine brain immersed in gel inside a 3D printed human skull with
200 W of acoustic power (Fig. 203).
Results
The signal-to-noise ratio of our array was found to be twice as high
as the body coil in the center of the image where heating occurred.
Furthermore it showed up to 5 times the SNR at the surface of the
phantom (Fig. 201). The array displayed 84 % transmission of acous-
tic energy and no measureable beam distortion, allowing it to be ar-
bitrarily placed in front of the transducer (Fig. 202).
The 4-channel array was easily able to track the heating inside the skull
phantom, imparting no significant attenuation or distortion (Fig. 203).
Conclusions
Utilizing the materials and processes described here it is possible to
create high SNR arrays that minimally interact with heating in MR
guided HIFU, giving clinicians excellent images to guide therapy.Fig. 200 (abstract A179). a) a(i) Acoustic energy measured at the
focal point with (ii) no obstruction, (iii) typical tuning capacitor and
conductor, and (iv) thin printed tuning capacitor. B) Fabrication of
printed coil C) Photograph of acoustically transparent arrayA180Multi-echo pseudo-golden angle stack of stars thermometry with
high spatial and temporal resolution
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Objectives
Radial acquisitions offer several unique advantages for proton reson-
ance frequency (PRF) shift thermometry for guiding focused ultra-
sound therapy in the breast. Frequently sampling the k-space center
provides motion robust images, as well as the ability to correct for
respiration induced off resonance.1 It has been shown that arbitrary
high spatial and temporal resolution can be achieved in dynamic





Breast Coronal 13th Echo Phase, TE = 17.22 ms 1.18 0.90
Combined Echo Phase 0.56 0.44
Breast Sagittal 13th Echo Phase, TE = 17.22 ms 1.9 1.86
Combined Echo Phase 0.71 0.81
Pork Phantom 13th Echo Phase, TE = 17.22 ms 0.69 0.63
Combined Echo Phase 0.41 0.24
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angle and applying a sliding k-space weighted image contrast (KWIC)
filter,2 to the reconstruction.3 This work investigates a pseudo-golden
angle 3D multi-echo stack of stars acquisition to simultaneously
measure PRF shift temperature, T2* and ρ (signal magnitude at TE =
0), correct respiration induced off resonance, and provide water/fat
separation with high spatial and temporal resolution.
Methods
A 3D multi-echo stack of stars spoiled gradient echo (GRE) sequence
was modified to use a pseudo-golden angle increment to repeat the k-
space trajectory after 377 views, ~137.56°. Experiments were performed
in a normal breast volunteer on a Siemens 3 T Trio scanner to assess
the effectiveness of this sequence and reconstruction technique in cor-
onal and sagittal slabs (1.3x1.3x3mm, FOV = 166 mm, Matrix Size =
128x128x8, Flip Angle = 10°, TR = 20 ms, 13 Echoes, TE’s = 2.46/3.69/
4.92/6.15/7.38/8.61/8.84/11.07/12.3/13.53/14.76/15.99/17.22 ms). Using
the same imaging parameters and Ambu bag movement to simulate
respiration, a pork phantom was heated with FUS. Reconstruction: After
accurately locating the k-space center,4 the slope of the phase with TE
at the k-space center was used for respiration correction.1 Data was
then reconstructed using a sliding filter with 13 lines in the innermost
ring (1.56 s temporal resolution), with each successive ring using
enough lines to meet the Nyquist criteria. The KWIC filtered k-space dis-
tribution repeats after 29 reconstructed time points. Echo phase was
combined using a weighted least squares estimate. PRF temperature
was also calculated using the combined echo phase. T2*/ρ maps were
calculated using linear regression of the log of the magnitude images
along the echo dimension.
Results
Figure 204 shows the water and fat images produced from the se-
quence using the three point Dixon method. Figure 205 shows the
standard deviation through time images of the PRF temperature mea-
surements for four cases: PRF temperatures were calculated using both
the first time point and the time point with the same k-space sampling
pattern as the reference phase for the 13th echo phase and the com-
bined echo phase. Table 8 lists the spatially averaged precision of all tis-
sue voxels in the breast and pork for the four cases. Figure 206 shows
the PRF temperature, and percent change in ρ and T2* values vs. time
of the hottest voxel while heating with FUS in pork.
Conclusions
All measurements display a structured artifact based on the k-space
sampling pattern used for reconstruction. For this reason, a pseudo and
not pure golden angle increment was chosen to cause the artifact to re-
peat and thus be removable in temperature difference measurements.
The method shown here provides promising results for this sequence
and reconstruction method for use in free breathing interventional treat-
ments. The respiration correction also corrects main field drift.1 The high
bandwidth multi-echo readout offers several advantages as it removes
the need for fat saturation, provides fat/water images, and T2*/ρ mea-
surements which could be used as another possible measure of
temperature change, especially in adipose tissues which do not exhibit a
PRF shift with temperature.5 Echo combination significantly improves
PRF temperature precision.Fig. 204 (abstract A180). Three point Dixon images produced by
the sequence and reconstruction. Top: Coronal breast. Middle:
Sagittal breast. Bottom: Pork phantomReferences
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Fig. 205 (abstract A180). Standard deviation of temperature
through time maps for Top: Coronal and sagittal breast. Bottom:
Pork phantom. Maps are derived for four cases. Using just the phase
information from the 13th echo or from the combined echo phase,
and using the 1st time point as the reference phase or a sampling
pattern based library of phase references
Fig. 206 (abstract A180). Percent change in ρ (rho - red) and T2*
(green) and calculated PRF temperature change (blue) for the
hottest voxel during heating in tissue with FUS in the pork
phantom. A sampling pattern based library was used for all 3
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